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Insulin resistance refers to reduced insulin action in metabolic and vascular target 
tissues, hence higher than normal concentration of insulin is required to maintain 
normoglycemia and other actions of insulin, hence it may be considered as a 
euglycemic pre-diabetic state. The growing incidence of insulin resistance and type 2 
diabetes is seriously threatening human health globally. The development of insulin 
resistance leads to many of the metabolic abnormalities associated with this syndrome. 
The syndrome includes a cluster of clinical problems such as hypertension, 
dyslipidemia and obesity along with insulin resistance leading to a substantial 
increase in cardiovascular risk. These patients tend to have impaired fasting plasma 
glucose levels, which increase the prevalence of more atherogenic, small dense low-
density lipoprotein (LDL) particles. 
During last decade several studies have been conducted to understand the 
mechanisms contributing to the state of insulin resistance. Insulin signalling pathways 
have been dissected in different insulin responsive tissues such as skeletal muscles, 
adipose tissues, fibroblasts as well as ovaries to elucidate the mechanism. These 
studies suggest a post receptor signalling defect where metabolic action of insulin is 
affected. The first chapter on Molecular mechanisms in Insulin resistance describes the 
insulin signaling pathways and broadly describes various mechanisms capable of 
producing an Insulin resistant state. 
Metabolic regulation in cells is largely dependent on mitochondria, which play an 
important role in energy homeostasis by metabolizing nutrients and producing ATP. 
Imbalance between energy intake and expenditure leads to mitochondrial dysfunction, 
characterized by a reduced ratio of energy production (ATP production) to respiration. 
Genetic and environmental factors including diet, exercise, aging, and stress affect 
both mitochondrial function and insulin sensitivity. Recently, it has been shown that 
mitochondrial dysfunction is associated with insulin resistance in skeletal muscle, as 
well as in other tissues, including liver, fat, heart, vessels, and pancreas. Thus, insulin 
resistance caused in part by mitochondrial dysfunction may contribute to a common 
pathophysiologic etiology for many chronic diseases. Notably, SIRT3, a member of 
sirtuins located in mitochondria, can regulate the function of mitochondrial proteins 
via reversible posttranslational modification in response to metabolic stress.  
Imbalanced acetylation status of mitochondrial proteins by decreased expression and 
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activity of SIRT3 has been demonstrated as one of the factors in the pathogenesis of 
insulin resistance in mice and human. The chapter by author Wang CH et al., describes 
the effect of mitochondrial dysfunction on Insulin sensitivity. 
Genetic and epidemiological studies strongly suggest that insulin resistance is, at least 
in part, genetically determined. However, the involved genes and their effective 
variants are mostly unknown. The numerous genes have been suggested as a potential 
candidate gene for insulin resistance. The chapter titled ‘Impact of genetic 
polymorphisms on Insulin resistance’ by author Evrim Komurcu-Bayrak provides an 
update on the genetics of Insulin resistance. 
The mechanisms that underlie metabolic syndrome and its cardiometabolic 
consequences may very well vary between ethnicities. It has been a recurring theme 
that the interactions between poor nutritional status, physical inactivity, and genetic 
predisposition might contribute to the disparities in the prevalence and characteristics 
of MetS and its components between ethnicities and the subgroups within. The 
incidence, component characteristics and complications of the metabolic syndrome in 
Puerto Ricans has been described in the chapter titled ‘The Metabolic Syndrome in 
Hispanics - The Role of Insulin Resistance and Inflammation’ by author Dr Altieri et al. 
wherein, they have highlighted the fact that the metabolic syndrome may be milder in 
Puerto Rico than in the mainland United States because it is characterized by less 
aggressive coronary artery disease and a relatively normal lipid profile.  
The role of white adipose tissue (WAT) as an ordinary tissue responsible for  
lipid energy storage has been replaced due to studies that demonstrate the  
central activity of WAT in lipid and glucose metabolism and its ability to secrete 
factors with endocrine, paracrine and autocrine effects. For example, recent studies 
suggest that pro-inflammatory and anti-inflammatory substances produced by WAT 
contribute to the development of insulin resistance. The pro-inflammatory role of 
adipose tissue and association of appetite regulatory peptides with Insulin resistance 
have been covered in detail  in the two chapters by authors Torres-Leal et al. and 
Maria Orbetzova. 
The next section focuses on the systemic effects of Insulin Resistance. The chapter 
titled ‘Cardiovascular and renal complications in obesity and obesity-related medical 
conditions’ by Prof. Masuo and Lambert GV focuses on the sympathetic nervous 
system activity and insulin resistance in metabolic and their role in the 
etiopathogenesis of cardiovascular and renal complications in these patients. Another 
chapter in the same section focuses on the Myocardial Insulin Resistance, wherein the 
authors Eugene F du Toit and Daniel G Donner have beautifully described how 
myocardial insulin resistance translates to compromised intracellular insulin 
signalling and reduced glucose oxidation rates and adversely affects myocardial 
mechanical function and tolerance to ischemia and reperfusion. 
        Preface XI 
 
The chapter on Ultrasonographic measurement of visceral fat by author Alempijevic T 
et al. describes how Ultrasonography can be used as a simple and reliable method for 
measuring both subcutaneous and visceral fat in clinical settings. 
Furthermore, the development of insulin resistance, is associated with increased tissue 
renin–angiotensin system activity and increasingly appears to be a nexus between 
components of the syndrome. The chapter titled ‘Anti-hypertensive agents and their 
benefits beyond blood pressure control’ by authors Nadya Merchant and Bobby V 
Khan describe the effect of various antihypertensive agents especially angiotensin 
receptor blockers on various biomarkers of insulin resistance. 
The purpose of this book is to provide contemporary factual information on Insulin 
resistance. The articles in this issue provide a valuable overview of insulin resistance, 
by integrating the recent advances which have occurred in various seemingly 
disparate fields. Thus, I have relied on the expertise of several outstanding 
contributors who are recognized authorities in their respective areas. I hope that this 
book will serve as a valuable resource for all clinicians in the related fields and also for 
the students. 
 
Dr. Sarika Arora 
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1. Introduction 
The metabolic syndrome is an agglomeration of interrelated risk factors that is associated 
with nearly 5-fold increased risk for type 2 diabetes mellitus (DM) and a 2-fold increased 
risk of coronary artery disease (CAD) [1]. Reaven first suggested this cluster of metabolic 
abnormalities in 1988. It is characterized by insulin resistance, visceral adiposity, 
dyslipidemia and a systemic pro-inflammatory and pro-coagulant state [2]. Insulin 
resistance is defined as reduced insulin action in metabolic and vascular target tissues, 
hence higher than normal concentration of insulin is required to maintain normoglycemia. 
On a cellular level, it indicates an inadequate strength of insulin signaling from the insulin 
receptor downstream to the final substrates of insulin action involved in multiple metabolic 
and mitogenic aspects of cellular function [3]. 
The development of insulin resistance leads to many of the metabolic abnormalities 
associated with this syndrome. Patients with insulin resistance tend to have impaired 
fasting plasma glucose levels, which increase the prevalence of more atherogenic, small 
dense low-density lipoprotein (LDL) particles. The growing incidence of insulin resistance 
and metabolic syndrome (MS) is seriously threatening human health globally.  Individuals 
with MS have a 30%–40% probability of developing diabetes and/or CVD within 20 years, 
depending on the number of components present [4]. 
In the United States (US), the prevalence of the MS in the adult population was estimated to 
be more than 25%. Similarly, the prevalence of MS in seven European countries was 
approximately 23%. It was estimated that 20%–25% of South Asians have developed MS and 
many more may be prone to it [5,6]. The main reason why MS is attracting scientific and 
commercial interest is that the factors defining the syndrome are all factors associated with 
increased morbidity and mortality in general and from CVD in particular [7].  
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Insulin Resistance 4 
Though, Insulin resistance has been recognized as a basis of CVD and diabetes type II, its 
etiology still remains elusive. Recent studies have contributed to a deeper understanding of 
the underlying molecular mechanisms of Insulin resistance. This review provides a detailed 
understanding of these basic pathophysiological mechanisms which may be critical for the 
development of novel therapeutic strategies to treat/ prevent metabolic syndrome. 
2. Signalling through Insulin receptor and its downstream Pathways 
Insulin action is initiated by an interaction of insulin with its cell surface receptor [8]. The 
insulin receptor (IR) is a heterotetramer consisting of two α subunits and two β subunits that 
are linked by disulphide bonds. Insulin binds to the extracellular α subunit of the insulin 
receptor and activates the tyrosine kinase in the β subunit {figure 1). Binding of insulin to IR 
effects a series of intramolecular transphosphorylation reactions, where one β subunit 
phosphorylates its adjacent partner on a specific tyrosine residue. Once the tyrosine kinase 
of insulin receptor is activated, it promotes autophosphorylation of the β subunit itself, 
where phosphorylation of three tyrosine residues (Tyr-1158, Tyr-1162, and Tyr-1163) is 
required for amplification of the kinase activity [9].  It then recruits different substrate 
adaptors such as the Insulin Receptor Substrate (IRS) family of proteins. Although IRs are 
present on the surface of virtually all cells, their expression in classical insulin target tissues, 
i.e. muscle, liver and fat, is extremely high [10]. Tyrosine phosphorylated IRS then displays 
binding sites for numerous signaling partners. Phosphorylated IRS proteins serve as 
multisite docking proteins for various effector molecules possessing src homology 2 (SH2) 
domains, including phosphatidylinositol 3-kinase (PI 3-kinase) regulatory subunits (p85, 
p55 p50, p85, and p55PIK), the tyrosine kinases Fyn and Csk, the tyrosine protein 
phosphatase SHP-2/Syp, as well as several smaller adapter molecules such as the growth 
factor receptor binding proteins Grb-2, Crk, and Nck [11]. Activation of these SH2 domain 
proteins initiates signaling cascades, leading to the activation of multiple downstream 
effectors that ultimately transmit the insulin signal to a branching series of intracellular 
pathways that regulate cell differentiation, growth, survival, and metabolism. Four 
members of the IRS family have been identified that are considerably similar in their general 
architecture [12-15]. IRS proteins share a similar structure characterized by the presence of 
an NH2-terminal pleckstrin homology (PH) domain adjacent to a phosphotyrosine-binding 
(PTB) domain followed by a variable-length COOH-terminal tail that contains a number of 
Tyr and Ser phosphorylation sites. The PH domain is critical for IR-IRS interactions. Plasma 
membrane phospholipids, cytoskeletal elements, and protein ligands mediate these 
interactions [16, 17]. In contrast, the PTB domain interacts directly with the juxtamembrane 
(JM) domain of the insulin and IGF-I receptors [18, 19], and hindrance of these interactions 
(by Ser/Thr phosphorylation) negatively affects insulin signaling [19]. A third domain, the 
kinase regulatory loop binding (KRLB) is found only in IRS-2 [20, 21]. This domain interacts 
with the phosphorylated regulatory loop of the IR, whereas the phosphorylation of two Tyr 
residues within the KRLB are crucial for this interaction [22]. 
PI3 kinase is a target of the IRS proteins (IRS-1 and IRS-2) which phosphorylates specific 
phosphoinositides to form phosphatidylinositol 4,5 bisphosphate (PIP2) to 
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phosphatidylinositol 3,4,5 triphosphate; in turn, this activates ser/thr kinase, i.e. 
phosphoinositide-dependent kinase-1 (PDK1) [23, 24]. Known substrates of the PDKs are the 
protein kinase B (PKB) and also atypical forms of protein kinase C (PKC) [25]. 
Downstream from PI 3-kinase, the serine/threonine kinase Akt (also called PKB) triggers 
insulin effects on the liver. Phosphatidylinositol-dependent kinase (PDK) and PKB/Akt have 
a pleckstrin homology domain that enables these molecules to migrate toward the plasma 
membrane [26]. Activated Akt induces glycogen synthesis, through inhibition of GSK-3; 
protein synthesis via mTOR and downstream elements; and cell survival, through inhibition 
of several pro-apoptotic agents (Bad, Forkhead family transcription factors, GSK-3). Insulin 
stimulates glucose uptake in muscle and adipocytes via translocation of GLUT4 vesicles to 
the plasma membrane [27- 29]. This suggests that the impairment of insulin activity leading 
to insulin resistance is linked to insulin signalling defects. 
Recently, an alternative PI 3-kinase independent mechanism to enhance GLUT4 
translocation and glucose uptake was described. According to this model, binding of insulin 
to its receptor finally activates the small G-protein TC10 via the scaffolding protein CAP 
(Cbl-associated protein) resulting in GLUT4 translocation and enhanced glucose uptake [30]. 
Insulin signaling also has growth and mitogenic effects, which are mostly mediated by the 
Akt cascade as well as by activation of the Ras/MAPK pathway. A negative feedback signal 
emanating from Akt/PKB, PKCΖ, p70 S6K and the MAPK cascades results in serine 
phosphorylation and inactivation of IRS signaling [31, 32]. Insulin signalling molecules 
involved in metabolic and mitogenic action have been demonstrated to play a role in 
cellular insulin resistance. A few recent reports indicate that some PKC isoforms may have a 
regulatory effect on insulin signalling. The expression levels and activity of a few PKC 
isoforms are found to be associated with insulin resistance [33-35]. 
Recent data from PKB knockout animal models provide an insight into the role of PKB in 
normal glucose homeostasis. While disruption of PKB/Akt1 isoform in mice have not shown 
to cause any significant perturbations in metabolism, mice with a knock out of the 
PKB(Akt2) isoform show insulin resistance ending up with a phenotype closely resembling 
Type 2 diabetes in humans [36-37]. Subsequent studies [38- 40] in insulin-resistant animal 
models and humans have consistently demonstrated a reduced strength of insulin signaling 
via the IRS-1/PI 3-kinase pathway, resulting in diminished glucose uptake and utilization in 
insulin target tissues. Recent studies on inherited insulin post-receptor mutations in humans 
have detected a missense mutation in the kinase domain of PKB (Akt2) in a family of 
severely insulin resistant patients. The mutant PKB was unable to phosphorylate 
downstream targets and to mediate inhibition of phosphoenolpyruvate carboxykinase 
(PEPCK), a gluconeogenic key enzyme [41]. Another recent study, involving the stimulation 
of PI3K and Akt-1, -2, and -3 by insulin and epidermal growth factors (EGFs) in skeletal 
muscles from lean and obese insulin-resistant humans showed that Insulin activated all Akt 
isoforms in lean muscles, whereas only Akt-1 was activated in obese muscles. Insulin 
receptor substrate (IRS)-1 expression was reduced in obese muscles, and this was 
accompanied by decreased Akt-2 and -3 stimulation. In contrast, insulin- or EGF-stimulated 
phosphotyrosine-associated PI3K activity was not different between lean and obese muscles. 
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phosphoinositide-dependent kinase-1 (PDK1) [23, 24]. Known substrates of the PDKs are the 
protein kinase B (PKB) and also atypical forms of protein kinase C (PKC) [25]. 
Downstream from PI 3-kinase, the serine/threonine kinase Akt (also called PKB) triggers 
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protein synthesis via mTOR and downstream elements; and cell survival, through inhibition 
of several pro-apoptotic agents (Bad, Forkhead family transcription factors, GSK-3). Insulin 
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translocation and glucose uptake was described. According to this model, binding of insulin 
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Insulin signaling also has growth and mitogenic effects, which are mostly mediated by the 
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cellular insulin resistance. A few recent reports indicate that some PKC isoforms may have a 
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normal glucose homeostasis. While disruption of PKB/Akt1 isoform in mice have not shown 
to cause any significant perturbations in metabolism, mice with a knock out of the 
PKB(Akt2) isoform show insulin resistance ending up with a phenotype closely resembling 
Type 2 diabetes in humans [36-37]. Subsequent studies [38- 40] in insulin-resistant animal 
models and humans have consistently demonstrated a reduced strength of insulin signaling 
via the IRS-1/PI 3-kinase pathway, resulting in diminished glucose uptake and utilization in 
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have detected a missense mutation in the kinase domain of PKB (Akt2) in a family of 
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accompanied by decreased Akt-2 and -3 stimulation. In contrast, insulin- or EGF-stimulated 
phosphotyrosine-associated PI3K activity was not different between lean and obese muscles. 
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These results showed that a defect in the ability of insulin to activate Akt-2 and -3 may 
explain the impaired insulin-stimulated glucose transport in insulin resistance [42]. 
This suggests that the impairment of insulin activity leading to insulin resistance is linked to 
insulin signalling defects. These insulin signalling pathways are shown in figure1. 
3. Mechanisms related to Insulin resistance 
Two separate, but likely, complementary mechanisms have recently emerged as a potential 
explanations for Insulin resistance. First, changes in IRS-1 either due to mutations or serine 
phosphorylation of IRS proteins can reduce their ability to attract PI 3-kinase, thereby 
minimizing its activation. A number of serine kinases that phosphorylate serine residues of 
IRS-1 and weaken insulin signal transduction have been identified. Additionally, 
mitochondrial dysfunction has been suggested to trigger activation of several serine kinases, 
leading to a serine phosphorylation of IRS-1. Second, a distinct mechanism involving 
increased expression of p85α has also been found to play an important role in the 
pathogenesis of insulin resistance. Conceivably, a combination of both increased expression 
of p85α and increased serine phosphorylation of IRS-1 is needed to induce clinically 
apparent insulin resistance. 
4. Mutations of IRS as a cause of Insulin resistance 
IRS-1 protein is a gene product of IRS-1 gene. In humans, rare mutations of the IRS-1 protein 
are associated with insulin resistance [43] and disruption of the IRS-1 gene in mice results in 
insulin resistance mainly of muscle and fat [44]. The genetic analysis of the IRS-1 gene has 
revealed several base-pair changes that result in amino acid substitutions [45-47]. The most 
common amino acid change is a glycine to arginine substitution at codon 972 (G972R), 
which has an overall frequency of ≈6% in the general population [48], with a carrier 
prevalence of 9% among Caucasians [49]. This mutation has been reported to significantly 
impair IRS-1 function in experimental models [50], and clinical studies have shown that this 
genetic variant is associated with reduced insulin sensitivity [51]. Expression of this variant 
in 32-D cells is associated with a significant (20-30%) impairment of insulin-stimulated PI3-
kinase activity, as well as reduced binding of IRS-1 to the p85 regulatory subunit of PI3-
kinase. Genotype/phenotype studies stratified according to body mass index (BMI) indicate 
that obese subjects who are heterozygous for the mutant allele have a 50% decrease in 
insulin sensitivity, compared with wild-type obese subjects. This suggests that there may be 
an interaction between the mutant allele and obesity, such that, in the presence of obesity, 
the mutant variant may aggravate the obesity-associated insulin resistance [49]. Moreover, 
earlier observations have indicated that the presence of a mutated IRS-1 gene is associated 
with dyslipidemia, further suggesting that this gene variant may have a significant effect on 
several risk factors for CAD [48, 50-52]. 
Interestingly, IRS-2 knockout mice not only show insulin resistance of muscle, fat and liver, 
but also manifest diabetes as a result of cell failure [53]. This phenotype with severe 
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hyperglycemia as a consequence of peripheral insulin resistance and insufficient insulin 
secretion due to a significantly reduced β-cell mass reveals many similarities to type 2 
diabetes in man and outlines the role of IRS proteins for the development of cellular insulin 
resistance. Homozygous knockout mice lacking a single allele of IRS-1 gene lack any 
significant phenotype, whereas homozygous disruption of the IRS-1 gene results in a mild 
form of insulin resistance [54]. IRS-1 homozygous null mice (IRS-1-/-) do not show a clear 
diabetic phenotypic expression, presumably because of pancreatic β cell compensation. IRS-
2−/− mice, on the other hand, developed diabetes as a result of severe insulin resistance 
paired with β-cell failure [55, 56]. Even though β cell mass was reduced in IRS-2−/− mice, 
individual β cell showed normal or increased insulin secretion in response to glucose [55]. 
In regard to insulin signaling, experiments in immortalized neonatal hepatocytes show that 
the lack of IRS-2 is not compensated for by an elevation of IRS-1 protein content or an 
increase in tyrosine phosphorylation [57]. Previous experiments performed in peripheral 
tissues of IRS-1−/− mice by Yamauchi et al. [44] suggested that IRS-2 could be a major player 
in hepatic insulin action. However, to what extent reduced IRS-2 contributes to insulin 
resistance in the liver remains uncertain. In humans, a number of polymorphisms have been 
identified in the IRS-2 gene. Among those, the amino acid substitution Gly1057Asp has been 
found in various populations with a prevalence sufficiently high to modulate a population’s 
risk of type 2 diabetes. In Caucasians, Finns, and Chinese, however, this variant has not 
shown an associated with type 2 diabetes [58, 59]. Although the polymorphism was 
associated with decreased insulin sensitivity and impaired glucose tolerance in women with 
polycystic ovary syndrome [60], it showed no association with insulin sensitivity in other 
studies [59, 61, 62]. In contrast, another study in women with polycystic ovary syndrome 
found that homozygous carriers of the Gly1057 allele had higher 2-h plasma glucose 
concentrations during an oral glucose tolerance test (OGTT) [63]. Decreased serum insulin 
and C-peptide concentrations during an OGTT were reported in middle-aged glucose-
tolerant Danish males carrying the Asp1057 allele [62]. However, using formal β-cell 
function tests, associations with insulin secretion were not reproduced in German, Finnish, 
and Swedish populations [59, 61, 62]. 
5. Serine phosphorylation of IRS as a cause of Insulin resistance 
IRS-1 contains 21 putative tyrosine phosphorylation sites, several of which are located in 
amino acid sequence motifs that bind to SH-2 domain proteins, including the p85 regulatory 
subunit of PI 3-kinase, Grb-2, Nck, Crk, Fyn, Csk, phospholipase Cγ, and SHP-2 [64]. IRS-1 
contains also > 30 potential serine/threonine phosphorylation sites in motifs recognized by 
various kinases such as casein kinase II, protein kinase C, protein kinase B/Akt, and 
mitogen-activated protein (MAP) kinases [12, 64]. 
Human IRS-2 contains 22 potential tyrosine phosphorylation sites, but only 13 are conserved 
in IRS-1. The amino acid sequence identity between IRS-1 and IRS-2 is 43%, with some 
domains such as the PH and PTB domains exhibiting higher degrees of identity (65 and 
75%, respectively). The COOH-terminal domains of IRS-1 and IRS-2 are poorly conserved, 
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These results showed that a defect in the ability of insulin to activate Akt-2 and -3 may 
explain the impaired insulin-stimulated glucose transport in insulin resistance [42]. 
This suggests that the impairment of insulin activity leading to insulin resistance is linked to 
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minimizing its activation. A number of serine kinases that phosphorylate serine residues of 
IRS-1 and weaken insulin signal transduction have been identified. Additionally, 
mitochondrial dysfunction has been suggested to trigger activation of several serine kinases, 
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increased expression of p85α has also been found to play an important role in the 
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apparent insulin resistance. 
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IRS-1 protein is a gene product of IRS-1 gene. In humans, rare mutations of the IRS-1 protein 
are associated with insulin resistance [43] and disruption of the IRS-1 gene in mice results in 
insulin resistance mainly of muscle and fat [44]. The genetic analysis of the IRS-1 gene has 
revealed several base-pair changes that result in amino acid substitutions [45-47]. The most 
common amino acid change is a glycine to arginine substitution at codon 972 (G972R), 
which has an overall frequency of ≈6% in the general population [48], with a carrier 
prevalence of 9% among Caucasians [49]. This mutation has been reported to significantly 
impair IRS-1 function in experimental models [50], and clinical studies have shown that this 
genetic variant is associated with reduced insulin sensitivity [51]. Expression of this variant 
in 32-D cells is associated with a significant (20-30%) impairment of insulin-stimulated PI3-
kinase activity, as well as reduced binding of IRS-1 to the p85 regulatory subunit of PI3-
kinase. Genotype/phenotype studies stratified according to body mass index (BMI) indicate 
that obese subjects who are heterozygous for the mutant allele have a 50% decrease in 
insulin sensitivity, compared with wild-type obese subjects. This suggests that there may be 
an interaction between the mutant allele and obesity, such that, in the presence of obesity, 
the mutant variant may aggravate the obesity-associated insulin resistance [49]. Moreover, 
earlier observations have indicated that the presence of a mutated IRS-1 gene is associated 
with dyslipidemia, further suggesting that this gene variant may have a significant effect on 
several risk factors for CAD [48, 50-52]. 
Interestingly, IRS-2 knockout mice not only show insulin resistance of muscle, fat and liver, 
but also manifest diabetes as a result of cell failure [53]. This phenotype with severe 
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hyperglycemia as a consequence of peripheral insulin resistance and insufficient insulin 
secretion due to a significantly reduced β-cell mass reveals many similarities to type 2 
diabetes in man and outlines the role of IRS proteins for the development of cellular insulin 
resistance. Homozygous knockout mice lacking a single allele of IRS-1 gene lack any 
significant phenotype, whereas homozygous disruption of the IRS-1 gene results in a mild 
form of insulin resistance [54]. IRS-1 homozygous null mice (IRS-1-/-) do not show a clear 
diabetic phenotypic expression, presumably because of pancreatic β cell compensation. IRS-
2−/− mice, on the other hand, developed diabetes as a result of severe insulin resistance 
paired with β-cell failure [55, 56]. Even though β cell mass was reduced in IRS-2−/− mice, 
individual β cell showed normal or increased insulin secretion in response to glucose [55]. 
In regard to insulin signaling, experiments in immortalized neonatal hepatocytes show that 
the lack of IRS-2 is not compensated for by an elevation of IRS-1 protein content or an 
increase in tyrosine phosphorylation [57]. Previous experiments performed in peripheral 
tissues of IRS-1−/− mice by Yamauchi et al. [44] suggested that IRS-2 could be a major player 
in hepatic insulin action. However, to what extent reduced IRS-2 contributes to insulin 
resistance in the liver remains uncertain. In humans, a number of polymorphisms have been 
identified in the IRS-2 gene. Among those, the amino acid substitution Gly1057Asp has been 
found in various populations with a prevalence sufficiently high to modulate a population’s 
risk of type 2 diabetes. In Caucasians, Finns, and Chinese, however, this variant has not 
shown an associated with type 2 diabetes [58, 59]. Although the polymorphism was 
associated with decreased insulin sensitivity and impaired glucose tolerance in women with 
polycystic ovary syndrome [60], it showed no association with insulin sensitivity in other 
studies [59, 61, 62]. In contrast, another study in women with polycystic ovary syndrome 
found that homozygous carriers of the Gly1057 allele had higher 2-h plasma glucose 
concentrations during an oral glucose tolerance test (OGTT) [63]. Decreased serum insulin 
and C-peptide concentrations during an OGTT were reported in middle-aged glucose-
tolerant Danish males carrying the Asp1057 allele [62]. However, using formal β-cell 
function tests, associations with insulin secretion were not reproduced in German, Finnish, 
and Swedish populations [59, 61, 62]. 
5. Serine phosphorylation of IRS as a cause of Insulin resistance 
IRS-1 contains 21 putative tyrosine phosphorylation sites, several of which are located in 
amino acid sequence motifs that bind to SH-2 domain proteins, including the p85 regulatory 
subunit of PI 3-kinase, Grb-2, Nck, Crk, Fyn, Csk, phospholipase Cγ, and SHP-2 [64]. IRS-1 
contains also > 30 potential serine/threonine phosphorylation sites in motifs recognized by 
various kinases such as casein kinase II, protein kinase C, protein kinase B/Akt, and 
mitogen-activated protein (MAP) kinases [12, 64]. 
Human IRS-2 contains 22 potential tyrosine phosphorylation sites, but only 13 are conserved 
in IRS-1. The amino acid sequence identity between IRS-1 and IRS-2 is 43%, with some 
domains such as the PH and PTB domains exhibiting higher degrees of identity (65 and 
75%, respectively). The COOH-terminal domains of IRS-1 and IRS-2 are poorly conserved, 
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displaying only 35% identity, which arises largely from similar tyrosine phosphorylation 
motifs surrounded by variable stretches of amino acid sequence. The middle of IRS-2 
possesses a unique region comprising amino acids 591–786 that interacts specifically with 
the kinase regulatory loop binding (KRLB) domain of the insulin receptor β subunit [65]. 
Since this region is absent in IRS-1, this domain may contribute to the signaling specificity of 
IRS-2. In addition, IRS-1 and IRS-2 may regulate unique signaling pathways because of 
different tissue distribution, subcellular localization, kinetics of activation/deactivation, or 
specificity of interaction with downstream effectors [66-68]. For example, it has been shown 
that IRS-1 and IRS-2 differ in their subcellular localization since IRS-1 is twofold more 
concentrated in the intracellular membrane compartment than in cytosol, whereas IRS-2 is 
twofold more concentrated in cytosol than in the intracellular membrane compartment [69]. 
Further studies have shown that IRS-2 is dephosphorylated more rapidly and activates PI 3-
kinase more transiently than IRS-1, thus indicating that differences in kinetics of activation 
may contribute to the diversity of the insulin signaling transduced by IRS-1 and IRS-2 
[69,70]. 
Since, IRS-1 and IRS-2 have the longest tails, which contain ∼20 potential Tyr 
phosphorylation sites. Many of the Tyr residues gather into common Tyr-phosphorylated 
consensus motifs (YMXM or YXXM) that bind SH2 domains of their effector proteins. 
Spatial matching is required for successful protein-protein interaction. Ser/Thr 
phosphorylation of IRS proteins in close proximity to their PTB (receptor-binding) region 
impedes the binding of the SH2 domains of these effectors, thus inhibiting insulin signaling 
[71]. 
Serine phosphorylation of IRS proteins can occur in response to a number of intracellular 
serine kinases [72].The causes of IRS-1 serine phosphorylation are- 
1. mTOR- p70S6 kinase, Amino acids, Hyperinsulinemia 
2. JNK-  Stress, Hyperlipidemia, Inflammation 
3. IKK- Inflammation 
4. TNFα- Obesity, Inflammation 
5. Mitochondrial dysfunction 
6. PKC θ- Hyperglycemia, Diacylglycerol, Inflammation 
Recent studies have demonstrated hyper-serine phosphorylation of IRS-1 on Ser302, Ser307, 
Ser612, and Ser632 in several insulin-resistant rodent models [73- 76] as well as in lean insulin-
resistant offspring of type 2 diabetic parents [77]. Further evidence for this hypothesis stems 
from recent studies in a muscle-specific triple serine to alanine mutant mouse (IRS-1 Ser → 
Ala302, Ser → Ala307, and Ser → Ala612), which has been shown to be protected from high-fat 
diet–induced insulin resistance in vivo [78]. Based on in vitro studies, serine 
phosphorylation may lead to dissociation between insulin receptor/IRS-1 and/or IRS-1/PI 3-
kinase, preventing PI 3-kinase activation [79, 80] or increasing degradation of IRS-1 [81].  
Ser318 of IRS-1 is a potential target for PKCζ [82], JNK, and kinases along the PI3K-mTOR 
pathway [83]. It is located in close proximity to the PTB domain. Therefore, its 
phosphorylation presumably disrupts the interaction between IR and IRS-1. 
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Phosphorylation of Ser318 is not restricted to insulin stimulation. Elevated plasma levels of 
leptin, an adipokine produced by adipocytes [84], also stimulates the phosphorylation of 
Ser318. This down regulates insulin-stimulated Tyr phosphorylation of IRS-1 and glucose 
uptake. 
In a recent study using skeletal muscle biopsies from 11 humans, the mTOR-S6K pathway 
was shown to negatively modulate glucose metabolism under nutrient abundance [151]. In 
agreement with previous studies, phosphorylation of Ser312 and Ser636 of IRS-1 was 
implicated as part of this negative regulation [85, 86]. Increased phosphorylation of Ser636 of 
IRS-1 was observed in myotubes of patients with type 2 diabetes. Inhibition of ERK1/2 with 
PD-98059 reduced this phosphorylation, thereby implicating ERK1/2 in the phosphorylation 
of Ser636 in human muscle [87].  
To unveil the importance of phosphorylated Ser/Thr residues of human IRS-1, Yi et al. [88] 
adopted a mass spectrometry approach. More than 20 Ser residues of IRS-1 were found to 
undergo insulin-stimulated phosphorylation in human muscle biopsies, three of which were 
newly identified sites: Thr495, Ser527, and Ser1005. This report validates previous in vitro and in 
vivo studies in animal models and suggests that the same strategy could be employed to 
identify phosphorylated Ser/Thr sites under conditions of insulin resistance, obesity, or type 
2 diabetes. 
Impaired hepatic glycogen storage and glycogen synthase activity is a common finding in 
insulin resistance [89] and polymorphisms in the glycogen synthase gene have been 
described in insulin resistant patients. The most frequent mutations are the so-called XbaI 
mutations and Met416Val within intron 14 and exon 10, respectively. Currently, there are 
conflicting data on the correlation of these polymorphisms with insulin resistance and Type 
2diabetes mellitus [90-92]. 
Recently, a hypothesis that mitochondrial dysfunction or reduced mitochondrial content 
accompanied by a decreased mitochondrial fatty acid oxidation and accumulation of fatty 
acid acyl CoA and diacylglycerol can cause insulin resistance has gained substantial 
experimental support [93- 95]. The mechanism of insulin resistance in these cases has been 
suggested to involve activation of a novel PKC that either by itself or via IKKβ or JNK-1 
could lead to increased serine phosphorylation of IRS-1. Severe mitochondrial dysfunction 
can result in diabetes that is typically associated with severe β-cell dysfunction and 
neurological abnormalities [96]. In a study ,using 13C/31P MRS, it was found that in the 
healthy lean elderly volunteers with severe muscle insulin resistance, there is∼40% 
reduction in rates of oxidative phosphorylation activity associated with increased 
intramyocellular and intrahepatic lipid content [94]. This study suggests that an acquired 
loss of mitochondrial function associated with aging predisposes elderly subjects to 
intramyocellular lipid accumulation, which results in insulin resistance [78]. Further, it  
was found that mitochondrial density was reduced by 38% in the insulin-resistant offspring 
[77].  
[This topic has been dealt in details in subsequent chapter by Wang etal.] 
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implicated as part of this negative regulation [85, 86]. Increased phosphorylation of Ser636 of 
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described in insulin resistant patients. The most frequent mutations are the so-called XbaI 
mutations and Met416Val within intron 14 and exon 10, respectively. Currently, there are 
conflicting data on the correlation of these polymorphisms with insulin resistance and Type 
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accompanied by a decreased mitochondrial fatty acid oxidation and accumulation of fatty 
acid acyl CoA and diacylglycerol can cause insulin resistance has gained substantial 
experimental support [93- 95]. The mechanism of insulin resistance in these cases has been 
suggested to involve activation of a novel PKC that either by itself or via IKKβ or JNK-1 
could lead to increased serine phosphorylation of IRS-1. Severe mitochondrial dysfunction 
can result in diabetes that is typically associated with severe β-cell dysfunction and 
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[77].  
[This topic has been dealt in details in subsequent chapter by Wang etal.] 
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The proinflammatory novel PKCθ has been found to cause serine phosphorylation of IRS-1 
[97, 98], while PKCθ knockout mice have been shown to be protected from fat-induced 
insulin resistance [75]. Increased activity of PKCθ, along with increased activity of JNK, has 
also been found in skeletal muscle of obese and type 2 diabetic subjects [99, 100], supporting 
a potential role of these serine kinases in the pathogenesis of insulin resistance. 
 
Figure 1. Insulin signaling pathway showing that the binding of insulin with Insulin receptor (IR) leads 
to phosphorylation of tyrosine residues followed by activation of downstream signalling pathways 
which result in recruitment in recruitment of GLUT-4 transporter to the plasma membrane and entry of 
glucose molecules within the cell. Serine phosphorylation of IRS protein has an inhibitory effect on 
downstream pathways resulting in insulin Resistance. 
6. Increased expression of p85 
A molecular mechanism that can potentially lead to insulin resistance is a disruption in the 
balance between the amounts of the PI 3-kinase subunits [101]. PI 3-kinase belongs to the 
class 1a 3-kinases [102], which exist as heterodimers, consisting of a regulatory subunit p85, 
which is tightly associated with a catalytic subunit, p110.  Most tissues express two forms of 
regulatory subunit, p85α and p85β, and two forms of catalytic subunit, p110α and p110β 
[102]. p85α and p85β share the highest degree of homology in the C-terminal half of the 
molecules, which contains two SH2 domains that bind to tyrosine-phosphorylated proteins 
and an inter-SH2 domain that interacts with the catalytic subunit. The N-terminal halves of 
p85α and p85β contain an SH3 domain, a BCR homology region, and two proline-rich 
domains, but these domains are less well conserved between the two molecules. Two 
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isoforms of p85α truncated in the N-terminal region, identified as AS53 (or p55α) [103, 104] 
and p50α [105, 106], as well as p85α itself, are derived from a single gene (Pik3r1). p85β and 
another short isoform with limited tissue distribution termed p55γ/p55PIK are encoded by 
separate genes [107]. Normally, the regulatory subunit exists in stoichiometric excess to the 
catalytic one, resulting in a pool of freep85 monomers not associated with the p110 catalytic 
subunit. However, there exists a balance between the free p85 monomer and the p85-p110 
heterodimer, with the latter being responsible for the PI 3-kinase activity [108-110]. Because 
the p85 monomer and the p85-p110 heterodimer compete for the same binding sites on the 
tyrosine-phosphorylated IRS proteins, an imbalance could cause either increased or 
decreased PI 3-kinase activity [111]. Increase or decrease in expression of p 85 would result 
in a shift in the balance either in the favour of free p85 or p85-p110 complexes [108-110].  
One of the first indications that an imbalance between the abundance of p85 and p110 can 
alter PI 3-kinase activity came from experiments with l-6 cultured skeletal muscle cells 
treated with dexamethazone [111]. This treatment significantly reduced PI 3-kinase activity, 
despite an almost fourfold increase in expression of p85α (no change in p85β) and only a 
minimal increase in p110. The authors concluded that p85α competes with the p85-p110 
heterodimer, thus, reducing PI 3-kinase activity. 
Subsequently, animals with a targeted disruption of p85α (p85+/− heterozygous mice) have 
been found to have a higher ratio of p85-p110 dimer to free p85 and to be more sensitive to 
insulin [101, 111-114].  
The possibility of mismatch between free p85 and p85-p110 complexes has been recently 
supported by studies in insulin-resistant states induced by human placental growth 
hormone [115], obesity, and type 2 diabetes [100] and by short-term overfeeding of lean non-
diabetic women [116]. Barbour etal [117] have demonstrated that insulin resistance of 
pregnancy is likely due to increased expression of skeletal muscle p85 in response to 
increasing concentrations of human placental growth hormone. Furthermore, women 
remaining insulin resistant postpartum have been found to display higher levels of p85 in 
the muscle [118].  
Another small study of eight healthy lean women without a family history of diabetes, by 
Cornier et al showed that 3 days of overfeeding (50% above usual caloric intake) led to a 
significant increase in expression of p85α, ratio of p85α to p110, and a decline in insulin 
sensitivity. Within this experimental time frame, overfeeding did not cause any change in 
serine phosphorylation of either IRS-1 or S6K1, suggesting that increased expression of p85α 
may be an early molecular step in the pathogenesis of the nutritionally induced insulin 
resistance [116]. 
7. Role of the adipose tissue in insulin resistance  
Insulin has 3 major target tissues—skeletal muscle, liver and adipose tissue. It has been 
postulated that the insulin receptor (IR) is overexpressed in the cells of these tissues. Also only 
these three organs in the body are capable of glucose deposition and storage; no other cells can 
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The proinflammatory novel PKCθ has been found to cause serine phosphorylation of IRS-1 
[97, 98], while PKCθ knockout mice have been shown to be protected from fat-induced 
insulin resistance [75]. Increased activity of PKCθ, along with increased activity of JNK, has 
also been found in skeletal muscle of obese and type 2 diabetic subjects [99, 100], supporting 
a potential role of these serine kinases in the pathogenesis of insulin resistance. 
 
Figure 1. Insulin signaling pathway showing that the binding of insulin with Insulin receptor (IR) leads 
to phosphorylation of tyrosine residues followed by activation of downstream signalling pathways 
which result in recruitment in recruitment of GLUT-4 transporter to the plasma membrane and entry of 
glucose molecules within the cell. Serine phosphorylation of IRS protein has an inhibitory effect on 
downstream pathways resulting in insulin Resistance. 
6. Increased expression of p85 
A molecular mechanism that can potentially lead to insulin resistance is a disruption in the 
balance between the amounts of the PI 3-kinase subunits [101]. PI 3-kinase belongs to the 
class 1a 3-kinases [102], which exist as heterodimers, consisting of a regulatory subunit p85, 
which is tightly associated with a catalytic subunit, p110.  Most tissues express two forms of 
regulatory subunit, p85α and p85β, and two forms of catalytic subunit, p110α and p110β 
[102]. p85α and p85β share the highest degree of homology in the C-terminal half of the 
molecules, which contains two SH2 domains that bind to tyrosine-phosphorylated proteins 
and an inter-SH2 domain that interacts with the catalytic subunit. The N-terminal halves of 
p85α and p85β contain an SH3 domain, a BCR homology region, and two proline-rich 
domains, but these domains are less well conserved between the two molecules. Two 
 
Molecular Basis of Insulin Resistance and Its Relation to Metabolic Syndrome 11 
isoforms of p85α truncated in the N-terminal region, identified as AS53 (or p55α) [103, 104] 
and p50α [105, 106], as well as p85α itself, are derived from a single gene (Pik3r1). p85β and 
another short isoform with limited tissue distribution termed p55γ/p55PIK are encoded by 
separate genes [107]. Normally, the regulatory subunit exists in stoichiometric excess to the 
catalytic one, resulting in a pool of freep85 monomers not associated with the p110 catalytic 
subunit. However, there exists a balance between the free p85 monomer and the p85-p110 
heterodimer, with the latter being responsible for the PI 3-kinase activity [108-110]. Because 
the p85 monomer and the p85-p110 heterodimer compete for the same binding sites on the 
tyrosine-phosphorylated IRS proteins, an imbalance could cause either increased or 
decreased PI 3-kinase activity [111]. Increase or decrease in expression of p 85 would result 
in a shift in the balance either in the favour of free p85 or p85-p110 complexes [108-110].  
One of the first indications that an imbalance between the abundance of p85 and p110 can 
alter PI 3-kinase activity came from experiments with l-6 cultured skeletal muscle cells 
treated with dexamethazone [111]. This treatment significantly reduced PI 3-kinase activity, 
despite an almost fourfold increase in expression of p85α (no change in p85β) and only a 
minimal increase in p110. The authors concluded that p85α competes with the p85-p110 
heterodimer, thus, reducing PI 3-kinase activity. 
Subsequently, animals with a targeted disruption of p85α (p85+/− heterozygous mice) have 
been found to have a higher ratio of p85-p110 dimer to free p85 and to be more sensitive to 
insulin [101, 111-114].  
The possibility of mismatch between free p85 and p85-p110 complexes has been recently 
supported by studies in insulin-resistant states induced by human placental growth 
hormone [115], obesity, and type 2 diabetes [100] and by short-term overfeeding of lean non-
diabetic women [116]. Barbour etal [117] have demonstrated that insulin resistance of 
pregnancy is likely due to increased expression of skeletal muscle p85 in response to 
increasing concentrations of human placental growth hormone. Furthermore, women 
remaining insulin resistant postpartum have been found to display higher levels of p85 in 
the muscle [118].  
Another small study of eight healthy lean women without a family history of diabetes, by 
Cornier et al showed that 3 days of overfeeding (50% above usual caloric intake) led to a 
significant increase in expression of p85α, ratio of p85α to p110, and a decline in insulin 
sensitivity. Within this experimental time frame, overfeeding did not cause any change in 
serine phosphorylation of either IRS-1 or S6K1, suggesting that increased expression of p85α 
may be an early molecular step in the pathogenesis of the nutritionally induced insulin 
resistance [116]. 
7. Role of the adipose tissue in insulin resistance  
Insulin has 3 major target tissues—skeletal muscle, liver and adipose tissue. It has been 
postulated that the insulin receptor (IR) is overexpressed in the cells of these tissues. Also only 
these three organs in the body are capable of glucose deposition and storage; no other cells can 
 
Insulin Resistance 12 
store glucose. Removal of excess postprandial glucose by insulin occurs due to glucose uptake 
and storage in insulin sensitive target cells. About 75% of insulin-dependent postprandial 
glucose disposal occurs into the skeletal muscle [119]; therefore, it is the major target cell. 
While insulin-stimulated glucose disposal in adipose tissue is of little quantitative importance 
compared with that in muscle, regulation of lipolysis with subsequent release of glycerol and 
FFA into the circulation by insulin has major implications for glucose homeostasis. 
It is widely accepted that increased availability and utilization of FFA contribute to the 
development of skeletal muscle insulin resistance [120-122]. Moreover, FFA have been 
shown to increase endogenous glucose production both by stimulating key enzymes and by 
providing energy for gluconeogenesis [123]. Finally, the glycerol released during 
triglyceride hydrolysis serves as a gluconeogenic substrate [124]. Consequently, resistance to 
the antilipolytic action of insulin in adipose tissue resulting in excessive release of FFA and 
glycerol would have deleterious effects on glucose homeostasis. 
Patients suffering from insulin resistance and type 2 diabetes frequently display signs of 
abnormal lipid metabolism, increased circulatory concentration and elevated deposition of 
lipids in the skeletal muscle [125]. Increase in plasma FFA reduces insulin-stimulated 
glucose uptake, whereas a decrease in lipid content improves insulin activity in the skeletal 
muscle cells, adipocytes and liver [126]. Lipid-associated insulin resistance has also been 
shown to be linked to Glut4 translocation defects [27]. Studies have shown that raising 
plasma fatty acids in both rodents [75] and humans [127] abolishes insulin activation of IRS-
1–associated PI 3-kinase activity in skeletal muscle where IRS-1 is most prevalent. 
Adipose tissue can modulate whole body glucose metabolism by regulating levels of 
circulating free fatty acids (FFA) and also by secreting adipokines, thereby acting as an 
endocrine organ. However, the underlying mechanism of FFA-induced impairment of 
insulin signals is still unclear. The molecular mechanism underlying defective insulin-
stimulated glucose transport activity can be attributed to increases in intramyocellular lipid 
metabolites such as fatty acyl CoAs and diacylglycerol, which in turn activate a 
serine/threonine kinase cascade, thus leading to defects in insulin signaling through Ser/Thr 
phosphorylation of insulin receptor substrate-1 [78]. 
Some of the PKC isoforms represent such signalling molecules. PKC isoforms are classified 
as classical (cPKCα, βI, βII, γ), novel (nPKCδ, ε, θ, η) and atypical (aPKCζ, λ). cPKCs are 
activated by Ca+2 and diacylglycerol (DAG), nPKCs are activated by only DAG and aPKCs 
respond to neither Ca+2 nor DAG [128]. Among all these PKC isoforms, nPKCs are said to 
have a modulatory role in insulin signalling. Recent reports also demonstrate a link between 
nPKCs and FFA induced insulin resistance. 
Diacylglycerol is an attractive trigger for fat-induced insulin resistance in skeletal muscle, 
since it has been shown to increase in muscle during both lipid infusions and fat feeding and 
it is a known activator of novel protein kinase C (PKC) isoforms [78].  
Recent studies have revealed that accumulation of intracellular lipid metabolites activate a 
serine kinase cascade involving PKC-ε, leading to decreased insulin receptor kinase activity 
 
Molecular Basis of Insulin Resistance and Its Relation to Metabolic Syndrome 13 
resulting in 1) lower insulin-stimulated IRS-2 tyrosine phosphorylation, 2) lower IRS-2–
associated PI 3-kinase activity, and 3) lower AKT2 activity [129] . These fat-induced defects 
in insulin signalling in turn result in reduced insulin stimulation of glycogen synthase 
activity, resulting in decreased insulin-stimulated hepatic glucose uptake and reduced 
insulin stimulation of hepatic glucose production. Furthermore, reduced activity of AKT2 
results in decreased phosphorylation of forkhead box protein O (FOXO), allowing it to enter 
the nucleus and activate the transcription of the rate-controlling enzymes of 
gluconeogenesis (phosphoenolpyruvate carboxykinase, glucose-6-phosphate phosphatase). 
Increased gluconeogenesis further exacerbates hepatic insulin resistance and results in 
fasting hyperglycemia [129- 131]. Mitochondrial glycerol-3-phosphate acyltransferase 
(mtGPAT) is a key enzyme in de novo fat synthesis in liver, and recent studies in mtGPAT 
knockout mice have clearly implicated intracellular accumulation of diacylglycerol in 
triggering fat-induced insulin resistance in liver through activation of PKC-ε [132]. These 
data have important implications for the development of novel therapeutic agents to reverse 
and prevent hepatic insulin resistance associated with non-alcoholic fatty liver and type 2 
diabetes [133]. 
Lipid infusion in rats and humans impaired insulin-stimulated glucose disposal into the 
muscle and concomitant activation of PKCθ and PKCδ [134, 135]. PKCδ has been shown to 
be a possible candidate for phosphorylation of the IR on serine residues [136]. These result 
in defects in the insulin signalling pathway imposing insulin resistance.  
Recently, the PPARγ co-activator-1 (PGC-1) has been recognized as playing a major role in 
glucose homeostasis of the organism. Work mainly by Spiegelman’s group demonstrated a 
crucial role of PGC-1 in the regulation of GLUT4 in muscle cells [137]. (PGC)-1α and PGC-1 
β are transcriptional factor co-activators that regulate mitochondrial biogenesis. In addition 
AMP kinase, which is activated during exercise and ischemia by a reduction in the 
ATP/AMP ratio, has been shown to be an important regulator of mitochondrial biogenesis, 
mediating its effects through MEF2- and CREB-mediated increased PGC-1α expression [138-
141]. Extracellular stimuli such as cold, thyroid hormone, and exercise stimulate 
mitochondrial biogenesis through PGC-1 in brown fat and skeletal muscle. Increased PGC-1 
protein expression leads to increases in the target genes, including nuclear respiratory factor 
(NRF)-1. NRF-1 is a transcription factor stimulating many nuclear-encoded mitochondrial 
genes such as OXPHOS genes and also mitochondrial transcription factor A (mtTFA), a key 
transcriptional factor for the mitochondrial genome. mtTFA can bind to the D-loop of the 
mitochondrial genome and increase transcription of mitochondrial genes and replication of 
mitochondrial DNA [142]. 
A recent study by Ling et al. [143] demonstrated an age dependent decrease in muscle gene 
expression of PGC-1 α and PGC-1 β in young and elderly dizygotic and monozygotic twins 
without known diabetes  
Adipose tissue also acts as an endocrine organ producing adipokines which modulate 
glucose homeostasis [144]. Currently, those most intensely discussed are tumor necrosis 
factor-α (TNF α), leptin, adiponectin and resistin. At a molecular level, TNF α increases 
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fasting hyperglycemia [129- 131]. Mitochondrial glycerol-3-phosphate acyltransferase 
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glucose homeostasis [144]. Currently, those most intensely discussed are tumor necrosis 
factor-α (TNF α), leptin, adiponectin and resistin. At a molecular level, TNF α increases 
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serine phosphorylation of IRS-1 and down-regulates GLUT4 expression, thereby 
contributing to insulin resistance [38]. Furthermore, mice lacking TNF α function were 
protected from obesity-induced insulin resistance [145]. The role of leptin in regulating food 
intake and energy expenditure is well established. Humans with leptin deficiency or leptin 
receptor mutations are severely obese [146,147]. The adiponectin has insulin-sensitizing 
effects as it enhances inhibition of hepatic glucose output as well as glucose uptake and 
utilization in fat and muscle. The expression of adiponectin is decreased in obese humans 
and mice [148]. Thus, in humans, adiponectin levels correlate with insulin sensitivity. 
Because of its insulin-antagonistic effects, the adipocytokine resistin has attracted a lot of 
research interest. This is mainly based on data obtained in-vitro and from some animal 
models. Resistin decreases insulin-dependent glucose transport in-vitro and increases fasting 
blood glucose concentrations and hepatic glucose production in-vivo [149, 150]. 
8. Insulin resistance and Forkhead box protein O (FOXO) 
The fasting hyperglycaemia in patients with Type 2 diabetes is the clinical correlate of the 
increased glucose production by the liver because of insulin resistance. This is as a result of 
the lack of inhibition of the two key gluconeogenic enzymes, phospho-enolpyruvate 
carboxykinase (PEPCK) and the glucose-6- phosphatase (G6Pase) catalytic subunit. Studies 
in hepatoma cells [151,152] suggest that Foxo1 and -3 regulate the transcription of reporter 
genes containing insulin response elements from the PEPCK and G6Pase promoters. 
Furthermore, Foxo1 is phosphorylated in an insulin-responsive manner by PIP3-dependent 
kinases, such as Akt. Reduced activity of AKT2 results in decreased phosphorylation of 
Foxo protein, allowing it to enter the nucleus and activate the transcription of these rate-
controlling enzymes of gluconeogenesis [151,153]. There is increasing evidence that Foxo-
proteins are critically involved in the insulin dependent regulation of gluconeogenic gene 
expression and insulin-resistancein-vivo [154, 155]. In addition, the PPARγco-activator-1 
(PGC-1), a factor integrating the effects of glucocorticoids and cAMP on gluconeogenic 
geneexpression in the liver [156, 157] is also regulated by PKB and Foxo1 [158].  
9. FFA induced Inhibition of Insulin receptor (IR) gene expression by 
PKCε 
Clearly, the IR is one of the major targets in FFA-induced impairment of insulin activity. 
Recent studies performed in-vivo suggested that glucose uptake rather than intracellular 
glucose metabolism is the rate-limiting step for fatty acid induced insulin resistance in 
humans [159]. This indicates a mechanism in which accumulation of intracellular fatty acids 
or their metabolites results in an impairment of signaling through IRS/PI 3-kinase. 
Recent evidence has shown that PDK1 can directly phosphorylate all PKCs including nPKCs 
[160]. The PKCε isotype has recently been shown to be related to insulin resistance. Insulin 
stimulation of PDK1 phosphorylation is inhibited by an FFA, i.e. palmitate. PKCε 
phosphorylation is dependent on PDK1; FFA incubation of skeletal muscle cells and 
adipocytes inhibited PDK1 phosphorylation but surprisingly increased PKCε 
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phosphorylation. Inhibition of PDK1 by FFA is reflected in Akt phosphorylation as Akt 
phosphorylation is also dependent on PDK1 [161]. It has been shown that myristic acid 
incubation of HEPG2 cells causes myristoylation of PKCε which results in constitutive 
phosphorylation of PKCεat thr566/ser729 in the kinase domain required for PKCε activity. 
This phosphorylation was totally independent of PDK1, which the workers demonstrated 
by using PDK1 knockout cells. In the same way, addition of palmitate to skeletal muscle 
cells or adipocytes may affect palmitoylation of PKCε resulting in constitutive 
phosphorylation of PKCε [162, 163]. Taken together, it is clear that FFA causes PDK1-
independent phosphorylation of PKCε which in turn translocates to the nucleus, and its 
time of entry into the nucleus coincides with inhibition of IR gene transcription.  
10. Conclusion 
In this review, current developments contributing to understanding of insulin resistance 
and to the pathogenesis of metabolic syndrome has been discussed. Among the many 
molecules involved in the intracellular processing of the signal provided by insulin, IRS-2, 
PKB, Foxo protein and p85 regulatory subunit of PI-3 kinase have attracted particular 
interest, because their dysfunction results in insulin resistance in-vivo. It has been well 
established that FFA are responsible for insulin resistance. This review focuses on the 
current trends in research in this important domain and throws light on certain possibilities 
regarding the manner in which FFA inhibits insulin activity. 
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1. Introduction 
There are two major types of diabetes mellitus. Type 1 diabetes is caused by the loss of 
insulin-secreting  cells of the pancreas, which leads to a deficiency of insulin in the human 
body. Type 2 diabetes, known as non-insulin-dependent diabetes mellitus (NIDDM), is 
characterized by insulin resistance of insulin-responsive tissues, such as the muscle and 
adipose tissues. Inability of glucose disposal in these tissues after a meal leads to the 
elevation of glucose level in the blood circulation of the patients. Subsequently, the long-
term effect of hyperglycemia may induce inflammation and oxidative damage to other 
organs and result in many complications such as cardiovascular disease, blindness, 
amputations and renal failure [1]. Unfortunately, type 2 diabetes has high prevalence 
compared to type 1 diabetes in modern societies because the pathogenesis of this disease is 
quite complicated, multi-factorial, and is strongly associated with lifestyle, dietary habits, 
and environmental toxins. In light of these findings, many biomedical researchers and 
clinicians have made great efforts to better understand the pathophysiology of insulin 
resistance and to explore new avenues for the therapy of type 2 diabetes [2]. 
2. Mitochondrial role in the regulation of cellular metabolism 
2.1. Overview of mitochondria 
Mitochondria play important roles in energy metabolism, apoptosis and biosynthesis of 
heme and pyrimidine nucleotides because many vital biochemical reactions take place in the 
organelles. They are also called the powerhouse of mammalian cells because they generate a 
majority of ATP required by the cells. Mitochondria contain key enzymes involved in the 
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tricarboxylic acid (TCA) cycle,  oxidation of fatty acids and the electron carriers of the 
respiratory chain. Metabolic intermediates generated from catabolism of carbohydrates and 
lipids by TCA cycle and oxidation provide reducing equivalents (NADH and FADH2), 
which are funneled into the electron transport chain that consists of a series of respiratory 
enzyme complexes I, II, III and IV. The proton gradient generated from the electron 
transport chain across the inner membrane is then utilized by Complex V to drive the 
phosphorylation of ADP to produce ATP in mitochondria to meet the energy need of the 
cell [3]. Mitochondrion has its own genome, mtDNA, which is a 16.6 kb circular double-
stranded DNA. Mammalian mtDNA encodes 2 rRNAs, 22 tRNAs and 13 polypeptides 
required for the assembly of respiratory enzymes. Each mammalian cell contains several 
hundreds to more than a thousand of mitochondria, and each mitochondrion contains 2-10 
copies of mtDNA to meet different energy needs of the cells. Most importantly, mtDNA is 
naked, compact, and has no efficient DNA repair systems, which renders it prone to free 
radical attack and oxidative damage, and thereby increases its risk of acquiring DNA 
mutations. More than one hundred mutations in mtDNA have been reported to be 
associated with human diseases [4].  
2.2. Regulation of mitochondrial biogenesis 
The mitochondrial biogenesis of the human cells is controlled by extracellular stimuli such 
as low temperature, thyroid hormone, fasting, and exercise through up-regulation of the 
master control, peroxisome proliferator-activated receptor gamma co-activator 1�(PC-
1). PC-1 can promote nuclear respiratory factor 1 (NRF-1) and NRF-2 to transcribe their 
target genes that produce many nuclear DNA-encoded mitochondrial proteins and 
mitochondrial transcription factor A (mtTFA), which is a key transcriptional factor for the 
expression of genes encoded by the mitochondrial genome. A great majority of the nuclear 
DNA-encoded proteins are translocated from the cytosol to mitochondria and are assembled 
with mtDNA-encoded proteins to form functional respiratory enzyme complexes on the 
inner membrane. Because mitochondrial biogenesis is a complicated process involved with 
the expression of genes in the two genomes, the communication between mitochondria and 
the nucleus is essential for the proper functioning of mitochondria under different 
physiological conditions [5, 6]. 
2.3. ROS and antioxidant enzyme system in mitochondria 
Mitochondria are also the major source of intracellular reactive oxygen species (ROS). 
Within mitochondria, the superoxide anions (O2.-) are produced in the reaction between O2 
and the electrons leaked out from Complex I and III of the respiratory chain. Subsequently, 
the O2.- can be converted to lipid-permeable hydrogen peroxide (H2O2) by the Mn-
dependent superoxide dismutase (MnSOD), and further changes to more reactive hydroxyl 
radicals (OH.-) via Fenton reaction. There is a set of enzymatic and non-enzymatic ROS-
scavenging system to protect cells from the assault by ROS. The H2O2 can be reduced to H2O 
by catalase (CAT), glutathione peroxidase (Px) or a group of small cysteine-containing 
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proteins such as thioredoxins (Trx) and peroxiredoxins (Prx) [7-9]. Nevertheless, 
overproduction of ROS by defective mitochondria and inefficient antioxidant enzyme 
system may cause oxidative damage to cellular components such as DNA, especially 
mtDNA, proteins, and lipids of target tissues in aging and age-related diseases [10]. It has 
been reported that mitochondrial defects caused by mtDNA mutation or oxidative stress 
also play a role in insulin resistance or diabetes [11-13]. 
3. Mitochondrial dysfunction contributes to insulin resistance and type 2 
diabetes 
In the early 1990s, diabetes has been discovered to be one of the symptoms associated 
with some of the mitochondrial diseases such as mitochondrial encephalopathy, lactic 
acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes and 
deafness (MIDD) syndrome, and patients with these syndromes frequently harbor an A to 
 transition at nucleotide position 3243 of mtDNA [11]. However, until recent years 
diabetes has been usually thought as a secondary effect of aging or age-related diseases in 
patients with an mtDNA mutation. Several recent studies provided the linkage between 
mitochondrial dysfunction or defects in mitochondrial biogenesis and the pathogenesis of 
insulin resistance or type 2 diabetes [12-22]. These studies showed that the tissues of mice 
and human subjects with insulin insensitivity or type 2 diabetes displayed lower 
expression levels of the genes encoding subunits constituting respiratory enzymes, 
decrease in the activities of respiratory enzyme complexes, decreased expression of genes 
involved in mitochondrial biogenesis, mutation or deletion of mtDNA, decrease in the 
bioenergetic capacity, or defects in oxidation of fatty acids. In summary, impairment in 
the mitochondrial OXPHOS function was a common observation in insulin-responsive 
muscle and adipose tissues of diabetic mice or patients. Most importantly, the amplitude 
of the decline of mitochondrial function was found to be related to the severity of diabetic 
symptoms and insulin resistance. These findings support the notion that mitochondrial 
dysfunction is one of the major etiological factors for insulin resistance and type 2 
diabetes. 
4. Mitochondrial DNA alteration causes insulin resistance and type 2 
diabetes 
In order to prove the concept that mitochondrial dysfunction is involved in the 
development of insulin resistance, chemical treatments and genetic manipulation have 
been used to impair mitochondria by alteration of the quantity or quality of mtDNA. Park 
and Lee [23] observed a decrease of insulin sensitivity and impaired activation of insulin 
signaling in mtDNA-depleted muscle cells after chronic treatment with a low dose of 
ethidium bromide (EtBr). Moreover, repletion of mtDNA by removal of EtBr revealed that 
the defects in insulin response could be recovered [23]. Besides, Pravenec et al. [24] 
demonstrated that sequence variations in mtDNA could directly lead to metabolic 
dysregulation that includes glucose intolerance and insulin insensitivity in the conplastic 
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proteins such as thioredoxins (Trx) and peroxiredoxins (Prx) [7-9]. Nevertheless, 
overproduction of ROS by defective mitochondria and inefficient antioxidant enzyme 
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decrease in the activities of respiratory enzyme complexes, decreased expression of genes 
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development of insulin resistance, chemical treatments and genetic manipulation have 
been used to impair mitochondria by alteration of the quantity or quality of mtDNA. Park 
and Lee [23] observed a decrease of insulin sensitivity and impaired activation of insulin 
signaling in mtDNA-depleted muscle cells after chronic treatment with a low dose of 
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demonstrated that sequence variations in mtDNA could directly lead to metabolic 
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strains of rats. In addition, defects in oxidative phosphorylation caused by treatment of 
oligomycin A, an inhibitor of Complex V, also resulted in a decline of insulin-stimulated 
glucose uptake and inactivation of Akt and IRS-1 in the insulin signaling pathway in 
murine C2C12 myotube cells [25]. The above two lines of experiments clearly 
demonstrated a relationship between mtDNA alteration-induced mitochondrial 
dysfunction and insulin insensitivity. 
4.1. Overproduction of ROS impairs insulin signaling 
Excess ROS production from defective mitochondria has been considered as one of the 
possible unifying factors leading to insulin resistance. Increased concentration of glucose in 
the culture medium was found to significantly increase the ROS level and led to insulin 
resistance in mouse adipocytes and rat primary adipocytes and this effect could be 
prevented by pre-treatment of the adipocytes with the antioxidant N-acetylcysteine [26, 27]. 
After administration with ROS-scavenging enzymes, the insulin sensitivity of muscle cells 
was found to be improved in diabetic mice [28]. Recent studies also demonstrated that the 
amount of superoxide anions generated by mitochondria was increased in four different 
animal models of insulin resistance. Furthermore, it was reported that by addition of 
mitochondria-targeting superoxide dismutase mimetics to decrease the level of ROS could 
alleviate insulin resistance in the insulin-insensitive animals [29]. The mechanisms 
underlying the disruption of insulin signaling by overproduction of ROS have been 
extensively investigated in the past decade. It was demonstrated that, at a certain 
concentration range, ROS could cause an increase in the activity of multiple stress-sensitive 
serine/threonine kinases such as p38 MAPK, JNK, ERK, and NFB and elicit subsequent 
phosphorylation of IRS1 and downstream signaling proteins, which may culminate in the 
compromise of insulin sensitivity [30]. 
4.2. Accumulation of fatty acids impairs insulin signaling 
It is thought that impaired lipid metabolism resulted from defects in  oxidation of fatty 
acids is involved in the disturbance of insulin signaling. Accumulation of intracellular 
lipids by the decreased activities of carnitine palmitoyl transferase (CPT), which 
transports long-chain fatty acids into mitochondria, and long-chain acyl-CoA 
dehydrogenase (LCAD), an enzyme involved in  oxidation of fatty acids, led to insulin 
resistance in insulin-targeting cells [31]. It has been demonstrated that an accumulation of 
fatty acid metabolites, such as diacylglycerol, fatty acyl-CoA and ceramides, could induce 
activation of serine/threonine protein kinases such as PKC and PKC in human tissues 
[32]. In turn, the activation of PKCs phosphorylates IRS-1 and IRS-2 on serine/threonine 
residues to inhibit their enzymatic function and activate the downstream PI3K/Akt 
signaling pathway. The above-mentioned observations suggest that ROS overproduction 
and lipid accumulation elicited by mitochondrial dysfunction may play a role in the 
dysregulation of insulin signaling pathway, which then leads to an attenuation of insulin 
response in affected tissues. 
Mitochondrial Dysfunction in Insulin Insensitivity 
and Type 2 Diabetes and New Insights for Their Prevention and Management 31 
4.3. Loss of mild stress-induced AMPKα activation may lead to insulin 
resistance 
Low concentration of ROS is a normal byproduct of cellular functions and is known as the 
secondary messenger in the regulation of intracellular signaling to adapt to the extracellular 
environment. But prolong exposure to oxidative environment may lead to oxidative damage 
to tissue cells and development of diseases. Recent studies revealed that activation of AMPK 
by low dose of ROS is involved in the activation of antioxidant defense system, the influx of 
glycolysis and lipid metabolism [33, 34]. The activation of the downstream targets of AMPK, 
including LUT4, PFK2, and ACC, enhances the  oxidation of fatty acids and the basal and 
insulin-stimulated glucose uptake. Besides, activated AMPK can directly phosphorylate the 
forkhead transcription factor 3a (FOXO3a) to promote its nuclear translocation and 
formation of a transcription complex, which in turn up-regulates the expression of 
thioredoxin and peroxiredoxin [35]. It has been shown that activation of the AMPK-FOXO3a 
pathway via AICAR or metformin, an antidiabetic drug, can decrease the intracellular ROS 
level to improve insulin sensitivity in epithelial cells [35, 36]. These findings indicate that 
mild oxidative stress-elicited activation of AMPK and FOXO3a may safeguard glucose 
homeostatsis and redox status in healthy subjects. Taken together, the decrease in the 
sensitivity and capacity of the response to low-level oxidative stress may play a role in 
insulin insensitivity and type 2 diabetes. 
5. The roles of sirtuins in the maintenance of glucose homeostasis and 
their defects in insulin resistance and type 2 diabetes 
5.1. Introduction of sirtuins 
Sirtuins are a highly conserved family of proteins that exhibit NAD+-dependent protein 
deacetylase and ADP-ribosyltransferase activities. Mammals contain seven sirtuins that are 
confined in different subcellular compartments and regulate diverse functions, such as 
intermediary metabolism, energy homeostasis, and oxidative stress. SIRT1, SIRT6 and SIRT7 
are primarily localized to the nucleus, SIRT2 is a cytosolic protein, and SIRT3, SIRT4 and 
SIRT5 are all located in mitochondria. Sirtuins can regulate the function of enzymes or 
transcription factors by deacetylation of target proteins to cope with nutrient deprivation or 
metabolic stress. In addition to getting involved in the regulation of aging and longevity, 
some of the sirtuins have emerged as important regulators of glucose homeostasis. Sirtuins 
may regulate the activities of some of the regulatory proteins or enzymes involved in the 
insulin-mediated signaling pathways and regulation of mitochondrial function, which in 
turn determine the sensitivity and acuity of biochemical response to high blood glucose of 
the muscle and other peripheral tissues in the human body. 
5.2. SIRT1 and type 2 diabetes 
Accumulating evidence has established that SIRT1 contributes to the pathogenesis of type 2 
diabetes through its effect on oxidative metabolism of the liver, skeletal muscle, adipose 
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tissue, and pancreatic  cells, which indicate that mammalian sirtuins play an essential role 
in the pathogenesis of diabetes and aging-associated metabolic diseases [37]. Increasing 
evidence has suggested that SIRT1 provides overall protection against type 2 diabetes. 
SIRT1-overexpressing transgenic mice showed significant protection from the adverse 
effects of high-fat diet, including hepatic inflammation and impaired insulin sensitivity [38, 
39]. In addition, administration of resveratrol and SIRT1-activating compounds was found 
to improve glucose homeostasis and insulin sensitivity in diet-induced and genetically-
predisposed type 2 diabetic mice [40, 41]. It has been reported that certain sequence 
variations of the SIRT1 gene is strongly associated with type 2 diabetes and obesity in a 
Dutch population [42]. Taken together, these findings suggest that SIRT1 plays a role in the 
pathogenesis of type 2 diabetes and its manipulation has great potential in the prevention 
and treatment of type 2 diabetes in animals and the human. 
5.3. SIRT3 and type 2 diabetes 
In recent years, it has become increasingly clear that reversible lysine acetylation is an 
important posttranslational modification of mitochondrial proteins for the regulation of 
their proper function [43]. A number of proteomics studies have revealed that many key 
metabolic enzymes are acetylated in mitochondria and that their enzymatic activities are 
regulated by changes in acetylation in response to environmental stimuli [44]. Among seven 
members of the sirtuin family, three sirtuins (SIRT3, SIRT4 and SIRT5) are primarily located 
and exert functions in mitochondria. It is a remarkable fact that SIRT3 is the most important 
one regarding the regulation of mitochondrial function because it is responsible for 
deacetylation of the majority of mitochondrial proteins [45]. SIRT3 has been shown to 
control multiple key metabolic pathways through its deacetylase activity in response to 
nutrient deprivation. For example, SIRT3 can deacetylate and activate the mitochondrial 
enzyme acetyl-CoA synthetase 2 (AceCS2). The oxidation of acetate is required for the 
generation of ATP and heat under low-glucose or ketogenic condition [46, 47]. Besides, 
SIRT3 has been shown to deacetylate long-chain acyl-CoA dehydrogenase (LCAD) during 
fasting and thereby promotes -oxidation of fatty acids in the liver mitochondria [48]. 
Recently, some studies provide critical insights into the connection between SIRT3 and the 
pathogenesis of type 2 diabetes and metabolic syndrome. It has been demonstrated that the 
SIRT3 expression in skeletal muscle is reduced in animal models of type 1 and type 2 
diabetes and that results in the decrease of mitochondrial bioenergetic function and over-
production of ROS, which in turn disturbs insulin signaling pathway leading to insulin 
insensitivity [49]. These findings suggest that decreased SIRT3 expression and activity could 
contribute to the metabolic abnormalities in skeletal muscle and pathogenesis of diabetes 
mellitus. On the other hand, mitochondrial dysfunction induced by SIRT3 deficiency in 
pancreaticcells might contribute to the defects in insulin secretion upon stimulation with 
various insulin secretagogues [50]. In a recent study, Hirschey and coworkers [51] showed 
that loss of SIRT3 and resultant mitochondrial protein hyperacetylation contribute to 
obesity, hyperlipidemia, insulin resistance, and steatohepatitis. In addition, they identified a 
single nucleotide polymorphism in the human SIRT3 gene, which causes a loss of the 
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enzyme activity of SIRT3 and is highly associated with the prevalence of metabolic 
syndrome. Abundant evidence has been accumulated to show the importance of reversible 
acetylation/deacetylation of mitochondrial proteins through the action of SIRT3 and its 
potential role in the development of insulin resistance and metabolic disorders. Thus, site-
specific acetylation of mitochondrial proteins and the development of new SIRT3-targeted 
drugs may serve as therapeutic tools to regain normal cellular redox status and energy 
homeostasis in the patients with diabetes and insulin resistance, as well as some of the 
mitochondrial diseases. 
6. Defects in the secretion or function of adipokines as an important 
contributor to insulin resistance or type 2 diabetes 
6.1. Regulation of glucose homeostasis by adipocyte-derived adipokines 
The adipose tissue has traditionally been considered as the site for lipid storage in the 
human body. In recent years, a growing number of studies have revealed that adipose 
tissues can perform endocrine function in secreting several adipokines, which can modulate 
the intermediary metabolism and glucose homeostasis in the peripheral tissues. Adipocyte-
derived adipokines can be divided into two groups according to their action in the 
regulation of glucose metabolism in the mammals. One group is called as “anti-
hyperglycemic adipokines”, which include leptin, adiponectin, omentin, and visfatin. They 
enhance insulin sensitivity in the peripheral tissues to increase glucose utilization and 
decrease the glucose level in blood circulation. Another group of adipokines is termed “pro-
hyperglycemic adipokines” or “pro-inflammatory adipokines”, which include resistin, TNF-
, and RBP4 since they tend to result in an increase of blood glucose and systemic 
inflammation. The imbalance of these two groups of adipokines in blood has been 
frequently observed in patients with insulin resistance [52, 53]. 
6.2. Adiponectin improves insulin sensitivity 
Adiponectin has been considered the most important adipokine due to its higher 
concentration in blood than the others and a decrease in its level is highly correlated with 
type 2 diabetes [54]. Several clinical studies demonstrated that the plasma level of 
adiponectin in obese subjects or patients with type 2 diabetes was significantly lower 
compared with those of normal subjects, and that blood glucose was higher and insulin 
sensitivity was largely decreased in mice with adiponectin deficiency [55, 56]. Besides, 
administration or overexpression of adiponectin in mice can enhance insulin sensitivity and 
glucose utilization to ameliorate the symptoms of insulin resistance [57-59]. This indicates 
that dysregulation of secretion of adipokines from adipose tissues is an important 
contributor for the pathogenesis of type 2 diabetes. Thus, adiponectin has become the most 
attractive adipokine and its function has been gradually unraveled. The underlying 
mechanism of adiponectin in improvement of insulin sensitivity and fatty acid  oxidation 
in skeletal muscle has been demonstrated by Yamauchi and his colleagues [60]. They 
showed that the phosphorylation and activation of AMPK is stimulated when adiponectin 
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binds to adiponectin receptor 1 (AdipoR1), which is a seven-transmembrane receptor 
specifically expressed in the skeletal muscle. In turn, AMPK can induce LUT4 
translocation to the plasma membrane for the increase of glucose uptake. On the other hand, 
the phosphorylated AMPK also activates acetyl-CoA carboxylase to increase the oxidation 
of fatty acids through independent pathways. 
6.3. Bi-directional regulation of the biogenesis and function of mitochondria by 
adiponectin 
Because the decrease of adiponectin expression and the biogenesis and function of 
mitochondria have been observed concurrently in adipose tissues of diabetic mice and 
human subjects [22], some researchers made an effort to elucidate the connection between 
these two cellular events. Koh and coworkers demonstrated that the biogenesis and function 
of mitochondria are important for the maintenance of the adiponectin level in adipocytes 
[61]. They found that adiponectin expression and the mitochondrial content in adipose 
tissues were both reduced in obese mice, and these changes could be reversed by the 
administration of rosiglitazone, a mainstay drug used for treatment of diabetes. Induction of 
mitochondrial biogenesis via adenoviral overexpression of nuclear respiratory factor-1 
(NRF-1) in cultured adipocytes increased the expression of adiponectin. Besides, they found 
that inhibition of mitochondrial function by a respiratory inhibitor or uncoupler decreased 
the level of adiponectin in plasma through activation of ROS-dependent kinase such as JNK. 
This finding suggests that mitochondrial function is linked to adiponectin synthesis in 
adipocytes, and explain the observation that mitochondrial dysfunction is associated with 
the defects of secretion and function of adiponectin, which may lead to systemic insulin 
resistance in obesity and type 2 diabetes. 
On the other hand, a recent study also showed that adiponectin can increase the activity of 
PC-1α and enhance the biogenesis and respiratory function of mitochondria in muscle 
cells [62]. The study provided evidence that adiponectin induces extracellular Ca2+ influx 
through binding to AdipoR1, which is essential for subsequent activation of 
Ca2+/calmodulin-dependent protein kinase kinase  (CaMKK), AMPK and SIRT1. 
Adiponectin ultimately causes an increase in the expression of PC-1by CaMK, a 
downstream target of CaMKK, and increase in the activity of PC-1 by deacetylation of 
SIRT1. These events may in turn elevate the biogenesis and function of mitochondria in 
muscle cells. This new insight into the up-regulation of mitochondrial function by 
adiponectin signaling accounts for the long-term effect of adiponectin on the gene 
expression and provides a biochemical mechanism by which adiponectin improves insulin 
sensitivity of the muscle. 
7. Environmental toxins in mitochondrial dysfunction and insulin 
insensitivity 
Because of the increasing prevalence of type 2 diabetes and metabolic syndrome in 
westernized and industrialized countries, type 2 diabetes is thought as an “epidemic 
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disease”. With this consideration in mind, scientists conjectured that one of the causative 
factors for type 2 diabetes is probably related to the environmental impact of 
industrialization. A growing body of evidence has indicated that the cause of type 2 diabetes 
and metabolic syndrome is strongly associated with some environmental pollutants and 
mitochondrial toxins. Persistent organic pollutants (POPs), which are organic compounds 
present in many herbicides, insecticides, rodenticides, industrial products and wastes, are 
resistant to photolytic degradation and other chemical or biological destruction processes. 
Owning to these chemical characteristics, POPs can be present for a long time in our 
environment and are accumulated in the human body. Thus, POPs are potential 
environmental risk factors that may affect the human health [63].  
7.1. POPs cause insulin insensitivity 
By analysis of the results from National Health and Nutrition Examination Survey in 
1999-2000, Lee and colleagues found that the prevalence rate of type 2 diabetes was highly 
correlated with the serum concentration of POPs of the American population [64, 65]. 
Contamination of POPs in the human diets might be a contributor to the pathogenesis of 
metabolic diseases including the diabetes. For example, atrazine (ATZ, 2-chloro-4-
ethylamine-6-isopropylamino-S-triazine), one of the herbicides, has been extensively used 
in the corn fields of the United States since the early 1960s. Interestingly, the time and 
areas of ATZ usage are matched with the timing of increase in the incidence of obesity 
and other metabolic syndromes [66, 67]. In addition, long-term exposure of Australian 
outdoor workers to pesticides was found to associate with the disturbance of glucose 
homeostasis, including higher blood glucose and insulin resistance in these subjects [68]. 
It was demonstrated that mice fed with a high-fat diet with POPs-contaminated farmed 
salmon fillet would exaggerate insulin resistance, visceral obesity, and glucose intolerance 
[69]. However, remission of the above symptoms was observed in the mice fed with 
farmed salmon fillet containing low level of POPs [69]. Furthermore, the mortality rate of 
diabetes was positively correlated with the concentration of exposed pesticides [70]. In or-
der to establish a cause and effect relationship in humans, Lee et al. [71, 72] approached 
the Nested case control study to measure the serum levels of POPs in certain population 
before the development of metabolic disease phenotypes. The results revealed that 
increased serum levels of some POPs were highly associated with the incidence of 
adiposity, dyslipidemia, and insulin resistance in a healthy population. This finding 
indicates that exposure to low dose of POP may contribute to excess adiposity and other 
features of metabolic syndrome. 
7.2. Impairment of mitochondrial dysfunction by POPs 
Several studies have demonstrated that environmental toxins could cause oxidative damage 
to mitochondria, the organelles are most susceptible to extrinsic toxins including POPs. It 
has been shown that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), one of the POPs, caused a 
loss of mitochondrial membrane potential and increase of ROS production in mammalian 
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binds to adiponectin receptor 1 (AdipoR1), which is a seven-transmembrane receptor 
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cells. The oxygen consumption rate was increased, due to the uncoupling of respiration, and 
the intracellular ATP content and ADP/O ratio were decreased due to defects in FoF1-ATPase 
in the affected tissues of TCDD-treated mice [73]. Recently, some animal studies revealed 
that POPs could result in insulin insensitivity by impairment of mitochondrial function. It 
was found that chronic exposure to POPs led to mitochondrial dysfunction, morphological 
disruption of mitochondria, decreased activities of respiratory enzymes and decreased 
oxygen consumption rate in the liver and skeletal muscle of mice [74]. Besides, POPs were 
found to down-regulate the expression of leptin in adipose tissues and inactivated insulin 
signaling pathway in the skeletal muscle [75]. These subsequently resulted in insulin resis-
tance, hyperlipidemia, abdominal obesity, and hepatosteatosis in mice and the severity of 
these symptoms was more pronounced in the mice fed on high-fat diets. Moreover, 
mitochondria could be the primary organelles involved in the initiation of inflammation, 
leading to chronic damage in the affected cells or organs. High level of polychlorinated 
biphenyls (PCBs) could promote accumulation of lipids and expression of pro-inflammatory 
adipokines, which decreased the expression of adiponectin and the insulin-stimulated 
glucose uptake in the adipose tissue, leading to systemic obesity and obesity-associated 
atherosclerosis [76]. Taken the findings from the epidemiological survey and the above 
observations together, we suggest that the mitochondrial dysfunction resulted from 
environmental pollutants or toxins play a role in the pathogenesis and prevalence of type 2 
diabetes and insulin resistance. 
8. Improvement of the biogenesis and function of mitochondria by 
exercise and pharmaceutical agents for treatment of insulin resistance 
and type 2 diabetes 
In light of the observations of mitochondrial impairment and increased oxidative stress in 
the patients with type 2 diabetes, it has been thought that an increase of mitochondrial 
function or scavengers of ROS may be effective therapies for these patients. Biomedical 
researchers and clinicians have made considerable efforts in looking for possible ways to 
improve insulin sensitivity in target tissues through up-regulation of the mitochondrial 
function or antioxidant defense system. In this section, we provide experimental evidence to 
demonstrate increase of mitochondrial function and enhancement of the antioxidant defense 
by exercise, treatment of natural products or pharmaceutical agents that can effectively 
ameliorate the symptoms of insulin resistance and type 2 diabetes. 
8.1. Anti-diabetic drugs 
Clinically, the thiazolidinediones (TZDs) have been commonly used to treat patients with 
type 2 diabetes by increasing insulin sensitivity of the muscle and adipose tissues. These 
drugs include pioglitazone, rosiglitazone, and troglitazone, which belong to the group of 
PPAR agonists and can up-regulate the expression of PC-1, a master control of 
mitochondrial biogenesis, and a set of genes involved in the regulation of oxidative 
metabolism [77]. Recent studies revealed that these drugs not only increase insulin 
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sensitivity of cells, but also significantly improve the mitochondrial biogenesis, function and 
morphology in vitro and in vivo [78, 79]. New insights in improving mitochondrial function 
by these anti-diabetic drugs further substantiate the idea that manipulation of mitochondrial 
gene expression is a feasible therapy for the patients with insulin insensitivity or type 2 
diabetes. 
8.2. Regular exercise 
It is worth mentioning that mitochondrial biogenesis can be up-regulated by regular 
exercise through the activation of PC-1and its downstream targets including mtTFA and 
nuclear respiratory factors NRF1 and NRF2 [80, 81], which regulate the expression of a 
number of polypeptides constituting the respiratory enzyme complexes. These molecular 
events culminate in the increase of the bioenergetic function of mitochondria and thereby 
improve the insulin sensitivity of the animals or human subjects doing regular exercise [82]. 
In light of these laboratory findings and the documentation that exercise can alleviate the 
symptoms of patients with type 2 diabetes [83], we suggest that the increase of the 
biogenesis and function of mitochondria is one of the key underlying mechanisms by which 
exercise improves the insulin sensitivity of patients with type 2 diabetes.  
8.3. Natural products and chemicals 
Resveratrol (3,5,4'-trihydroxystilbene), a polyphenol and a well-known antioxidant, has 
been demonstrated to be able to promote mitochondrial biogenesis and fatty acid  
oxidation as well as insulin sensitivity in a mouse model [84]. Resveratrol treatment was 
found to lead to the decrease of PC-1 acetylation through activation of SIRT1 and thereby 
increased the activity of PC-1. In turn, an array of oxidative metabolism-related genes 
was up-regulated and mitochondrial OXPHOS was also elevated in the muscle tissues of the 
mice that had been treated with resveratrol. Moreover, resveratrol increased insulin 
sensitivity in the muscle and protected mice from obesity or insulin resistance when fed on a 
high-fat diet [40]. Additionally, epigallocatechin-3-gallate (EC), which is the most 
effective and abundant catechin in green tea, has been reported to have the antioxidant, anti-
obesity and anti-cancer activities [85]. Several studies on cultured adipocytes and animal 
models demonstrated that EC decreased intracellular levels of ROS and inhibited 
extracellular signal-related kinases (ERK) activation. Moreover, EC was found to activate 
the AMPK to elevate mitochondrial function and -oxidation of fatty acids to decrease the 
accumulation of lipids [86]. All of these downstream effects of EC would be of great use 
to improve insulin sensitivity of the target tissue cells.  
On the other hand, attention should be paid to the therapeutic potential of pyruvate in the 
treatment of diabetes. Pyruvate, an intermediate located at the key position of glucose 
metabolism, has been involved in anaerobic glycolysis and aerobic respiration. Some 
beneficial effects were reported about the administration of pyruvate to patients harboring 
with A3243 or A8344 mutation of mtDNA [87]. Pyruvate can not only improve the 
intracellular redox status by elimination of hydrogen peroxide via non-enzymatic reaction, 
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On the other hand, attention should be paid to the therapeutic potential of pyruvate in the 
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intracellular redox status by elimination of hydrogen peroxide via non-enzymatic reaction, 
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but also increases ATP production by oxidation of NADH to NAD+ by lactate 
dehydrogenease (LDH). The high level of NAD+ may also enhance the activity of SIRT3, an 
NAD+-dependent deacetylase. In addition, it was found that through the inhibition of TNF 
production and NFB signaling pathways pyruvate could ameliorate the inflammatory 
symptom of insulin resistance [88]. 
8.4. Increase of antioxidant defense  
Treatment of lipoic acid, an antioxidant, could not only decrease the intracellular ROS but 
also enhance insulin-stimulated glucose utilization in skeletal muscle of diabetic animals 
with insulin resistance. Yaworsky et al. [89] demonstrated that lipoic acid significantly 
increased insulin-stimulated glucose uptake of adipocytes through rapid translocation of 
lut1 and lut4 to the plasma membrane via the activation of insulin signaling pathway, 
which includes an increase in tyrosine phosphorylation of IR and IRS-1 as well as activation 
of PI3K and Akt. In addition to its antioxidant activity, lipoic acid was found to significantly 
increase mitochondrial biogenesis and function, including oxygen consumption rate and -
oxidation of fatty acids in adipocytes [90]. All of these effects of lipoic acid were enhanced 
by co-treatment of cells with acetyl L-carnitine (ALCAR), another mitochondrial nutrient 
[91]. These findings suggest that lipoic acid improves insulin sensitivity of adipocytes 
through its ability to elevate the antioxidant capacity and to enhance mitochondrial 
function. In addition, several studies have demonstrated that increasing antioxidant 
capacities by addition of cell- permeabilized MnSOD [29, 30] or overexpression of catalase 
[92, 93] and Px3 [94] to reduce intracellular ROS could improve insulin sensitivity in 
cultured cells or mice. Taken together, the above-mentioned observations clearly indicate 
that therapeutic agents targeting to mitochondria or antioxidant defense system could 
ameliorate the symptoms or insulin insensitivity in cultured cells and animals, and perhaps 
also in the patients. These findings also support the notion that mitochondrial function is 
essential for the maintenance of insulin sensitivity and glucose homeostasis in the human 
body. 
9. Concluding remarks 
This chapter has provided an overview of recent advances in the understanding of 
mitochondrial role in the insulin insensitivity and type 2 diabetes, including the clinical 
observations and possible mechanisms of the insulin insensitivity induced by mitochondrial 
dysfunction in the insulin-responsive tissues. Mitochondrial defects resulted from 
inheritable A3243 or A8344 mutation of mtDNA or environmental pollutants and toxins 
or dysregulated acetylation status of metabolic enzymes may lead to an overproduction of 
intracellular ROS and lipids. These events culminate in the inactivation of the insulin 
signaling pathway and result in insulin insensitivity in muscle and adipocytes. 
Improvement of insulin sensitivity and glucose homeostasis may be achieved by the 
strategy to up-regulate mitochondrial biogenesis, function and antioxidant defense through 
exercise, therapeutic agents, and dietary supplement of antioxidants or natural products 
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(Figure 1). These recent advances not only provide novel information for us to better 
understand the connection between mitochondrial dysfunction and metabolic diseases but 
also lead us to a new avenue in the prevention and treatment of type 2 diabetes or metabolic 
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1. Introduction 
The identification of DNA polymorphisms in human populations is an important step 
towards understanding the contribution of functional genetic variants to predisposition of 
diseases or clinical phenotypes. Approach to the determination of the predisposition uses 
polymorphisms as marker for a disease in an affected DNA population compared to a 
control DNA population. Subsequently, the polymorphisms statistically associated with the 
disease group may be directly informative or linked to the probable causative variant. There 
are currently over 10 million single nucleotide polymorphisms (SNPs) including 
insertion/deletion variants in public databases that potentially provide a marker set for 
disease-gene association studies. This large variant set might not represent the variants 
causative of disease because it was performed in genomes of only a limited number of 
individuals. For this reason, the discovery genetic variation in regions of functional DNA 
sequence in the genomes of individuals with disease is important for disease-gene 
association studies. However, this situation is not practicable for complex polygenic disease. 
Therefore, recently, genome-wide association (GWA) or candidate gene approaches are used 
in the understanding of the molecular genetic background of complex polygenic disease.  
Insulin resistance has a complex and heterogeneous genetic background. Insulin resistance 
is caused by the reduced ability of peripheral target tissues to respond properly to insulin 
stimulation. Insulin resistance predates beta cell dysfunction and plays the crucial role in the 
pathogenesis of type 2 diabetes. In addition, insulin resistance is considered the core factor 
in the pathogenesis of atherosclerosis and the metabolic syndrome, and is often associated 
with obesity, hypertension and also a dyslipidemic profile characterized by high plasma 
triacylglycerol concentrations and low HDL-C (Reaven, 1988; Filippi et al., 2004). Until now, 
many hypotheses have been proposed to explain the molecular mechanisms of insulin 
resistance such as insulin signaling cascade, the role of free fatty acids, adipocytokines, and 
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inflammation (Perseghin et al., 2003; Bhattacharya et al. 2007; Choi & Kim, 2010; Erion & 
Shulman, 2010; Muoio &, Newgard, 2008). Given the crucial roles of pathways in the 
pathogenesis of liver and muscle insulin resistance, understanding the molecular 
mechanism of insulin resistance is vital for the development of new and more effective 
therapies for metabolic disorders. The homeostasis model assessment (HOMA) index for 
insulin resistance was calculated as the product of fasting plasma insulin (in microunits per 
milliliter) and fasting plasma glucose (in millimoles per liter), divided by 22.5 (Matthews et 
al. 1985). Higher HOMA values indicate higher insulin resistance.  
Genetic and epidemiological studies strongly suggest that insulin resistance is, at least in 
part, genetically determined. However, the involved genes and their effective variants are 
mostly unknown. The numerous genes have been suggested as a potential candidate gene 
for insulin resistance, but the findings of these studies were controversial. This chapter is to 
provide an overview of our recent understanding of genetic predisposition to insulin 
resistance. It is aimed to summarize the results of the recent studies about the genetics of 
insulin resistance.  
2. Genes related to the lipid homeostasis 
2.1. The polymorphisms of the FABP genes  
Fatty acid-binding proteins (FABPs) are members of a superfamily of lipid-binding proteins. 
These tissue specific proteins (FABP1-4) play the physiological role in the uptake, 
intracellular metabolism and excretion of long-chain fatty acids (LCFA) (Zimmerman & 
Veerkamp, 2002). The polymorphisms of these genes have been studied in several metabolic 
phenotypes such as obesity, metabolic syndrome, hypertriglyceridemia and insulin 
sensitivity (Mansego et al. 2012). 
The liver FABP (FABP1) is an abundant cytosolic lipid-binding protein that regulates lipid 
transport and metabolism. The c.334-135G>A polymorphism (rs2197076) located in the 3 
prime untranslated region (UTR) of the FABP1 gene was associated with the risk of type 2 
diabetes and HOMA index in the Spanish population. In this study, it has been shown that 
carriers of the allele A of this polymophism had HOMA index values higher than 
homozygotes GG. However, none of the other analyzed variants in FABP2, FABP3 and 
FABP4 genes were associated with type 2 diabetes and insulin resistance in this study 
(Mansego et al. 2012). 
The intestinal FABP (FABP2) plays a key role in the absorption and intracellular transport of 
dietary LCFA (Weiss, 2002). Therefore, the FABP2 gene has been suggested as a possible 
candidate gene for type 2 diabetes and insulin resistance. In vitro experiments have shown 
that Ala54Thr polymorphism increases the affinity of FABP2 for LCFA and is associated 
with increased triglyceride transport in human intestinal cells (Baier et al., 1996; Prochazka 
et al., 1993). Previous studies have reported significant associations between the FABP2 gene 
and increased prevalence of insulin resistance (Baier et al., 1995; Mitchell et al., 1995; 
Yamada et al. 1997; Chiu et al., 2001; Kim et al., 2001) as well as no association was found in 
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Finnish individuals (Sipiläinen et al., 1997) and Spanish population (Mansego et al. 2012). 
Baier et al. reported the significant associations between the common FABP2 Ala54Thr 
polymorphism (rs1799883) and increased fasting insulin concentration, fasting fatty acid 
oxidation, and decreased insulin sensitivity in Pima Indians, a population with a high 
prevalence of obesity and type 2 diabetes (Baier et al., 1995). Furthermore, the linkage 
analysis of the FABP2 locus with insulin resistance was also found in a study in Mexican 
Americans who were of a mixed American-Indian and -European ancestry (Mitchell et al., 
1995). However, sib-pair analysis failed to detect any linkage of the FABP2 locus or the 
Ala54Thr polymorphism with diabetes-related phenotypes in other ethnic groups. The 
homozygous Thr54/Thr54 genotype has found the associations with higher fasting insulin 
levels and also TNF-α levels in 33 adult obese women (Albala et al., 2004). However, the 
findings of this study would need to be confirmed in studies involving a larger number of 
subjects. A number of conflicting and inconclusive studies have investigated the possible 
association of the FABP2 Ala54Thr polymorphism with insulin resistance. A meta-analysis 
of these published studies has suggested that the Thr54 allele of the FABP2 Ala54Thr is 
weakly associated with a higher degree of insulin resistance, higher fasting insulin and 
blood glucose level. As gender and ethnicity probably were important variables in 
determining associative risk with insulin resistance and type 2 diabetes, Zhao et al. have 
performed subgroup analyses of gender and ethnicity. These weak effects of Ala54Thr 
polymorphism on insulin resistance and fasting insulin have been particularly established in 
East Asians (Zhao et al., 2010). 
2.2. The polymorphisms of the ELOVL6 gene 
Elongase of long chain fatty acids family 6 (ELOVL6) is expressed in lipogenic tissues. This 
enzyme specifically catalyze the elongation of saturated and monounsaturated fatty acids 
with 12, 14 and 16 carbons. A population-based study has suggested that the genetic 
variations in the ELOVL6 gene are related with insulin resistance. In this study, five SNPs of 
the ELOVL6 gene and their haplotypes were analyzed. In this population from southern 
Spain, carriers of the minor alleles of the rs9997926 and rs6824447 polymorphisms had a 
lower risk of having high HOMA index, whereas carriers of the minor allele rs17041272 had 
a higher risk of being insulin resistant. Finally, Morcillo et al. has suggested that the 
ELOVL6 gene could be a future therapeutic target in the treatment of diabetes and related 
disorders (Morcillo et al., 2011). However, the validation of associations between this novel 
candidate gene and insulin resistance should be performed in different and large 
populations. 
2.3. The polymorphisms of the APOE gene 
Apolipoprotein E (ApoE) is primarily involved in plasma lipid homeostasis. However, a 
number of studies with experimental mouse models have shown that apoE also has an 
important role in the development of obesity and insulin resistance (Kypreos et al., 2009; 
Gao et al., 2007). ApoE is involved in excess fat accumulation and energy metabolism, 
including the regulation of food intake and energy expenditure. Therefore, excess fat 
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inflammation (Perseghin et al., 2003; Bhattacharya et al. 2007; Choi & Kim, 2010; Erion & 
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part, genetically determined. However, the involved genes and their effective variants are 
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These tissue specific proteins (FABP1-4) play the physiological role in the uptake, 
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sensitivity (Mansego et al. 2012). 
The liver FABP (FABP1) is an abundant cytosolic lipid-binding protein that regulates lipid 
transport and metabolism. The c.334-135G>A polymorphism (rs2197076) located in the 3 
prime untranslated region (UTR) of the FABP1 gene was associated with the risk of type 2 
diabetes and HOMA index in the Spanish population. In this study, it has been shown that 
carriers of the allele A of this polymophism had HOMA index values higher than 
homozygotes GG. However, none of the other analyzed variants in FABP2, FABP3 and 
FABP4 genes were associated with type 2 diabetes and insulin resistance in this study 
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dietary LCFA (Weiss, 2002). Therefore, the FABP2 gene has been suggested as a possible 
candidate gene for type 2 diabetes and insulin resistance. In vitro experiments have shown 
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with increased triglyceride transport in human intestinal cells (Baier et al., 1996; Prochazka 
et al., 1993). Previous studies have reported significant associations between the FABP2 gene 
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Finnish individuals (Sipiläinen et al., 1997) and Spanish population (Mansego et al. 2012). 
Baier et al. reported the significant associations between the common FABP2 Ala54Thr 
polymorphism (rs1799883) and increased fasting insulin concentration, fasting fatty acid 
oxidation, and decreased insulin sensitivity in Pima Indians, a population with a high 
prevalence of obesity and type 2 diabetes (Baier et al., 1995). Furthermore, the linkage 
analysis of the FABP2 locus with insulin resistance was also found in a study in Mexican 
Americans who were of a mixed American-Indian and -European ancestry (Mitchell et al., 
1995). However, sib-pair analysis failed to detect any linkage of the FABP2 locus or the 
Ala54Thr polymorphism with diabetes-related phenotypes in other ethnic groups. The 
homozygous Thr54/Thr54 genotype has found the associations with higher fasting insulin 
levels and also TNF-α levels in 33 adult obese women (Albala et al., 2004). However, the 
findings of this study would need to be confirmed in studies involving a larger number of 
subjects. A number of conflicting and inconclusive studies have investigated the possible 
association of the FABP2 Ala54Thr polymorphism with insulin resistance. A meta-analysis 
of these published studies has suggested that the Thr54 allele of the FABP2 Ala54Thr is 
weakly associated with a higher degree of insulin resistance, higher fasting insulin and 
blood glucose level. As gender and ethnicity probably were important variables in 
determining associative risk with insulin resistance and type 2 diabetes, Zhao et al. have 
performed subgroup analyses of gender and ethnicity. These weak effects of Ala54Thr 
polymorphism on insulin resistance and fasting insulin have been particularly established in 
East Asians (Zhao et al., 2010). 
2.2. The polymorphisms of the ELOVL6 gene 
Elongase of long chain fatty acids family 6 (ELOVL6) is expressed in lipogenic tissues. This 
enzyme specifically catalyze the elongation of saturated and monounsaturated fatty acids 
with 12, 14 and 16 carbons. A population-based study has suggested that the genetic 
variations in the ELOVL6 gene are related with insulin resistance. In this study, five SNPs of 
the ELOVL6 gene and their haplotypes were analyzed. In this population from southern 
Spain, carriers of the minor alleles of the rs9997926 and rs6824447 polymorphisms had a 
lower risk of having high HOMA index, whereas carriers of the minor allele rs17041272 had 
a higher risk of being insulin resistant. Finally, Morcillo et al. has suggested that the 
ELOVL6 gene could be a future therapeutic target in the treatment of diabetes and related 
disorders (Morcillo et al., 2011). However, the validation of associations between this novel 
candidate gene and insulin resistance should be performed in different and large 
populations. 
2.3. The polymorphisms of the APOE gene 
Apolipoprotein E (ApoE) is primarily involved in plasma lipid homeostasis. However, a 
number of studies with experimental mouse models have shown that apoE also has an 
important role in the development of obesity and insulin resistance (Kypreos et al., 2009; 
Gao et al., 2007). ApoE is involved in excess fat accumulation and energy metabolism, 
including the regulation of food intake and energy expenditure. Therefore, excess fat 
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accumulation via an apoE-dependent pathway might play a role in the development of 
insulin resistance (Kypreos et al., 2006). Some studies have suggested that the APOE 
ε2/ε3/ε4 polymorphism may modify the effect of insulin on CHD or some CHD risk factors, 
including obesity and lipid profile levels (Després et al., 1993; Valdez et al., 1995; Elosua et 
al., 2003), whereas the Framingham Offspring Study and Turkish Adult Risk Factor (TARF) 
Study found that this polymorphism was not associated with insulin resistance (Meigs et al., 
2000; Komurcu-Bayrak et al., 2011). Two other of the functional SNPs, i.e., -219G>T 
(rs405509) and +113G>C (rs440446) in APOE gene had shown association with plasma apoE 
concentrations (Lambert et al., 2000; Moreno et al., 2003), insulin resistance (Viitanen et al., 
2001), insulin sensitivity in response to a diet rich in satured fats (Moreno et al., 2005). In a 
cross-sectional study, the impacts of these polymorphisms have been analyzed on lipid, 
apolipoprotein, glucose, and serum insulin concentrations in the TARF cohort, a 
representative of Turkish adults. In this study, the -219G>T and +113G>C genotypes and 
diplotypes of haplotype 2 (TCε3) showed negative correlation to serum fasting insulin and 
the HOMA index, but not to serum lipids. The significant associations between these 
functional polymorphisms and fasting insulin levels and the HOMA index were found only 
in the apoE3 group (ε3ε3 genotypes of the APOE ε2/ε3/ε4 polymorphism) without type 2 
diabetes (Komurcu-Bayrak et al., 2011). On the other hand, a large population-based family 
study related with type 2 diabetes found a relationship for the polymorphisms of the APOE 
gene and the nearby muscle glycogen synthase (GYS1) gene on chromosome 19 with 
cardiovascular mortality, independently of each other (Fredriksson et al., 2007). Other 
functional polymorphisms in the GYS1 gene may relate to developing insulin resistance.  
3. Genes related to the energy metabolism 
3.1. The polymorphisms of the UCP genes 
Uncoupling protein 2 and 3 (UCP2 and UCP3) play an important role in human energy 
homeostasis (Brand et al., 200 4) and have been considered candidate genes for obesity, type 
2 diabetes and insulin resistance. Thus, UCP2 and UCP3 are involved in regulating ATP 
synthesis, generation of reactive oxygen species and glucose-stimulated insulin secretion by 
pancreatic β cells. The -866G>A (rs659366) polymorphism of UCP2 gene was located in a 
region with putative binding sites for two β-cell transcription factors (Dalgaard et al., 2003). 
A number of studies have been performed seeking for an association between genetic 
variants in this gene cluster with type 2 diabetes and/or insulin resistance. These studies 
have demonstrated association of the -866A-allele with increased (D’Adamo et al., 2004; 
Krempler et al., 2002; Gable et al., 2006) and decreased (Wang et al., 2004; Bulotta et al., 2005; 
Lyssenko et al., 2005; Rai et al., 2007) risk of type 2 diabetes as well as no association at all 
(Kovacs et al., 2005; Reis et al., 2004; Zee et al., 2011). Finally, the two recent meta-analysis 
on the association of type 2 diabetes with -866G>A polymorphism concluded that this 
variant does not confer increased risk of type 2 diabetes (Xu et al., 2011; 40, Andersen et al., 
2012). However, Andersen et al has found an association between this variant and obesity in 
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Danish individuals and established case-control studies. This study has shown that the -
866G-allele was associated with elevated fasting serum insulin levels and insulin resistance 
(HOMA index) and decreased insulin sensitivity in Danish subjects (Andersen et al., 2012). 
Furthermore, in a study performed with a Spanish group of 193 obese children and 
adolescents and 170 controls, Ochoa et al. reported that the -55C>T (rs1800849) 
polymorphism of the UCP3 gene directly associated with higher fasting insulin levels and 
insulin resistance in heterozygous subjects from the control group. In addition, they found 
that the individual polymorphisms were not associated with obesity, but the (-866G) - (Del; 
45 bp) - (-55T) haplotype was significantly associated with obesity and its presence in the 
control group increased about nine times the insulin resistance risk (Ochoa et al., 2007). 
Recently, a study has demonstrated that morbidly obese patients with –55CT genotype 
(n=15) had higher weight, fat mass, and insulin resistance (HOMA index) than the 
individuals with −55CC genotype (n=32) (de Luis Roman et al., 2010). 
3.2. The polymorphisms of the ADRB genes 
β-adrenoceptors (ADRB1, ADRB2, ADRB3) in the sympathetic nervous system play a role in 
regulating energy expenditure and lipolysis. ADRBs gene variation is an intense area of 
investigation because β-adrenoceptors are well described in organ system distribution, 
catecholamine-mediated physiological processes, disease states and treatment targets 
(Eisenach & Wittwer, 2010). One of the most studied polymorphism (rs1801253) in the 
ADRB1 gene encode for arginine or glycine in amino acid 389 (Arg389Gly).  In 238 healthy 
young Caucasians and African-Americans, Gly389 carriers had a higher level of insulin and 
insulin resistance than non-carriers, and this allele was more prevalent in the subjects with 
higher body mass index (BMI; Lima et al. 2007). In previous studies, it has been found that 
this polymorphism was associated with serum insulin levels and insulin resistance (HOMA 
index) but, no association with obesity among Swedish women (Mottagui-Tabar et al., 2008). 
However, there are limited number of studies evaluating the association between these 
genes and insulin resistance. In larger scale studies with different populations should be 
performed for these genes to support the association between genotype and phenotype. 
4. Genes encoding hormones and hormone receptors  
4.1. The polymorphisms of the APM1, ADIPOR1, and ADIPOR2 genes 
Adiponection is an adipokine secreted by adipocytes. The polymorphisms in adiponectin 
(APM1,ADIPOQ, ACRP30) gene, and its receptors (ADIPOR1 and ADIPOR2) are strongly 
associated with metabolic syndrome, obesity, type 2 diabetes and, insulin resistance. High 
adiponectin predicts increased insulin sensitivity (Tschritter et al. 2003). There is evidence 
indicating that insulin directly affects plasma adiponectin (Möhlig et al., 2002; Hung et al., 
2008; Brame et al., 2005). In recent studies, plasma adiponectin concentrations were 
reduced in type 2 diabetes and obesity (Arita et al., 1999; Lindsay et al. 2002; Spranger et 
al., 2003). Furthermore, administration of thiazolidinediones (TZD), an insulin-sensitising 
class of drugs, to insulin-resistant subjects significantly increased the plasma adiponectin 
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accumulation via an apoE-dependent pathway might play a role in the development of 
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apolipoprotein, glucose, and serum insulin concentrations in the TARF cohort, a 
representative of Turkish adults. In this study, the -219G>T and +113G>C genotypes and 
diplotypes of haplotype 2 (TCε3) showed negative correlation to serum fasting insulin and 
the HOMA index, but not to serum lipids. The significant associations between these 
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Danish individuals and established case-control studies. This study has shown that the -
866G-allele was associated with elevated fasting serum insulin levels and insulin resistance 
(HOMA index) and decreased insulin sensitivity in Danish subjects (Andersen et al., 2012). 
Furthermore, in a study performed with a Spanish group of 193 obese children and 
adolescents and 170 controls, Ochoa et al. reported that the -55C>T (rs1800849) 
polymorphism of the UCP3 gene directly associated with higher fasting insulin levels and 
insulin resistance in heterozygous subjects from the control group. In addition, they found 
that the individual polymorphisms were not associated with obesity, but the (-866G) - (Del; 
45 bp) - (-55T) haplotype was significantly associated with obesity and its presence in the 
control group increased about nine times the insulin resistance risk (Ochoa et al., 2007). 
Recently, a study has demonstrated that morbidly obese patients with –55CT genotype 
(n=15) had higher weight, fat mass, and insulin resistance (HOMA index) than the 
individuals with −55CC genotype (n=32) (de Luis Roman et al., 2010). 
3.2. The polymorphisms of the ADRB genes 
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insulin resistance than non-carriers, and this allele was more prevalent in the subjects with 
higher body mass index (BMI; Lima et al. 2007). In previous studies, it has been found that 
this polymorphism was associated with serum insulin levels and insulin resistance (HOMA 
index) but, no association with obesity among Swedish women (Mottagui-Tabar et al., 2008). 
However, there are limited number of studies evaluating the association between these 
genes and insulin resistance. In larger scale studies with different populations should be 
performed for these genes to support the association between genotype and phenotype. 
4. Genes encoding hormones and hormone receptors  
4.1. The polymorphisms of the APM1, ADIPOR1, and ADIPOR2 genes 
Adiponection is an adipokine secreted by adipocytes. The polymorphisms in adiponectin 
(APM1,ADIPOQ, ACRP30) gene, and its receptors (ADIPOR1 and ADIPOR2) are strongly 
associated with metabolic syndrome, obesity, type 2 diabetes and, insulin resistance. High 
adiponectin predicts increased insulin sensitivity (Tschritter et al. 2003). There is evidence 
indicating that insulin directly affects plasma adiponectin (Möhlig et al., 2002; Hung et al., 
2008; Brame et al., 2005). In recent studies, plasma adiponectin concentrations were 
reduced in type 2 diabetes and obesity (Arita et al., 1999; Lindsay et al. 2002; Spranger et 
al., 2003). Furthermore, administration of thiazolidinediones (TZD), an insulin-sensitising 
class of drugs, to insulin-resistant subjects significantly increased the plasma adiponectin 
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levels, and this effect was correlated with the amelioration of insulin resistance in these 
subjects (Maeda et al., 2001). Many studies have, in fact, reported the association between 
polymorphisms of the APM1, ADIPOR1, and ADIPOR2 and adiponectin concentrations, 
insulin resistance, type 2 diabetes and metabolic syndrome phenotypes (Kondo et al., 
2002; Hara et al., 2002; Menzaghi et al., 2002; Stumvoll et al., 2002; Hivert et al., 2008; 
Menzaghi et al.,2007; Sheng et al., 2008; Ferguson et al., 2010). While, in the study from 
Stumvoll et al, the +45T>G (rs2241766) polymorphism was associated with obesity and 
derangement of insulin sensitivity (Stumvoll et al., 2002), in the study from Melistas et al, 
this polymorphism was associated with lower insulin levels in Greek women without 
diabetes (Melistas et al., 2009). In a study from Menzaghi et al, a haplotype of the 
adiponectin gene was associated with several features of insulin resistance in nondiabetic 
individuals, including low serum adiponectin levels (Menzaghi et al., 2002). In addition, 
the +276G>T (rs1501299) polymorphism in the adiponectin gene was associated with 
higher insulin levels and insulin resistance (HOMA index) in Italian population from the 
Lazio region (diabetes and/or the metabolic syndrome was excluded) (Filippi et al., 2004) 
and in Greek female population without diabetes (Melistas et al., 2009). The association of 
the -11391G>A (rs17300539) polymorphism with plasma insulin and HOMA index was 
independent of plasma adiponectin in another study, which implies a direct effect of this 
polymorphism on plasma insulin and insulin sensitivity (Henneman et al., 2010).  
Recently, Vasseur et al have reported on the association of a haplotype G-G (including -
11391G>A and -11377C>G polymorphisms located in the APM1 proximal promoter) with 
plasma adiponectin levels and type 2 diabetes, although no association with HOMA index 
was observed (Vasseur et al., 2002). The reasons for partially discrepant results between 
polymorphisms in these genes and metabolic measures could be due to the different 
genetic background of the studied populations or environmental interactions, particularly 
dietary factors. Gene-nutrient interactions can modulate in the development of metabolic 
phenotypes. Although, so far, there has been little focus on gene-nutrient interactions 
with adiponectin and its receptors, two studies found that there was an interaction 
between the rs266729 polymorphism of APM1 and the percentage of dietary-derived 
energy from fat with the development of obesity in women (Santos et al., 2006) and an 
association between this polymorphism and also the rs10920533 polymorphism of 
ADIPOR1 and plasma saturated fatty acids with the insulin resistance (Ferguson et al., 
2010). 
4.2. The polymorphisms of the D2 and TSHR genes 
Thyroid hormones are known to upregulate the expression of glucose transporter type 4 
(GLUT4) in skeletal muscle, and consequently increase glucose uptake (Weinstein et al., 
1994). Thyroxine (T4), a major secretory product of the thyroid gland, needs to be 
converted to triiodothyronine (T3) to exert its biological activity. Type 2 deiodinase (D2) 
catalyzes T4 to T3 conversion, and plays a critical role in maintaining intracellular T3 
levels in specialized tissues, such as the anterior pituitary and brown adipose tissue 
(Bianco et al., 2005). Thr92Ala polymorphism of D2 gene showed an association with 
lower glucose disposal rate in nondiabetic subjects and also a higher prevalence of insulin 
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resistance in Pima Indians and Mexican–Americans (Mentuccia et al., 2002). Furthermore, 
D2 Ala/Ala genotype was also associated in previous studies with increased insulin levels 
and increased insulin resistance (increased HOMA index) and also worse glycemic control 
(increased HbA1c levels) in a cohort of patients with type 2 diabetes (Grozovsky et al., 
2009; Dora et al., 2010). In addition, this polymorphism was associated with greater 
insulin resistance in type 2 diabetes patients and with lower enzyme activity in thyroid 
tissue samples (Canani et al., 2005). However, some population-based studies failed to 
demonstrate an association between the D2 Thr92Ala polymorphism and increased risk 
for type 2 diabetes (Mentuccia et al., 2005; Maia et al., 2007; Grarup et al. 2007). Thyroid 
hormone interacts with the TSH receptor (TSHR) in the thyroid gland. A previous study 
has investigated the association between serum thyroid parameters and the TSHR 
Asp727Glu polymorphism in nondiabetic elderly men. Peeters et al. reported that this 
polymorphism was associated with relative insulin resistance. Carriers of the Glu727 
allele had also a significantly higher glucose, insulin, HOMA index and leptin levels, but 
no association with serum TSH levels (Peeters et al., 2007). Peeters et al. have suggested 
that this association was studied in one cohort only, and as the mechanism remains to be 
elucidated, replication of results in an independent cohort (of healthy elderly subjects) 
was essential. 
4.3. The polymorphisms of the SHBG gene 
Some studies have suggested that the polymorphisms in genes encoding sex hormones may 
be effective on the development of insulin resistance. Previous studies have shown that 
androgen supplementation in the presence of central obesity and low testosterone levels 
increases insulin sensitivity in men (Mårin et al., 1992; Simon et al., 2001; Boyanov et al., 
2003). Moreover, polycystic ovarian syndrome was associated with higher risk of type 2 
diabetes and insulin resistance in women (Dunaif, 1995). Recent studies have demonstrated 
that higher levels of circulating sex hormone binding protein (SHBG) were associated with 
reduce risk of type 2 diabetes (Ding et al., 2009; Perry et al., 2010). In addition, rs6259, rs6257 
and rs1799941 polymorphisms in the SHBG gene were strongly associated with SHBG levels 
and type 2 diabetes (Zeggini et al., 2008; Perry et al., 2010). However, there was no evidence 
that this variant is associated with diabetes-related intermediate traits, including several 
measures of insulin secretion and resistance (Perry et al., 2010). 
4.4. The polymorphisms of the LEP and LEPR genes 
Leptin (LEP), a hormone secreted by adipocytes, and its receptor (LEPR) are other candidate 
genes for insulin resistance.  Common variants in the LEPR gene have been associated with 
hyperinsulinemia (Lakka et al., 2000; Wauters et al., 2002), type 2 diabetes (Lakka et al., 
2000), obesity, and leptin levels (Chagnon et al., 1999; Chagnon et al., 2000; Chagnon et al., 
2001; de Luis Roman et al., 2006). However, the roles of leptin and its receptor in the 
development of metabolic traits in the general population are less clear. A few studies have, 
in fact, reported the association between polymorphisms of the LEP and LEPR genes and 
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1994). Thyroxine (T4), a major secretory product of the thyroid gland, needs to be 
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(Bianco et al., 2005). Thr92Ala polymorphism of D2 gene showed an association with 
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resistance in Pima Indians and Mexican–Americans (Mentuccia et al., 2002). Furthermore, 
D2 Ala/Ala genotype was also associated in previous studies with increased insulin levels 
and increased insulin resistance (increased HOMA index) and also worse glycemic control 
(increased HbA1c levels) in a cohort of patients with type 2 diabetes (Grozovsky et al., 
2009; Dora et al., 2010). In addition, this polymorphism was associated with greater 
insulin resistance in type 2 diabetes patients and with lower enzyme activity in thyroid 
tissue samples (Canani et al., 2005). However, some population-based studies failed to 
demonstrate an association between the D2 Thr92Ala polymorphism and increased risk 
for type 2 diabetes (Mentuccia et al., 2005; Maia et al., 2007; Grarup et al. 2007). Thyroid 
hormone interacts with the TSH receptor (TSHR) in the thyroid gland. A previous study 
has investigated the association between serum thyroid parameters and the TSHR 
Asp727Glu polymorphism in nondiabetic elderly men. Peeters et al. reported that this 
polymorphism was associated with relative insulin resistance. Carriers of the Glu727 
allele had also a significantly higher glucose, insulin, HOMA index and leptin levels, but 
no association with serum TSH levels (Peeters et al., 2007). Peeters et al. have suggested 
that this association was studied in one cohort only, and as the mechanism remains to be 
elucidated, replication of results in an independent cohort (of healthy elderly subjects) 
was essential. 
4.3. The polymorphisms of the SHBG gene 
Some studies have suggested that the polymorphisms in genes encoding sex hormones may 
be effective on the development of insulin resistance. Previous studies have shown that 
androgen supplementation in the presence of central obesity and low testosterone levels 
increases insulin sensitivity in men (Mårin et al., 1992; Simon et al., 2001; Boyanov et al., 
2003). Moreover, polycystic ovarian syndrome was associated with higher risk of type 2 
diabetes and insulin resistance in women (Dunaif, 1995). Recent studies have demonstrated 
that higher levels of circulating sex hormone binding protein (SHBG) were associated with 
reduce risk of type 2 diabetes (Ding et al., 2009; Perry et al., 2010). In addition, rs6259, rs6257 
and rs1799941 polymorphisms in the SHBG gene were strongly associated with SHBG levels 
and type 2 diabetes (Zeggini et al., 2008; Perry et al., 2010). However, there was no evidence 
that this variant is associated with diabetes-related intermediate traits, including several 
measures of insulin secretion and resistance (Perry et al., 2010). 
4.4. The polymorphisms of the LEP and LEPR genes 
Leptin (LEP), a hormone secreted by adipocytes, and its receptor (LEPR) are other candidate 
genes for insulin resistance.  Common variants in the LEPR gene have been associated with 
hyperinsulinemia (Lakka et al., 2000; Wauters et al., 2002), type 2 diabetes (Lakka et al., 
2000), obesity, and leptin levels (Chagnon et al., 1999; Chagnon et al., 2000; Chagnon et al., 
2001; de Luis Roman et al., 2006). However, the roles of leptin and its receptor in the 
development of metabolic traits in the general population are less clear. A few studies have, 
in fact, reported the association between polymorphisms of the LEP and LEPR genes and 
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insulin resistance (Wauters et al., 2001; de Luis et al., 2008; Gu et al., 2012; Takahashi-Yasuno 
et al., 2004; Ren et al., 2004). While, in the study from Wauters et al, Lys109Arg, Gln223Arg, 
and Lys656Asn polymorphisms in LEPR gene were associated with insulin and glucose 
metabolism in postmenopausal obese women with impaired glucose homeostasis (Wauters 
et al., 2001), in the study from de Luis et al, Lys656Asn polymorphism was associated with 
higher levels of insulin, HOMA, and leptin in men without diabetes (de Luis et al., 2008) , in 
the study from Gu et al, Lys109Arg was associated with waist-to-hip ratio, oral glucose 
tolerance test (OGTT)-2h glucose, and HOMA index in Chinese subjects with essential 
hypertension, but no correlation between Lys109Arg polymorphism and hypertension were 
found (Gu et al., 2012). Also’ -2549C>A polymorphism in the promoter region of the LEP 
gene is related to fasting plasma leptin level (Mammès et al., 1998; Le Stunff et al., 2000; Gu 
et al., 2012), obesity phenotypes (Mammès et al., 1998; Mammès et al., 2000; Le Stunff et al., 
2000), and also fasting serum insulin level and HOMA index in Chinese patient with type 2 
diabetes (Ren et al., 2004).  However, the findings of the study from Ren et al. should be 
confirmed with studies involving larger number of subjects and different populations. 
4.5. The polymorphisms of the RBP4 gene 
Retinol-binding protein 4 (RBP4) is an adipokine with potential contribution to systemic 
insulin resistance (Yang et al., 2005).  The -803G>A promoter polymorphism (rs3758539) of 
RBP4 gene is associated with increased risk for obesity and type 2 diabetes in adults 
(Munkhtulga et al., 2010 ; Munkhtulga et al., 2007; van Hoek et al., 2008). Munkhtulga et al. 
have reported in 2010 that the -803A allele of this polymorphism was associated with higher 
BMI in Japanese men and women and in Mongolian women (Munkhtulga et al., 2010) and 
also in 2007 they found that the rare alleles of four SNPs (-803G>A, +5169C>T, +6969G>C, 
+7542T>del) were associated with increased risk of diabetes in Mongolian case-control study 
(Munkhtulga et al., 2007). van Hoek et al. have shown that homozygosity for the −803A 
allele was associated with increased risk of type 2 diabetes in the Rotterdam population (van 
Hoek et al., 2008). More recent studies failed to confirm an association of this variant with 
circulating RBP4 levels, type 2 diabetes susceptibility, adiposity or metabolic parameters 
(Friebe et al., 2011; Kovacs et al., 2007; Shea et al., 2010; Wu et al., 2009; Craig et al., 2007). 
Shea et al. have analyzed five SNPs including -803G>A polymorphism within RBP4 gene 
and they have found a significant association between the minor allele of rs10882280 (C>A 
intron) and rs11187545 (A>G intron) polymorphisms and higher serum HDL-C levels in 
Newfoundland population, but not between insulin resistance and any polymorphism (Shea 
et al., 2010). Craig et al. have found that only a haplotype (-804G, 390G, 406T, 759G, 6969G, 
9476T, 10670G, and 11881C) in RBP4 gene showed an association with type 2 diabetes in 
African Americans and Caucasians. Furthermore, -803G>A and +9476T>G (rs34571439) 
polymorphisms were associated with reduced insulin secretion, and +390C>G (novel) with 
reduced insulin sensitivity in Caucasians (Craig et al., 2007). The discrepancy among 
previous publications about insulin resistance may be resolved by analyzing a larger 
number of samples. 
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4.6. The polymorphisms of the RETN gene 
Resistin (RETN), a hormone secreted by adipocytes, has been examined as candidate gene 
for obesity and type 2 diabetes and insulin resistance.  However, there are many conflicting 
findings about these metabolic phenotypes. Osawa et al. have reported that the GG 
genotype of RETN -420C>G promoter polymorphism (rs1862513), increased type 2 diabetes 
susceptibility (Osawa et al., 2004) and fasting plasma resistin (Osawa et al., 2007; Azuma et 
al., 2004) in the Japanese population. Silha et al. and Osawa et al. have found correlation 
between resistin levels and insulin resistance (Silha et al.,2003; Osawa et al., 2007), but not 
Lee et al. (Lee et al., 2003). Some genetic association studies have found an association 
between certain resistin gene variants and insulin resistance in Finnish nondiabetic 
individuals (Conneely et al., 2004), in nondiabetic Caucasians from Sicily and Gargano areas 
of Italy (Pizzuti et al., 2002), and in 20 nondiabetic Caucasians (Wang et al., 2002), while 
others report no such association in 60 Japanese obese nondiabetic individuals (Azuma et 
al., 2004) and  in 258 families with 323 affected with polycystic ovary syndrome offspring 
(Urbanek et al., 2003). These conflicting findings have made it difficult to determine a role 
for resistin in insulin resistance. The reasons for discrepant results are not known, and may 
reside in the different genetic background of the studied populations or the different-
designed studies. 
5. Genes related to the renin-angiotensin system 
The renin-angiotensin system (RAS) plays a central role in the regulation of insulin 
sensitivity (Reaven, 1995; Higashiura et al., 2000; Ura et al., 1999). Many studies have 
examined the genetic effect of homozygous deletion polymorphism (DD) in exon 16 of the 
angiotensin-converting enzyme gene (ACE) in insulin resistance, but their results have been 
controversial (Katsuya et al., 1995; Perticone et al., 2001; Yamamoto et al., 1999). 
Hypertension is related to insulin resistance and a number of studies have reported an 
association between RAS gene polymorphisms and hypertension (Sugimoto et al. 2004; Jin et 
al., 2003; Kikuya et al., 2003; Ono et al., 2003). Akasaka et al., 2006; The insertion/deletion 
(I/D) polymorphism of the angiotensin-converting enzyme gene (ACE), the Met235Thr 
polymorphism of the angiotensinogen gene (AGT), and the 1166A>C polymorphism of the 
angiotensin II type 1 receptor gene (AGTR1) were not associated with HOMA index, 
whereas borderline association was found between the 1166A>C polymorphism and 
dichotomous categorization of insulin resistance (defined as HOMA index ≥1.73). However, 
further studies are required to confirm the impact of these candidate gene polymorphisms 
in the larger and different populations. 
6. Genes related to the inflammation  
6.1. The polymorphisms of the TNF-α gene  
Tumor necrosis factor alpha (TNF-α) is a multifunctional proinflammatory cytokine and 
also an adipokine produced in adipocytes. Increased levels of the TNF-α have been shown 
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to elevate the risk of insulin resistance by impairing β cell function and glucose homeostasis 
(Hotamisligil et al., 1993; Hotamisligil et al., 1994; Katsuki et al., 1998). In addition, the TNF-
α affects lipid metabolism and may lead to hypertriglyceridemia by decreasing hepatic 
lipoprotein lipase activity and by increasing hepatic de novo fatty acid synthesis (Zinman et 
al., 1999). Circulating levels of TNF-α have also been reported to correlate with insulin 
resistance and type 2 diabetes (Hotamisligil & Spiegelman, 1994; Hu et al., 2004). Previous 
studies have shown that TNF-α -308G>A polymorphism is associated with insulin resistance 
(Fernandez-Real et al., 1997), obesity (Hoffstedt et al., 2000), type 2 diabetes (Vendrell et al., 
2003; Kubaszek et al., 2003) and metabolic syndrome (Gupta et al., 2012). However, many 
other studies have reported conflicting results, with no association between this variant and 
insulin resistance (Gupta et al., 2012; Ranjith et al., 2008). A meta-analysis of many published 
studies including different populations has suggested that -308A TNF-α gene variant is 
associated with increased risk of developing obesity compared with controls and 
significantly higher systolic arterial blood pressure and plasma insulin levels (Sookoian et 
al., 2005). On the other hand, another recent meta-analyses has reported that TNF-α -
238G>A and -308G>A polymorphisms were not associated with type 2 diabetes mellitus; 
however, -308G>A polymorphism was positively associated with type 1 diabetes (Feng et 
al., 2009a; Feng et al., 2009b; Feng et al., 2011). TNF-α -857C>T polymorphism is also 
associated with obese type 2 diabetes (Kamizono et al. 2000) and insulin resistance in 
Japanese diabetic subjects with adiponectin +276GG genotype (Ohara et al., 2012). The study 
of Ohara et al has shown interaction of TNF-α and adiponectin genes with insulin resistance 
and fatty liver (Ohara et al., 2012). 
6.2. The polymorphisms of the IL-6 gene 
Interleukin-6 (IL-6) is a proinflammatory cytokine that is associated with type 2 diabetes and 
insulin resistance (Di Renzo et al., 2008; Wannamethee et al., 2007; Hu et al., 2004). Recent 
studies has demonstrated that the association between -174G>C polymorphism (rs1800795) 
in the promoter region of the IL-6 gene and insulin resistance is modified by body mass 
index (BMI), with the -174C allele associated with higher insulin resistance and type 2 
diabetes in individuals with obesity (Herbert et al., 2006; Mohlig et al., 2004; Goyenechea et 
al., 2007; Di Renzo et al., 2008; Underwood et al., 2012). However, in meta-analysis including 
5383 diabetes cases and 12 069 controls, it has been found that -174G>C polymorphism was 
not associated with the risk of type 2 diabetes (Qi et al., 2006). The reasons underlying the 
discrepancy among studies are unclear. Other genetic or environmental factors may play 
important roles in modulating the relationships. 
7. Conclusion 
The insulin resistance is highly heritable and originates from the interactions of multiple 
genes and environmental factors. Figure 1 shows the main factors contributing to the 
development of insulin resistance and type 2 diabetes. However, the molecular mechanism 
of insulin resistance is not clear yet. Until now, goal of many studies was to use a candidate 
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gene approach to identify genes associated with insulin resistance and several genes have 
been investigated in many association-based studies. However, most of the time, results of 
these studies reveal conflicting findings. These discrepant results might be due to 
differences in the study populations and design of these studies. In addition, the candidate 
gene polymorphisms have been searched in a number of small-scale studies with variable 
results. Limited number meta-analyses have been done to demonstrate the effect of several 
candidate gene polymorphisms on insulin resistance. But, the larger, well-characterized and 
independent association studies will be needed. On the other hand, the use of genome-wide 
association (GWA) studies will identify novel polymorphisms related to insulin resistance. 
This knowledge will allow the determination of the genetic predisposition to the insulin 
resistance and new approaches to treatment and prevention of the clinical phenotypes such 
as type 2 diabetes, obesity, hypertension and metabolic syndrome. 
 
Figure 1. General overview of genetic and environmental factors contributing to the development of 
insulin resistance and type 2 diabetes. The combination of genetic predisposition (genetic 
polymorphisms effecting free fatty acid metabolism, insulin signalling, adipokines and cytokines) and 
some environmental factors such as excessive dietary intake and physical inactivity results with the 
occurrence of adipocytogenesis, lipodystrophy and obesity which increase the development risk of 
insulin resistance. Insulin resistance predates pancreatic beta cell dysfunction and plays the crucial role 
in the pathogenesis of type 2 diabetes. 
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1. Introduction 
The acknowledgment of the metabolic syndrome (MetS) as a pathological entity is one of the 
most important advancements in the management of cardiovascular disease in the last 2 
decades. Increasing awareness and research of this syndrome has led to a deeper 
understanding of how different metabolic risk factors such as inflammation, insulin 
resistance and vascular pathologies such as coronary heart disease (CHD) interact and 
aggravate one another. The existence of MetS may imply uniformity in pathology across a 
range of populations. However, this is not the case: the mechanisms that underlie MetS and 
the cardiometabolic consequences they hold may very well vary between ethnicities. The 
following chapter aims to encompass MetS from its most fundamental principles with a 
focus on inflammation and insulin resistance to the novel research pertaining to its 
pathophysiology and management, with an emphatic eye on the Hispanic population. 
2. Metabolic syndrome in Hispanics 
The inner workings of MetS have yet to be fully elucidated; thus it remains difficult to 
evaluate how they differ between specific ethnic populations. Nevertheless, it remains a 
possibility that the processes involved in the syndrome, such as insulin resistance and 
inflammation, differ in degree and function with relation to Hispanic compared to non- 
Hispanic populations. It has been a recurring theme that the interactions between poor 
nutritional status, physical inactivity, and genetic predisposition might contribute to the 
disparities in the prevalence and characteristics of MetS and its components between 
ethnicities and the subgroups within; this subject has been studied to the extent that even 
the diagnostic criteria for MetS established by the AHA/NHLBI were challenged when 
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adapted to a specific Andean population[1]. Moreover, researchers have found that a single 
DNA variation in the form of a guanine base pair on a gene already linked to a higher risk of 
Coronary Heart Disease (CHD) in other races confers a fivefold reduction in risk in African-
Americans[2]. Lately, research has uncovered mutations in the Brain-derived neurotrophic 
factor (BDNF) gene, or Bdnf gene, which result in human obesity[58]. Mice having a truncated 
long Bdnf 3′ UTR genetic transcript developed severe hyperphagic obesity. In these mice, the 
ability of the adipocytokine leptin to activate hypothalamic neurons and inhibit food intake 
was compromised despite normal activation of leptin receptors. All these studies, whether 
they involve humans or mice, provide a window into a genetic basis for MetS. 
Despite the obvious limits of studying a population that does not represent the entire 
Hispanic world, investigations exploring cardiovascular disease and MetS in Puerto Ricans 
provide invaluable information in understanding the interrelationship between genetics, 
environment and culture in the modification of cardiovascular health. Previous data support 
the fact that, given the same cardiovascular risk factors, Puerto Rico has a lower prevalence 
of CHD than other fully industrialized countries such as the United States[3]; however, the 
validity of these data may not be as strong today as when published nearly 3 decades ago: 
recent epidemiologic data show that, although mortality from CHD and stroke has been 
steadily decreasing in the United States in the past 4 decades, it has been increasing in 
Puerto Rico[4]. On the other hand, a recent investigation that examined the medical records 
of 173 patients with MetS who received treatment in the Cardiovascular Center of Puerto 
Rico and the Caribbean showed that these patients were devoid of aggressive CHD, 
meaning less ventricular tachycardia, less myocardial infarctions and less strokes, and had a 
relatively normal lipid profile (except for a mild elevation in serum triglycerides)[5], 
supporting the notion that island-based Puerto Ricans acquire a milder form of MetS than 
mainland populations (this notion extends to Hispanics and Caucasians living in the 
continental U.S.).[6] Furthermore, several investigators have reported that the incidence of 
ventricular tachycardia, a complication caused by remodeling and ischemia of the heart, is 
lower in Puerto Rico than in the United States[7], even when adjusting for a higher 
prevalence of MetS in Puerto Rico[8]. Interestingly, the number of cases recorded in this 
study showed an increased incidence of atrial fibrillation[9]; this may be thought to be a 
result of differential remodelling of the left ventricle and atrial function between ethnicities. 
In addition, the prevalence of CHD is lower in Puerto Rico than in the United States, despite 
a higher incidence of Diabetes Mellitus in the island than in the U.S. (16% vs. 8%)[10]. 
Nonetheless, the prevalence of CHD in Puerto Rico is increasing: In the 1980s, it was 50% 
lower than in the United States; it is only 20% lower today[10]. This is most likely due to 
external factors such as the increasingly unhealthy diet and sedentary lifestyle of many of 
the island’s inhabitants. 
3. Importance of the Renin-Angiotensin System (RAS) 
The RAS is a complicated and essential system in the regulation of vascular homeostasis. 
Angiotensin II (AngII) is cleaved from angiotensin I (AngI) by angiotensin converting 
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enzyme (ACE), which is localized on the surface of endothelial cells and in the media and 
adventia of the aorta[11]; a soluble form of ACE is also found in plasma. AngI is formed from 
angiotensinogen, which is secreted from the liver and cleaved by renin, which in turn is 
found in the juxta-glomerular cells in the kidney[12]. The traditional RAS inhibitors, 
angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor 
blockers (ARBs), target the main RAS axis described above. However, there are additional 
enzymes associated with the production of AngII, such as by Cathepsin G[13], as well as 
other, more novel angiotensin molecules that serve as potential therapeutic targets: the 
ACE2/Ang-(1–9) axis is a new and important pathway to compensate for the 
vasoconstrictive and hyperproliferative RAS axis. A direct mechanism implicated in the 
production of these distinctive angiontensin molecules involves ACE2[14], a novel 
component of the RAS that converts AngI to Ang-(1-9) and AngII to Ang-(1-7), a peptide 
with vasodilator and anti-proliferative properties. The induction of ACE2 not only holds 
therapeutic promise by producing the anti-inflammatory Ang-(1-7), but also by reducing 
AngII levels, thereby conferring a twofold protection against cardiovascular remodeling 
from ongoing hypertension and inflammation. 
Concomitant to the progression of the RAS, hyperglycemia promotes the deposition of 
advanced glycation end products (AGEs) that are formed from the non-enzymatic glycation 
of proteins and lipids after contact with reducing sugars[15]. The accumulation of AGEs is an 
important factor in the development and progression of vascular injury in diabetes-
associated atherosclerosis. Both hyperglycemia and induction of the main RAS axis will 
increase oxidative stress and increase the rate of the atherosclerotic process that ultimately 
end in apoptosis and necrosis of myocytes[16, 17], hence propagating the deleterious effects of 
inflammation, insulin resistance and endothelial dysfunction. 
The inhibition of the RAS by ACE inhibitors and ARBs has been mainstay therapy to reduce 
the onset and/or progression of hypertension, left ventricular dysfunction, diabetic renal 
disease and atherosclerosis. For example, inhibitors of the RAS seem to be more effective 
than other medications in halting the progression of dilated cardiomyopathy in hamsters 
that have an inherited mutation that predisposes to such a disease[18]. In rodents, 
pharmacological or genetic disruption of RAS action prevents weight-gain, promotes insulin 
sensitivity and relieves hypertension[19], suggesting that ACE inhibitors or ARBs may 
present an effective treatment for MetS in humans. In addition, when obese individuals lose 
weight, both adipose tissue mass and systemic RAS activity are reduced[20,21]. An increase in 
adipose tissue angiotensinogen has been reported in diet-induced obesity[22,23]: further 
evidence that lifestyle changes are integral to targeting the underlying mechanisms of MetS.  
4. Inflammation and insulin resistance 
Systemic inflammation[24-25] is a fundamental process in the development of cardiovascular 
disease in patients with MetS, and this process starts with the activation of the neuro-
hormonal system; we have data that shows elevated intra-coronary levels of AngII and 
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endothelin I (EI) in some patients with Diabetes Mellitus Type 2 (DMT2). We measured 
these peptides in 5 patients with DMT2 and concomitant MetS, normal coronary arteries 
and sub-normal ejection fraction (49 ± 5%), and discovered that the levels of AngII and EI 
were elevated in the coronary sinus (coronary efflux) and aorta of these patients when 
compared to the control group, which consisted of 5 patients with DMT2 but without MetS 
that were catheterized and found to have normal coronary arteries and a normal ejection 
fraction[26]. In the former, MetS group, AngII levels inside the coronary sinus and aorta were 
46 ± 18 and 35 ± 15 pg/ml, respectively, while AngII levels were 10 ± 2 pg/ml inside both 
chambers of the control group (P < 0.001). Furthermore, in the group with MetS, the EI levels 
inside the coronary sinus and aorta were elevated at 14 ± 4 and 13 ± 6 pg/ml in both 
chambers, respectively, compared to 3 ± 1 pg/ml inside both chambers of the control group 
(P < 0.001).  
This elevation of AngII and EI will activate angiotensin II receptor type 1 (AT1) and produce 
inflammatory cytokines, increase macrophage chemo-attractants and activate reactive 
oxygen species that produce oxidative stress in myocytes and smooth muscle cells[27]. This 
will not only induce the apoptosis and necrosis of myocytes, but also promote the 
proliferation and migration of smooth muscle cells, resulting in the atherosclerotic lesions 
that increase the incidence of myocardial infarcts[28]. Likewise, AngII, acting via angiotensin 
II receptor type 2 (AT2), has potent pro-inflammatory, pro-oxidant and pro-thrombotic 
effects[29]. Moreover, it has been shown that infusion of AngII in rats increases serum levels 
of AGEs. The oxidative and apoptotic effects of both hyperglycemia and AngII are most 
likely key in inducing diabetic cardiomyopathy[27,28], which explains why our patients with 
MetS have a subnormal ejection fraction, as opposed to the patients without MetS who have 
a normal ejection fraction, despite normal coronary arteries in both groups.  
Omega-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (OHA) have also been 
shown to be anti-inflammatory; they are enzymatically converted to resolvins, which are very 
potent anti-inflammatory agents[30]. Resolvins diminish the activation and production of 
superoxide, increase nitric oxide and decrease inflammatory cytokines- this mechanism will 
counterbalance inflammation and, as a consequence, insulin resistance. It has been shown that 
Omega-3 in high doses will reduce the incidence of myocardial infarction and, in some 
patients, revert insulin resistance. We have reported the normalization of the 2-hour post-
prandial levels of blood sugar with the use of Omega-3[6]. The mean 2-hour post-prandial 
glucose levels in 10 patients decreased from a mean value of 205±40mg/dl to 119±13mg/dl 
(P<0.003). This change occurred after using 6000mg per day of pure Omega-3 for about 6 
months. The effect of Omega-3 is mediated through the insulin receptors of the cells. At 
present, we are studying these receptors in order to explain this increase in insulin sensibility.  
Adipose tissue is a hormonally active endocrine tissue, producing cytokines, which 
influence other body tissues. Adiponectin is one such adipocytokine that protects 
cardiovascular tissue from ischemic injury and increases insulin sensitivity by stimulating 
fatty acid oxidation, decreasing plasma triglycerides and improving glucose metabolism[33,34]. 
Another adipocytokine, secreted-frizzled-related-protein-5 (Sfrp5), has been found to have 
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significant metabolic consequences; incorporation of Wnt signaling pathways, which 
classically regulate developmental processes in many organisms, in adipocytes has led to 
evidence that obesity induces a reduction in the Sfrp5 production along with an increase in 
Wnt5a expression, leading to augmented inflammatory signalling and insulin resistance[36]. 
Conversely, Sfrp5 acts as an anti-inflammatory molecule, restraining the chronic inflammatory 
state and improving insulin sensitivity. On the other hand, tumor necrosis factor- α (TNF-α) 
and interleukin-6 (IL-6) are insulin antagonizing adipocytokines[37] that are associated to 
augmentation of inflammation and insulin resistance. As seen, inflammation is a complicated 
issue in obesity that has to be stopped due to deleterious effects produced in the 
cardiovascular system, such as the reduction in ejection fraction observed in our sample of 
patients with MetS and normal coronaries: a diabetic cardiomyopathy undoubtedly brought 
on by chronic inflammation and insulin resistance[40].  
Insulin resistance is a fundamental mechanism underlying MetS and its components. Insulin 
is an anabolic hormone that exerts its effects primarily by promoting glycogen synthesis in 
the liver and muscle, increasing triglyceride synthesis in adipose tissue, and augmenting 
protein synthesis and inhibiting proteolysis. Therefore, the consequences of insulin 
resistance are multiple-fold. Truly, there are other processes involved in the development of 
insulin resistance other than inflammation. Abnormalities in fat storage and mobilization 
have been implicated in the pathogenesis of insulin resistance[38]. Abdominal obesity in 
particular has been shown to be most associated with insulin resistance and MetS. However, 
it has been observed that general obesity is not universal in MetS and insulin resistance. In 
addition, many obese subjects do not have metabolic abnormalities. Systemic chronic 
inflammation[39], on the other hand, paints the most complete picture of insulin resistance as 
it is the result of all altered cytokine production and signaling pathways in the body. A more 
accessible marker for this inflammation can be obtained by measuring C-reactive protein 
(CRP); 40% of our patients with MetS had an elevated CRP. Clinically, each of the diagnostic 
component criteria of the metabolic syndrome has been associated with increased levels of 
CRP[41], elevation of which bears a negative prognostic implication in the population 
involved - this biomarker has been associated to the development of heart disease, although 
this observation is not totally clear[31,32]. CRP production is located in the liver, a process 
induced by pro-inflammatory cytokines; this non-specific marker of inflammation has an 
important role in the host innate defense mechanism, but also regulates the amount of 
inflammatory response by activating the complement system. CRP can be used to monitor 
the status of the inflammatory system, and has been used to monitor the effect of statins in 
the inflammatory process of MetS[35]. In the Jupiter trial, rosuvastatin (20mg/day) reduced 
the systemic marker of CRP.  
Finally, a novel and important piece in the development of insulin resistance consists of 
aldosterone-induced insulin resistance through the increase in insulin-like growth factor-1 
(IGF-1) and hybrid receptors[42]. This research has demonstrated that aldosterone induces 
vascular remodeling through the IGF-1 and hybrid receptors and suggests that blocking the 
effects of aldosterone may attenuate and reduce angiopathy in hypertensive patients with 
hyperinsulinemia.  
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5. Circadian rhythm and the metabolic syndrome 
Common disorders of circadian behavior and sleep, such as night-shift work and jetlag, are 
associated with increased hunger, decreased glucose and lipid metabolism and changes in 
hormonal processes involved in satiety[43]. Short-duration and poor-quality sleep have been 
shown to predict the development of DMT2 and obesity after age, BMI and various other 
confounding variables are considered and taken into account[44]. In addition, the induction 
of hunger may be associated to a reduction in circulating levels of leptin brought on by sleep 
deprivation[45]. Cardiovascular disease and hypertension are also related with sleep loss, as 
the risk of a fatal heart attack increases 45% in individuals who chronically sleep 5 hours per 
night or less[46]. Disruption of the circadian clock can lead to obesity, inflammation and 
insulin resistance[47]. 
6. Management 
6.1. Diet and exercise 
Lifestyle approaches to treating and preventing MetS greatly improve metabolic parameters 
by reducing body weight and increasing the level of physical activity. Multiple studies of 
obese patients with DMT2, hypertension or hypercholesterolemia have shown that weight 
improves the cardiovascular profile, including glycemic control, in both diabetic and non-
diabetic individuals. Furthermore, lifestyle changes[48] comprising reduced total/saturated fat 
intake and increased polyunsaturated fat/fiber intake have been shown to significantly 
reduce multiple metabolic and inflammatory parameters such as CRP, central obesity and 
triglyceride levels. The ATTICA[49] epidemiological study showed that adherence to the 
Mediterranean diet was associated with 20% lower odds of having MetS, irrespective of age, 
sex, physical activity, lipids and blood pressure levels. On the other hand, consumption of a 
high fat diet induces changes in the fat microbia, producing inflammation that is associated 
with hyperphagia and an obese phenotype. In addition, data on the Hispanic and Asian 
diets with relation to diabetes have demonstrated that rice consumption is associated to an 
elevated risk of developing DMT2, presumably due to the higher glycemic index of rice 
when compared to whole grain[50]. Physical activity is a cornerstone in weight balance. 
However, only part of the beneficial effect of physical activity on the metabolic and 
cardiovascular profile is mediated through body weight changes. Physical activity improves 
insulin sensitivity, increases HDL levels, lowers blood pressure and maintains immune 
system health, which is very important in reducing inflammation and, as a consequence, 
insulin resistance[51]. 
6.2. Pharmacotherapy 
Although intensified therapeutic lifestyle modifications may prevent the onset and 
progression of MetS, some patients may require drug therapy. While the individual 
components (e.g. glucose intolerance, hypertension, dyslipidemia) are all appropriate 
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targets for treatment, newer therapies that manage the syndrome centrally may benefit from 
such a collective approach and thus prove more effective. Although traditional approaches 
to the separate risk factors have proven effective, increasing attention is now being directed 
at the management of insulin resistance, obesity and inflammation. Orlistat, sibutramine, 
and rimonabant are approved for long-term treatment of obesity; however, sibutramine is 
known to cause secondary hypertension and thus is not the ideal choice of therapy in obese 
patients with MetS. As was mentioned above, statins and RAS inhibitors have proven anti-
inflammatory properties that may augment insulin sensitivity. Glitazones and metformin 
have been used increasingly over the recent years for the management of insulin resistance. 
The ongoing search for new strategies to combat the MetS has shed light on new molecules 
that may prove to be effective therapeutic targets in treating the syndrome; in vivo studies 
have established that atherosclerosis driven by the inhibition of stearoyl-coenzyme A 
desaturase 1 (SCD1), an enzyme involved in fatty acid metabolism, can be completely 
prevented by the omega-3 polyunsaturated fatty acids in dietary fish-oils[52]. Moreover, our 
data showing that in some patients, high doses of omega-3 polyunsaturated fatty acids will 
normalize the 2-hour post-prandial glucose levels in a sample from Puerto Rico is 
promising. 
6.3. Bariatric surgery 
Given that lifestyle changes and pharmacology may not be sufficient to achieve durable and 
effective weight loss, surgery to treat obesity and MetS has become an attractive alternative. 
In addition to weight loss, patients may enjoy improvement in other metabolic parameters 
such as insulin resistance and other obesity-related comorbidies. Bariatric surgery has been 
shown to reverse diabetes, hypertension, sleep apnea and hyperlipidemia[53], however, 
selection of candidates must be a strict process in view of peri- and postoperative 
complications and costs associated with different surgical procedures. 
7. Social importance 
The economic cost of combating obesity and associated comorbidies is estimated to exceed 
$100 billion annually in the United States[54]. With recent data showing the increasing 
burden of obesity throughout the world, it can be expected that the rates of MetS will be 
increasing. A study that aims to assess the independent contributions of MetS and its 
individual components to 10-year medical costs among a sample of elderly individuals 
showed that total costs to Medicare were 20% higher among participants with the MetS[55]. 
Another study found that risk factors for metabolic syndrome, such as obesity, high blood 
pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-
fold, or about $2,000 per year; for each additional risk factor those costs rise an average of 
24%[56]. These figures are even more alarming in the context of the prevalence of the MetS in 
relation to socio-economic position: social class has been shown to have an inverse relation 
to MetS[57]. 
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burden of obesity throughout the world, it can be expected that the rates of MetS will be 
increasing. A study that aims to assess the independent contributions of MetS and its 
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to MetS[57]. 
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8. Conclusion 
In an age when millions of people are estimated to be afflicted by the MetS, new 
perspectives into this cluster of risk factors are imperative if we are to evolve its 
management: the focus on inflammation and insulin resistance is crucial in order to halt or 
delay the disease as soon as it is detected. Moreover, the public health of Hispanic 
populations throughout the world has been evidenced to pose a significant public health 
problem that should be addressed specifically because of the distinct metabolic 
characteristics this ethnicity may hold. Likewise, this approach should prompt further 
investigation into parallel cardiometabolic particularities in other ethnicities. 
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1. Introduction 
The discovery of leptin in 1994 provoked the interest in the adipose tissue which was no 
longer considered as an inert tissue storing energy in the form of triglycerides but as the 
greatest endocrine organ in human body [1, 2]. As a growing number of people suffer from 
obesity and metabolic syndrome, understanding the mechanisms by which various 
hormones and neurotransmitters have influence on energy balance, weight control and 
insulin resistance has been a subject of intensive research.  
The regulation of appetite and feeding is a homeostatic mechanism. A powerful and 
complex physiological system exists to balance energy intake and expenditure, in order that 
sufficient energy is available and body weight remains stable [2, 3]. This system is composed 
of both afferent signals and efferent effectors. A large number of factors originating 
throughout the body send afferent signals to a smaller number of functional centers in the 
central nervous system (CNS), that then mediate interactions with efferent pathways to 
regulate energy expenditure and energy intake [4]. Thus, central circuits in the brain rely on 
peripheral signals indicating satiety levels and energy stores, as well as higher cortical 
factors such as emotional and reward pathways [5].  
There are numerous peptides involved in the regulation of energy homeostasis, some of 
which are produced centrally and others peripherally in the gastrointestinal tract (GI), with 
some produced at both locations. These peptides are known as members of the ‘gut-brain 
axis’ [6]. Since the discovery of secretin, which was confirmed to stimulate pancreatic 
exocrine secretion, more than 40 other GI tract hormones have been discovered. 
Anticipation of a meal and the presence of food in the stomach and the small intestine 
stimulate secretion of many of these hormones from the gut through mechanical and 
chemical stimuli. These signals are involved in the initiation of food intake as well as 
termination of meals [7]. However, many of the same hormones are also expressed in the 
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CNS, acting to translate metabolic information between the GI tract and the brain [8]. In 
normal subjects, body weight is tightly regulated despite day-to-day variations in food 
intake and energy expenditure. Obesity is due to a state in which energy intake exceeds 
energy expenditure over a prolonged period of time. In humans it is also of note that 
psychological and emotional factors can drive food intake in excess of actual need [7]. 
In summary, signals relaying information such as the nutritional and energy status of the 
body converge within the CNS. Thus, CNS mediates energy balance in the body, the 
hypothalamus playing a main role in this process. The arcuate nucleus (ARC) is a key 
hypothalamic nucleus in the regulation of appetite and is involved in integrating peripheral 
satiety and adiposity signals via orexigenic and anorexigenic neuropeptide transmission to 
other hypothalamic and extrahypothalamic brain regions [9]. Proximity of ARC to the 
median eminence and the fact that it is not fully insulated from the circulation by the blood 
brain barrier makes it strategically positioned to integrate the great number of peripheral 
signals controlling food intake [5]. There are two major neuronal populations in the ARC 
implicated in the regulation of feeding. One population co-expresses Neuropeptide Y (NPY) 
and agouti-related protein (AgRP) and increases food intake. The second population of 
neurons co-expresses cocaine- and amphetamine-related transcript (CART) and pro-
opiomelanocortin (POMC), the precursor to the melanocortin receptor agonist, α-
melanocyte-stimulating hormone (-MSH), and inhibits food intake. Neuronal projections 
from these two populations then communicate with other hypothalamic areas involved in 
appetite regulation such as the paraventricular nucleus (PVN), ventromedial nucleus 
(VMN), dorsomedial nucleus (DMN) and lateral hypothalamic area (LHA) [10].  
Receptors for leptin and insulin are expressed on both of these types of neurons, suggesting 
that they are responsive to circulating levels of these hormonal signals, acting as effectors for 
altering food intake in response to variations in energy balance as indicated by body 
adiposity [11]. Leptin is secreted by adipocytes and circulates at concentrations proportional 
to fat mass. Restriction of food intake for a relatively longer period, results in a supression of 
leptin levels, which can be reversed by refeeding or administration of insulin. Insulin is a 
major metabolic hormone. Like leptin, levels of plasma insulin vary directly with changes in 
adiposity being influenced to a great extent by peripheral insulin sensitivity. The latter is 
related to total body fat stores and fat distribution, with visceral fat being the key 
determinant [12]. Plasma insulin increases at times of positive energy balance and decreases 
at times of negative energy balance. However, unlike leptin, insulin secretion increases 
rapidly after a meal, whereas leptin levels are relatively insensitive to meal ingestion. Both 
leptin and insulin cross the blood-brain barrier, stimulate anorexigenic α-MSH/CART 
neurons and inhibit orexigenic NPY/AgRP neurons, thus activating the catabolic pathways 
and inhibiting the anabolic pathways (Figure 1). When energy stores are low, production of 
leptin from adipose tissue, and thus circulating leptin concentrations fall, leading to 
increased production of hypothalamic neurotransmitters that strongly increase food intake, 
such as NPY, galanin, and AgRP and decreased levels of α-MSH, CART, and neurotensin 
that reduce food intake and increase energy expenditure [8, 13]. 
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CRH, corticotrophin-releasing hormone; MCH, melanin-concentrating hormone, 5-HT, 5-hydroxytryptamine; NE, 
norepinephrine; (- - ) inhibition; ( ) stimulation. 
Figure 1. Schematic action of leptin and insulin on the hypothalamus. 
In addition to leptin and insulin, receptors for ghrelin are also located on arcuate AgRP/NPY 
neurons, which are activated by central ghrelin administration. Furthermore, peripheral 
ghrelin administration activates neurons in the ARC and AgRP and NPY have been 
demonstrated to be requisite mediators of the hyperphagia induced by systemic ghrelin [11]. 
So, meal-generated satiety signals from the GI tract do interact with longer-term adiposity 
signals, such as insulin and leptin in energy balance [8]. 
NPY is one of the most abundant peptides of the hypothalamus and one of the most potent 
orexigenic factors. The majority of neurons expressing NPY in the hypothalamus are found 
within the ARC and most co-express AgRP [14]. Synthesis and release of NPY are both 
regulated by leptin binding to its hypothalamic receptor. NPY links afferents reflecting the 
nutritional status of the organism from endocrine, gastrointestinal, and central and 
peripheral nervous systems to effectors of energy intake and expenditure [15]. NPY 
stimulates appetite inducing hyperphagia, increase of fat depots, decrease of thermogenesis, 
and suppression of sympathetic activity. NPY is known to be involved in other 
physiological functions, such as cardiovascular regulation, affective disorder, memory 
retention, neuroendocrine control. When leptin levels increase after food intake, the latter 
binds to its receptors in the hypothalamus which leads to discontinuation of NPY secretion 
[5, 16]. The decrease of NPY concentration in obesity probably plays a role of a counter-
regulatory factor intended to prevent further weight gain. Thus, NPY becomes one of the 
main regulators of food intake, body weight and energy expenditure. 
Ghrelin is a fast-acting hormone, seemingly playing a role in meal initiation. Secreted 
predominantly from the stomach, ghrelin is the natural ligand for the growth hormone 
secretagogue-receptor (GHS-R) in the pituitary gland, thus fulfilling the criteria of a brain–
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gut peptide [5, 6]. Although the majority of ghrelin is produced peripherally, there are 
ghrelin immunoreactive neurons within the hypothalamus that have terminals on 
hypothalamic NPY/AgRP, POMC and corticotropin releasing hormone (CRH) neurons [17], 
as well as orexin fibres in the LHA [18]. It was found that ghrelin acts to promote appetite in 
two ways—directly, by depolarizing the orexigenic NPY/AgRP neurons, and indirectly, by 
increasing the tonic inhibition exerted by the NPY/AgRP neurons over the anorexigenic 
POMC/CART neurons. Both of these ultimately enhance appetite [4, 17, 18]. The ability of 
ghrelin to increase food intake and body weight is mediated through the stimulation of NPY 
production in the hypothalamic ARC, where it antagonizes the inhibitory effect on NPY 
secretion displayed by leptin and insulin [19]. 
The purpose of this chapter is to provide background information on the relationship 
between the main appetite regulatory peptides NPY and ghrelin, and insulin resistance. The 
role of NPY and ghrelin in food intake and body weight control in humans, and their 
mechanism of action are discussed, focusing on association with glucose metabolism and 
insulin resistance.  
2. Neuropeptide Y (NPY) 
NPY is one of the most abundant peptides of the hypothalamus and one of the most potent 
orexigenic (appetite-increasing) factors [20]. It is a 36-amino acid peptide that was first 
isolated from porcine brain in 1982 [21] (Fugure 2). It is a member of the PP-fold family of 
peptides which consists of NPY, peptide YY (PYY), pancreatic polypeptide (PP) and peptide 
Y (PY) [22]. 
 
Figure 2. Structure of NPY. 
NPY is synthesized by cell bodies in the ARC and transported axonally to the PVN where 
the highest concentrations are found [23]. NPY-expressing neurons are prominent also in the 
DMN and the VMN [24]. All these regions of the brain influence feeding behavior and 
energy balance.  
NPY is also found in circulating blood, where it comes mainly from the adrenal medulla and 
sympathetic nerves, but this peripheral hormone does not cross the blood-brain barrier [25, 
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26]. NPY is present in the pancreas, in both the islet cells and in sympathetic nerve terminals 
[27, 28].  
Regulation of NPY synthesis and release 
The levels of hypothalamic NPY mRNA and NPY release increase with fasting and decrease 
after refeeding [29-31]. When fed with a high-carbohydrate diet; diabetic rats exhibit 
increased gene expression of the NPY in the hypothalamic ARC, and high-fat diet 
suppressed NPY expression [32]. Thus, NPY synthesis as well as its receptorial expression 
are sensitive to changes in the metabolic status and food availability. While starvation and 
food deprivation increase NPY release [30], in obese subjects the activity of NPY neurones is 
down-regulated in the attempt to restrain overeating of palatable food [33]. These facts 
support the existence of a long loop control system in energy metabolism between the brain 
and adipose tissue. Several peripheral factors are involved in the modulation of this system. 
Among them insulin and leptin display an inhibitory effect; glucocorticoids and ghrelin act 
as stimulatory afferent signals [34]. 
It has been reported that leptin is a major inhibitory regulator of the activation by ghrelin of 
the orexigenic network of NPY [35]. Circulating leptin crosses the blood brain barrier and 
binds to the long form of the leptin receptor, Ob-Rb, in the hypothalamus [36]. The Ob-Rb is 
expressed widely within the hypothalamus but particularly in the ARC, VMN, DMN and 
LHA. Several experimental studies demonstrate that systemic administration of leptin 
inhibits NPY gene overexpression through a specific action in the ARC. Cells within the 
ARC express both NPY and leptin receptors, and leptin directly activates anorectic POMC 
neurons and inhibits orexigenic AgRP/NPY neurons [37]. All available data can be 
summarized as follows: when leptin levels increase after food intake, the latter binds to its 
receptors in the hypothalamus which leads to discontinuation of NPY secretion. When 
production of leptin from adipose tissue is reduced, the circulating leptin concentrations fall, 
and this lead to enhanced production of NPY that strongly increase food intake.  
Receptors for ghrelin are also located on arcuate AgRP/NPY neurons, which are activated by 
central ghrelin administration. Ghrelin acts by depolarizing the orexigenic NPY/AgRP 
neurons, and by increasing the tonic inhibition exerted by the NPY/AgRP neurons over the 
anorexigenic POMC/CART neurons [11]. c-Fos expression increases within NPY-
synthesizing neurons in the ARC after peripheral administration of ghrelin [38], and ghrelin 
fails to increase food intake following ablation of the ARC [39]. Studies of knockout mice 
demonstrate that both NPY and AgRP signalling mediate the effect of ghrelin, although 
neither neuropeptide is obligatory [40]. 
Insulin is a major metabolic hormone produced by the pancreas and the first adiposity signal 
to be described. Little or no insulin is produced in the brain itself [41, 42]. Insulin levels are 
dependent on peripheral insulin sensitivity that is related to total body fat stores and fat 
distribution, with visceral fat being a key determinant of insulin sensitivity [12]. Once insulin 
enters the brain, it acts as an anorexigenic signal, decreasing food intake and subsequently 
body weight. It was found that both the NPY and melanocortin systems are important 
downstream targets for the effects of insulin on food intake and body weight. Insulin 
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penetrates the blood–brain barrier via a saturable, receptor-mediated process, at levels which 
are proportional to the circulating insulin [43]. Insulin receptors are widely distributed in the 
brain, with highest concentrations found in the olfactory bulbs and the hypothalamus [44]. 
Within the hypothalamus, there is particularly high expression of insulin receptors in the ARC; 
they are also present in the DMH, PVN, and suprachiasmatic and periventricular regions [45]. 
Hypothalamic NPY is a potential mediator of the regulatory effects of insulin. The increase of 
NPY levels in the PVN and prepro-NPY mRNA in the ARC during fasting are inhibited by 
intracerebroventricular (icv) administration of insulin. Fasting, therefore, increases NPY 
biosynthesis along an ARC-PVN pathway in the hypothalamus via a mechanism dependent 
on low insulin levels [46]. NPY expression is increased in insulin-deficient, streptozocin-
induced diabetic rats and this effect is reversed with insulin therapy [47, 48]. Insulin receptors 
have been found also on POMC neurons in the ARC [49]. Administration of insulin into the 
third ventricle of fasted rats increases POMC mRNA expression and the reduction of food 
intake caused by icv injection of insulin is blocked by a POMC antagonist [49]. Furthermore, 
POMC mRNA is reduced by 80% in rats with untreated diabetes, and this can be attenuated 
by peripheral insulin treatment which partially reduces the hyperglycaemia [50].  
Glucocorticoid hormones play a critical role in energy balance and also appear to mediate at 
least some of their actions through the central NPY axis. They may regulate NPY-induced 
insulin release and NPY signaling within the VMH of the hypothalamus. Glucocorticoid-
receptor immunoreactivity is found within the rat CNS, including the ARC, VMH, and PVN 
[51]. Many of these receptors are expressed at the nucleus of NPY-containing, endocrine-
related neurons and coexist in regions containing high NPY receptor density [52]. In rats, 
excessive corticosterone promotes body fat gain and hyperinsulinemia [53] and also 
increases NPY synthesis and Y1-receptor mRNA expression, at least within the ARC ([54, 
55]. Conversely, removal of glucocorticoids by adrenalectomy reduces hyperphagia and 
body weight of obese (fa/fa) rats [56], abolishes obesity induced by VMH lesions [57], and 
prevents obesity induced by chronic central NPY infusion in normal rats [58]. However, it 
has been reported that adrenalectomy does not alter NPY-1 (Y1)-receptor mRNA expression 
in the ARC [54]. Chronic icv infusion of NPY induces hyperphagia, hyperinsulinemia, and 
insulin resistance in rats, and these effects are blocked by previous adrenalectomy [59]. 
Wisialowski et al. [60] have demonstrated that adrenalectomy also abolishes the insulin 
release caused by an acute icv injection of NPY and this is associated with significant 
reduction in Y1- and Y5-receptor mRNA expression specifically within the VMH. These 
experiments imply that glucocorticoids are necessary for icv NPY to stimulate insulin 
release and suggest that the latter manifest this regulatory role through alterations in Y1- 
and Y5-receptor expression in the VMH [60]. Taken together, all these observations indicate 
that glucocorticoids have a regulatory role in long-term central NPY signaling. 
As concerns plasma NPY, its concentrations rise in response to muscular exercise [61] and in 
disorders such as pheochromocytoma and renal failure [62]. 
Mechanisms of action of NPY – NPY receptors 
PP-fold family of peptides bind to seven transmembrane-domain G-protein-coupled 
receptors [63]. Heterogeneity among NPY (and PYY) receptors was first proposed on the 
 
Appetite Regulatory Peptides and Insulin Resistance 95 
basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert 
three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional 
potentiating effect on norepinephrine (NE)-evoked vasoconstriction; and 3) a prejunctional 
suppression of stimulated NE release. The two latter phenomena are probably reciprocal, 
since NE affect NPY mechanisms similarly [64]. Six different NPY receptors have been 
identified ([65], of which five have been cloned and characterized. Y1–Y5 receptors have 
been demonstrated in rat brain, but Y6, identified in mice, is absent in rats and inactive in 
primates [66]. The Y1, Y2, Y4 and Y5 receptors, cloned in the hypothalamus, have all been 
postulated to mediate the orexigenic effects of NPY. Biological redundancies are likely to 
exist between Y1 and Y5 receptor signaling [67].  
NPY initiates appetite drive directly through its receptors, particularly the Y1-5 (NPY5-R), 
and by the simultaneous inhibition of anorexigenic melanocortin signalling in the ARC [68]. 
NPY5-R is thought to be the main receptor involved in NPY-induced food intake since a 
reduction in food intake after an icv injection of antisense oligonucleotides directed against 
NPY5-R is demonstrated in rats [69].  
Although the large number of Y receptors has made it difficult to delineate their individual 
contributions, recent studies analyzing  NPY and Y receptor-overexpressing, knockout, and 
conditional-knockout mouse models have started to unravel some of the complexity.  To 
elucidate the role of NPY1-R in food intake, energy expenditure, and other possible 
functions, Kushi et al. [70] have generated  NPY1-R-deficient mice (Y1-R-/-) by gene 
targeting. Contrary to their hypothesis that the lack of NPY signaling via Y1-R would result 
in impaired feeding and weight loss, Y1-R-/- mice showed a moderate obesity and mild 
hyperinsulinemia without hyperphagia. The authors suggest either that the Y1-R in the 
hypothalamus is not a key molecule in the leptin/NPY pathway, which controls feeding 
behavior, or that its deficiency is compensated by other receptors, such as NPY5-R. Probably 
the mild obesity found in Y1-R-/- mice was caused by the impaired control of insulin 
secretion and/or low energy expenditure [70]. This model could be useful for studying the 
mechanism of mild obesity and abnormal insulin metabolism in noninsulin-dependent 
diabetes mellitus. 
In order to investigate the role of different Y receptors in the NPY-induced obesity 
syndrome, Lin et al. [71] used recombinant adeno-associated viral vector to overexpress 
NPY in mice deficient of selective single or multiple Y receptors (including Y1, Y2, and Y4). 
Results from this study demonstrated that long-term hypothalamic overexpression of NPY 
lead to marked hyperphagia, hypogonadism, body weight gain, enhanced adipose tissue 
accumulation, hyperinsulinemia, and other hormonal changes characteristic of an obesity 
syndrome. NPY-induced hyperphagia, hypogonadism, and obesity syndrome persisted in 
all genotypes studied (Y1−/−, Y2−/−, Y2Y4−/−, and Y1Y2Y4−/− mice). However, triple deletion of 
Y1, Y2, and Y4 receptors prevented NPY-induced hyperinsulinemia. These findings suggest 
that Y1, Y2, and Y4 receptors under this condition are not crucially involved in NPY’s 
hyperphagic, hypogonadal, and obesogenic effects, but they are responsible for the central 
regulation of circulating insulin levels by NPY [71].  
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A lot of investigators’ data point that NPY5-R mediates the feeding response to exogenous 
and endogenous NPY. It may be involved in energy balance and is, therefore, a 
susceptibility candidate gene for obesity and related disorders such as the metabolic 
syndrome and type 2 diabetes mellitus. It is hypothesized that the feeding effect of NPY 
may indeed be mediated by a combination of receptors rather than a single one. Also, 
increasing evidence points to the existence of other as yet unidentified Y receptors, which 
may mediate NPY’s orexigenic actions, and it remains possible that, under certain 
physiological conditions, NPY may bind and activate receptors for which it normally has no 
or only low affinities. 
Analogs of NPY with high selectivity for the Y1 and Y5 receptor subtypes strongly stimulate 
food intake in rodents, and icv administration of specific Y5 receptor agonists increases food 
intake and body weight in mice [72]. A clinical study examining a therapeutic intervention 
based on the NPY system has been performed by Erundu et al. [73]. The authors tested the 
hypothesis that blockade of the NPY5-R will lead to weight loss in humans using MK-0557, 
a potent, highly selective, orally active NPY5-R antagonist. MK-0557 has no significant 
binding to the human NPY1-R, NPY2-R, NPY4-R, or mouse NPY6-R at concentrations of 10 
μM. These data indicate a >7500-fold selectivity for the NPY5-R relative to the other NPY 
receptor subtypes. MK-0557 was administered to 547 obese subjects, who showed 
statistically significant weight loss at 12 weeks compared to subjects treated with placebo 
[73]. These observations clearly indicate that antagonizing the NPY5-R induces weight loss 
in humans. After that a long-term trial over 52 weeks was performed in 1661 subjects (832 
completed). There was a a mean weight loss of 3.4 kg in those who completed the trial, 
which was significantly greater than the weight loss seen in the placebo-treated group. 
Significantly more subjects lost ≥5% and ≥10% of initial body weight with the NPY5-R 
antagonist than did so on placebo. The authors conclude, however, that the magnitude of 
the weight loss observed was not clinically significant, and this conclusion is supported by 
the observation that there were no significant improvements in secondary endpoints such as 
glucose and lipid levels and blood pressure measurements [73]. While several potential new 
obesity therapies that act through the CNS pathways or peripheral adiposity signals are in 
early-phase clinical trials, the above study serves to point out that manipulation of the 
homeostatic mechanisms involving hypothalamic/brainstem pathways for a clinically 
significant outcome in obese patients remains a major challenge [74]. 
Link between NPY, obesity and insulin resistance 
NPY is a powerful stimulant of food intake. Numerous studies in rodent models have 
demonstrated that administration of NPY into the PVN stimulates feeding [75, 76] and that 
repeated injections of NPY result in persistent feeding and the development of obesity by 
promoting fat accumulation [77, 78]. Central administration of NPY was found to reduce 
energy expenditure, resulting in reduced brown fat thermogenesis [79], suppression of 
sympathetic nerve activity [80] and inhibition of the thyroid axis [81]. There are some data 
that NPY activates hypothalamic-pituitary-adrenal axis (HPA) [82], that is implicated in the 
regulation of metabolism and energy balance. An acute injection of NPY into the PVN 
produces increases in circulating ACTH and corticosterone in both conscious and 
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anesthetized rats [83]. ARC NPY neurons project to the ipsilateral PVN [84], and repeated 
icv injection of NPY into the PVN in normal rats causes hyperphagia, an increase in basal 
plasma insulin level and morning cortisol level, independent of increased food intake, 
increased metabolic activity of white adipose tissue and muscle insulin resistance, and 
results in obesity [85, 86]. Several of these metabolic effects are still present when increased 
food intake is prevented by food restriction [85]. It was shown that Y5 receptor subtype is 
involved in the activation of HPA axis mediated by NPY [82].  
Interestingly, injection of NPY directly into the VMH significantly increases food intake [75], 
and NPY-induced feeding is enhanced in VMH-lesioned rats [87]. Lesions of the VMH in 
rodents also cause multiple changes in metabolic status, including hyperphagia, 
hyperglycemia, and hyperinsulinaemia [88]. Enhanced NPY expression in the VMH is 
associated with obesity [89]. Furthermore, NPY has been shown to directly inhibit over one 
fifth of spontaneously active rat VMH neurons, and this inhibition is potentiated by 
overfeeding [90]. Therefore, the mechanism by which acute icv NPY stimulates insulin 
release in the absence of feeding may be by inhibiting the spontaneous activity of the VMH 
through Y1 and Y5 receptors. A reduction of these receptors with adrenalectomy would 
then reduce the ability of NPY to inhibit VMH neurons. These data suggest the VMH may 
also be a site of action for NPY in the development of obesity; however, the mechanisms by 
which NPY is involved in each aspect of central energy regulation remain to be defined.  
Some investigators found that acute icv NPY administration had no affect on plasma 
glucose levels, indicating that NPY-induced insulin release is not simply a secondary 
response to changes in peripheral glucose [60, 91]. The decreased basal insulin levels and 
lack of insulin release in response to NPY injection in adrenalectomized rats with 
downregulation of Y1-and Y5-receptor mRNA in the VMH, demonstrated in the study of 
Wisialowski et al. [60], highlights the role for Y1-and Y5-receptors in the etiology of NPY-
induced hyperinsulinemia, insulin resistance, and obesity.  
Van den Hoek et al. [92] found that icv administration of NPY in the third ventricule in rats 
acutely hampers the capacity of insulin to suppress endogenous glucose production via 
activation of sympathetic nerves innervating the liver The authors discusssed a possible 
explanation for the role of NPY in sympathetic overdrive and hepatic insulin resistance that 
are typical for obese subjects with the metabolic syndrome [92]. In a study of Singhal et al. 
[93] the ability of resistin to increase hepatic insulin resistance and modulate the levels of 
various mediators in the liver was abolished in mice lacking NPY as well as in mice 
pretreated with icv NPY Y1 receptor antagonist. The authors established a crucial link 
between NPY and resistin’s ability to regulate hepatic insulin resistance possibly via 
induction of SOCS3 (suppressor of cytokine signaling-3), tumor necrosis factor (TNF)-α and 
interleukin 6 (IL6). Additionally, NPY is critical to mediating the decrease in STAT3 (signal 
transducer-activated transcript-3) phosphorylation by central resistin [93]. 
It was found that the obesity syndrome, induced by injection of NPY into the CNS of rats, 
closely resembles the phenotype of either leptin deficient ob/ob mice, or leptin resistant db/db 
mice [58, 85]. In these animals, genetic alterations of the satiety effect of leptin within the 
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closely resembles the phenotype of either leptin deficient ob/ob mice, or leptin resistant db/db 
mice [58, 85]. In these animals, genetic alterations of the satiety effect of leptin within the 
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hypothalamus result in an overexpression of NPY leading to a complex syndrome including 
hyperphagia, increased fat storage and obesity. The experimental studies in ob/ob mice 
demonstrate that systemic administration of leptin inhibits NPY gene overexpression 
through a specific action in the ARC and exerts a hypoglycemic action that is partly 
independent of its weight-reducing effects. It must be pointed that both effects occur before 
reversal of the obesity syndrome. Defective leptin signaling due to either leptin deficiency 
(in ob/ob mice) or leptin resistance (in db/db mice) therefore leads directly to hyperglycemia 
and the overexpression of hypothalamic NPY, that is implicated in the pathogenesis of the 
obesity syndrome [94]. Moreover, the obesity syndrome produced by icv administration of 
NPY is characterised by increased expression of the ob gene in adipose tissue [58]. On the 
other hand leptin, the ob gene product, has been shown to inhibit NPY synthesis and release 
from hypothalamic nuclei in ob/ob mice. Correction of the obese state induced by genetic 
leptin deficiency reduces elevated levels of both blood glucose and hypothalamic NPY 
mRNA [95].  
Although NPY seems to be an important orexigenic signal, NPY-null mice have normal 
body weight and adiposity [96, 97]. This absence of an obese phenotype may be due to the 
presence of compensatory mechanisms or alternative orexigenic pathways, such as those 
which signal via AgRP [98]. It is possible that there is evolutionary redundancy in orexigenic 
signalling in order to avert starvation. This redundancy may also contribute to the difficulty 
elucidating the receptor subtype that mediates NPY-induced feeding [99].  
In searching the role of NPY in human obesity and metabolic disorders, polymorphisms in 
the NPY5-R gene have been studied by other authors in several populations. Thus, NPY5-R 
gene was sequenced by Jenkinson et al. [100], and several single nucleotide polymorphisms 
(SNPs) were genotyped in the Pima Indians with three novel SNPs being identified, which 
were described as polymorphism 1, 2, and 3 (P1, P2, and P3). All three SNPs are in non-
coding regions. There were genotype differences in lean and obese Pima Indians for P2 and 
for a 3 SNP haplotype [100]. A silent single nucleotide polymorphism within the NPY5-R 
coding sequence showed no evidence of association with BMI in children and adolescents 
[101]. In contrast, a novel polymorphism in the intervening segment between exons of the 
genes encoding NPY1-R and NPY5-R was associated with reduced serum triglyceride (TG) 
levels and HDL-cholesterol in a severely obese cohort [102] that should be considered as a 
protective lipid profile. Roche et al. [103] investigated the potential implication of NPY, 
NPY-Y1 and -Y5 subtype receptors [rNPY-Y1/-Y5] in the development of human obesity. 
Two complementary genetic approaches were used: 1) linkage analyses between obesity and 
polymorphic markers located nearby NPY and rNPY-Y1/-Y5 genes in 93 French Caucasian 
morbidly obese families; 2) single strand conformation polymorphism (SSCP) scanning of 
the coding region of the NPY and rNPYY1 genes performed in 50 unrelated obese patients 
ascertained. No evidence of linkage between morbid obesity or obesityrelated quantitative 
traits and NPY and rNPY-Y1/Y5 regions was found in this population. Moreover, SSCP 
scanning revealed no mutation in the coding region of NPY and rNPY-Y1 genes among 
obese subjects. The authors suggest that NPY and NPY-Y1/ Y5 receptors are unlikely to be 
implicated in the development of human morbid obesity, at least in the French Caucasian 
population [103]. 
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In addition to the above data, genetic association of NPY receptor Y5 (NPY5R) SNPs with 
metabolic syndrome was studied in 439 Mexican American individuals by Coletta et al. 
[104]. Minor alleles for five of nine genetic variants (rs11100493, rs12501691, P1, rs11100494, 
rs12512687) of the NPY5-R SNPs were found to be significantly associated with both 
increased plasma TG levels and decreased high-density lipoprotein (HDL) concentrations 
[104]. In addition, the minor allele for SNP P2 was significantly associated with a decreased 
homeostasis model assessment of -cell function (HOMA-%). Linkage disequilibrium 
between SNPs pairs indicated one haplotype block of five SNPs (rs11100493), and low HDL-
cholesterol are highly associated with insulin resistance states, such as type 2 diabetes 
mellitus, obesity, and the metabolic syndrome. So, these results provide evidence for 
association of SNPs in the NPY5R gene with atherogenic dyslipidemia in insulin resistance. 
In the course of identification of genes implicated in the development of human obesity, 
further genome-wide searches could be successful for identifying multiple predisposing 
loci. 
It has become apparent, that upon vigorous electrical stimulation or intense stressors motor 
neurons on the sympathetic nerve system (SNS) may secrete NPY as well as NE [105]. 
Acting through NPY receptors on vascular and adipose tissue, secreted NPY may play an 
important role in the pathophysiology of obesity and metabolic syndrome. Thus, Kuo et al. 
[105] demonstrated that stress exaggerated diet-induced obesity through a peripheral 
mechanism in the abdominal white adipose tissue that is mediated by NPY. The authors 
found that stressors such as exposure to cold or aggression lead to NPY release from SNS, 
which in turn upregulates NPY and its Y2 receptors (NPY2-R) in a glucocorticoid-dependent 
manner in the abdominal fat. This positive feedback response by NPY lead to abdominal fat 
enhancement. Release of NPY and activation of NPY2-R stimulated fat angiogenesis, 
macrophage infiltration, and the proliferation and differentiation of new adipocytes, 
resulting in abdominal obesity and a metabolic syndrome-like condition. NPY, like stress, 
stimulated fat growth, whereas pharmacological inhibition or fat-targeted knockdown of 
NPY2R is anti-angiogenic and anti-adipogenic. Thus, manipulations of NPY2-R activity 
within fat tissue offer new ways to remodel fat and treat obesity and metabolic syndrome 
[105]. 
NPY may be an important intra-islet paracrine hormone [38]. When produced by pancreatic 
islets, its expression is dependent on the prevailing endocrine environment. Islet NPY 
appears to constrain insulin release under a variety of conditions. Whether peripheral NPY 
has a hormone-like action and directly influences glucose metabolism and/or insulin 
secretion in vivo is under investigation. It this context NPY, at high concentrations, may 
contribute to the modulation of insulin secretion in vitro. NPY nerve fibers occur in the 
mouse pancreas and that most of these NPY nerve fibers are nonadrenergic. Furthermore, in 
the mouse, NPY enhances basal plasma insulin levels at high dose levels under in vivo 
conditions. At lower dose levels it inhibits glucose-induced, but not cholinergically induced 
insulin secretion [106]. It has also been reported that NPY may reduce plasma glucose 
concentrations during exercise by inhibiting glycogen breakdown in the splanchnic 
compartment [107, 108]. Moreover, the potential relation between circulating NPY and the 
pathophysiological consequences of obesity need further investigation.  
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In addition to the above data, genetic association of NPY receptor Y5 (NPY5R) SNPs with 
metabolic syndrome was studied in 439 Mexican American individuals by Coletta et al. 
[104]. Minor alleles for five of nine genetic variants (rs11100493, rs12501691, P1, rs11100494, 
rs12512687) of the NPY5-R SNPs were found to be significantly associated with both 
increased plasma TG levels and decreased high-density lipoprotein (HDL) concentrations 
[104]. In addition, the minor allele for SNP P2 was significantly associated with a decreased 
homeostasis model assessment of -cell function (HOMA-%). Linkage disequilibrium 
between SNPs pairs indicated one haplotype block of five SNPs (rs11100493), and low HDL-
cholesterol are highly associated with insulin resistance states, such as type 2 diabetes 
mellitus, obesity, and the metabolic syndrome. So, these results provide evidence for 
association of SNPs in the NPY5R gene with atherogenic dyslipidemia in insulin resistance. 
In the course of identification of genes implicated in the development of human obesity, 
further genome-wide searches could be successful for identifying multiple predisposing 
loci. 
It has become apparent, that upon vigorous electrical stimulation or intense stressors motor 
neurons on the sympathetic nerve system (SNS) may secrete NPY as well as NE [105]. 
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important role in the pathophysiology of obesity and metabolic syndrome. Thus, Kuo et al. 
[105] demonstrated that stress exaggerated diet-induced obesity through a peripheral 
mechanism in the abdominal white adipose tissue that is mediated by NPY. The authors 
found that stressors such as exposure to cold or aggression lead to NPY release from SNS, 
which in turn upregulates NPY and its Y2 receptors (NPY2-R) in a glucocorticoid-dependent 
manner in the abdominal fat. This positive feedback response by NPY lead to abdominal fat 
enhancement. Release of NPY and activation of NPY2-R stimulated fat angiogenesis, 
macrophage infiltration, and the proliferation and differentiation of new adipocytes, 
resulting in abdominal obesity and a metabolic syndrome-like condition. NPY, like stress, 
stimulated fat growth, whereas pharmacological inhibition or fat-targeted knockdown of 
NPY2R is anti-angiogenic and anti-adipogenic. Thus, manipulations of NPY2-R activity 
within fat tissue offer new ways to remodel fat and treat obesity and metabolic syndrome 
[105]. 
NPY may be an important intra-islet paracrine hormone [38]. When produced by pancreatic 
islets, its expression is dependent on the prevailing endocrine environment. Islet NPY 
appears to constrain insulin release under a variety of conditions. Whether peripheral NPY 
has a hormone-like action and directly influences glucose metabolism and/or insulin 
secretion in vivo is under investigation. It this context NPY, at high concentrations, may 
contribute to the modulation of insulin secretion in vitro. NPY nerve fibers occur in the 
mouse pancreas and that most of these NPY nerve fibers are nonadrenergic. Furthermore, in 
the mouse, NPY enhances basal plasma insulin levels at high dose levels under in vivo 
conditions. At lower dose levels it inhibits glucose-induced, but not cholinergically induced 
insulin secretion [106]. It has also been reported that NPY may reduce plasma glucose 
concentrations during exercise by inhibiting glycogen breakdown in the splanchnic 
compartment [107, 108]. Moreover, the potential relation between circulating NPY and the 
pathophysiological consequences of obesity need further investigation.  
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Vettor et al. [109] found that peripheral NPY infusion in normal rats increased the overall 
rate of glucose disposal by increasing insulin responsiveness in skeletal muscle. Plasma 
leptin was significantly increased by hyperinsulinaemia, but was not affected by NPY 
infusion. Both the early and late phase of the insulin response to hyperglycaemia were 
significantly reduced by NPY. Based on their data for an increased glycolytic flux combined 
with a blunted increase in lactate, the authors suggested that NPY may raise insulin 
mediated glucose disposal by increasing its utilisation through the oxidative pathways. 
Intravenous NPY did not influence glucose metabolism in adipose tissue and leptin release 
[109].  
The above data indicate that NPY has different effects on insulin secretion when 
administered acutely via intracerebroventricular or intravenous routes. Thus, peripheral 
NPY plays a clear inhibitory role in glucose-induced insulin secretion. It is also possible that 
the duration of treatment, and not just the route of administration, may be a relevant factor. 
Several appetite-regulating genes (MCH, CRH, NPY, cholecystokinin, etc.) as well as their 
corresponding receptors, are expressed in the adipose tissue. The coexistance of locally 
produced NPY and NPYR-2 suggests a NPY autocrine/paracrine system of regulation of 
adipocyte function. Kos et al. reported that NPY is not only expressed but also secreted by 
human adipose tissue and insulin increases NPY secretion [110]. Direct effects of NPY on 
adipocyte function are also described. Thus, NPY was as potent as insulin in increasing both 
leptin and resistin secretion from pre-adipocytes from visceral fat in vitro [105]. Treatment 
of human subcutaneous adipocytes with recombinant human NPY downregulates leptin 
receptor [110], exerts an anti-lipopytic effect probably mediated by adenylate cyclase 
inhibition [111], and promotes the proliferation of pre-adipocytes [105, 112]. Probably, the 
enhanced local expression of NPY within visceral adipose tissue may contribute to the 
molecular mechanisms underlying increased visceral adiposity. The anti-lipolytic action on 
NPY can promote an increase in adipocyte size in hyperinsulinaemic conditions, such as 
abdominal obesity and metabolic syndrome.  
As compared to the numerous experimental and genetic studies, the clinical studies on 
circulatory NPY in obesity are not so many. It is interesting that significant alteration of NPY 
circulatory levels is not found in adults after weight reduction [113] as well as in adolescents 
[114] besides the progressive decrease of leptin levels. Probably, the leptin control on 
hypothalamic production of NPY cannot be estimated by the levels of the latter in 
peripheral circulation. 
In one of our recent studies on different morphological types of obesity [115], NPY levels in 
obese women were lower than those of the normal weight controls, the differences being 
significant when comparing the obese group as a whole and the subgroup with android 
obesity only (Table 1). There was a reverse correlation between NPY and body weight, and 
percentage body fat. In analogy with the comparisons regarding NPY, leptin levels did not 
differ significantly between the two groups of obese women. Our data are in accordance 
with the data of Zahorska-Markiewicz et al. in obese women and in women with normal 
weight [113]. Notwithstanding the absence of statistically significant differences in leptin 
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and NPY levels between our obese patients, we observed that at relatively highest leptin 
levels NPY had relatively lowest levels, and vice versa. This was supported by the 
ascertained negative correlation between the two hormones. In the control group, 
significantly lower leptin levels were associated with significantly higher NPY levels as 
compared to the obese group. We can suggest that the decrease of NPY concentration in 
obesity may play a role of a counter-regulatory factor intended to prevent further weight 
gain. In this and previous study of ours [116] we did not find significant differences in 
circulatory levels of resistin and TNF between lean women and women with both gynoid 
and android obesity. The latter were insulin-resistant with significantly higher basal 















* 2.350.59 15.756.79 4.591.13* 20.138.17*# 4.341.68*# 
Gynoid obesity
(n=27) 17.149.05 2.240.76 18.186.07 5.211.19 10.475.24 2.181.34 
Controls 
(n=24) 10.025.98 2.091.19 19.179.08 5.991.18 8.033.22 1.690.98 
(All data are expressed as meanSD.* - significant difference as compared to the control group; # - significant difference 
as compared to the group with gynoid obesity) 
Table 1. Hormonal parameters and HOMA-index in the women with obesity and normal weight 
women [115].  
The NPY levels were found similar in a group of patients with gestational diabetes mellitus 
and in pregnant women with normal glucose tolerance in a study of Ilhan et al [117]. 
Notably, the NPY concentration correlated positively with insulin levels in patients with 
type 2 diabetes mellitus [117]. These data suggest a potential involvement of circulating 
NPY in diabetes pathology that needs further purposeful studies.  
NPY and reproductive function 
Having in mind the fact, that NPY secretion is increased in response to metabolic challenges 
that inhibit luteinizing hormone releasing hormone (LHRH) secretion (e.g., fasting) and 
decreased by treatments that restore the metabolic deficit and reinstate reproductive 
function (e.g., re-feeding) [20], several studies have focused on the role of NPY in 
reproductive processes.  
A modulating action of NPY on the gonadotropic and somatotropic systems in experimental 
animals has been reported. NPY affects luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) release from anterior pituitary cells in vitro and enhances LHRH-induced 
LH secretion [118]. In female rats NPY decreased LH release in pituitary cell culture in vitro 
[119]. Barb et al. [120] conducted 2 experiments in ovariectomized prepubertal gilts to test 
the hypothesis that NPY stimulates appetite and modulates LH and growth hormone (GH) 
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produced NPY and NPYR-2 suggests a NPY autocrine/paracrine system of regulation of 
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adipocyte function are also described. Thus, NPY was as potent as insulin in increasing both 
leptin and resistin secretion from pre-adipocytes from visceral fat in vitro [105]. Treatment 
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enhanced local expression of NPY within visceral adipose tissue may contribute to the 
molecular mechanisms underlying increased visceral adiposity. The anti-lipolytic action on 
NPY can promote an increase in adipocyte size in hyperinsulinaemic conditions, such as 
abdominal obesity and metabolic syndrome.  
As compared to the numerous experimental and genetic studies, the clinical studies on 
circulatory NPY in obesity are not so many. It is interesting that significant alteration of NPY 
circulatory levels is not found in adults after weight reduction [113] as well as in adolescents 
[114] besides the progressive decrease of leptin levels. Probably, the leptin control on 
hypothalamic production of NPY cannot be estimated by the levels of the latter in 
peripheral circulation. 
In one of our recent studies on different morphological types of obesity [115], NPY levels in 
obese women were lower than those of the normal weight controls, the differences being 
significant when comparing the obese group as a whole and the subgroup with android 
obesity only (Table 1). There was a reverse correlation between NPY and body weight, and 
percentage body fat. In analogy with the comparisons regarding NPY, leptin levels did not 
differ significantly between the two groups of obese women. Our data are in accordance 
with the data of Zahorska-Markiewicz et al. in obese women and in women with normal 
weight [113]. Notwithstanding the absence of statistically significant differences in leptin 
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and NPY levels between our obese patients, we observed that at relatively highest leptin 
levels NPY had relatively lowest levels, and vice versa. This was supported by the 
ascertained negative correlation between the two hormones. In the control group, 
significantly lower leptin levels were associated with significantly higher NPY levels as 
compared to the obese group. We can suggest that the decrease of NPY concentration in 
obesity may play a role of a counter-regulatory factor intended to prevent further weight 
gain. In this and previous study of ours [116] we did not find significant differences in 
circulatory levels of resistin and TNF between lean women and women with both gynoid 
and android obesity. The latter were insulin-resistant with significantly higher basal 
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Table 1. Hormonal parameters and HOMA-index in the women with obesity and normal weight 
women [115].  
The NPY levels were found similar in a group of patients with gestational diabetes mellitus 
and in pregnant women with normal glucose tolerance in a study of Ilhan et al [117]. 
Notably, the NPY concentration correlated positively with insulin levels in patients with 
type 2 diabetes mellitus [117]. These data suggest a potential involvement of circulating 
NPY in diabetes pathology that needs further purposeful studies.  
NPY and reproductive function 
Having in mind the fact, that NPY secretion is increased in response to metabolic challenges 
that inhibit luteinizing hormone releasing hormone (LHRH) secretion (e.g., fasting) and 
decreased by treatments that restore the metabolic deficit and reinstate reproductive 
function (e.g., re-feeding) [20], several studies have focused on the role of NPY in 
reproductive processes.  
A modulating action of NPY on the gonadotropic and somatotropic systems in experimental 
animals has been reported. NPY affects luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) release from anterior pituitary cells in vitro and enhances LHRH-induced 
LH secretion [118]. In female rats NPY decreased LH release in pituitary cell culture in vitro 
[119]. Barb et al. [120] conducted 2 experiments in ovariectomized prepubertal gilts to test 
the hypothesis that NPY stimulates appetite and modulates LH and growth hormone (GH) 
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secretion, and that leptin modifies such acute effects of NPY on feeding behavior and LH 
and GH secretion. In the first one, gilts received icv injections of NPY. In the second one gilts 
received icv injections of leptin, NPY or NPY + leptin, and feed intake was measured. The 
authors found that NPY suppressed LH secretion and the 100 μg dose stimulated GH 
secretion. NPY reversed the inhibitory effect of leptin on feed intake and suppressed LH 
secretion, but serum GH concentrations were unaffected [120]. In another experiment in 
prepubertal gilts, Barb et al. [121] demonstrated that NPY did not alter basal LH secretion 
nor 10(-8) M LHRH-induced increase in LH secretion but 10(-9) M LHRH-stimulated LH 
secretion was reduced by NPY and was not different from control or LHRH alone. At the 
same time NPY increased basal GH secretion and enhanced the GH response to growth 
hormone releasing factor (GRF) at the level of the pituitary gland [121]. These data support 
the modulating role of NPY on GH and LH secretion. Experimental evidence in rodents and 
monkeys suggests that NPY preferentially exerts inhibitory effects on LHRH-LH secretion 
when estrogen levels are low [122, 123]. In primates, the role of NPY as a regulator of 
gonadotropin secretion is complicated by the observation that age may influence the effects 
of NPY (inhibitory or stimulatory), as does the site of exogenous NPY administration [124, 
125]. An important physiological role for NPY as a modulator of neuroendocrine activity 
which culminates in the preovulatory surge of LH is discussed [118] 
All above mentioned and many similar results support the hypothesis that NPY modulates 
feed intake, and LH and GH secretion and may serve as a neural link between metabolic 
state and the reproductive, as well as the growth axis. 
Clinical evidence suggests that NPY exerts primarily an inhibitory effect on the 
hypothalamic-pituitary-ovarian (HPO) axis in humans. Thus, a role for NPY in 
hypothalamic amenorrhea is inferred from the observation that NPY levels in the 
cerebrospinal fluid and serum are elevated in underweight amenorrheic women, and are 
returned to normal after long-term weight restoration in women who resumed normal 
menstrual cycling [126-128]. Starvation-induced alterations of neuropeptide activity 
probably contribute to neuroendocrine dysfunctions in anorexia nervosa. Kaye et al. [126] 
made the conclusion, that in girls with anorexia nervosa a disturbance of CNS corticotropin 
releasing hormone (CRH) activity is likely to be responsible for hypercortisolemia, while a 
disturbance of CNS NPY may contribute to amenorrhea [126]. In addition, disturbances of 
these neuropeptides could contribute to other symptoms such as increased physical activity, 
hypotension, reduced sexual interest, depression, and pathological feeding behavior [129]. 
Similarly, a role for NPY in the initiation of puberty is suggested by the observation that 
concentrations of NPY in girls with delayed puberty are higher than in girls matched for 
weight and body composition who exhibited normal pubertal development [130].  Higher 
concentrations of NPY in girls with constitutional delay of puberty (CDP) may be 
responsible for the disorder and reduced levels of IGF-I. Correlation of NPY with % body fat 
suggests an involvement of this neuropeptide in the process of fat accumulation associated 
with CDP [130]. 
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Of great interest is to focus on the role of NPY in one of the most common endocrine-
metabolic diseases, affecting up to 10% of women of reproductive age, the polycystic ovary 
syndrome (PCOS) [131, 132]. It is widely accepted that PCOS is a prototype of a sex specific 
metabolic syndrome [132-134]. Obesity is present in 30–70% of affected women depending 
on the setting of the study and the ethnical background of the subjects, and it is 
characterized by central distribution of fat [133, 135, 136]. In women with PCOS, 
hyperinsulinemia, dyslipidemia, and/or hypertension are highly dependent on obesity, 
which worsens all of the clinical manifestations of PCOS [133, 136-138]. At present there is 
an increasing body of evidence of high levels of atherogenic adipocytokines and low levels 
of adiponectin in women with PCOS that change according to variations of fat mass [139]. 
Endocrine function of the adipocytes is regulated mainly by nutritional status, and both 
these factors are complexly interweaved in the energy storing mechanism in the adipose 
tissue [140]. It is still not fully elucidated if there are consistent differences in the levels or in 
the effects of appetite-regulating hormones as is NPY in PCOS.  
Manneras et al. [141] demonstrated an enhanced mesenteric (visceral) adipose tissue 
expression of NPY in a rat model of PCOS in comparison with normal rats. Exercise reduced 
adiposity and adipose NPY expression and additionally normalized ovarian cyclicity [141]. 
Women with PCOS may exhibit altered leptin sensitivity of the hypothalamic NPY neurons 
to leptin inhibition, and higher plasma NPY levels have been observed in women with 
PCOS compared to nonPCOS controls; this may perturb LHRH secretion [142]. Thus, 
Baranowska et al. [143] found elevated NPY levels in both lean and overweight women with 
anovulatory PCOS. The increase in NPY in their study was independent of the increase in 
BMI. In obese women with PCOS, plasma leptin was increased compared to lean women 
[143]. Bidzińńska-Speichert et al. [144] also found higher leptin and NPY levels and lower 
galanin levels in PCOS women as compared to healthy controls [144]. These data are in 
conformity with observations from our recent on-going study where we found significantly 
higher NPY and leptin levels in obese insulin-resistant PCOS women as compared to 
nonPCOS weight matched women [Orbetzova, unpublished data]. It can be suggested that 
the feedback system in the interaction between leptin and NPY is disturbed in PCOS.  
In contrast, Romualdi et al. [145] demonstrated that in basal conditions, obese PCOS women 
exhibited lower NPY levels than obese controls. Ghrelin injection markedly increased NPY 
in controls, whereas PCOS women showed a deeply blunted NPY response to the stimulus. 
Metformin treatment induced a significant decrease in insulin levels and the concomitant 
recovery of NPY secretory capacity in response to ghrelin in PCOS women. Leptin levels, 
which were similar in the two groups, were not modified by ghrelin injection; metformin 
did not affect this pattern. The authors conclude that hyperinsulinaemia seems to play a 
pivotal role in the alteration of NPY response to ghrelin in obese PCOS women. This 
derangement could be implicated in the pathophysiology of obesity in these patients [145]. 
The limitations of this very interesting study on the ghrelin–NPY relationship in PCOS is the 
small number of patients (seven obese, hyperinsulinaemic subjects with PCOS and seven 
obese control women) and the data need further purposeful investigation. 
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Interventions that influence reproductive and metabolic function in PCOS may also affect 
levels of the adipose tissue hormones and regulators of appetite, such as NPY. It has been 
postulated that some of the effects of insulin-sensitizing agents in PCOS may be mediated 
through changes in adipocytokines levels. Some authors demonstrated that treatment of 
women with PCOS with insulin-sensitising agents induces a reduction in serum leptin levels 
[146-149]. In this context our recent data from a study comprising of 2 groups of overweight 
insulin-resistant PCOS women [150] showed that a 3-month treatment with metformin 
(Group 1) and rosiglitazone (Group 2), added to an oral hormone contraceptive (OHC) (a 
standard combination of ethynil oestradiol 35 g plus cyproterone acetate 2 mg) resulted in 
decrease of atherogenic adipocytokines (leptin, resistin, and TNFα) (Table 2) that may have 
beneficial effects in the future prevention of atherosclerosis and cardiovascular diseases in 
this risk cohort of young women. But the serum concentrations of NPY also decreased that 
is in support of some our previous [151] and other authors [143, 144] data for impaired NPY-
leptin link in PCOS. The change of NPY and adipocytokines was associated with weight loss 
only in the metformin group that is an expected effect of the drug and in conformity with 





Group 1 (n=32) 
Metformin + OHC 
Group 2 (n= 34) 
Rosiglitazone +OHC 
0 months 3 months 0 months 3 months 
Leptin (ng/ml) 13.173.42 6.401.40** 15.544.49 7.171.59** 
Resistin (ng/ml) 2.190.67 1.630.45** 2.610.79 1.680.41** 
TNF (pg/ml) 12.525.78 8.473.09*** 13.454.30 9.604.16**** 
NPY (ng/ml) 4.511.18 3.640.46* 4.541.47 3.211.25**** 
Weight (kg) 78.2420.14 75.5018.66** 82.4116.17 82.2315.80 
BMI (kg/m2) 28.454.38 27.453.73** 29.274.24 29.224.27 
Waist (cm) 88.697.72 86.635.92* 88.978.05 88.247.63 
Fats (%) 35.5610.10 33.988.77 35.5512.40 34.7213.09 
Fats (kg) 29.7715.20 27.2313.39* 32.3017.86 31.3317.94 
* - p<0.05 – vs basal; ** - p<0.01 – vs basal; *** - p=0.001 – vs basal; ****- p<0.001 – vs basal 
Table 2. NPY, adipose tissue hormones, and some clinical characteristics of the groups before and after 
treatment [150] 
Having in mind that the decrease in NPY and adipocytokines was not in parallel with 
changes in body weight and composition in the rosiglitazone group and was associated with 
only slignt and non significant influence on hyperinsulinaemia, resp. insulin resistance, 
additional direct adipose tissue and/or disease specific effects of the treatment may come 
into consideration that needs further elucidation. 
3. Ghrelin  
Ghrelin was discovered by Kojima et al. [152] in rat stomach extracts in 1999. This peptide 
has been identified in many species, including mammals, avians, amphibians, reptiles, and 
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fish [153-159] and the sequence of first seven amino acids of the N-terminal region of ghrelin 
are highly conserved between species [160]. 
Ghrelin is an orexigenic factor released primarily from the oxyntic cells of the stomach, but 
also from duodenum, ileum, caecum and colon [161, 162]. Gastric ghrelin cells had been 
classified as X/A-like cells by their round, compact, electron-dense secretory granules that 
distinguish them electron-microscopically from other previously characterized gastric 
endocrine cell types before the discovery of ghrelin [161, 163]. Ghrelin has also been 
detected in many other organs, such as the bowel, pancreas, kidney, placenta, lymphatic 
tissue, gonads, thyroid, adrenal, lung, pituitary and hypothalamus, and in different human 
neoplastic tissues and related cancer cell lines, such as gastric and intestinal carcinoids, 
lymphomas and thyroid, breast, liver, lung and prostate carcinomas. Levels of ghrelin 
expression in these normal and tumoral tissues or cell lines are lower than in the 
stomach, and although the potential physiological role of ghrelin as an autocrine/paracrine 
factor in these tissues is still under investigation [164].  
In mice, rats and humans, ghrelin is an acyl-peptide consisting of 28 amino acids, sharing a 
36% structural resemblance to motilin [165]. A hydroxyl group of serine at position 3 of the 
ghrelin molecule is esterified with an octanoic acid. The esterification increases the 
hydrophobicity of the ghrelin molecule, and is essential for most of its biological activities 
[152,166-168]. An enzyme that catalyses the acyl-modification of ghrelin was discovered in 
2008 by Yang et al. [169], was renamed ghrelin O-acyltransferase (GOAT). In vivo studies 
showed that GOAT gene disruption in mouse models completely abolished ghrelin 
acylation [170, 171]. GOAT inhibition leading to weight reduction and beneficial metabolic 
effects [172] is therefore a useful target for future development of therapeutic compounds 
for obesity and metabolic syndrome. 
Ghrelin receptor 
Ghrelin was discovered via its growth hormone releasing effect as an endogenous agonist of 
the GHS-R, that is still the only receptor so far described [152, 173, 174]. The GHS-R was first 
identified in 1996 as a seven transmembrane domain peptide totaling 366 amino acids. It is a 
G protein-coupled receptor (GPCR) that is linked to both Gq and Gs signaling pathways. It 
generates intracellular signaling through its Gα11 subunit, although the specific intracellular 
pathways elicited by this receptor are dependent on the tissue type in which it is expressed 
[175].  
There are two splice variants - GHS-R type 1a that is the receptor to which ghrelin binds and 
through which it exerts its stimulatory effects on growth hormone release [152, 161, 176, 
177], and GHS-R type 1b, which is a COOH-terminal truncated form of the type 1a receptor, 
and is physiologically inactive [178]. Ghrelin administration does not increase food intake in 
mice lacking GHS-R type 1a, suggesting that the orexigenic effects may be mediated by the 
above receptor; however, these mice have normal appetite and body composition [173, 179]. 
Ghrelin exists as two different molecular forms in both gastric ghrelin-producing cells and 
circulation: 1) acylated ghrelin (with the n-octanoic acid at the serine-3 position), which is 
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essential for activation of GHS-R1a and modulation of neuroendocrine and orexigenic 
effects; and 2) nonacylated ghrelin (des-acyl ghrelin), which is the most abundant form in 
the stomach and circulation but is unable to activate GHS-R1a, and to exhibit further GH-
releasing activity [180] (Figure 3). Nonetheless, food intake is induced by des-acyl ghrelin, 
administered by icv injection, to the same extent as ghrelin [181]. Nonacylated ghrelin exerts 
some cardiovascular and antiproliferative actions. Because the genome database does not 
contain another GPCR that resembles GHS-R, probably des-acyl ghrelin acts by binding 
different GHS-R subtypes or as yet unidentified receptor families  [178, 182]. 
 
Figure 3. Structure of nonacylated and acylated ghrelin 
GHS-R1a is widely distributed in the body with high expression levels in the hypothalamus 
and in all three components of the dorsal vagal complex, including the area postrema, the 
nucleus of the solitary tract (NTS), the dorsal motor nucleus of the vagus and 
parasympathetic preganglionic neurons [183]. Low expression is detected in other brain 
areas and in numerous other tissues including the myocardium, stomach, small intestine, 
pancreas, colon, adipose tissue, liver, kidney, lung, placenta and peripheral T-cells [152, 161, 
182, 184-187].  
The ghrelin receptor is well conserved across all vertebrate species examined, including a 
number of mammals, bird and fish. This strict conservation suggests that ghrelin and its 
receptor serve essential physiological functions [188]. Some studies have also described 
ghrelin analogues which show dissociation between the feeding effects and stimulation of 
GH, suggesting that GHS-R type 1a may not be the only receptor mediating the effects of 
ghrelin on food intake [189]. 
The gene encoding ghrelin also encodes another peptide, called obestatin. The administration 
of obestatin reduces food intake and weight gain in rats via activation of GPR3, an orphan 
G-protein coupled receptor [190, 191]. Therefore, one gene produces two products with 
opposing metabolic effects, which are exercised through different receptors [192]. 
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Ghrelin as a member of the ‘gut-brain axis’ 
The human body is endowed with a complex physiological system that maintains relatively 
constant body weight and fat stores despite the wide variations in daily energy intake and 
energy expenditure. With weight loss, compensatory physiological adaptations result in 
increased hunger and decreased energy expenditure, while opposite responses are triggered 
when body weight increases. This regulatory system is formed by multiple interactions 
between the gastrointestinal tract (GIT), adipose tissue, and the CNS and is influenced by 
behavioural, sensorial, autonomic, nutritional, and endocrine mechanisms [2, 3]. 
The hypothalamus (particularly the ARC) and the brain (particularly the NTS) are the main 
sites of convergence and integration of the central and peripheral signals that regulate food 
intake and energy expenditure [193, 194]. There are mechanisms of short-term regulation 
(satiety signals) which determine the beginning and the end of a meal (hunger and satiation) 
and the interval between meals (satiety) [195], and long-term regulatory factors (signals of 
adiposity) which help the body to regulate energy depots. Thus, meal-generated satiety 
signals from the GIT do interact with longer-term adiposity signals, such as insulin and 
leptin in maintaining energy balance. Satiety signals from the GIT are transmitted primarily 
through vagal and spinal nerves to the NTS. There is, however, a large integration and 
convergence of these signals by neural connections between the ARC nucleus, NTS, and 
vagal afferent fibres. The nervous system, in turn, influences gastric and pancreatic exocrine 
secretion, gastrointestinal motility, blood supply, and secretion of gut hormones [191].  
The GIT contributes with several peptides that have incretin-, hunger-, and satiety-
stimulating actions, such as ghrelin, glucagon-like peptide 1 (GLP-1), peptide YY (PYY), 
oxyntomodulin (OXM), and cholecystokinin (CCK) and that are considered as members of 
the ‘gut-brain axis’. Many of the GIT hormones that affect food intake are also synthesized 
in the brain, such as CCK, GLP-1, apolipoprotein A-IV, gastrin-releasing peptide, PYY, and 
ghrelin. Generally, peptides that reduce (or increase) food intake when administered 
systemically usually have the same action when administered centrally. This has been 
demonstrated for CCK, GLP-1, apolipoprotein A-IV, gastrin-releasing peptide, neuromedin 
B, and ghrelin [5, 6, 191]. 
Ghrelin is expressed in a group of neurons adjacent to the third ventricle, between the 
DMN, VMN, PVN and ARC. These neurons terminate on NPY/AgRP, POMC and 
corticotrophin-releasing hormone neurons, and are able to stimulate the activity of ARC 
NPY neurons, forming a central circuit which could mediate energy homeostasis [17]. The 
central ghrelin neurons also terminate on orexin-containing neurons within the LHA [18], 
and icv administration of ghrelin stimulates orexin-expressing neurons [18, 196]. The 
feeding response to centrally administered ghrelin is attenuated after administration of anti-
orexin antibody and in orexin-null mice [18].  
Ghrelin reaches the hypothalamus through the circulation, and the brain stem through vagal 
innervation. The integrity of the vagus nerve is crucial for ghrelin effects since vagotomy 
prevents its orexigenic effect in animal models and humans. Ghrelin is thought to exert its 
orexigenic action via the ARC in a pattern representing a functional antagonism to leptin. c-
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Fos expression increases within ARC NPY-synthesizing neurons after peripheral 
administration of ghrelin [197], and ghrelin fails to increase food intake following ablation 
of the ARC [198]. Studies of knockout mice demonstrate that both NPY and AgRP signalling 
mediate the effect of ghrelin, although neither neuropeptide is obligatory [179]. GHS-R are 
also found on the vagus nerve [185], and administration of ghrelin leads to c-Fos expression 
in the area postrema and NTS [196, 199], suggesting that the brainstem may also participate 
in ghrelin signalling. The orexigenic action of ghrelin occurs independently of its 
stimulatory effects on GH secretion [176, 198, 200]. It is more likely that the physiological 
role of ghrelin is to prepare the body for an influx of metabolic energy [201-203]. 
Administration of ghrelin, either centrally or peripherally, increases food intake and body 
weight and decreases fat utilization in rodents [176, 204]. Furthermore, central infusion of 
anti-ghrelin antibodies in rodents inhibits the normal feeding response after a period of 
fasting, suggesting that ghrelin is an endogenous regulator of food intake [199]. Human 
subjects who receive ghrelin intravenously demonstrate a potent increase in food intake of 
28% [205], and rising pre-prandial levels correlate with hunger scores in humans initiating 
meals spontaneously [202]. Chronic administration increases body weight, not only by 
stimulating food intake, but also by decreasing energy expenditure and fat catabolism [165, 
176, 199]. 
In summary, the orexigenic effect of hypothalamic ghrelin is regulated through a neuronal 
network involving food intake. Fasting results in increased release of ghrelin from the 
stomach (the exact mechanism of this remains obscure) leading to increased plasma ghrelin 
levels, which reach the hypothalamus either via the blood stream directly in areas with no 
blood–brain barrier, or by crossing the blood–brain barrier via a saturable transport system 
or via the vagus nerve and the NTS [206]. Ghrelin's effect on appetite is mediated by an 
effect both on the hypothalamus and the NTS.To stimulate the release of the orexigenic 
peptides, ghrelin-containing neurons send efferent fibers onto NPY/AgRP-expressing 
neurons. On the other hand, to suppress the release of the anorexigenic peptide, ghrelin-
containing neurons send efferent fibers onto POMC neurons [17]. Leptin directly inhibits 
appetite-stimulating effects of NPY and AgRP, whereas hypothalamic ghrelin augments 
NPY gene expression and blocked leptin-induced feeding reduction. Thus, ghrelin and 
leptin have a competitive interaction in feeding regulation [188].  
Regulation of ghrelin secretion 
Serum ghrelin concentrations vary widely throughout the day. The most known factor for 
the regulation of ghrelin secretion is feeding [201] - ghrelin decreases after food intake, and 
increases when fasting with higher values during the night sleep [180, 201, 207]. In people 
on a fixed feeding schedule, circulating ghrelin levels are thought to be regulated by both 
calorie intake and circulating nutritional signals [162, 176]. Thus, blood glucose levels may 
play an important role in the regulation of ghrelin secretion: oral or intravenous 
administration of glucose decreases plasma ghrelin concentration [208].  Ghrelin levels fall 
in response to the ingestion of food, but not following gastric distension by water intake 
suggesting that mechanical distension of the stomach alone clearly does not induce ghrelin 
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release [176, 209, 210]. In healthy subjects, a longer fasting period during the day (i.e. 
irregular meal pattern typical for several eating disorders) increases ghrelin concentration, 
but does not affect postprandial ghrelin response to a mixed meal [211]. The described 
pattern of secretion raised the concept of ghrelin as a hunger hormone, responsible for meal 
initiation. However, one study has failed to show a correlation between the ghrelin level and 
the spontaneous initiation of a meal in humans [212], and an alteration of feeding schedule 
in sheep has been shown to modify the timing of ghrelin peaks [213]. Recently Schüssler et 
al. showed that ghrelin levels increased significantly during a 30-min. interval following a 
presentation of pictures with food in healthy volunteers and suggested that in addition the 
sight of food can elevate ghrelin levels [214]. 
The most remarkable inhibitory input on ghrelin secretion is represented by the activation of 
somatostatin (SS) receptors as indicated by evidence that native SS, its natural analog 
cortistatin, and a synthetic analog such as octreotide lower circulating ghrelin levels in 
humans [215]. Ghrelin secretion in humans is under the stimulatory control of the 
cholinergic, namely muscarinic receptors, and acetylcholine is the first stimulatory 
neurotransmitter shown to play a stimulatory role on ghrelin secretion in humans [216]. 
In rats, ghrelin shows a bimodal peak, which occurs at the end of the light and dark periods 
[217]. In humans, ghrelin levels vary diurnally in phase with leptin, which is high in the 
morning and low at night [201].  
It should be considered that ghrelin secretion may be a conditioned response which occurs 
to prepare the metabolism for an influx of calories. But, whatever the precise physiological 
role of ghrelin, it appears not to be an essential regulator of food intake, as ghrelin-null 
animals do not have significantly altered body weight or food intake on a normal diet [218]. 
Relationship between ghrelin and glucose-insulin homeostasis  
Current extensive study data of ghrelin’s role in metabolic processes indicate its 
unambiguous relation with control on glucose homeostasis and β-cell function. Both GHS-
R1a and GHS-R1b are present in animal and human endocrine pancreas [219, 220]. Ghrelin 
is also present in pancreas, and epsilon pancreatic cells have been suggested to be a putative 
ghrelin-expressing cell type [221]. Moreover, a specific receptor able to bind both acylated 
and nonacylated ghrelin has also been demonstrated within the human pancreas; this is 
therefore a non-GHS-R1a [168, 222]. Ongoing studies support the hypothesis that ghrelin, 
independently of its acylation, modulates glucose metabolism at the hepatic level [223].  
Exogenic ghrelin short-tem effects induce hyperglycaemia in experimental rodents via an GH-
independent mechanism of action [224]. In contrast, ghrelin-receptor antagonists may 
improve glucose tolerance in rats, with no weight gain due to increased insulin secretion 
[225]. Acute administration of ghrelin to humans increases plasma glucose levels and 
amplifies the hyperglycaemic effect of arginine [226]. This hyperglycaemic effect might 
result from the endocrine effects of ghrelin as well as from direct effects on hepatocytes in 
which it modulates glycogen synthesis and gluconeogenesis [227]. Although data of ghrelin 
long-term effects are insufficiently clarified, a tendency of an increase in plasma glucose levels 
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Fos expression increases within ARC NPY-synthesizing neurons after peripheral 
administration of ghrelin [197], and ghrelin fails to increase food intake following ablation 
of the ARC [198]. Studies of knockout mice demonstrate that both NPY and AgRP signalling 
mediate the effect of ghrelin, although neither neuropeptide is obligatory [179]. GHS-R are 
also found on the vagus nerve [185], and administration of ghrelin leads to c-Fos expression 
in the area postrema and NTS [196, 199], suggesting that the brainstem may also participate 
in ghrelin signalling. The orexigenic action of ghrelin occurs independently of its 
stimulatory effects on GH secretion [176, 198, 200]. It is more likely that the physiological 
role of ghrelin is to prepare the body for an influx of metabolic energy [201-203]. 
Administration of ghrelin, either centrally or peripherally, increases food intake and body 
weight and decreases fat utilization in rodents [176, 204]. Furthermore, central infusion of 
anti-ghrelin antibodies in rodents inhibits the normal feeding response after a period of 
fasting, suggesting that ghrelin is an endogenous regulator of food intake [199]. Human 
subjects who receive ghrelin intravenously demonstrate a potent increase in food intake of 
28% [205], and rising pre-prandial levels correlate with hunger scores in humans initiating 
meals spontaneously [202]. Chronic administration increases body weight, not only by 
stimulating food intake, but also by decreasing energy expenditure and fat catabolism [165, 
176, 199]. 
In summary, the orexigenic effect of hypothalamic ghrelin is regulated through a neuronal 
network involving food intake. Fasting results in increased release of ghrelin from the 
stomach (the exact mechanism of this remains obscure) leading to increased plasma ghrelin 
levels, which reach the hypothalamus either via the blood stream directly in areas with no 
blood–brain barrier, or by crossing the blood–brain barrier via a saturable transport system 
or via the vagus nerve and the NTS [206]. Ghrelin's effect on appetite is mediated by an 
effect both on the hypothalamus and the NTS.To stimulate the release of the orexigenic 
peptides, ghrelin-containing neurons send efferent fibers onto NPY/AgRP-expressing 
neurons. On the other hand, to suppress the release of the anorexigenic peptide, ghrelin-
containing neurons send efferent fibers onto POMC neurons [17]. Leptin directly inhibits 
appetite-stimulating effects of NPY and AgRP, whereas hypothalamic ghrelin augments 
NPY gene expression and blocked leptin-induced feeding reduction. Thus, ghrelin and 
leptin have a competitive interaction in feeding regulation [188].  
Regulation of ghrelin secretion 
Serum ghrelin concentrations vary widely throughout the day. The most known factor for 
the regulation of ghrelin secretion is feeding [201] - ghrelin decreases after food intake, and 
increases when fasting with higher values during the night sleep [180, 201, 207]. In people 
on a fixed feeding schedule, circulating ghrelin levels are thought to be regulated by both 
calorie intake and circulating nutritional signals [162, 176]. Thus, blood glucose levels may 
play an important role in the regulation of ghrelin secretion: oral or intravenous 
administration of glucose decreases plasma ghrelin concentration [208].  Ghrelin levels fall 
in response to the ingestion of food, but not following gastric distension by water intake 
suggesting that mechanical distension of the stomach alone clearly does not induce ghrelin 
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release [176, 209, 210]. In healthy subjects, a longer fasting period during the day (i.e. 
irregular meal pattern typical for several eating disorders) increases ghrelin concentration, 
but does not affect postprandial ghrelin response to a mixed meal [211]. The described 
pattern of secretion raised the concept of ghrelin as a hunger hormone, responsible for meal 
initiation. However, one study has failed to show a correlation between the ghrelin level and 
the spontaneous initiation of a meal in humans [212], and an alteration of feeding schedule 
in sheep has been shown to modify the timing of ghrelin peaks [213]. Recently Schüssler et 
al. showed that ghrelin levels increased significantly during a 30-min. interval following a 
presentation of pictures with food in healthy volunteers and suggested that in addition the 
sight of food can elevate ghrelin levels [214]. 
The most remarkable inhibitory input on ghrelin secretion is represented by the activation of 
somatostatin (SS) receptors as indicated by evidence that native SS, its natural analog 
cortistatin, and a synthetic analog such as octreotide lower circulating ghrelin levels in 
humans [215]. Ghrelin secretion in humans is under the stimulatory control of the 
cholinergic, namely muscarinic receptors, and acetylcholine is the first stimulatory 
neurotransmitter shown to play a stimulatory role on ghrelin secretion in humans [216]. 
In rats, ghrelin shows a bimodal peak, which occurs at the end of the light and dark periods 
[217]. In humans, ghrelin levels vary diurnally in phase with leptin, which is high in the 
morning and low at night [201].  
It should be considered that ghrelin secretion may be a conditioned response which occurs 
to prepare the metabolism for an influx of calories. But, whatever the precise physiological 
role of ghrelin, it appears not to be an essential regulator of food intake, as ghrelin-null 
animals do not have significantly altered body weight or food intake on a normal diet [218]. 
Relationship between ghrelin and glucose-insulin homeostasis  
Current extensive study data of ghrelin’s role in metabolic processes indicate its 
unambiguous relation with control on glucose homeostasis and β-cell function. Both GHS-
R1a and GHS-R1b are present in animal and human endocrine pancreas [219, 220]. Ghrelin 
is also present in pancreas, and epsilon pancreatic cells have been suggested to be a putative 
ghrelin-expressing cell type [221]. Moreover, a specific receptor able to bind both acylated 
and nonacylated ghrelin has also been demonstrated within the human pancreas; this is 
therefore a non-GHS-R1a [168, 222]. Ongoing studies support the hypothesis that ghrelin, 
independently of its acylation, modulates glucose metabolism at the hepatic level [223].  
Exogenic ghrelin short-tem effects induce hyperglycaemia in experimental rodents via an GH-
independent mechanism of action [224]. In contrast, ghrelin-receptor antagonists may 
improve glucose tolerance in rats, with no weight gain due to increased insulin secretion 
[225]. Acute administration of ghrelin to humans increases plasma glucose levels and 
amplifies the hyperglycaemic effect of arginine [226]. This hyperglycaemic effect might 
result from the endocrine effects of ghrelin as well as from direct effects on hepatocytes in 
which it modulates glycogen synthesis and gluconeogenesis [227]. Although data of ghrelin 
long-term effects are insufficiently clarified, a tendency of an increase in plasma glucose levels 
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appears to be presented [224]. Many of the studies in patients with type 1 diabetes show low 
ghrelin levels, probably as a manifestation of a compensatory mechanism against 
hyperglycaemia [225]. 
Numerous studies indicate a negative association between systemic ghrelin and insulin 
levels [184, 228]. Thus, ghrelin is found to inhibit insulin secretion both in vitro and in vivo in 
most human and animal studies [226, 229]. In humans the acute administration of ghrelin 
inhibits spontaneous and arginine-stimulated insulin secretion but does not affect the 
insulin response to the oral glucose tolerance test (OGTT) [226, 230, 231]. In addition, the 
regulation of insulin secretion by ghrelin is closely related to the blood glucose level. Date et 
al. [232] reported that ghrelin stimulates insulin release in the presence of high levels of 
glucose (8.3mM) that could independently cause insulin release from cultured islet cells. In 
contrast, ghrelin had no effect on insulin release in the context of a basal level of glucose (2.8 
mM) [232]. Antagonism of the pancreatic ghrelin can enhance insulin release to meet 
increased demand for insulin in high-fat diet-induced obesity of mice [233].  
Ghrelin might influence some of the peripheral effects of insulin. Thus, it is found to 
stimulate hepatic glucose production [227], reinforce the action of insulin on glucose 
disposal in mice [234], inhibit adinopectin secretion [235] and stimulate secretion of the 
counter-regulatory hormones, including GH, cortisol, adrenaline [236] and possibly 
glucagon [237]. In healthy subjects, in the absence of GH and cortisol secretion, ghrelin 
acutely decreased peripheral, but not hepatic, insulin sensitivity together with stimulation of 
lipolysis. These effects occurred without detectable suppression of AMP-activated protein 
kinase phosphorylation (an alleged second messenger for ghrelin) in skeletal muscle [238]. 
So, ghrelin also exerts direct metabolic effects towards induction of insulin resistance 
independent of the regulation by counter-regulatory hormones.  
Insulin in turn decreases ghrelin levels, regardless of changes in glucose concentrations  
[239]. Broglio et al. [240] have found that both oral and intravenous insulin suppress ghrelin, 
although they exhibit opposite effects on glucose levels. The same authors have shown that 
protein-induced inhibition of ghrelin is enabled by oral administration, while intravenous 
arginine does not lead to ghrelin reduction regardless of insulin elevations, which is a fact of 
interest and of relation to protein diets [240]. 
Given all the above data, it is proposed that ghrelin could have an important function in 
glucose homeostasis and insulin release, independent of GH secretion [241]. Data of 
administration of GHSR1a antagonists suggest that these compounds improve long-term 
glucose tolerance and insulin resistance. Since there are some differences about the role of 
ghrelin on insulin secretion [188], further research on ghrelin-insulin interrelationship is 
expected. At least theoretically, ghrelin and/or its signalling manipulation could be used for 
the treatment or prevention of diseases of glucose homeostasis. 
Ghrelin in obesity, diabetes mellitus and metabolic syndrome 
In addition to a probable role in meal initiation, ghrelin seems to be an adiposity-related 
hormone that is involved in the long-term regulation of body weight Plasma ghrelin levels 
are inversely correlated with body mass index and current evidence strongly suggests that 
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ghrelin could contribute to obesity and the metabolic syndrome [225]. Variations within the 
ghrelin gene may contribute to early-onset obesity [242, 243] or be protective against fat 
accumulation [225], but the role of ghrelin polymorphisms in the control of body weight 
continues to be controversial [244, 245].  
It has been shown that ghrelin secretion differs between lean and obese subjects. Thus, 
plasma ghrelin concentration is found to be low in obese people and high in lean people in 
some studies [207, 208, 246]. The expression of ghrelin receptors in the hypothalamus 
increases markedly with either fasting or chronic food restriction [247], as does the 
hypothalamic response to a ghrelin-receptor agonist [248], which is consistent with a feed-
forward loop that enhances ghrelin-mediated stimulation of appetite during energy deficit. 
Anorexic individuals have high circulating ghrelin which falls to normal levels after weight 
gain [249]. The suppressed plasma ghrelin levels in obese subjects normalize after diet-
induced weight loss [250]. The postprandial falls of serum ghrelin concentrations are 
proportional to energy intake in lean subjects, but not in obese subjects. Unlike lean 
individuals, obese subjects do not demonstrate the same rapid post-prandial drop in ghrelin 
levels [251]. Moreover, obesity is associated with much lower overall reduction of 
postprandial ghrelin levels and an absence of nocturnal elevations as seen in subjects of 
normal weight [194, 195, 210]. This may result in increased food intake and contribute to 
obesity.  The fall in plasma ghrelin concentration after bariatric surgery, despite weight loss, 
is thought to be partly responsible for the suppression of appetite and weight loss seen after 
these operations [252].  
The severe hyperphagia seen in Prader–Willi syndrome is associated with elevated ghrelin 
levels [253] that is in contrast to other forms of obesity, and it has been hypothesized that 
ghrelin might contribute to the nature of this syndrome. Moreover, there are similarities 
between the clinical features of Prader–Willi syndrome and those predicted from 
overstimulation of NPY by ghrelin (e.g. hyperphagic obesity, hypogonadotropic 
hypogonadism and dysregulation of GH) and the correlation between ghrelin levels and 
hyperphagia and excessive obesity, in these patients [254]. Indeed, the high ghrelin levels in 
obese people with Prader–Willi syndrome make the carriers of the syndrome logical first-
line candidates for testing the weight reducing effects of ghrelin-blocking agents 
Recently, the role of ghrelin in diabetes mellitus has been investigated: polymorphisms of 
the ghrelin gene are associated with the risk of diabetes [255], ghrelin promotes regeneration 
of b-cells in streptozocin-treated newborn rats, preventing the development of diabetes in 
disease-prone animals after b-cell destruction [256], and ghrelin antagonists partially reverse 
hyperphagia in uncontrolled, streptozocin-diabetic rats [257]. It has been found that fasting 
ghrelin concentrations are lower in people with type 2 diabetes mellitus than in non-diabetic 
people, even after adjusting for BMI. It has also been shown that the decrease in circulating 
ghrelin is proportionate to the degree of insulin insensitivity. We also found significant 
negative correlation between ghrelin and fasting insulin, and HOMA-index, respectively, in 
insulin resistant women with type 2 diabetes mellitus [258]. These observations suggest that 
ghrelin and insulin sensitivity are linked. All the data indicate that ghrelin might have a role 
in the pathogenesis and therapy of diabetes, contributing to either the impairment of insulin 
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appears to be presented [224]. Many of the studies in patients with type 1 diabetes show low 
ghrelin levels, probably as a manifestation of a compensatory mechanism against 
hyperglycaemia [225]. 
Numerous studies indicate a negative association between systemic ghrelin and insulin 
levels [184, 228]. Thus, ghrelin is found to inhibit insulin secretion both in vitro and in vivo in 
most human and animal studies [226, 229]. In humans the acute administration of ghrelin 
inhibits spontaneous and arginine-stimulated insulin secretion but does not affect the 
insulin response to the oral glucose tolerance test (OGTT) [226, 230, 231]. In addition, the 
regulation of insulin secretion by ghrelin is closely related to the blood glucose level. Date et 
al. [232] reported that ghrelin stimulates insulin release in the presence of high levels of 
glucose (8.3mM) that could independently cause insulin release from cultured islet cells. In 
contrast, ghrelin had no effect on insulin release in the context of a basal level of glucose (2.8 
mM) [232]. Antagonism of the pancreatic ghrelin can enhance insulin release to meet 
increased demand for insulin in high-fat diet-induced obesity of mice [233].  
Ghrelin might influence some of the peripheral effects of insulin. Thus, it is found to 
stimulate hepatic glucose production [227], reinforce the action of insulin on glucose 
disposal in mice [234], inhibit adinopectin secretion [235] and stimulate secretion of the 
counter-regulatory hormones, including GH, cortisol, adrenaline [236] and possibly 
glucagon [237]. In healthy subjects, in the absence of GH and cortisol secretion, ghrelin 
acutely decreased peripheral, but not hepatic, insulin sensitivity together with stimulation of 
lipolysis. These effects occurred without detectable suppression of AMP-activated protein 
kinase phosphorylation (an alleged second messenger for ghrelin) in skeletal muscle [238]. 
So, ghrelin also exerts direct metabolic effects towards induction of insulin resistance 
independent of the regulation by counter-regulatory hormones.  
Insulin in turn decreases ghrelin levels, regardless of changes in glucose concentrations  
[239]. Broglio et al. [240] have found that both oral and intravenous insulin suppress ghrelin, 
although they exhibit opposite effects on glucose levels. The same authors have shown that 
protein-induced inhibition of ghrelin is enabled by oral administration, while intravenous 
arginine does not lead to ghrelin reduction regardless of insulin elevations, which is a fact of 
interest and of relation to protein diets [240]. 
Given all the above data, it is proposed that ghrelin could have an important function in 
glucose homeostasis and insulin release, independent of GH secretion [241]. Data of 
administration of GHSR1a antagonists suggest that these compounds improve long-term 
glucose tolerance and insulin resistance. Since there are some differences about the role of 
ghrelin on insulin secretion [188], further research on ghrelin-insulin interrelationship is 
expected. At least theoretically, ghrelin and/or its signalling manipulation could be used for 
the treatment or prevention of diseases of glucose homeostasis. 
Ghrelin in obesity, diabetes mellitus and metabolic syndrome 
In addition to a probable role in meal initiation, ghrelin seems to be an adiposity-related 
hormone that is involved in the long-term regulation of body weight Plasma ghrelin levels 
are inversely correlated with body mass index and current evidence strongly suggests that 
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ghrelin could contribute to obesity and the metabolic syndrome [225]. Variations within the 
ghrelin gene may contribute to early-onset obesity [242, 243] or be protective against fat 
accumulation [225], but the role of ghrelin polymorphisms in the control of body weight 
continues to be controversial [244, 245].  
It has been shown that ghrelin secretion differs between lean and obese subjects. Thus, 
plasma ghrelin concentration is found to be low in obese people and high in lean people in 
some studies [207, 208, 246]. The expression of ghrelin receptors in the hypothalamus 
increases markedly with either fasting or chronic food restriction [247], as does the 
hypothalamic response to a ghrelin-receptor agonist [248], which is consistent with a feed-
forward loop that enhances ghrelin-mediated stimulation of appetite during energy deficit. 
Anorexic individuals have high circulating ghrelin which falls to normal levels after weight 
gain [249]. The suppressed plasma ghrelin levels in obese subjects normalize after diet-
induced weight loss [250]. The postprandial falls of serum ghrelin concentrations are 
proportional to energy intake in lean subjects, but not in obese subjects. Unlike lean 
individuals, obese subjects do not demonstrate the same rapid post-prandial drop in ghrelin 
levels [251]. Moreover, obesity is associated with much lower overall reduction of 
postprandial ghrelin levels and an absence of nocturnal elevations as seen in subjects of 
normal weight [194, 195, 210]. This may result in increased food intake and contribute to 
obesity.  The fall in plasma ghrelin concentration after bariatric surgery, despite weight loss, 
is thought to be partly responsible for the suppression of appetite and weight loss seen after 
these operations [252].  
The severe hyperphagia seen in Prader–Willi syndrome is associated with elevated ghrelin 
levels [253] that is in contrast to other forms of obesity, and it has been hypothesized that 
ghrelin might contribute to the nature of this syndrome. Moreover, there are similarities 
between the clinical features of Prader–Willi syndrome and those predicted from 
overstimulation of NPY by ghrelin (e.g. hyperphagic obesity, hypogonadotropic 
hypogonadism and dysregulation of GH) and the correlation between ghrelin levels and 
hyperphagia and excessive obesity, in these patients [254]. Indeed, the high ghrelin levels in 
obese people with Prader–Willi syndrome make the carriers of the syndrome logical first-
line candidates for testing the weight reducing effects of ghrelin-blocking agents 
Recently, the role of ghrelin in diabetes mellitus has been investigated: polymorphisms of 
the ghrelin gene are associated with the risk of diabetes [255], ghrelin promotes regeneration 
of b-cells in streptozocin-treated newborn rats, preventing the development of diabetes in 
disease-prone animals after b-cell destruction [256], and ghrelin antagonists partially reverse 
hyperphagia in uncontrolled, streptozocin-diabetic rats [257]. It has been found that fasting 
ghrelin concentrations are lower in people with type 2 diabetes mellitus than in non-diabetic 
people, even after adjusting for BMI. It has also been shown that the decrease in circulating 
ghrelin is proportionate to the degree of insulin insensitivity. We also found significant 
negative correlation between ghrelin and fasting insulin, and HOMA-index, respectively, in 
insulin resistant women with type 2 diabetes mellitus [258]. These observations suggest that 
ghrelin and insulin sensitivity are linked. All the data indicate that ghrelin might have a role 
in the pathogenesis and therapy of diabetes, contributing to either the impairment of insulin 
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sensitivity or to the restraint of body-mass gain. Nonetheless, because of the controversy 
about the cause-and-effect relationship between ghrelin levels and diabetes mellitus, further 
investigations are needed to elucidate the precise role of ghrelin (and its variants) in the 
development and treatment of this disease.  
Low plasma ghrelin levels are associated with metabolic cluster per se, which indicates that 
ghrelin might be a useful biomarker for the metabolic syndrome [228, 259]. Thus, conditions 
of severe metabolic syndrome due to insulin resistance, such as in obese Pima Indians, are 
related with reduced fasting ghrelin plasma levels [207]. In a study on the relation between 
metabolic parameters, ghrelin, leptin and IGF-1 in a cohort of 1,045 individuals, Ukkola et al. 
[260] have found that low ghrelin levels are associated with metabolic syndrome and type 2 
diabetes mellitus only in presence of insulin and leptin resistance. At high leptin levels, 
ghrelin concentrations decrease linearly with increasing the number of metabolic syndrome 
components [260]. In patients on haemodialysis, fasting ghrelin levels negatively correlate 
with metabolic syndrome manifestation, ghrelin shows a tendency to decrease with 
increasing the number of the metabolic syndrome components, and the waist circumference 
appears to be an independent predictor of its levels [261]. 
In patients with the metabolic syndrome and low ghrelin levels, intraarterial administration 
of ghrelin rapidly improves endothelial function [262]. Similar to insulin, ghrelin stimulates 
an increased nitrogen oxide (NO) production in cultured bovine aortic endothelial cells in a 
dose- and time-dependent manner. It has been found that ghrelin-induced NO production 
in human aortic endothelial cells is arrested by their pre-treatment with a NO-synthase 
inhibitor, phosphatidylinositol synthase (PI 3)-kinase inhibitor, selective GHSR-1а 
antagonist or “exclusion” of these receptors. On the other hand, ghrelin has been found to 
stimulate enhanced phosphorylation of Akt (Ser473) and endothelial NO-synthase in human 
aortic endothelial cells, as well as phosphorylation of mitogen-activated protein (МАР) 
kinase, but not of МАР-kinase-dependent production of the vasoconstrictor endothelin-1 in 
bovine aortic endothelial cells. With regard to these data it may be concluded that ghrelin 
exhibits characteristic, rapid vascular effects, presented as stimulated NO production in the 
endothelium via signal pathways including the GHSR-1a, PI 3-kinase, Akt and endothelial 
NO-synthase, which may be taken into consideration for the development of innovative 
therapeutic strategies for endothelial dysfunction in diabetes and insulin resistance [262]. 
Vlasova et al. have found that peripheral injection of a ghrelin antagonist in experimental 
animals (rats) increases arterial pressure and pulse rate via at least partial activation of the 
sympathetic nervous system [263]. These findings direct our attention to eventual 
cardiovascular adverse effects, when administering ghrelin antagonists as a therapeutic 
strategy for reducing food intake, particularly in patients at a high cardiovascular (CV) risk 
(e.g., patients with metabolic syndrome). 
Ghrelin’s role in processes of reproduction and PCOS 
Presently not so much is known of ghrelin effects on processes of reproduction. 
Experimental models in rats have shown that ghrelin plays a role at different levels of the 
hypothalamic-pituitary-ovary axis regulation. Its central route of administration in female 
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rats results in suppression of the LH secretion at various stages of estrus [264]. In in vitro 
settings, ghrelin also inhibits gonadotropin-releasing hormone (GnRH) secretion from the 
hypothalamus [264]. At a pituitary level, ghrelin exhibits either stimulating or inhibiting 
action on basal LH secretion, depending on the menstrual cycle stage. However, the in vitro 
GnRH-stimulated LH release is inhibited by ghrelin, regardless of the steroid medium [265]. 
In rhesus monkeys, the confirmed inhibitory effect of ghrelin on the GnRH-LH system 
suggests that in primates, ghrelin exhibits a central regulatory effect on processes of 
reproduction [266].  
It was shown by Kluge et al. that ghrelin suppresses the secretion of LH and FSH in healthy 
women [267]. Ghrelin levels have been found to be higher in anovulatory women with 
excessive physical loading-induced anorexia nervosa and amenorrhea, as well as in normal 
weight-women with hypothalamic amenorrhea [268-270]. In normal-weight women with 
amenorrhea, the increased ghrelin levels have been associated with disturbed dietary habits 
and regimen [271]. It is not clear whether disturbances in ghrelin secretion play a direct role 
in neuroendocrine regulation of the hypothalamic-pituitary-ovary axis or present a marker 
of the metabolic status itself.  
In males, ghrelin has an additional inhibitory role, decreasing human chorionic 
gonadotropin (hCG)- and cAMP-stimulated testosterone secretion [272] and the expression 
of the gene encoding stem cell factor that is a key mediator of spermatogenesis and a 
putative regulator of Leydig-cell development [273]. In hypogonadal males, a positive 
correlation between ghrelin and androgens persists after testosterone replacement therapy 
[274]. 
There is no consensus on whether alterations in levels of appetite-regulating hormones, such 
as ghrelin, are associated with PCOS. Fasting ghrelin levels were found decreased in most 
[275-279], but not in all studies [280, 281] in women with PCOS. Thus in 2002, Pagotto et al. 
[275] first demonstrated that ghrelin levels were lower in obese women with PCOS, 
compared with these in weight-matched healthy controls. Ghrelin has been inversely 
correlated with insulin resistance markers. These correlations have persisted even after 
therapy (hypocaloric diet plus metformin or placebo) for improving insulin sensitivity. In 
both groups, weight reduction has resulted in minimal changes of plasma ghrelin levels. 
The observed negative correlation between ghrelin and androstenedione, but not between 
ghrelin and testosterone or other androgens, is interesting [275]. In PCOS, Schofl et al. have 
confirmed lower ghrelin levels that are in a close correlation with insulin resistance rates 
[276]. After therapy with metformin in insulin-resistant women, ghrelin levels have 
increased, but in insulin-sensitive women with PCOS, ghrelin levels have been comparable 
to these in controls. Furthermore, the authors have found no correlation between ghrelin 
and the body mass index (BMI) [276], which suggests a ghrelin-insulin resistance 
interrelation apart from ghrelin activity in controlling appetite, body weight, respectively. 
Panidis et al. [282] have reported that women with PCOS and hyperandrogenaemia have 
significantly lower ghrelin levels compared to healthy controls and PCOS carriers with 
clinical hyperandrogenism but normal androgen levels. Ghrelin levels in the latter are lower 
than these found in the control group, but the differences are not statistically significant. The 
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sensitivity or to the restraint of body-mass gain. Nonetheless, because of the controversy 
about the cause-and-effect relationship between ghrelin levels and diabetes mellitus, further 
investigations are needed to elucidate the precise role of ghrelin (and its variants) in the 
development and treatment of this disease.  
Low plasma ghrelin levels are associated with metabolic cluster per se, which indicates that 
ghrelin might be a useful biomarker for the metabolic syndrome [228, 259]. Thus, conditions 
of severe metabolic syndrome due to insulin resistance, such as in obese Pima Indians, are 
related with reduced fasting ghrelin plasma levels [207]. In a study on the relation between 
metabolic parameters, ghrelin, leptin and IGF-1 in a cohort of 1,045 individuals, Ukkola et al. 
[260] have found that low ghrelin levels are associated with metabolic syndrome and type 2 
diabetes mellitus only in presence of insulin and leptin resistance. At high leptin levels, 
ghrelin concentrations decrease linearly with increasing the number of metabolic syndrome 
components [260]. In patients on haemodialysis, fasting ghrelin levels negatively correlate 
with metabolic syndrome manifestation, ghrelin shows a tendency to decrease with 
increasing the number of the metabolic syndrome components, and the waist circumference 
appears to be an independent predictor of its levels [261]. 
In patients with the metabolic syndrome and low ghrelin levels, intraarterial administration 
of ghrelin rapidly improves endothelial function [262]. Similar to insulin, ghrelin stimulates 
an increased nitrogen oxide (NO) production in cultured bovine aortic endothelial cells in a 
dose- and time-dependent manner. It has been found that ghrelin-induced NO production 
in human aortic endothelial cells is arrested by their pre-treatment with a NO-synthase 
inhibitor, phosphatidylinositol synthase (PI 3)-kinase inhibitor, selective GHSR-1а 
antagonist or “exclusion” of these receptors. On the other hand, ghrelin has been found to 
stimulate enhanced phosphorylation of Akt (Ser473) and endothelial NO-synthase in human 
aortic endothelial cells, as well as phosphorylation of mitogen-activated protein (МАР) 
kinase, but not of МАР-kinase-dependent production of the vasoconstrictor endothelin-1 in 
bovine aortic endothelial cells. With regard to these data it may be concluded that ghrelin 
exhibits characteristic, rapid vascular effects, presented as stimulated NO production in the 
endothelium via signal pathways including the GHSR-1a, PI 3-kinase, Akt and endothelial 
NO-synthase, which may be taken into consideration for the development of innovative 
therapeutic strategies for endothelial dysfunction in diabetes and insulin resistance [262]. 
Vlasova et al. have found that peripheral injection of a ghrelin antagonist in experimental 
animals (rats) increases arterial pressure and pulse rate via at least partial activation of the 
sympathetic nervous system [263]. These findings direct our attention to eventual 
cardiovascular adverse effects, when administering ghrelin antagonists as a therapeutic 
strategy for reducing food intake, particularly in patients at a high cardiovascular (CV) risk 
(e.g., patients with metabolic syndrome). 
Ghrelin’s role in processes of reproduction and PCOS 
Presently not so much is known of ghrelin effects on processes of reproduction. 
Experimental models in rats have shown that ghrelin plays a role at different levels of the 
hypothalamic-pituitary-ovary axis regulation. Its central route of administration in female 
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rats results in suppression of the LH secretion at various stages of estrus [264]. In in vitro 
settings, ghrelin also inhibits gonadotropin-releasing hormone (GnRH) secretion from the 
hypothalamus [264]. At a pituitary level, ghrelin exhibits either stimulating or inhibiting 
action on basal LH secretion, depending on the menstrual cycle stage. However, the in vitro 
GnRH-stimulated LH release is inhibited by ghrelin, regardless of the steroid medium [265]. 
In rhesus monkeys, the confirmed inhibitory effect of ghrelin on the GnRH-LH system 
suggests that in primates, ghrelin exhibits a central regulatory effect on processes of 
reproduction [266].  
It was shown by Kluge et al. that ghrelin suppresses the secretion of LH and FSH in healthy 
women [267]. Ghrelin levels have been found to be higher in anovulatory women with 
excessive physical loading-induced anorexia nervosa and amenorrhea, as well as in normal 
weight-women with hypothalamic amenorrhea [268-270]. In normal-weight women with 
amenorrhea, the increased ghrelin levels have been associated with disturbed dietary habits 
and regimen [271]. It is not clear whether disturbances in ghrelin secretion play a direct role 
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ghrelin and testosterone or other androgens, is interesting [275]. In PCOS, Schofl et al. have 
confirmed lower ghrelin levels that are in a close correlation with insulin resistance rates 
[276]. After therapy with metformin in insulin-resistant women, ghrelin levels have 
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Panidis et al. [282] have reported that women with PCOS and hyperandrogenaemia have 
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than these found in the control group, but the differences are not statistically significant. The 
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authors have concluded that PCOS-associated hyperandrogenaemia results in reduced 
ghrelin concentrations [282]. Although PCOS-associated hyperandrogenaemia and 17-OH-
progesterone levels are inversely related to ghrelin levels, anovulation and polycystic ovary 
morphology are associated with higher ghrelin concentrations [283]. Thus, it has been 
hypothesized that different clinical and biochemical manifestations of the syndrome might 
be associated with different concentrations of ghrelin. 
In support of the relation between PCOS and ghrelin, there are data of increased ghrelin 
levels after a 3-month treatment with an oral contraceptive containing both ethinyl 
oestradiol and drospirenone in women with PCOS [284]. Similar to other studies, ghrelin is 
negatively correlated with the BMI, waist/hip ratio, insulin, homeostatic model assessment 
(HOMA) index and free testosterone [284]. According to a study conducted by Fusco et al., 
ghrelin administration in normal weight-women and obese PCOS patients has exerted 
glucose-enhancing and insulin-lowering effects, the latter absent in the normal weight-
controls [285], which supports the relation between ghrelin and hormonal/metabolic 
disorders in PCOS. 
One of studies that have not confirmed changes in ghrelin levels in women with PCOS is 
this conducted by Orio et al. [280]. The authors have found no correlation between ghrelin 
and either of the hormonal or biochemical parameters (including insulin and insulin 
resistance markers), but only a correlation between ghrelin and the BMI [280]. These data 
support the relation determined between ghrelin and the body weight only and exclude the 
effects of the disease itself. These findings are in a sense similar to those observed by Bik et 
al., who have not found significant differences in ghrelin levels between a group of normal 
weight PCOS women and a group of normal weight healthy women; however, ghrelin was 
significantly lower in healthy obese women compared to lean women with PCOS [286]. 
Impaired ghrelin suppression after a test meal and increased feeling of hunger and 
decreased feeling of satiety (according to visual analogue scales) have been described in a 
small group of obese women with PCOS, even after weight reduction [287], which has been 
also confirmed by another study, comparing lean and obese women with PCOS and 
relevant, weight-matched controls [288]. Romualdi et al. [289] gave more detailed evaluation 
of ghrelin and polypeptide YY responses following oral load with a test meal (527 kcal, 
distributed by contents in 24.1% fats, 54.4% carbohydrates and 21.5% proteins) in women 
with PCOS. Low baseline ghrelin levels and reduced suppression after meals, more 
pronounced in the obese than in the lean patients was shown. The authors have found no 
correlation between ghrelin and the androgens; however, a negative correlation has been 
established between ghrelin and the НОМА-index. Compared to controls, PCOS women 
had a significantly suppressed neuropeptide Y response to injected ghrelin, as the response 
has restored after treatment with metformin and significant insulin reduction. In this 
experimental setting, leptin has undergone no significant changes [289]. Obviously, 
hyperinsulinaemia is the factor which exerts effect on the ghrelin-neuropeptide Y relation. 
We found significantly lower ghrelin levels in women with PCOS compared to healthy 
controls (21.78 ± 2.12 ng/ml versus 34.67 ± 3.57 ng/ml; p = 0.04), as ghrelin was inversely 
correlated with insulin levels at a degree similar to these of insulin resistance markers. 
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Negative correlations were also found with the BMI, waist measurement and waist-to-hip 
ratio, in conformity with most of the studies at present. Furthermore, the observed negative 
correlation between ghrelin and testosterone (r = −0.315; p < 0.05), and this between ghrelin 
and leptin (r = −0.306; p<0.05) disappear after the exclusion of BMI, waist-to-hip ratio and 
HOMA-index [290]. In a comparative study on ghrelin levels in insulin-resistant women 
with PCOS and women with type 2 diabetes and higher insulin resistance, ghrelin levels 
have been significantly lower in syndrome carriers versus diabetics [291]. Based on our data 
we consider that ghrelin levels in women with PCOS reflect both the metabolic and 
hormonal disturbances, typical for the syndrome. 
A recent study conducted by Panidis et al. [292] has confirmed that alterations in ghrelin 
secretion are intrinsic for the disease itself and has demonstrated that active (acetylated) 
ghrelin/total ghrelin ratio is decreased in normal weight-women with PCOS, as the 
anomalies are most pronounced in the severe forms of the syndrome, including all 
diagnostic criteria: hyperandrogenia, chronic anovulation and morphologically polycystic 
ovaries [292]. Based on the proven changes in women with PCOS and various phenotype 
manifestations, some authors have even suggested ghrelin to be used as a predictive marker 
of PCOS and have found through a plot-analysis of the receiver operating characteristic 
curve (ROC) a sensitivity of 70% and specificity of 86% with a cut-off value of 34.1 ng/ml, 
below which the diagnosis of PCOS is likely, while a cut-off ghrelin value below 9 ng/ml is 
highly specific for PCOS [293].  
In conclusion, there is, probably, an anomaly in ghrelin regulation in PCOS, related not only 
to overweight and insulin resistance. The mechanisms associating abnormal ghrelin 
regulation with the disease are still to be elucidated. However, the pathological and 
therapeutic importance of this association is unclear. Independent effects of ghrelin on the 
hypothalamic-pituitary-gonadal axis with an inhibitory effect on the LH secretion and a 
decreased LH response to GnRH, typical for the syndrome, may also be taken into 
consideration. 
4. Conclusion 
Given the growing epidemic of obesity, it has become increasingly important to understand 
the physiological processes that regulate body weight. Regulation of food intake and 
metabolism is maintained by complex pathways and neuronal circuits which themselves 
receive peripheral signals such as gut hormones. Metabolically important abdominal obesity 
with an excess of visceral fat accumulation results in altered release of adipokines, leading 
to CNS mediated skeletal muscle and hepatic insulin resistance. The central regulation of 
energy balance has become even more fascinating and complex with the characterization of 
mechanisms of action of NPY, the most abundant hypothalamic orexigenic factor. Much 
attention has recently centered on ghrelin, the only known circulating orexigen. Insulin 
resistance and compensatory hyperinsulinemia are independently associated with 
suppression of ghrelin that furthers our understanding of the variable expression of ghrelin 
in humans.  
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With continued research, it should be possible to elucidate exactly how the associations 
among insulin resistance, hyperinsulinemia, and orexigens (NPY and ghrelin) participate in 
the more intricate web of factors that regulate body weight. Better understanding of the 
mechanisms involved in the regulation of energy metabolism will become a background for 
development of new therapeutic approaches against obesity, insulin resistance, metabolic 
syndrome, and other nutritional disorders. 
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1. Introduction 
A sustained increase in body mass, particularly fat mass, an unhealthy diet and a sedentary 
lifestyle trigger metabolic alterations such as metabolic syndrome, obesity, and type 2 
diabetes mellitus (2DM). These metabolic conditions increase the cardiovascular disease 
risks and have become epidemic public health problems (Grundy 2002). Individuals who 
are overweight and obese are associated with almost 70% of 2DM risk in the U.S. (Sherwin 
et al., 2004).  
2DM is characterized by insulin resistance and hyperglycemia. Insulin resistance – which 
can be triggered by the presence of metabolic stressors, such as high-fat diets, obesity and 
high blood non-esterified fatty acids (FA) levels (Phillips et al., 2006; Roche et al., 2005) – is 
featured as the primary metabolic dysfunction responsible for the development of the 
metabolic syndrome. With regard to the relationship between high-fat diets, obesity, and 
2DM, it is highlighted that the presence of high blood non-esterified FA concentrations 
compromises insulin sensitivity, reducing the action of this hormone in peripheral tissues, 
such as the liver, skeletal muscle and adipose tissue. It also impairs glucose and lipid 
metabolism, with the development of compensatory hyperinsulinemia (Saltiel, 2005) As well 
as in the obesity, insulin resistance is accompanied by the presence of a chronic low-grade 
inflammatory state (Dandona et al., 2004; Ghanim et al., 2004; Roche 2004).  
The amount of white adipose tissue (WAT) may represent more than 50% of total body mass 
in obese individuals (body mass index ≥ 30 kg/m2). The adiposity (and obesity) depends on 
the size and the number of the adipocytes, the last being regulated by adipogenesis. 
The role of WAT as an ordinary tissue responsible for lipid energy storage has been replaced 
due to studies that demonstrate the central activity of WAT in lipid and glucose metabolism 
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and its ability to secrete factors with endocrine, paracrine and autocrine effects. For 
example, recent studies suggest that pro-inflammatory and anti-inflammatory substances 
produced by WAT contribute to the development of insulin resistance (Weisberg et al., 2003; 
Xu et al., 2004). 
2. The White Adipose Tissue (WAT) 
The adipose tissue is classified in two major depots distributed throughout the body: WAT 
and brown adipose tissue (BAT). BAT is implicated in cold- and diet-induced thermogenesis 
(non-shivering thermogenesis), modulation of body temperature, energy expenditure and 
adiposity (Saito et al., 2009; Yoneshiro et al., 2011). WAT is specialized in the storage of 
energy in the form of triacylglycerol (TAG), it protects other organs and tissues from ectopic 
fat accumulation and, consequently, from lipotoxicity.  
Until the 1990s, the functions related to WAT were only associated with passive energy 
storage (an inert depot for excess metabolic fuel), thermal insulation and organ protection 
from mechanical damage. The discovery of leptin, a hormone derived from WAT that can 
"tell" the state of these energy reserves to the central nervous system, introduced a new 
perspective on the study of adipose tissue role in the body energy homeostasis and 
metabolism. Subsequently, a number of new substances secreted by WAT have been 
characterized, which allowed its classification as an endocrine organ, capable of controlling 
the metabolism of several tissues and organs (Fonseca-Alaniz 2006; 2007). 
Besides adipocytes, WAT contains connective tissue matrix (collagen and reticular fibers), 
nerve fibers, stromovascular cells, lymph nodes, immune cells (e.g., macrophages), 
fibroblasts and preadipocytes (undifferentiated adipose cells), some of which are also 
capable of secreting many bioactive products into the bloodstream (Fain et al., 2004; 
Kershaw et al., 2004). 
White adipocytes are responsible for the storage of energy as TAG in a single lipid droplet 
during periods of abundant energy supply and for the mobilization of TAG when there is a 
calorie deficit. Adipocytes are capable of changing size according to the metabolic needs of 
the organism. During the development of obesity, there is an increase in the size 
(hypertrophy due to excessive lipid storage) and/or in the number (hyperplasia due to 
preadipocyte differentiation into mature adipocytes) of cells (Drolet et al., 2008).  
Adipocytes express receptors for several hormones, cytokines and growth factors and also 
produce a number of protein/hormones (collectively referred to as “adipokines” or 
“adipocytokines”), all of which enable adipose tissue to communicate with other tissues and 
organs, such as skeletal muscle, endothelium and the central nervous system. Through this 
interaction network, WAT participates in modulating important biological processes, 
including food intake, energy metabolism, neuroendocrine and immune functions, 
angiogenesis, regulation of blood pressure and inflammation. 
The adipokine secretory profile differs according to adipocyte size. For example, leptin 
mRNA expression is higher in large adipocytes compared to smaller adipocytes in the same 
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obese individual (Hamilton et al., 1995). Additionally, the cell size of human abdominal 
subcutaneous adipose tissue correlates with adipose interleukin-6(IL-6) gene expression and 
its secretion in vitro (Sopasakis et al., 2004). Among the adipokines secreted by WAT, there 
are some pro-inflammatory and anti-inflammatory factors, including cytokines, chemokines, 
acute-phase proteins and angiogenic factors. 
3. Obesity and inflammation in WAT  
Obesity is considered a public health problem, as there has been a dramatic increase in the 
worldwide prevalence of this condition over the past 20 years. According to data from the 
Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System, 
obesity prevalence was under 20% in only one state (Colorado) in the U.S. in 2007, whereas 
the remaining states saw incidence levels equal to or greater than 25% (in 
http://www.cdc.gov/brfss/ abourth.htm). Additionally, one study predicted that the 
incidence of obesity in U.S. adults (above 15 years old) will increase from 32% to 44.2% in 
men and from 37.8% to 48.3% in women from 2002 to 2010 (Yach  et al., 2006). 
Obesity, particularly due to excessive accumulation of visceral fat, elevates the risk of 
developing many health conditions, including respiratory complications, coronary heart 
disease, 2DM, osteoarthritis and hypertension, and is associated with a nearly 8-year 
reduction in life expectancy (Kopelman 2000; Trayhurn et al., 2006). 
The accumulation of fat mass during the development of obesity is characterized by 
adipocytes hyperplasia and hypertrophy and is associated with increased angiogenesis, 
macrophage infiltration, production of extracellular matrix components, endothelial cell 
activation and production and release of several inflammatory mediators (Bourlier et al., 
2008; Henegar et al., 2008). Many of pro-inflammatory molecules are secreted by the 
adipocytes, whereas others are predominantly derived from WAT infiltrated macrophages. 
The dysregulation of pro- and anti-inflammatory cytokines/adipokines functions and their 
production in obese individuals, lead to a state of chronic low-grade inflammation and may 
promote obesity-linked metabolic disorders and cardiovascular diseases such as insulin 
resistance, metabolic syndrome and atherosclerosis.  
In addition to the enlargement of adipocytes, obesity also promotes WAT macrophage 
accumulation, which can also contribute to inflammation. Recent studies demonstrated that 
both genetically obese mice and diet-induced obese mice are characterized by a significant 
increase in the number of WAT macrophages (Davies et al., 2008; Murano et al., 2008). 
Macrophage infiltration and the mRNA expression of monocyte chemotactic protein-1 
(MCP-1) and colony-stimulating factor-1 (CSF1) was higher in omental visceral fat 
compared to subcutaneous fat from lean humans and these observations were aggravated in 
obesity, particularly in intra-abdominal obesity (Harman-Boehm et al., 2007). 
Obesity increases the numbers of macrophages and also induces phenotypic switch in the 
WAT macrophage polarization. It has been demonstrated that in mice with diet-induced 
obesity there is a shift in the activation state of WAT macrophages from a M2a state, 
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obese individual (Hamilton et al., 1995). Additionally, the cell size of human abdominal 
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obesity there is a shift in the activation state of WAT macrophages from a M2a state, 
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characterized by the expression of anti-inflammatory cytokines (e.g., interleukin-10) to a M1 
state, characterized by the production of high levels of anti-inflammatory cytokines [e.g., 
tumor necrosis factor-alpha (TNF-α) and IL-6] (Lumeng et al., 2008). This obesity-induced 
switch in WAT macrophage polarization is due to recruitment of inflammatory monocytes 
from the circulation and not to the conversion of resident M2a macrophages to M1 
macrophages in situ (Lumeng et al., 2008). 
4. Adipogenesis and inflammation in WAT 
Adipocytes derive from multipotent mesenchymal stem cells that reside in the stroma of the 
adipose tissue (Rosen et al., 2006). These multipotent cells become preadipocytes when they 
lose their ability to differentiate into other mesenchymal lineages and become committed to 
the adipocyte lineage. This early stage of adipocyte differentiation is known as 
determination or commitment and it is still poorly characterized. The next phase of 
adipogenesis involves activation of a cascade of transcriptional events, including the nuclear 
hormone receptor PPARγ and CCAAT/enhancer binding protein alpha (C/EBPα), which 
drive the expression of great importance in WAT, such as genes of glucose and lipid 
metabolism and adipokines, establishing thus, the differentiated state (Rosen et al., 2006).  
The preadipocytes acquire the characteristics of mature adipocytes, such as accumulation of 
lipid droplets and the ability to respond to hormones such as insulin. The understanding of 
the events involved in adipogenesis has markedly increased in the last two decades with the 
use of clonal cells and non-clonal precursors of adipocytes from rodents and humans. 
Glucocorticoids and insulin-like growth factor 1 (IGF-I) were identified as the most efficient 
adipogenic agents in ex vivo experiments (Aihaud & Hauner, 2004). 
As mentioned, the development of obesity results from both, the hypertrophy and the 
hyperplasia (or adipogenesis) of fat cells. Increase in the size of adipocytes is not an 
unlimited process. Eventually, the growth reaches a maximum level beyond which the 
ability of fat storage is exhausted and new cells are being slowly recruited and emerge from 
this tissue (15-50% of the adipose tissue cells represents a reservoir of mesenchymal stem 
cells including preadipocytes that can divide and differentiate in response to various 
extracellular agents). Very large adipocytes get into exhausted ability to store fat and 
become more lipolytic. This process allows an increase in free FA (FFA) plasma 
concentration that in turn may impair the function of non-adipose organs, a process called 
lipotoxicity (DeFronzo, 2004). The excess of circulating FFA is also a strong inducer of peripheral 
insulin resistance and increases the probability of 2DM and metabolic syndrome 
development.  
The WAT protects other organs and tissues from ectopic fat accumulation and consequently 
from the lipotoxicity that this phenomenon causes. The lipotoxicity, in turn, is an important 
cause of insulin resistance. It is important to emphasize that the adipocyte has metabolic 
features that make itself less susceptible to lipotoxicity due to its high capacity for detoxification 
of FA (Lundgren & Eriksson, 2004). So, the generation of new fat cells can act as a mechanism 
to attenuate this by increasing the cellularity without exhausting fat accumulation. 
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In obese subjects, the WAT appears hypertrophic. In addition, obesity coexists with a high 
degree of inflammation, especially in the WAT itself. Several pro-inflammatory cytokines 
generated in the WAT by the infiltration of macrophages or by these hypertrophic 
adipocytes cause insulin resistance in this tissue limiting its function. 
The balance between hyperplasic and hypertrophic activity in the WAT determines the size 
of the tissue. In obesity, the prevalence of hypertrophied cells causes an imbalance between 
the tissue mass increase and the unmatched blood flow, which leads ultimately to hypoxia, 
inflammation and macrophage infiltration in the tissue (Goossens, 2008). Macrophages 
release factors that affect the adipogenic process in human cells (Permana et al., 2006). There 
is also a decrease in the capacity of lipid buffering by the WAT with subsequent ectopic 
deposition of fat in other tissues. This fact coupled with the abnormal production of 
adipokines causes the disorders associated with obesity, mainly insulin resistance.  
Hypertrophic adipocytes are the main producers of pro-inflammatory cytokines, such as, 
TNFα, IL-6, resistin and MCP1. On the other hand, these cells exhibit a limited ability to 
synthesize and release an important anti-inflammatory adipokine, adiponectin, which is the 
most potent endogenous insulin sensitizer. Stimulation of in vivo adipogenesis can replace 
hypertrophic adipocytes by younger and smaller ones with greater ability to produce 
adiponectin at the expenses of pro-inflammatory adipokines (Figure 1). 
The WAT expansion in childhood obesity is recognized to result from the combination of 
both hypertrophy and hyperplasia of adipocytes. In opposition, for a long time, adults have 
been thought to present a fixed number of adipocytes and that changes in fat mass were 
mainly secondary to changes in the volume of fat cell. However, mature adipocytes exhibit 
remarkably intense and constant renewal (Spalding et al., 2008), and nowadays, it is known 
that the potential for generating new cells persists throughout the life of the individual in 
adipose tissue.  
5. Perivascular adipose tissue and inflammation 
Perivascular adipose tissue (PVAT) is an adipose tissue depot present around the majority 
of systemic blood vessels and has long been considered serving primarily as a supportive, 
mechanical purpose. Adipocytes from human PVAT reside at the adventitial border of 
blood vessels and are not separated from these vessels by a fascial layer or an elastic lamina 
(Chatterjee et al., 2009). PVAT expresses and secretes a variety of cytokines and chemokines, 
which may affect vascular physiology and play a pathological role in vascular diseases, like 
atherosclerosis (Henrichot et al., 2005; Gao et al., 2007). 
Atherosclerosis is a disease of large arteries characterized by endothelial cell dysfunction, 
inflammatory cell recruitment and foam cell formation (Lusis, 2000). A recent study 
demonstrated that the infiltration of inflammatory cells (accumulation of macrophages and 
T lymphocytes) was markedly increased at the interface between the PVAT and adventia of 
atherosclerotic aortas as compared to peripheral arteries, which are not affected by 
atherosclerotic lesions (Henrichot et al., 2005).  
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the tissue mass increase and the unmatched blood flow, which leads ultimately to hypoxia, 
inflammation and macrophage infiltration in the tissue (Goossens, 2008). Macrophages 
release factors that affect the adipogenic process in human cells (Permana et al., 2006). There 
is also a decrease in the capacity of lipid buffering by the WAT with subsequent ectopic 
deposition of fat in other tissues. This fact coupled with the abnormal production of 
adipokines causes the disorders associated with obesity, mainly insulin resistance.  
Hypertrophic adipocytes are the main producers of pro-inflammatory cytokines, such as, 
TNFα, IL-6, resistin and MCP1. On the other hand, these cells exhibit a limited ability to 
synthesize and release an important anti-inflammatory adipokine, adiponectin, which is the 
most potent endogenous insulin sensitizer. Stimulation of in vivo adipogenesis can replace 
hypertrophic adipocytes by younger and smaller ones with greater ability to produce 
adiponectin at the expenses of pro-inflammatory adipokines (Figure 1). 
The WAT expansion in childhood obesity is recognized to result from the combination of 
both hypertrophy and hyperplasia of adipocytes. In opposition, for a long time, adults have 
been thought to present a fixed number of adipocytes and that changes in fat mass were 
mainly secondary to changes in the volume of fat cell. However, mature adipocytes exhibit 
remarkably intense and constant renewal (Spalding et al., 2008), and nowadays, it is known 
that the potential for generating new cells persists throughout the life of the individual in 
adipose tissue.  
5. Perivascular adipose tissue and inflammation 
Perivascular adipose tissue (PVAT) is an adipose tissue depot present around the majority 
of systemic blood vessels and has long been considered serving primarily as a supportive, 
mechanical purpose. Adipocytes from human PVAT reside at the adventitial border of 
blood vessels and are not separated from these vessels by a fascial layer or an elastic lamina 
(Chatterjee et al., 2009). PVAT expresses and secretes a variety of cytokines and chemokines, 
which may affect vascular physiology and play a pathological role in vascular diseases, like 
atherosclerosis (Henrichot et al., 2005; Gao et al., 2007). 
Atherosclerosis is a disease of large arteries characterized by endothelial cell dysfunction, 
inflammatory cell recruitment and foam cell formation (Lusis, 2000). A recent study 
demonstrated that the infiltration of inflammatory cells (accumulation of macrophages and 
T lymphocytes) was markedly increased at the interface between the PVAT and adventia of 
atherosclerotic aortas as compared to peripheral arteries, which are not affected by 
atherosclerotic lesions (Henrichot et al., 2005).  
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Adapted from: Queiroz et al., 2009. 
Figure 1. Physiological balance between hypertrophy and hyperplasia. Obesity is determined by 
increasing both, the size and number of adipocytes. Adipogenesis can lead to a large number of new 
adipocytes (hyperplasia) which produce more adiponectin and less inflammatory adipokines. By the 
other side, hypertrophied adipocytes produce less adiponectin and more inflammatory adipokines. The 
prevalence of hypertrophied adipocytes in adipose tissue leads to a reduction in blood flow with 
subsequent hypoxia and macrophage infiltration. In addition, cytokines produced by macrophages 
inhibit adipogenesis. 
Some of PVAT-derived factors are typical proinflammatory cytokines that could influence 
the chronic inflammation in atherosclerosis. For example, adipocytes surrounding human 
coronary arteries secrete more IL-6, interleukin-8 (IL-8) and MCP-1 into the culture medium 
than subcutaneous and visceral (perirenal) adipocytes (Chatterjee et al., 2009). These 
mediators stimulate the chemotaxis of leucocytes to the vascular endothelium and their 
migration into the vascular wall, the proliferation of smooth muscle cells and the formation 
of neo-vessels, contributing, this way, to the atherogenesis (Thalmann, Meyer, 2007). 
Moreover, feeding mice with high-fat diet increased the amount of PVAT and their local 
expression of inflammatory genes as compared to mice fed a control diet (Henrichot et al., 
2005; Chatterjee et al., 2009). 
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Besides cytokines, PVAT also secretes classical adipocytokines such as leptin, and visfatin 
that are able to exert proatherogenic and prothrombotic actions by chemotactively attracting 
and activating inflammatory cells, producing endothelial dysfunction and stimulating 
smooth muscle cell proliferation and migration (Wang et al., 2009; Rajsherher et al., 2010). 
Recently, a study related that leptin and visfatin protein expression in adipose tissue 
surrounding abdominal aorta (periaortic adipose tissue) was positively correlated with 
aortic atherosclerotic lesions in humans individuals (Spiroglou et al., 2010) 
Taking together, emerging evidences suggest that obesity is accompanied by increase in 
PVAT mass, hypertrophy of perivascular adipocytes and differential release of cytokines 
and adipocytokines that could be implicated in the pathogenesis of obesity-associated 
vascular complications such as atherosclerosis by affecting, among others, the inflammatory 
process. 
6. Adipokines in obesity and inflammation  
One of the consequences of the chronic low-grade inflammation state associated with 
obesity is the development of insulin resistance as well as increased risk of 2DM 
development. 
The mechanisms linking obesity, inflammation and defects in insulin sensitivity seem to 
involve the contribution of macrophages-derived pro-inflammatory cytokines. For example, 
it was reported higher expression of macrophage-specific inflammatory-genes such as MCP-
1 and macrophage inflammatory protein-1 (MIP-1), in the fat depot of obese mice 
preceding accentuated increase in insulin production (Xu et al., 2003). Furthermore, the 
administration of rosiglitazone, an insulin-sensitizing drug, reduced the expression of these 
genes (Xu et al., 2003). 
WAT produces and secretes a number of substances with a wide range of biological activity. 
The adipose-derived proteins act both locally in autocrine and paracrine fashions and 
distally, mediating endocrine effects through the systemic circulation. Among the soluble 
factors produced by WAT, there are hormones, cytokines and growth factors (adipokines), 
which include leptin, adiponectin, resistin, visfatin and MCP-1 (see Table 1).  
Besides macrophages-derived pro-inflammatory elements, adipocytes also may contribute 
to development of obesity-related insulin-resistance. Accordingly, hypertrophic adipocytes 
from humans display elevated expression and secretion of pro-inflammatory adipokines 
(Skurk et al., 2007). On the other hand, the plasma levels of adiponectin, an insulin-
sensitizing adipokine, are reduced in obese individuals and inversely correlate with the 
degree of insulin resistance and hyperinsulinemia (Arita et al., 1999; Weyer et al., 2001) 
The first link between obesity, inflammation and insulin action came from a study 
developed by Hotamisligil and coworkers (1993). In this study, the authors demonstrated 
elevate expression of TNF-α mRNA in adipose tissue of obese animals models (fa/fa rat and 
ob/ob mouse) and the neutralization of TNF-α in obese fa/fa mice increased insulin action on 
glucose uptake (Hotamisligil et al., 1993). Uysal et al. (1997) showed that two different models 
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the chronic inflammation in atherosclerosis. For example, adipocytes surrounding human 
coronary arteries secrete more IL-6, interleukin-8 (IL-8) and MCP-1 into the culture medium 
than subcutaneous and visceral (perirenal) adipocytes (Chatterjee et al., 2009). These 
mediators stimulate the chemotaxis of leucocytes to the vascular endothelium and their 
migration into the vascular wall, the proliferation of smooth muscle cells and the formation 
of neo-vessels, contributing, this way, to the atherogenesis (Thalmann, Meyer, 2007). 
Moreover, feeding mice with high-fat diet increased the amount of PVAT and their local 
expression of inflammatory genes as compared to mice fed a control diet (Henrichot et al., 
2005; Chatterjee et al., 2009). 
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Besides cytokines, PVAT also secretes classical adipocytokines such as leptin, and visfatin 
that are able to exert proatherogenic and prothrombotic actions by chemotactively attracting 
and activating inflammatory cells, producing endothelial dysfunction and stimulating 
smooth muscle cell proliferation and migration (Wang et al., 2009; Rajsherher et al., 2010). 
Recently, a study related that leptin and visfatin protein expression in adipose tissue 
surrounding abdominal aorta (periaortic adipose tissue) was positively correlated with 
aortic atherosclerotic lesions in humans individuals (Spiroglou et al., 2010) 
Taking together, emerging evidences suggest that obesity is accompanied by increase in 
PVAT mass, hypertrophy of perivascular adipocytes and differential release of cytokines 
and adipocytokines that could be implicated in the pathogenesis of obesity-associated 
vascular complications such as atherosclerosis by affecting, among others, the inflammatory 
process. 
6. Adipokines in obesity and inflammation  
One of the consequences of the chronic low-grade inflammation state associated with 
obesity is the development of insulin resistance as well as increased risk of 2DM 
development. 
The mechanisms linking obesity, inflammation and defects in insulin sensitivity seem to 
involve the contribution of macrophages-derived pro-inflammatory cytokines. For example, 
it was reported higher expression of macrophage-specific inflammatory-genes such as MCP-
1 and macrophage inflammatory protein-1 (MIP-1), in the fat depot of obese mice 
preceding accentuated increase in insulin production (Xu et al., 2003). Furthermore, the 
administration of rosiglitazone, an insulin-sensitizing drug, reduced the expression of these 
genes (Xu et al., 2003). 
WAT produces and secretes a number of substances with a wide range of biological activity. 
The adipose-derived proteins act both locally in autocrine and paracrine fashions and 
distally, mediating endocrine effects through the systemic circulation. Among the soluble 
factors produced by WAT, there are hormones, cytokines and growth factors (adipokines), 
which include leptin, adiponectin, resistin, visfatin and MCP-1 (see Table 1).  
Besides macrophages-derived pro-inflammatory elements, adipocytes also may contribute 
to development of obesity-related insulin-resistance. Accordingly, hypertrophic adipocytes 
from humans display elevated expression and secretion of pro-inflammatory adipokines 
(Skurk et al., 2007). On the other hand, the plasma levels of adiponectin, an insulin-
sensitizing adipokine, are reduced in obese individuals and inversely correlate with the 
degree of insulin resistance and hyperinsulinemia (Arita et al., 1999; Weyer et al., 2001) 
The first link between obesity, inflammation and insulin action came from a study 
developed by Hotamisligil and coworkers (1993). In this study, the authors demonstrated 
elevate expression of TNF-α mRNA in adipose tissue of obese animals models (fa/fa rat and 
ob/ob mouse) and the neutralization of TNF-α in obese fa/fa mice increased insulin action on 
glucose uptake (Hotamisligil et al., 1993). Uysal et al. (1997) showed that two different models 
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of murine obesity (ob/ob and high-fat diet fed-mice) had significantly improved insulin 
sensitivity when TNF-α or TNF-α receptors were lacking and the TNF-α deficient obese 
mice displayed lower levels of circulating FFA than the obese wild-type counterparts. In 
addition, the treatment of obese rats with antibodies against TNF-α reduces insulin 
resistance (XU et al., 2004). These data demonstrate the deleterious effects of TNF-α on 
insulin action in obesity rodent models and one of the molecular mechanisms underlying 
TNF-α induced insulin resistance may involve a c-Jun N-terminal kinase (JNK) mediated 
serine phosphorylation of the insulin receptor substrate (IRS)-1, which inhibits normal 
tyrosine phosphorylation of IRS-1 and consequently reduces the activation of the insulin 
signaling cascade (Maury; Brichard, 2010).  
Though mature adipocytes secrete TNF- α, majority of its production takes place in 
macrophages (Maury et al., 2009). In obese humans, serum TNF-α concentration is elevated 
and decreases after weight loss (Dandona et al., 1998). TNF-α mRNA expression is increased 
in the adipose depots and correlates with insulin resistant in obese patients (Maury et al., 
2009; Kern et al., 2001). However, the treatment of patients with etanercept (a TNF-α 
inhibitor drug), for a four-week period, in order to neutralize the elevated TNF-α levels, 
increased circulating resistin and adiponectin levels, reduced muscle fat content, but did not 
promote improvements in insulin sensitivity (Lo et al., 2007; Bernstein et al., 2006). 
TNF-α possesses stimulatory effects on lipolysis by promoting a rise in cAMP levels and by 
stimulating the activity of hormone sensitive lipase along with perilipin downregulation via 
mitogen-activated protein kinase (MAPK) activation (Souza et al., 2003) . In WAT, TNF-α 
reduces the expression and activities of PPAR-γ, lipoprotein lipase and GLUT-4, resulting in 
diminished glucose uptake, FFA esterification and storage (Imai et al, 2004; Zhang et al, 
1996; Stephens et al, 1997). In the liver, TNF-α increases the expression of genes involved in 
the de novo synthesis of cholesterol and FA and, at the same time, reduces the expression of 
genes involved in glucose uptake, metabolism and FA oxidation (Guilherme et al, 2008). 
Thus the effects promoted by this cytokine on lipid metabolism result in high plasma levels 
of FFA, which also may contribute to the development of peripheral insulin resistance. 
IL-6 has been shown to be essential in reducing the inflammatory process by promoting the 
synthesis of anti-inflammatory cytokines and by negatively regulating inflammatory targets 
(Xing et al., 1998; Steensberg et al., 2003; Starkie et al., 2003). Thus, this protein has been 
classified as both a pro-inflammatory and anti-inflammatory adipokine; at some levels it 
acts as a defense mechanism but in chronic inflammation it is rather pro-inflammatory 
(Kamimura et al., 2003). 
In humans, IL-6 is secreted by a wide variety of cells: endothelial cells, keratinocytes, 
osteoblasts, myocytes, adipocytes, β pancreatic cells, monocytes, macrophages and a 
number of other tissues, including a few tumors (Kamimura et al., 2003; Carey et al., 2004). 
In healthy humans at resting state, IL-6 level is under 10 pg/mL. High circulating IL-6 levels 
can be found in several low-level inflammatory conditions such as sepsis, where their levels 
can reach above 10-1000 pg/mL (Friedland et al., 1992). WAT, especially visceral, may 
contribute to 10-35% of the basal circulating IL-6 levels in healthy individuals during the 
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resting state (Mohamed-Ali et al., 1997). Adipocytes are capable of producing and secreting 
IL-6 (Sopasakis  et al., 2004; Bastard et al., 2000; Fried et al., 1998; Vicennati et al., 2002; 
Krogh-Madsen et al., 2004), but contribute to a small fraction of the total IL-6 secreted by 
this tissue (Sopasakis  et al., 2004; Fried et al., 1998), since about 90% of IL-6 expressed in 
WAT is produced by cells other than adipocytes (Fried et al., 1998). 
IL-6 mRNA expression is increased in the obese adipose depots, reduces after weight loss and 
adipocyte hypertrophy is accompanied by an increase in IL-6 production (Sopasakis  et al., 
2004; Kern et al., 2001; Bastard et al., 2000; Fried et al., 1998). WAT IL-6 mRNA has been shown 
to be elevated in insulin resistant obese patients with and without 2DM (Kern et al., 2001; 
Bastard et al., 2000; Fried et al., 1998; Rotter et al., 2003), which correlates with reduced rates of 
insulin-stimulated glucose disposal both in vitro (from a glucose uptake assay in adipocytes) 
and in vivo (from a hyperinsulinemic normoglycemic clamp study) (Bastard et al., 2002).  
The cross-talk between IL-6 and insulin-dependent metabolism has been approached by 
several researchers over the past few years. Adverse effects on insulin action in the liver and 
WAT have been demonstrated in animals and in cell cultures (Klover et al., 2003; Senn et al., 
2002; Rotter et al., 2003; Senn et al., 2003; Sabio et al., 2008). This adipokine reduces insulin-
dependent hepatic glycogen synthesis (Klover et al., 2003; Senn et al., 2002) and glucose 
uptake in adipocytes (Rotter et al., 2003), whose effects could be mediated by the increased 
expression of suppressor of cytokine signaling (SOCS)-3, a protein that binds and inhibits 
the insulin receptor and also targets IRS proteins for proteosomal degradation, and by 
negative regulation of the transcription of IRS-1 (Rotter et al., 2003; Sabio et al., 2008). 
IL-6 has lipolytic properties in WAT and adipocyte cultures (Wallenius et al., 2002; van Hall 
et al., 2003; Trujillo et al., 2004; Petersen et al., 2005). In humans, infusion of IL-6 promotes a 
rise in FFA levels and stimulates total body fat oxidation (van Hall et al., 2003; Lyngso et al., 
2002). Studies in transgenic animals support the effect of IL-6 as a lipolytic factor. A 200% 
increase was observed in the number of soluble IL-6 receptors (IL-6/sIL-6R) in transgenic 
mice resulting in reduced body weight (Peters  et al., 1997), whereas IL-6 deficiency led to 
early-onset obesity (Wallenius et al., 2002). However, the obesity phenotype has not been 
observed in any other study involving IL-6 knockout mice (Di Gregorio et al., 2004). 
Circulating MCP-1 levels were increased in animal models of obesity (ob/ob mice and diet-
induced obesity mice) (Sartipy; Loskutoff, 2003; Takahashi et al., 2003) and in obese subjects 
(Christiansen et al, 2005; Bruun et al., 2005; Kim et al., 2006), and reduced after weight loss 
(Christiansen et al, 2005; Takahashi et al., 2003). Furthermore, adipose tissue MCP-1 mRNA 
expression also was enhanced and correlated with measures of adiposity in obese subjects 
(Christiansen et al, 2005; Dahlman et al., 2005). 
It was reported that adipocytes secrete MCP-1, a factor that is a potent chemoattractant for 
monocyte/macrophage infiltration (Christiansen et al., 2005; Skurk et al., 2007). Its secretion 
positively correlates with cell size (Skurk et al., 2007) and although it is produced by both 
fractions of WAT, it is more expressed in stroma vascular cells than in isolated adipocytes 
(Fain et al., 2004; Bruun et al., 2005). 
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of murine obesity (ob/ob and high-fat diet fed-mice) had significantly improved insulin 
sensitivity when TNF-α or TNF-α receptors were lacking and the TNF-α deficient obese 
mice displayed lower levels of circulating FFA than the obese wild-type counterparts. In 
addition, the treatment of obese rats with antibodies against TNF-α reduces insulin 
resistance (XU et al., 2004). These data demonstrate the deleterious effects of TNF-α on 
insulin action in obesity rodent models and one of the molecular mechanisms underlying 
TNF-α induced insulin resistance may involve a c-Jun N-terminal kinase (JNK) mediated 
serine phosphorylation of the insulin receptor substrate (IRS)-1, which inhibits normal 
tyrosine phosphorylation of IRS-1 and consequently reduces the activation of the insulin 
signaling cascade (Maury; Brichard, 2010).  
Though mature adipocytes secrete TNF- α, majority of its production takes place in 
macrophages (Maury et al., 2009). In obese humans, serum TNF-α concentration is elevated 
and decreases after weight loss (Dandona et al., 1998). TNF-α mRNA expression is increased 
in the adipose depots and correlates with insulin resistant in obese patients (Maury et al., 
2009; Kern et al., 2001). However, the treatment of patients with etanercept (a TNF-α 
inhibitor drug), for a four-week period, in order to neutralize the elevated TNF-α levels, 
increased circulating resistin and adiponectin levels, reduced muscle fat content, but did not 
promote improvements in insulin sensitivity (Lo et al., 2007; Bernstein et al., 2006). 
TNF-α possesses stimulatory effects on lipolysis by promoting a rise in cAMP levels and by 
stimulating the activity of hormone sensitive lipase along with perilipin downregulation via 
mitogen-activated protein kinase (MAPK) activation (Souza et al., 2003) . In WAT, TNF-α 
reduces the expression and activities of PPAR-γ, lipoprotein lipase and GLUT-4, resulting in 
diminished glucose uptake, FFA esterification and storage (Imai et al, 2004; Zhang et al, 
1996; Stephens et al, 1997). In the liver, TNF-α increases the expression of genes involved in 
the de novo synthesis of cholesterol and FA and, at the same time, reduces the expression of 
genes involved in glucose uptake, metabolism and FA oxidation (Guilherme et al, 2008). 
Thus the effects promoted by this cytokine on lipid metabolism result in high plasma levels 
of FFA, which also may contribute to the development of peripheral insulin resistance. 
IL-6 has been shown to be essential in reducing the inflammatory process by promoting the 
synthesis of anti-inflammatory cytokines and by negatively regulating inflammatory targets 
(Xing et al., 1998; Steensberg et al., 2003; Starkie et al., 2003). Thus, this protein has been 
classified as both a pro-inflammatory and anti-inflammatory adipokine; at some levels it 
acts as a defense mechanism but in chronic inflammation it is rather pro-inflammatory 
(Kamimura et al., 2003). 
In humans, IL-6 is secreted by a wide variety of cells: endothelial cells, keratinocytes, 
osteoblasts, myocytes, adipocytes, β pancreatic cells, monocytes, macrophages and a 
number of other tissues, including a few tumors (Kamimura et al., 2003; Carey et al., 2004). 
In healthy humans at resting state, IL-6 level is under 10 pg/mL. High circulating IL-6 levels 
can be found in several low-level inflammatory conditions such as sepsis, where their levels 
can reach above 10-1000 pg/mL (Friedland et al., 1992). WAT, especially visceral, may 
contribute to 10-35% of the basal circulating IL-6 levels in healthy individuals during the 
 
Adipose Tissue Inflammation and Insulin Resistance 145 
resting state (Mohamed-Ali et al., 1997). Adipocytes are capable of producing and secreting 
IL-6 (Sopasakis  et al., 2004; Bastard et al., 2000; Fried et al., 1998; Vicennati et al., 2002; 
Krogh-Madsen et al., 2004), but contribute to a small fraction of the total IL-6 secreted by 
this tissue (Sopasakis  et al., 2004; Fried et al., 1998), since about 90% of IL-6 expressed in 
WAT is produced by cells other than adipocytes (Fried et al., 1998). 
IL-6 mRNA expression is increased in the obese adipose depots, reduces after weight loss and 
adipocyte hypertrophy is accompanied by an increase in IL-6 production (Sopasakis  et al., 
2004; Kern et al., 2001; Bastard et al., 2000; Fried et al., 1998). WAT IL-6 mRNA has been shown 
to be elevated in insulin resistant obese patients with and without 2DM (Kern et al., 2001; 
Bastard et al., 2000; Fried et al., 1998; Rotter et al., 2003), which correlates with reduced rates of 
insulin-stimulated glucose disposal both in vitro (from a glucose uptake assay in adipocytes) 
and in vivo (from a hyperinsulinemic normoglycemic clamp study) (Bastard et al., 2002).  
The cross-talk between IL-6 and insulin-dependent metabolism has been approached by 
several researchers over the past few years. Adverse effects on insulin action in the liver and 
WAT have been demonstrated in animals and in cell cultures (Klover et al., 2003; Senn et al., 
2002; Rotter et al., 2003; Senn et al., 2003; Sabio et al., 2008). This adipokine reduces insulin-
dependent hepatic glycogen synthesis (Klover et al., 2003; Senn et al., 2002) and glucose 
uptake in adipocytes (Rotter et al., 2003), whose effects could be mediated by the increased 
expression of suppressor of cytokine signaling (SOCS)-3, a protein that binds and inhibits 
the insulin receptor and also targets IRS proteins for proteosomal degradation, and by 
negative regulation of the transcription of IRS-1 (Rotter et al., 2003; Sabio et al., 2008). 
IL-6 has lipolytic properties in WAT and adipocyte cultures (Wallenius et al., 2002; van Hall 
et al., 2003; Trujillo et al., 2004; Petersen et al., 2005). In humans, infusion of IL-6 promotes a 
rise in FFA levels and stimulates total body fat oxidation (van Hall et al., 2003; Lyngso et al., 
2002). Studies in transgenic animals support the effect of IL-6 as a lipolytic factor. A 200% 
increase was observed in the number of soluble IL-6 receptors (IL-6/sIL-6R) in transgenic 
mice resulting in reduced body weight (Peters  et al., 1997), whereas IL-6 deficiency led to 
early-onset obesity (Wallenius et al., 2002). However, the obesity phenotype has not been 
observed in any other study involving IL-6 knockout mice (Di Gregorio et al., 2004). 
Circulating MCP-1 levels were increased in animal models of obesity (ob/ob mice and diet-
induced obesity mice) (Sartipy; Loskutoff, 2003; Takahashi et al., 2003) and in obese subjects 
(Christiansen et al, 2005; Bruun et al., 2005; Kim et al., 2006), and reduced after weight loss 
(Christiansen et al, 2005; Takahashi et al., 2003). Furthermore, adipose tissue MCP-1 mRNA 
expression also was enhanced and correlated with measures of adiposity in obese subjects 
(Christiansen et al, 2005; Dahlman et al., 2005). 
It was reported that adipocytes secrete MCP-1, a factor that is a potent chemoattractant for 
monocyte/macrophage infiltration (Christiansen et al., 2005; Skurk et al., 2007). Its secretion 
positively correlates with cell size (Skurk et al., 2007) and although it is produced by both 
fractions of WAT, it is more expressed in stroma vascular cells than in isolated adipocytes 
(Fain et al., 2004; Bruun et al., 2005). 
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Increased MCP-1 levels in 2DM patients compared to non-diabetic subjects were reported in 
previous studies (Nomura et al., 2000; Ezenwaka et al., 2009). In addition, in a human 
population-based case-cohort study, elevated serum concentration of MCP-1 was associated 
with incident of type 2 diabetes (Herder et al., 2006).  
Some in vitro and in vivo studies have demonstrated the insulin resistance-inducing effects 
of MCP-1 and tried to establish the mechanisms by which it may reduce insulin action. 
Treatment of 3T3-L1 differentiated adipocytes with MCP-1 blunted the insulin-stimulated 
glucose uptake and reduced the expression of genes such as lipoprotein lipase, GLUT-4 and 
PPAR- (Sartipy and Loskutoff, 2003).  In primary human skeletal muscle cells, 
physiological levels of MCP-1 significantly reduced insulin-stimulated phosphorylation of 
Akt, GSK3 and GSK3 proteins, impairing insulin signaling and reducing insulin-
dependent glucose uptake (Sell et al., 2006). Mice with overexpression of MCP-1 in the WAT 
displayed normal adiposity, increased macrophage infiltration into fat depot and reduced 
systemic insulin sensitivity (evaluated by insulin tolerance and hyperinsulinemic-
euglycemic clamp tests) (Kamei et al., 2006). Furthermore, MCP-1 overexpression in WAT 
reduced insulin-stimulated tyrosine phosphorylation of IR and IRS proteins and decreased 
Akt phosphorylation in skeletal muscle and liver causing insulin resistance in both tissues of 
these mice (Kamei et al., 2006).  
Taken together, the results suggest MCP-1 as an inflammatory link between obesity and the 
development of insulin resistance. 
7. WAT mitochondria in obesity and inflammation  
While brown adipose tissue (BAT) converts mitochondrial energy into heat during 
adaptative thermogenesis, characterization of WAT mitochondria function is still incipient 
(Forner et al., 2009; De Pauw et al., 2009). A recent in vivo proteomics analysis in mice WAT 
and BAT shows that there are quantitative and qualitative differences between the 
mitochondria from both tissues: BAT mitochondria are more similar to muscle mitochondria 
and WAT mitochondria express proteins associated with anabolic functions and proteins 
involved in the degradation of xenobiotics (Forner et al., 2009). Recent studies suggest that 
mitochondrial biogenesis and metabolism are implicated in the regulation of various 
processes in WAT, such as pre-adipocytes proliferation, adipogenesis, carbohydrate and 
lipid metabolism, adipocyte de-differentiation, TAG accumulation and acquirement of BAT-
like characteristics (De Pauw et al., 2009; Forner et al., 2009; Tedesco et al., 2010; Bordicchia 
et al., 2012; Koponen et al., 2012) and impaired mitochondrial biogenesis contributes to the 
onset of obesity and related metabolic disorders, such as insulin resistance (Tedesco et al., 
2010).WAT mitochondrial biogenesis in mice is correlated with the up-regulation of genes 
involved in fatty acid oxidation and mitochondrial electron transport activity, boosting 
WAT catabolism (Granneman et al., 2005). Indeed, it was demonstrated that 
mitochondrial proliferation and remodeling are enhanced in 3T3-L1 cells during 
adipogenesis and the use of insulin sensitizers, such as rosiglitazone, leads to significant 
alterations in mitochondrial morphology and augmentation of the expression of several 
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mitochondrial proteins (Wilson-Fritch et al., 2003). These findings were later proven in 
vivo by the use of white adipocytes from ob/ob mice during the development of obesity 
and after treatment with the insulin-sensitizer rosiglitazone. Adipocytes from 
rosiglitazone-treated mice displayed increased mitochondrial mass, markedly enhanced 
oxygen consumption and significantly increased palmitate oxidation, suggesting that 
WAT enhanced lipid utilization may affect whole-body energy homeostasis and insulin 
sensitivity (Wilson-Fritch et al., 2004). Mitochondria are now considered as a target to 
improve whole-body sensitivity to insulin, mainly via enhanced WAT mitochondrial 
biogenesis, augmented FA uptake and FA oxidation which, in turn, may protect against 
adipocyte hypertrophy. Compounds with the potential to boost mitochondrial biogenesis 
are being investigated and, besides rosiglitazone and β3-adrenergic receptor activation, 
the combined use of R-α-lipoic acid and acetyl-L-carnitine to treat 3T3L1 adipocytes 
seems to enhance WAT mitochondrial population (Granneman et al., 2005; Shen et al., 
2008). Accordingly, it was recently demonstrated that mice WAT mitochondria activation 
leads to the augmentation of both glucose sensitivity and serum adiponectin levels via the 
upregulation of genes involved in lipid metabolism and mitochondrial functioning 
(Duivenvoorde et al., 2011). Noteworthy, mitochondria mild uncoupling reduces TAG 
content in 3T3-L1 adipocytes, suggesting that WAT mitochondria modulation is a 
potential target for the development of therapies against obesity (Si et al., 2009; Tejerina et 
al., 2009). 
WAT inflammation induces cytokine-mediated insulin resistance in adipocytes, triggering 
lipolysis and FAs release in the cytosol (Maassen et al., 2007). FAs play a pivotal role in the 
cell acting as an energetic substrate as well as a component of biomolecules. Nevertheless, 
elevated plasma levels of FFA are observed in conditions such as 2DM, obesity and sepsis, 
conditions associated with impaired immune function and a high prevalence of infections 
(Takahashi et al., 2012). 
Apart from ATP synthesis, one of the most important functions of mitochondria is the 
removal of circulating FFA through β-oxidation, which occurs in tissues where glucose 
homeostasis is relevant, such as liver, muscle and adipose tissue (Maassen et al., 2007). In 
WAT, an impairment in mitochondrial fatty acid β-oxidation with increased glucose uptake 
might result in TAG accumulation in preadipocytes (Vankoningsloo et al., 2005) and muscle 
(Schereurs et al., 2010), hepatic insulin resistance (Zhang et al., 2007) and pancreatic beta 
cells lipotoxicity (Maassen et al., 2007). Accordingly, an increase in WAT oxidative capacity 
is correlated to the reduction of local inflammatory responses (Granneman et al., 2005). 
Curiously, marine-derived eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids have 
an antiadipogenic effect via a metabolic switch in adipocytes, enhancing β-oxidation and 
upregulating mitochondrial biogenesis (Flachs et al., 2005).  
Thus, WAT oxidative capacity was recently unveiled and it is implicated in the regulation of 
FFA concentration and the prevention of TAG accumulation in many tissues. An 
enhancement of WAT mitochondrial β-oxidation and, consequently, fatty acid catabolism is 
considered as a subject for prevention and treatment of obesity, insulin resistance and 
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Increased MCP-1 levels in 2DM patients compared to non-diabetic subjects were reported in 
previous studies (Nomura et al., 2000; Ezenwaka et al., 2009). In addition, in a human 
population-based case-cohort study, elevated serum concentration of MCP-1 was associated 
with incident of type 2 diabetes (Herder et al., 2006).  
Some in vitro and in vivo studies have demonstrated the insulin resistance-inducing effects 
of MCP-1 and tried to establish the mechanisms by which it may reduce insulin action. 
Treatment of 3T3-L1 differentiated adipocytes with MCP-1 blunted the insulin-stimulated 
glucose uptake and reduced the expression of genes such as lipoprotein lipase, GLUT-4 and 
PPAR- (Sartipy and Loskutoff, 2003).  In primary human skeletal muscle cells, 
physiological levels of MCP-1 significantly reduced insulin-stimulated phosphorylation of 
Akt, GSK3 and GSK3 proteins, impairing insulin signaling and reducing insulin-
dependent glucose uptake (Sell et al., 2006). Mice with overexpression of MCP-1 in the WAT 
displayed normal adiposity, increased macrophage infiltration into fat depot and reduced 
systemic insulin sensitivity (evaluated by insulin tolerance and hyperinsulinemic-
euglycemic clamp tests) (Kamei et al., 2006). Furthermore, MCP-1 overexpression in WAT 
reduced insulin-stimulated tyrosine phosphorylation of IR and IRS proteins and decreased 
Akt phosphorylation in skeletal muscle and liver causing insulin resistance in both tissues of 
these mice (Kamei et al., 2006).  
Taken together, the results suggest MCP-1 as an inflammatory link between obesity and the 
development of insulin resistance. 
7. WAT mitochondria in obesity and inflammation  
While brown adipose tissue (BAT) converts mitochondrial energy into heat during 
adaptative thermogenesis, characterization of WAT mitochondria function is still incipient 
(Forner et al., 2009; De Pauw et al., 2009). A recent in vivo proteomics analysis in mice WAT 
and BAT shows that there are quantitative and qualitative differences between the 
mitochondria from both tissues: BAT mitochondria are more similar to muscle mitochondria 
and WAT mitochondria express proteins associated with anabolic functions and proteins 
involved in the degradation of xenobiotics (Forner et al., 2009). Recent studies suggest that 
mitochondrial biogenesis and metabolism are implicated in the regulation of various 
processes in WAT, such as pre-adipocytes proliferation, adipogenesis, carbohydrate and 
lipid metabolism, adipocyte de-differentiation, TAG accumulation and acquirement of BAT-
like characteristics (De Pauw et al., 2009; Forner et al., 2009; Tedesco et al., 2010; Bordicchia 
et al., 2012; Koponen et al., 2012) and impaired mitochondrial biogenesis contributes to the 
onset of obesity and related metabolic disorders, such as insulin resistance (Tedesco et al., 
2010).WAT mitochondrial biogenesis in mice is correlated with the up-regulation of genes 
involved in fatty acid oxidation and mitochondrial electron transport activity, boosting 
WAT catabolism (Granneman et al., 2005). Indeed, it was demonstrated that 
mitochondrial proliferation and remodeling are enhanced in 3T3-L1 cells during 
adipogenesis and the use of insulin sensitizers, such as rosiglitazone, leads to significant 
alterations in mitochondrial morphology and augmentation of the expression of several 
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mitochondrial proteins (Wilson-Fritch et al., 2003). These findings were later proven in 
vivo by the use of white adipocytes from ob/ob mice during the development of obesity 
and after treatment with the insulin-sensitizer rosiglitazone. Adipocytes from 
rosiglitazone-treated mice displayed increased mitochondrial mass, markedly enhanced 
oxygen consumption and significantly increased palmitate oxidation, suggesting that 
WAT enhanced lipid utilization may affect whole-body energy homeostasis and insulin 
sensitivity (Wilson-Fritch et al., 2004). Mitochondria are now considered as a target to 
improve whole-body sensitivity to insulin, mainly via enhanced WAT mitochondrial 
biogenesis, augmented FA uptake and FA oxidation which, in turn, may protect against 
adipocyte hypertrophy. Compounds with the potential to boost mitochondrial biogenesis 
are being investigated and, besides rosiglitazone and β3-adrenergic receptor activation, 
the combined use of R-α-lipoic acid and acetyl-L-carnitine to treat 3T3L1 adipocytes 
seems to enhance WAT mitochondrial population (Granneman et al., 2005; Shen et al., 
2008). Accordingly, it was recently demonstrated that mice WAT mitochondria activation 
leads to the augmentation of both glucose sensitivity and serum adiponectin levels via the 
upregulation of genes involved in lipid metabolism and mitochondrial functioning 
(Duivenvoorde et al., 2011). Noteworthy, mitochondria mild uncoupling reduces TAG 
content in 3T3-L1 adipocytes, suggesting that WAT mitochondria modulation is a 
potential target for the development of therapies against obesity (Si et al., 2009; Tejerina et 
al., 2009). 
WAT inflammation induces cytokine-mediated insulin resistance in adipocytes, triggering 
lipolysis and FAs release in the cytosol (Maassen et al., 2007). FAs play a pivotal role in the 
cell acting as an energetic substrate as well as a component of biomolecules. Nevertheless, 
elevated plasma levels of FFA are observed in conditions such as 2DM, obesity and sepsis, 
conditions associated with impaired immune function and a high prevalence of infections 
(Takahashi et al., 2012). 
Apart from ATP synthesis, one of the most important functions of mitochondria is the 
removal of circulating FFA through β-oxidation, which occurs in tissues where glucose 
homeostasis is relevant, such as liver, muscle and adipose tissue (Maassen et al., 2007). In 
WAT, an impairment in mitochondrial fatty acid β-oxidation with increased glucose uptake 
might result in TAG accumulation in preadipocytes (Vankoningsloo et al., 2005) and muscle 
(Schereurs et al., 2010), hepatic insulin resistance (Zhang et al., 2007) and pancreatic beta 
cells lipotoxicity (Maassen et al., 2007). Accordingly, an increase in WAT oxidative capacity 
is correlated to the reduction of local inflammatory responses (Granneman et al., 2005). 
Curiously, marine-derived eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids have 
an antiadipogenic effect via a metabolic switch in adipocytes, enhancing β-oxidation and 
upregulating mitochondrial biogenesis (Flachs et al., 2005).  
Thus, WAT oxidative capacity was recently unveiled and it is implicated in the regulation of 
FFA concentration and the prevention of TAG accumulation in many tissues. An 
enhancement of WAT mitochondrial β-oxidation and, consequently, fatty acid catabolism is 
considered as a subject for prevention and treatment of obesity, insulin resistance and 
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lipotoxicity (Granneman et al., 2005; Maassen et al., 2007; De Pauw et al., 2009; Schreurs et 
al., 2010; Gaidhu et al., 2011). 
8. Conclusion 
The chronic inflammatory state associated with obesity, particularly visceral obesity, favors 
the development of insulin resistance, metabolic syndrome, DM2, atherosclerosis, arterial 
hypertension and other cardiovascular diseases. In addition to its active role in energy 
metabolism, WAT secretes a number of substances with autocrine, paracrine and endocrine 
effects. Some WAT-derived factors contribute to the activation and infiltration of 
macrophages into fat depots. These macrophages, when activated, secrete cytokines that 
increase cell infiltration and inflammatory process. During this process, WAT turns into an 
inflamed organ that releases large amounts of FFA, which contributes to the lipid 
accumulation in non-adipose tissues, including liver and skeletal muscle. Inadequate lipid 
storage in these tissues is strongly associated with insulin resistance. 
WAT also secretes a large numbers of proteins that participate in the inflammatory 
response. Several recent studies suggest that cytokines secreted by both adipocytes and 
infiltrated macrophages impair insulin signaling in peripheral tissues and then, may 
represent an important link between WAT inflammation in obesity and the pathogenesis of 
insulin resistance and DM2. 
Moreover, the investigation of WAT mitochondrial function (and dysfunction) is recent and 
promising for a better understanding of WAT plasticity and metabolism and, consequently, 
for the development of new therapies to improve insulin sensitivity and treat obesity and 
related diseases. 
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8. Conclusion 
The chronic inflammatory state associated with obesity, particularly visceral obesity, favors 
the development of insulin resistance, metabolic syndrome, DM2, atherosclerosis, arterial 
hypertension and other cardiovascular diseases. In addition to its active role in energy 
metabolism, WAT secretes a number of substances with autocrine, paracrine and endocrine 
effects. Some WAT-derived factors contribute to the activation and infiltration of 
macrophages into fat depots. These macrophages, when activated, secrete cytokines that 
increase cell infiltration and inflammatory process. During this process, WAT turns into an 
inflamed organ that releases large amounts of FFA, which contributes to the lipid 
accumulation in non-adipose tissues, including liver and skeletal muscle. Inadequate lipid 
storage in these tissues is strongly associated with insulin resistance. 
WAT also secretes a large numbers of proteins that participate in the inflammatory 
response. Several recent studies suggest that cytokines secreted by both adipocytes and 
infiltrated macrophages impair insulin signaling in peripheral tissues and then, may 
represent an important link between WAT inflammation in obesity and the pathogenesis of 
insulin resistance and DM2. 
Moreover, the investigation of WAT mitochondrial function (and dysfunction) is recent and 
promising for a better understanding of WAT plasticity and metabolism and, consequently, 
for the development of new therapies to improve insulin sensitivity and treat obesity and 
related diseases. 
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1. Introduction 
Elevated sympathetic activation, as assessed using a variety of indices, has been observed in 
lean hypertensive and diabetic patients, and obese individuals [Huggett et al. 2006; Masuo et 
al. 2000]. Similarly, many epidemiological studies have shown that hypertensive patients, 
even those without increased adiposity, display a higher prevalence of insulin resistance, 
thereby indicating the possible association between sympathetic activation and insulin 
resistance in the pathogenesis of hypertension [Esler et al. 2006; Masuo et al. 2002; de Silva et 
al. 2009]. Overweight and obesity is a growing problem across the globe and has reached 
“epidemic” proportions. The prevalence of diabetes, especially type 2 diabetes, and 
hypertension are significantly increased with the prevalence of obesity. Obesity, itself, and 
type 2 diabetes and hypertension associated with obesity are known to be more closely 
linked with insulin resistance and elevated sympathetic nervous activity. It has been well 
documented that obesity, hypertension, and diabetes are risk factors for subsequent 
cardiovascular and renal complications. Many patients are both diabetic and hypertensive 
while they are obese, but not all diabetic patients have hypertension, indicating that insulin 
resistance is not the only mechanism for blood pressure elevation in diabetic-hypertensive 
patients. Several investigators have reported that sympathetic nervous activation plays an 
important role in cardiovascular complications in patients with hypertension, diabetes, and 
obesity. 
Sympathetic nervous activation accompanying insulin resistance is closely linked with left 
ventricular hypertrophy in otherwise healthy subjects [Masuo, et al. 2008]. In addition, 
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sympathetic activation may predict the development of renal injury in healthy normotensive 
subjects [Masuo, et al. 2010]. Weight loss associated suppression of sympathetic nervous 
activity is associated with improvement of insulin sensitivity and resultant improvement in 
renal function in obese patients [Masuo, et al. 2011b; Straznicky, et al. 2009b & 2011]. 
Furthermore, weight loss improved the prevalence of left ventricular hypertrophy [Masuo, 
et al. 2008], which is one of the predictors for future cardiac complications, renal 
complications (injury) [Masuo, et al. 2007] and hyperuricacidemia [Straznicky, et al. 
2011].These findings suggest that elevated sympathetic nerve activity associated with 
insulin resistance may contribute to the onset and maintenance of cardiovascular and renal 
complications in diabetes, and hypertension in obesity.  
Furthermore, genetic polymorphisms of the β2- and β3-adrenoceptor gene have been 
associated with obesity [Masuo, et al. 2005 & 2011a; Kawaguchi, et al. 2006], hypertension 
[Masuo, et al. 2005b & 2010b; Kawaguchi, et al. 2006], type-2 diabetes and insulin resistance 
[Masuo, et al. 2005 & 2010} in epidemiological studies and may also be implicit in the close 
relationship between insulin resistance and sympathetic nerve activation. Recently, Masuo 
et al. reported that β2-adrenoceptor polymorphisms (Arg16Gly) accompanying high plasma 
norepinephrine levels may contribute to the prevalence of left ventricular hypertrophy and 
renal dysfunction [Masuo, et al. 2010a, b & 2011b]. These investigations suggest that β2-
adrenoceptor polymorphisms are related to sympathetic activation and insulin resistance 
and may contribute to cardiovascular- and renal complications in obesity and obesity-
related hypertension or type 2 diabetes. 
This chapter will provide a synthesis of the current findings on the mechanisms of the onset 
and maintenance of cardiovascular and renal complications in obesity, hypertension and 
type 2 diabetes, with a particular focus on sympathetic nervous activity and insulin 
resistance. A better understanding of the relationships between sympathetic nervous 
activity and insulin resistance in these important clinical conditions might help with the 
clinical treatment of diabetes and hypertension in obesity and prevent further 
cardiovascular and renal complications in this at risk group.  
2. Prevalence of type 2 diabetes and hypertension in obesity 
The clustering of cardiovascular risk factors associated with obesity, in particular abdominal 
obesity, is well established [Athyrus, et al. 2011]. The prevalence of obesity and overweight 
increased in the United States between 1978 and 1991 [Mokdad, et al. 2001], and recent 
reports have suggested continuing increases [Ogden, et al. 2004]. The National Health and 
Nutrition Examination Survey (NHANES) I (1971-1974), NHANES II (1976-1980), and 
NAHNES III (1988-1994) were conducted by the National Center for Health Statistics, 
Centers for Disease Control and Prevention (CDC). These data from the continuous 
NHANES studies have  showed that the prevalence of obesity and overweight people 
increased significantly in the United States between 1960 and 2003 [Preis, et al. 2009; Ogden, 
et al. 2004; Flegal, et al. 2012]. Evidence from several studies indicates that obesity and 
weight gain are associated with an increased risk of hypertension [Masuo, et al. 2000 & 
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2005a, b, c] and diabetes [Resnick, et al. 2000; Ford, et al. 1997], and that intentional weight 
loss reduces the risk that overweight individuals will develop hypertension [Masuo, et al. 
2001b; Straznicky, et al. 2009b] or diabetes [Will, et al. 2002].  
Recent large cohort studies have showed an increasing prevalence of obesity in children 
and, importantly, obesity in children is strongly associated with several major health risk 
factors, including type 2 diabetes mellitus and hypertension [Hedley, et al. 2004]. 
Focusing on the close associations between obesity, hypertension and diabetes, the 
NHANES and the Behavioural Risk Factor Surveillance System (BRFSS) investigations 
[Mokdad, et al. 2003] showed very close relationships between the prevalence of obesity, 
hypertension, and diabetes. Further, the Framingham Heart Study [Preis, et al. 2009] 
showed that diabetic subjects had a 2-fold higher mortality risk consisting of cardiovascular 
and non-cardiovascular mortality.  
3. Sympathetic nervous activity in obesity, hypertension and diabetes 
The sympathetic nervous system represents a major pathophysiological hallmark of both 
hypertension and renal failure, and is an important target of the therapeutic intervention 
[Grassi, et al. 2012; Schlaich, et al. 2009]. The sympathetic nervous system participates in 
regulating the energy balance through thermogenesis. Reduced energy expenditure and 
resting metabolic rate are predictive of weight gain (obesity). It is also widely recognized that 
insulin resistance or hyperinsulinemia relates to obesity [Minicardi, et al. 1996; Farrannini, et al. 
1995; Ward, et al. 1996]. Many epidemiological and clinical studies have shown a close 
relationship between sympathetic nervous system activity and insulin levels in obesity 
[Masuo. et al. 2002]. Several studies of longitudinal design have examined the effect of body 
weight changes (weight loss or weight gain) on sympathetic nervous system activity and 
insulin sensitivity (fasting plasma insulin levels and the (homeostasis model assessment of 
insulin resistance,   HOMA-IR). Elevations of sympathetic nervous system activity and insulin 
levels during weight gain [Masuo, et al. 2000; Gentale, et al. 2007; Barms, et al. 2003], and 
reductions of sympathetic activity and insulin levels during weight loss [Anderson, et al. 1991; 
Straznicky, et al. 2009], are typically observed. While these longitudinal studies have clearly 
shown that heightened sympathetic nerve activity and insulin resistance are closely linked to 
obesity (weight gain), the onset of obesity and the maintenance of obesity, it remains to be 
elucidated, whether sympathetic hyperactivity or insulin resistance is the prime mover.  
The response of the sympathetic nervous system to change in plasma insulin levels after oral 
glucose loading (oral glucose tolerance test) are different between subjects with and without 
insulin resistance [Masuo, et al. 2005], between nonobese and obese subjects [Straznicky, et al. 
2009a], and between subjects with and without the metabolic syndrome [Straznicky. 2009b]. 
Recently, changes in the sympathetic nerve firing pattern were observed with sympatho-
inhibition during weight loss [Lambert, et al. 2011].  In addition, different regulation by insulin 
of regional (i.e. hind limb, kidney and brown adipose tissue) sympathetic outflow to 
peripheral tissue was observed in agouti obese mice compared to lean control mice [Morgani, 
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et al. 2010]. These observations provide the evidence of a strong linkage between the activity of 
the sympathetic nervous system and insulin levels. Huggett et al. [Huggett, et al. 2003] 
examined muscle sympathetic nerve activity (MSNA) in four groups of subjects, patients with 
essential hypertension and type 2 diabetes, patients with type 2 diabetes alone, patients with 
essential hypertension alone, and healthy normotensive controls. They found higher MSNA in 
the hypertensive-type 2 diabetic patients as compared with hypertensive alone patients or type 
2 diabetic alone patients, and higher MSNA in hypertensive alone patients or type 2 diabetic 
alone patients as compared with healthy normotensive controls. Fasting insulin levels were 
greater in hypertensive-type 2 diabetic patients and type 2 diabetic patients compared to 
hypertensive patients or healthy normotensive subjects. These findings, although obtained in 
patients still under medication, provided evidence that type 2 diabetic patients had elevated 
sympathetic nerve activity regardless of the prevailing blood pressure levels, and that the 
combination of hypertension and type 2 diabetes resulted in an augmentation in sympathetic 
nerve activity and levels of plasma insulin.  
Several investigations on the contributions of β2- and β3-adrenoceptor polymorphisms to 
type 2 diabetes also support a strong relationship between sympathetic nerve hyperactivity 
and insulin resistance in type 2 diabetes [Masuo, et al. 2004 & 2005a, b; Ikarashi, et al. 2004]. 
Figure 1 summarizes the relationships between sympathetic nerve activity and insulin 
resistance in obesity and type 2 diabetes mellitus (Figure 1). 
 
Obesity causes both insulin resistance/hyperinsulinemia and sympathetic nervous activation, and both link closely 
each other. Many investigations have shown that insulin resistance, sympathetic nervous activation, and adrenoceptor 
polymorphisms play important roles in the onset and maintenance of obesity, type 2 diabetes and hypertension.  
T2DM, type 2 diabetes, RAA, renin-angiotensin-aldosterone system; ADRB polymorphisms, adrenoceptor 
polymorphisms; SNS, sympathetic nervous system.  
Figure 1. Potential pathophysiological mechanisms in obesity, hypertension and type2diabetes (T2DM) 
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4. Insulin resistance in obesity, hypertension and type 2 diabetes 
Insulin resistance [Ferrannini, et al. 1998] is one of the criteria underpinning the 
development of the metabolic syndrome. The clinical evaluation of insulin resistance is 
growing interest because it is a strong predictor and plays an important role in the 
development of the metabolic syndrome, type 2 diabetes mellitus and hypertension. 
Table 1 shows the criteria for metabolic syndrome characterisation, as can be seen 
insulin resistance is prominent [Alberti, et al. 1998; Grundy, et al. 2004] (Table 1). 
Measuring insulin sensitivity is important to define insulin resistance. Table 2 
summarizes the methods usually used in clinical and epidemiological studies (Table 2). 
The hyperinsulinemic-euglycemic glucose clamp method is the gold standard and may 
be suitable for research investigations in specialized laboratories, but the homeostasis 
model assessment of insulin resistance (HOMA-IR) or fasting plasma insulin 
concentrations is more practical for epidemiological studies comprising a large number 
of subjects.   
4.1. Hyperinsulinemia as a marker of insulin resistance 
Insulin is an exceptional hormone in that its action is regulated not only by changes in 
concentration but also by changes in the sensitivity of target tissues. Inadequate insulin 
action can be the consequence of: (i) insufficient insulin concentration at the site of action, (ii) 
decreased tissue (effectors) responses to insulin, or (iii) a combination of low concentration 
and a decreased response. Regulation of circulating insulin levels is mainly (but not 
exclusively) achieved by changes in secretory rates. Nevertheless, the major determinant of 
insulin secretion, and therefore of plasma insulin concentration, is glucose. Any change in 
glucose concentration from the narrow normal range results in an insulin response 
appropriate to restore homeostasis. Thus, changes in insulin sensitivity occur in various 
physiological states and pathological conditions. 
For any amount of insulin secreted by the pancreas, the biological response of a given 
effector is dependent on its insulin sensitivity. The term insulin resistance customarily refers 
to glucose metabolism. Any decrease in insulin sensitivity (insulin resistance) is 
immediately translated into minute increases in blood glucose concentrations that will in 
turn act on the β-cell to produce a compensatory stimulus of insulin secretion, leading to a 
degree of hyperinsulinemia that is approximately proportional to the degree of effector 
resistance. Therefore, hyperinsulinemia may be responsible for insulin resistance. In steady-
state conditions, this compensatory hyperinsulinemia prevents a more exaggerated 
hyperglycaemia. The inability of β-cells to enhance insulin secretion means that blood 
glucose will keep increasing until the level of hyperglycaemia produces an adequate β-cell 
stimulus to attain the required insulin response. When the β-cell is unable to compensate for 
the prevalent insulin resistant state by further augmenting insulin secretion, hyperglycaemia 
continues to increase, producing impaired fasting glucose, impaired glucose tolerance and 
diabetes mellitus development.  
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nerve activity and levels of plasma insulin.  
Several investigations on the contributions of β2- and β3-adrenoceptor polymorphisms to 
type 2 diabetes also support a strong relationship between sympathetic nerve hyperactivity 
and insulin resistance in type 2 diabetes [Masuo, et al. 2004 & 2005a, b; Ikarashi, et al. 2004]. 
Figure 1 summarizes the relationships between sympathetic nerve activity and insulin 
resistance in obesity and type 2 diabetes mellitus (Figure 1). 
 
Obesity causes both insulin resistance/hyperinsulinemia and sympathetic nervous activation, and both link closely 
each other. Many investigations have shown that insulin resistance, sympathetic nervous activation, and adrenoceptor 
polymorphisms play important roles in the onset and maintenance of obesity, type 2 diabetes and hypertension.  
T2DM, type 2 diabetes, RAA, renin-angiotensin-aldosterone system; ADRB polymorphisms, adrenoceptor 
polymorphisms; SNS, sympathetic nervous system.  
Figure 1. Potential pathophysiological mechanisms in obesity, hypertension and type2diabetes (T2DM) 
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4. Insulin resistance in obesity, hypertension and type 2 diabetes 
Insulin resistance [Ferrannini, et al. 1998] is one of the criteria underpinning the 
development of the metabolic syndrome. The clinical evaluation of insulin resistance is 
growing interest because it is a strong predictor and plays an important role in the 
development of the metabolic syndrome, type 2 diabetes mellitus and hypertension. 
Table 1 shows the criteria for metabolic syndrome characterisation, as can be seen 
insulin resistance is prominent [Alberti, et al. 1998; Grundy, et al. 2004] (Table 1). 
Measuring insulin sensitivity is important to define insulin resistance. Table 2 
summarizes the methods usually used in clinical and epidemiological studies (Table 2). 
The hyperinsulinemic-euglycemic glucose clamp method is the gold standard and may 
be suitable for research investigations in specialized laboratories, but the homeostasis 
model assessment of insulin resistance (HOMA-IR) or fasting plasma insulin 
concentrations is more practical for epidemiological studies comprising a large number 
of subjects.   
4.1. Hyperinsulinemia as a marker of insulin resistance 
Insulin is an exceptional hormone in that its action is regulated not only by changes in 
concentration but also by changes in the sensitivity of target tissues. Inadequate insulin 
action can be the consequence of: (i) insufficient insulin concentration at the site of action, (ii) 
decreased tissue (effectors) responses to insulin, or (iii) a combination of low concentration 
and a decreased response. Regulation of circulating insulin levels is mainly (but not 
exclusively) achieved by changes in secretory rates. Nevertheless, the major determinant of 
insulin secretion, and therefore of plasma insulin concentration, is glucose. Any change in 
glucose concentration from the narrow normal range results in an insulin response 
appropriate to restore homeostasis. Thus, changes in insulin sensitivity occur in various 
physiological states and pathological conditions. 
For any amount of insulin secreted by the pancreas, the biological response of a given 
effector is dependent on its insulin sensitivity. The term insulin resistance customarily refers 
to glucose metabolism. Any decrease in insulin sensitivity (insulin resistance) is 
immediately translated into minute increases in blood glucose concentrations that will in 
turn act on the β-cell to produce a compensatory stimulus of insulin secretion, leading to a 
degree of hyperinsulinemia that is approximately proportional to the degree of effector 
resistance. Therefore, hyperinsulinemia may be responsible for insulin resistance. In steady-
state conditions, this compensatory hyperinsulinemia prevents a more exaggerated 
hyperglycaemia. The inability of β-cells to enhance insulin secretion means that blood 
glucose will keep increasing until the level of hyperglycaemia produces an adequate β-cell 
stimulus to attain the required insulin response. When the β-cell is unable to compensate for 
the prevalent insulin resistant state by further augmenting insulin secretion, hyperglycaemia 
continues to increase, producing impaired fasting glucose, impaired glucose tolerance and 
diabetes mellitus development.  
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4.2. Relationships between sympathetic nervous activity and insulin resistance 
in obesity, hypertension, and type 2 diabetes 
It is widely recognized that insulin resistance or hyperinsulinemia relates to obesity 
[Ferrannini, et al. 1991 & 1995; Ward, et al. 1996], but the precise relationships linking those 
factors remain controversial. Many epidemiological and clinical studies have shown a close 
relationship between sympathetic nervous system activity and insulin levels in obesity 
[Anderson, et al. 1991; Ward, et al. 1996; Masuo, et al. 2002]. Several studies of longitudinal 
design have examined the effect of body weight changes (weight loss or weight gain) on 
sympathetic nervous system activity and insulin sensitivity (fasting plasma insulin levels 
and HOMA-IR). Elevations of sympathetic nervous system activity and insulin levels during 
weight gain [Masuo, et al. 2000; Bernes, et al. 2003; Gentle, et al. 2007} and reductions of 
sympathetic nerve activity and insulin levels during weight loss [Masuo, et al. 2001; 
Andersson, et al. 1991; Straznicky, et al, 2010] have been observed. These longitudinal studies 
have shown that heightened sympathetic nerve activity and insulin resistance are closely 
linked to obesity (weight gain), the onset of obesity and the maintenance of obesity.  In 
addition, a calorie restricted diet and exercise may have different mechanism on weight 
loss-induced blood pressure reduction.  Figure 2 shows changes in neurohormonal 
parameters over a 24-week period weight loss regimens  with a mild calorie restricted diet 
alone, mild exercise alone, or a combination with a mild calorie restricted diet and mild 
exercise. This study showed that a calorie restricted diet contributed strongly to 
normalization/suppression of sympathetic activation, and exercise related to insulin 
resistance.  In addition, calorie restricted diet and exercise may have different mechanisms 
on weight loss-induced blood pressure reduction [Masuo, et al. 2012a].  
Reduced energy expenditure and resting metabolic rate are predictive of weight gain and 
obesity development. The sympathetic nervous system participates in regulating energy 
balance through thermogenesis (Figure 1). Landsberg and other investigators hypothesized 
that energy intake stimulates hyperinsulinemia and sympathetic nerve activity resulting in 
blood pressure elevations in a cycle in order to inhibit thermogenesis. Insulin-mediated 
sympathetic nerve stimulation in obese subjects is therefore considered part of a 
compensatory mechanism aimed at restoring the energy balance by increasing the metabolic 
rate [Landsberg. 2001]. Hyperinsulinemia and insulin resistance in obese subjects are all part 
of a response to limit further weight gain via stimulating sympathetic nerve activity and 
thermogenesis [Landsberg, 2001].  
On the other hand, Julius and Masuo generated a hypothesis based on data from their 
longitudinal studies that increased sympathetic nerve activity in skeletal muscle causes 
neurogenic vasoconstriction, thereby reducing blood flow to muscle and consequently 
inducing a state of insulin resistance by lowering glucose delivery and uptake in 
hypertension and obesity. Both blood pressure elevations and weight gain may reflect a 
primary increase in sympathetic nervous tone. Masuo et al. [Masuo, et al. 1997, 2000, and 
2003] demonstrated that high plasma norepinephrine could predict future blood pressure 
elevations accompanying deterioration in insulin resistance. This was observed in HOMA-
 

































































Sympathetic Nervous Activation and Insulin Resistance as Renal and Cardiac Risk 167 
4.2. Relationships between sympathetic nervous activity and insulin resistance 
in obesity, hypertension, and type 2 diabetes 
It is widely recognized that insulin resistance or hyperinsulinemia relates to obesity 
[Ferrannini, et al. 1991 & 1995; Ward, et al. 1996], but the precise relationships linking those 
factors remain controversial. Many epidemiological and clinical studies have shown a close 
relationship between sympathetic nervous system activity and insulin levels in obesity 
[Anderson, et al. 1991; Ward, et al. 1996; Masuo, et al. 2002]. Several studies of longitudinal 
design have examined the effect of body weight changes (weight loss or weight gain) on 
sympathetic nervous system activity and insulin sensitivity (fasting plasma insulin levels 
and HOMA-IR). Elevations of sympathetic nervous system activity and insulin levels during 
weight gain [Masuo, et al. 2000; Bernes, et al. 2003; Gentle, et al. 2007} and reductions of 
sympathetic nerve activity and insulin levels during weight loss [Masuo, et al. 2001; 
Andersson, et al. 1991; Straznicky, et al, 2010] have been observed. These longitudinal studies 
have shown that heightened sympathetic nerve activity and insulin resistance are closely 
linked to obesity (weight gain), the onset of obesity and the maintenance of obesity.  In 
addition, a calorie restricted diet and exercise may have different mechanism on weight 
loss-induced blood pressure reduction.  Figure 2 shows changes in neurohormonal 
parameters over a 24-week period weight loss regimens  with a mild calorie restricted diet 
alone, mild exercise alone, or a combination with a mild calorie restricted diet and mild 
exercise. This study showed that a calorie restricted diet contributed strongly to 
normalization/suppression of sympathetic activation, and exercise related to insulin 
resistance.  In addition, calorie restricted diet and exercise may have different mechanisms 
on weight loss-induced blood pressure reduction [Masuo, et al. 2012a].  
Reduced energy expenditure and resting metabolic rate are predictive of weight gain and 
obesity development. The sympathetic nervous system participates in regulating energy 
balance through thermogenesis (Figure 1). Landsberg and other investigators hypothesized 
that energy intake stimulates hyperinsulinemia and sympathetic nerve activity resulting in 
blood pressure elevations in a cycle in order to inhibit thermogenesis. Insulin-mediated 
sympathetic nerve stimulation in obese subjects is therefore considered part of a 
compensatory mechanism aimed at restoring the energy balance by increasing the metabolic 
rate [Landsberg. 2001]. Hyperinsulinemia and insulin resistance in obese subjects are all part 
of a response to limit further weight gain via stimulating sympathetic nerve activity and 
thermogenesis [Landsberg, 2001].  
On the other hand, Julius and Masuo generated a hypothesis based on data from their 
longitudinal studies that increased sympathetic nerve activity in skeletal muscle causes 
neurogenic vasoconstriction, thereby reducing blood flow to muscle and consequently 
inducing a state of insulin resistance by lowering glucose delivery and uptake in 
hypertension and obesity. Both blood pressure elevations and weight gain may reflect a 
primary increase in sympathetic nervous tone. Masuo et al. [Masuo, et al. 1997, 2000, and 
2003] demonstrated that high plasma norepinephrine could predict future blood pressure 
elevations accompanying deterioration in insulin resistance. This was observed in HOMA-
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IR (homeostasis model assessments of insulin resistance) in nonobese, normotensive 
subjects using longitudinal studies. Rocchini et al. [Rocchini, et al. 1990] reported that 
clonidine prevented insulin resistance development in obese dogs over a 6-week period, 
suggesting that sympathetic nervous activity might play a major role in the development of 
insulin resistance accompanying blood pressure elevation. The longitudinal studies 
[Straznicky, et al. 2005, 2009b & 2012. Masuo, et al. 2000, 2001b, 2003, 2005a, 2012] might 
provide strong evidence for a close linkage of high sympathetic nervous activity 
accompanying insulin resistance with the onset of hypertension. Heightened sympathetic 
nerve activity might play a major role in blood pressure elevations, and insulin resistance 
might play an ancillary mechanism for blood pressure elevation and genesis of 
hypertension. In hypertensive patients who already have heightened sympathetic nerve 
activity and insulin resistance, both heightened sympathetic nerve activity and insulin 
resistance are related to further blood pressure elevations.  
 
During weight loss with a mild calorie restricted diet, normalization of sympathetic activation measured by plasma 
norepinephrine was observed following significant weight loss and normalization of insulin resistance (HOMA-IR). 
On the other hand, in exercise alone group, normalization of insulin resistance was observed, and then weight loss and 
suppression of sympathetic activation. A low caloric diet and exercise may exert different effects on weight loss. NE, 
plasma norepinephrine levels; Fat, total body fat-mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HOMA, homeostasis model of assessment of insulin resistance. [Masuo, et al. 2012] 
Figure 2. When significant changes were observed comparisons between a calorie restricted diet vs. 
mild exercise alone vs. combination with diet + exercise over 24 weeks 
Very recently, Masuo et al. [Masuo, et al. 2012} showed the differences in mechanisms of 
weight loss-induced blood pressure reductions with neurohormonal parameters changes 
over 24 weeks with loss regimens (Figure 2). A calorie restricted diet caused 
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suppression/normalization of sympathetic activation measured with plasma norepinephrine 
levels followed by improvements of insulin resistance, whereas exercise improved insulin 
resistance followed by normalization of norepinephrine levels. BMI and blood pressure 
decreased after significant reductions in both plasma norepinephrine and HOMA-IR (Figure 
2).  Their investigations may help to explain why discordant results have been observed.  
However, at least their hypotheses showed a strong linkage between sympathetic activation, 
insulin resistance, obesity and hypertension.  
Valentine et al. [Valentine, et al. 2004] reported attenuation of hemodynamic and energy 
expenditure responses to isoproterenol infusion in hypertensive patients. Their findings that 
a generalized decrease of β-adrenergic responsiveness in hypertension supports the 
hypothesis that heightened sympathetic nerve activity through down-regulation of β-
adrenoceptor-mediated thermogenesis, may facilitate the development of obesity in 
hypertension. Their results suggested that sympathetic nerve activity-induced hypertension 
may subsequently lead to the development of obesity.  
Hoffmann et al. [Hoffmann, et al. 1999] investigated the effects of the acute induction of 
hyperglycemia on sympathetic nervous activity and vascular function in eight young 
normal control subjects. Muscle sympathetic nerve activity (MSNA) and forearm vascular 
resistance were measured before and during systemic infusion of 20% dextrose with low 
dose insulin with 60 min of hyperglycemia. Acute hyperglycemia caused sympathetic 
activation and peripheral vasodilation. Moreover, both acute and chronic hyperglycemia 
and hyperinsulinemia may enhance adrenergic vasoconstriction and decrease vasodilation 
in animal models (pithed rats) [Takatori, et al. 2006; Zamai, et al. 2008]. Insulin causes 
forearm vasoconstriction in obese, insulin resistant hypertensive humans [Gudbjornsdotti, et 
al. 1998]. On the other hand, van Veen et al. [van Veen, et al. 1999] found that hyperglycemia 
induced vasodilation in the forearm, but this vasodilation was not modified by 
hyperinsulinemia.  
4.3. Sympathetic nervous activity and leptin in obesity and the metabolic 
syndrome 
Interactions between the sympathetic nervous system and leptin are widely acknowledged 
with each being able to influence the other. Indeed, the leptin system mediates some of its 
action through the sympathetic nervous system [Haynes, et al. 1997; Kuo, et al. 2003]. 
Trayhurn et al. [Trayhurn, et al. 1995; Hardie, et al. 1996] investigated the effect of acute 
sympathetic nerve activation caused by exposure to cold on the expression of the leptin gene 
in white adipose tissue of lean mice, but not in obese mice. In addition, Masuo et al. reported 
the blunted linkage between the sympathetic nervous system and leptin in obese subjects 
[Masuo, et al. 2006; Kawaguchi, et al. 2006]. These studies, together with others, indicate that 
both insulin resistance and leptin may be regulated by the sympathetic nervous system. 
Masuo et al. [Masuo, et al. 2008] showed during oral glucose loading that plasma insulin and 
plasma norepinephrine increased in both insulin-sensitive and insulin-resistant subjects, but 
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IR (homeostasis model assessments of insulin resistance) in nonobese, normotensive 
subjects using longitudinal studies. Rocchini et al. [Rocchini, et al. 1990] reported that 
clonidine prevented insulin resistance development in obese dogs over a 6-week period, 
suggesting that sympathetic nervous activity might play a major role in the development of 
insulin resistance accompanying blood pressure elevation. The longitudinal studies 
[Straznicky, et al. 2005, 2009b & 2012. Masuo, et al. 2000, 2001b, 2003, 2005a, 2012] might 
provide strong evidence for a close linkage of high sympathetic nervous activity 
accompanying insulin resistance with the onset of hypertension. Heightened sympathetic 
nerve activity might play a major role in blood pressure elevations, and insulin resistance 
might play an ancillary mechanism for blood pressure elevation and genesis of 
hypertension. In hypertensive patients who already have heightened sympathetic nerve 
activity and insulin resistance, both heightened sympathetic nerve activity and insulin 
resistance are related to further blood pressure elevations.  
 
During weight loss with a mild calorie restricted diet, normalization of sympathetic activation measured by plasma 
norepinephrine was observed following significant weight loss and normalization of insulin resistance (HOMA-IR). 
On the other hand, in exercise alone group, normalization of insulin resistance was observed, and then weight loss and 
suppression of sympathetic activation. A low caloric diet and exercise may exert different effects on weight loss. NE, 
plasma norepinephrine levels; Fat, total body fat-mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HOMA, homeostasis model of assessment of insulin resistance. [Masuo, et al. 2012] 
Figure 2. When significant changes were observed comparisons between a calorie restricted diet vs. 
mild exercise alone vs. combination with diet + exercise over 24 weeks 
Very recently, Masuo et al. [Masuo, et al. 2012} showed the differences in mechanisms of 
weight loss-induced blood pressure reductions with neurohormonal parameters changes 
over 24 weeks with loss regimens (Figure 2). A calorie restricted diet caused 
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suppression/normalization of sympathetic activation measured with plasma norepinephrine 
levels followed by improvements of insulin resistance, whereas exercise improved insulin 
resistance followed by normalization of norepinephrine levels. BMI and blood pressure 
decreased after significant reductions in both plasma norepinephrine and HOMA-IR (Figure 
2).  Their investigations may help to explain why discordant results have been observed.  
However, at least their hypotheses showed a strong linkage between sympathetic activation, 
insulin resistance, obesity and hypertension.  
Valentine et al. [Valentine, et al. 2004] reported attenuation of hemodynamic and energy 
expenditure responses to isoproterenol infusion in hypertensive patients. Their findings that 
a generalized decrease of β-adrenergic responsiveness in hypertension supports the 
hypothesis that heightened sympathetic nerve activity through down-regulation of β-
adrenoceptor-mediated thermogenesis, may facilitate the development of obesity in 
hypertension. Their results suggested that sympathetic nerve activity-induced hypertension 
may subsequently lead to the development of obesity.  
Hoffmann et al. [Hoffmann, et al. 1999] investigated the effects of the acute induction of 
hyperglycemia on sympathetic nervous activity and vascular function in eight young 
normal control subjects. Muscle sympathetic nerve activity (MSNA) and forearm vascular 
resistance were measured before and during systemic infusion of 20% dextrose with low 
dose insulin with 60 min of hyperglycemia. Acute hyperglycemia caused sympathetic 
activation and peripheral vasodilation. Moreover, both acute and chronic hyperglycemia 
and hyperinsulinemia may enhance adrenergic vasoconstriction and decrease vasodilation 
in animal models (pithed rats) [Takatori, et al. 2006; Zamai, et al. 2008]. Insulin causes 
forearm vasoconstriction in obese, insulin resistant hypertensive humans [Gudbjornsdotti, et 
al. 1998]. On the other hand, van Veen et al. [van Veen, et al. 1999] found that hyperglycemia 
induced vasodilation in the forearm, but this vasodilation was not modified by 
hyperinsulinemia.  
4.3. Sympathetic nervous activity and leptin in obesity and the metabolic 
syndrome 
Interactions between the sympathetic nervous system and leptin are widely acknowledged 
with each being able to influence the other. Indeed, the leptin system mediates some of its 
action through the sympathetic nervous system [Haynes, et al. 1997; Kuo, et al. 2003]. 
Trayhurn et al. [Trayhurn, et al. 1995; Hardie, et al. 1996] investigated the effect of acute 
sympathetic nerve activation caused by exposure to cold on the expression of the leptin gene 
in white adipose tissue of lean mice, but not in obese mice. In addition, Masuo et al. reported 
the blunted linkage between the sympathetic nervous system and leptin in obese subjects 
[Masuo, et al. 2006; Kawaguchi, et al. 2006]. These studies, together with others, indicate that 
both insulin resistance and leptin may be regulated by the sympathetic nervous system. 
Masuo et al. [Masuo, et al. 2008] showed during oral glucose loading that plasma insulin and 
plasma norepinephrine increased in both insulin-sensitive and insulin-resistant subjects, but 
 
Insulin Resistance 170 
plasma leptin levels decreased in insulin-sensitive nonobese subjects and increased in 
insulin- resistant nonobese subjects. Straznicky et al. [Straznicky, et al. 2005] also reported 
the blunted responses of whole-body norepinephrine spillover, insulin, and plasma leptin 
during oral glucose loading in obese subjects with insulin resistance as compared to insulin 
sensitive subjects. In subjects with the metabolic syndrome, weight loss with a low caloric 
diet diminished the whole-body and regional sympathetic nerve activity, as indicated by 
determinants of the whole-body norepinephrine spillover to plasma and muscle 
sympathetic nerve activity. Of interest, the decrease in norepinephrine spillover to plasma 
after weight loss was positively and independently associated with the decrease in plasma 
leptin, but not with insulin sensitivity in overweight insulin resistant subjects, while in 
overweight subjects without insulin resistance, the decrease in plasma norepinephrine after 
weight loss correlated with the improvement of insulin sensitivity. 
4.4. Sympathetic nervous activity and insulin resistance in the metabolic 
syndrome 
The metabolic syndrome is a cluster of abnormalities with basic characteristics being insulin 
resistance and visceral obesity. The criteria/definitions of metabolic syndrome are shown in 
Table 1. Importantly, obesity and the metabolic syndrome are associated with significant co-
morbidities, such as type 2 diabetes, cardiovascular disease, stroke, and certain types of cancers.  
Huggett et al. [Huggett, et al. 2003 % 2004] demonstrated in a series of studies using 
microneurography (muscle sympathetic nerve activity, MSNA) that type 2 diabetic patients 
had elevated sympathetic nerve activity regardless of the prevailing level of blood pressure, 
and that the combination of hypertension and type 2 diabetes resulted in an augmentation 
in sympathetic nerve activity and levels of plasma insulin. They also compared MSNA and 
insulin levels in 23 non-diabetic offspring of type 2 diabetic patients and 23 normal control 
individuals [Huggett, et al. 2006]. In non-diabetic offspring of type 2 diabetic patients, the 
fasting plasma levels of insulin and MSNA were greater (p<0.009 and p<0.003) than control 
subjects. Sympathetic nerve activity was significantly correlated to insulin levels (p<0.0002) 
and resistance (p<0.0001) in offspring of type 2 diabetic patients, but not in control subjects. 
Sympathetic activation occurred in not only subjects with the metabolic syndrome, diabetic 
patients, but also in normotensive non-diabetic offspring of patients with type 2 diabetes 
with the degree of activation being in proportion to their plasma insulin levels. This series of 
studies indicates the presence of a mechanistic link between hyperinsulinemia and 
sympathetic activation, both of which could play a role in the subsequent development of 
cardiovascular risk factors. 
5. Cardiovascular and  renal complications in obesity, obesity-related 
hypertension and diabetes 
It has been documented that patients with obesity, hypertension and type 2 diabetes 
frequently have cardiovascular and renal complications. Obesity was closely associated with 
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an increase in blood pressure, left ventricular mass, and with early signs of disturbed left 
ventricular diastolic function [Wikstrand, et al. 1993], and changes in left ventricular 
morphology and diastolic function [Alpert, et al. 2012].  It is well known that sudden cardiac 
death is the most common cause of death in dialysis patients and is usually preceded by 
sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation [Alpert, et al. 
2011]. Left ventricular (LV) mass and loading conditions that may affect LV mass are 
important determinants of corrected QT intervals (QTc) in normotensive severely obese 
subjects [Mukergi, et al. 2011]. The RICARHD study (Cardiovascular risk in patients with 
arterial hypertension and type 2 diabetes study), was a multicenter and cross-sectional 
study, conducted in Spain and included 2,339 patients who were 55 years or more with 
hypertension and type 2 diabetes of greater than 6 months duration. Left ventricular 
hypertrophy (LVH) or renal damage (GFR<60 ml/min/1.73 m2 and/or albumin/creatinine 
ratio ≥0 mg/g or an urinary albumin excretion ≥30 mg/24 hours) were compared between 
these hypertensive and type 2 diabetes patients and healthy controls. The combined 
presence of both hypertension and type 2 diabetes were associated with an increased 
prevalence of established cardiovascular diseases. Similarly, the presence of both cardiac 
and renal damage was associated to the higher prevalence of cardiovascular diseases [Cea-
Calvo, et al. 2006].  
The Lifestyle Interventions and Independence for Elders (LIFE) study in 8,029 patients with 
stage II-III hypertension with LVH on ECG showed high prevalence of co-existence of LVH 
and albuminuria [Wachtell, et al. 2002]. In patients with moderately severe hypertension, 
LVH on two consecutive ECGs is associated with increased prevalence of micro- and macro-
albuminuria compared to patients without persistent LVH on ECG. High albumin excretion 
was related to LVH independent of age, blood pressure, diabetes, race, serum creatinine or 
smoking, suggesting parallel cardiac damage and albuminuria. 
5.1. Hyperglycemia and insulin resistance as risk factors of cardiovascular 
complications in type 2 diabetes 
Hyperglycemia and hyperinsulinemia or insulin resistance that is a characteristic of type 2 
diabetes and obesity play major roles in the cardiovascular complications of type 2 diabetes 
mellitus and obesity. Hyperglycemia is the major risk factor for microvascular complications 
(retinopathy, neuropathy, and nephropathy) in type 2 diabetes, however 70% or 80% of 
patients with type 2 diabetes die of macrovascular disease. Atherogenic dyslipidemia 
(elevated triglyceride levels, low HDL-cholesterol levels, high LDL-cholesterol levels) is the 
major cause of atherosclerosis in patients with type 2 diabetes [Reasner, et al. 2008]. 
Several investigators have demonstrated that insulin resistance could predict future type 2 
diabetes even in nonobese individuals [Morrison, et al. 2008], and even in children [Koska, et 
al. 2007; Morrison, et al. 2008] Insulin resistance accompanying sympathetic nerve activation 
may also predict future hypertension development [Masuo, et al. 1997, 1998, 2003, & 2005]. 
Insulin resistance coexisting with inflammation may predict cardiac disease but, 
interestingly, not stroke in the Japanese diabetic population [Matsumoto, et al. 2006]. 
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plasma leptin levels decreased in insulin-sensitive nonobese subjects and increased in 
insulin- resistant nonobese subjects. Straznicky et al. [Straznicky, et al. 2005] also reported 
the blunted responses of whole-body norepinephrine spillover, insulin, and plasma leptin 
during oral glucose loading in obese subjects with insulin resistance as compared to insulin 
sensitive subjects. In subjects with the metabolic syndrome, weight loss with a low caloric 
diet diminished the whole-body and regional sympathetic nerve activity, as indicated by 
determinants of the whole-body norepinephrine spillover to plasma and muscle 
sympathetic nerve activity. Of interest, the decrease in norepinephrine spillover to plasma 
after weight loss was positively and independently associated with the decrease in plasma 
leptin, but not with insulin sensitivity in overweight insulin resistant subjects, while in 
overweight subjects without insulin resistance, the decrease in plasma norepinephrine after 
weight loss correlated with the improvement of insulin sensitivity. 
4.4. Sympathetic nervous activity and insulin resistance in the metabolic 
syndrome 
The metabolic syndrome is a cluster of abnormalities with basic characteristics being insulin 
resistance and visceral obesity. The criteria/definitions of metabolic syndrome are shown in 
Table 1. Importantly, obesity and the metabolic syndrome are associated with significant co-
morbidities, such as type 2 diabetes, cardiovascular disease, stroke, and certain types of cancers.  
Huggett et al. [Huggett, et al. 2003 % 2004] demonstrated in a series of studies using 
microneurography (muscle sympathetic nerve activity, MSNA) that type 2 diabetic patients 
had elevated sympathetic nerve activity regardless of the prevailing level of blood pressure, 
and that the combination of hypertension and type 2 diabetes resulted in an augmentation 
in sympathetic nerve activity and levels of plasma insulin. They also compared MSNA and 
insulin levels in 23 non-diabetic offspring of type 2 diabetic patients and 23 normal control 
individuals [Huggett, et al. 2006]. In non-diabetic offspring of type 2 diabetic patients, the 
fasting plasma levels of insulin and MSNA were greater (p<0.009 and p<0.003) than control 
subjects. Sympathetic nerve activity was significantly correlated to insulin levels (p<0.0002) 
and resistance (p<0.0001) in offspring of type 2 diabetic patients, but not in control subjects. 
Sympathetic activation occurred in not only subjects with the metabolic syndrome, diabetic 
patients, but also in normotensive non-diabetic offspring of patients with type 2 diabetes 
with the degree of activation being in proportion to their plasma insulin levels. This series of 
studies indicates the presence of a mechanistic link between hyperinsulinemia and 
sympathetic activation, both of which could play a role in the subsequent development of 
cardiovascular risk factors. 
5. Cardiovascular and  renal complications in obesity, obesity-related 
hypertension and diabetes 
It has been documented that patients with obesity, hypertension and type 2 diabetes 
frequently have cardiovascular and renal complications. Obesity was closely associated with 
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an increase in blood pressure, left ventricular mass, and with early signs of disturbed left 
ventricular diastolic function [Wikstrand, et al. 1993], and changes in left ventricular 
morphology and diastolic function [Alpert, et al. 2012].  It is well known that sudden cardiac 
death is the most common cause of death in dialysis patients and is usually preceded by 
sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation [Alpert, et al. 
2011]. Left ventricular (LV) mass and loading conditions that may affect LV mass are 
important determinants of corrected QT intervals (QTc) in normotensive severely obese 
subjects [Mukergi, et al. 2011]. The RICARHD study (Cardiovascular risk in patients with 
arterial hypertension and type 2 diabetes study), was a multicenter and cross-sectional 
study, conducted in Spain and included 2,339 patients who were 55 years or more with 
hypertension and type 2 diabetes of greater than 6 months duration. Left ventricular 
hypertrophy (LVH) or renal damage (GFR<60 ml/min/1.73 m2 and/or albumin/creatinine 
ratio ≥0 mg/g or an urinary albumin excretion ≥30 mg/24 hours) were compared between 
these hypertensive and type 2 diabetes patients and healthy controls. The combined 
presence of both hypertension and type 2 diabetes were associated with an increased 
prevalence of established cardiovascular diseases. Similarly, the presence of both cardiac 
and renal damage was associated to the higher prevalence of cardiovascular diseases [Cea-
Calvo, et al. 2006].  
The Lifestyle Interventions and Independence for Elders (LIFE) study in 8,029 patients with 
stage II-III hypertension with LVH on ECG showed high prevalence of co-existence of LVH 
and albuminuria [Wachtell, et al. 2002]. In patients with moderately severe hypertension, 
LVH on two consecutive ECGs is associated with increased prevalence of micro- and macro-
albuminuria compared to patients without persistent LVH on ECG. High albumin excretion 
was related to LVH independent of age, blood pressure, diabetes, race, serum creatinine or 
smoking, suggesting parallel cardiac damage and albuminuria. 
5.1. Hyperglycemia and insulin resistance as risk factors of cardiovascular 
complications in type 2 diabetes 
Hyperglycemia and hyperinsulinemia or insulin resistance that is a characteristic of type 2 
diabetes and obesity play major roles in the cardiovascular complications of type 2 diabetes 
mellitus and obesity. Hyperglycemia is the major risk factor for microvascular complications 
(retinopathy, neuropathy, and nephropathy) in type 2 diabetes, however 70% or 80% of 
patients with type 2 diabetes die of macrovascular disease. Atherogenic dyslipidemia 
(elevated triglyceride levels, low HDL-cholesterol levels, high LDL-cholesterol levels) is the 
major cause of atherosclerosis in patients with type 2 diabetes [Reasner, et al. 2008]. 
Several investigators have demonstrated that insulin resistance could predict future type 2 
diabetes even in nonobese individuals [Morrison, et al. 2008], and even in children [Koska, et 
al. 2007; Morrison, et al. 2008] Insulin resistance accompanying sympathetic nerve activation 
may also predict future hypertension development [Masuo, et al. 1997, 1998, 2003, & 2005]. 
Insulin resistance coexisting with inflammation may predict cardiac disease but, 
interestingly, not stroke in the Japanese diabetic population [Matsumoto, et al. 2006]. 
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Hyperglycemia (i.e. elevated plasma glucose levels) can also predict hospitalization for 
congestive heart failure in patients at high cardiovascular risk [Held, et al. 2007]. 
Hyperglycemia and insulin resistance are risk factors of cardiovascular complications. 
5.2. Sympathetic nervous activity as a risk factor for cardiovascular 
complications and renal complications 
Heightened sympathetic nerve activity plays an important role in cardiovascular 
complications and cardiac risk in humans [Esler, et al. 2000]. There is consistent evidence 
that high plasma norepinephrine level, as an index of heightened sympathetic nerve 
activity, predicts mortality in cardiovascular diseases such as chronic congestive heart 
failure [Cohn et al. 1984; Brum, et al. 2006], left ventricular dysfunction [Grassi, et al. 2009], 
remodelling [Abel, et al. 2010], structural changes in obesity {Benedict, 1996}, and end-stage 
renal disease (ESRD) [Masuo, et al. 2007; Grassi, et al. 2012; Benedict, et al. 1996; Ksiazck, et al.  
2008]. Renal injury also predicts the development of cardiovascular disease [Masuo, et al. 
2007; Joles, et al. 2009].  
Hogarth et al. [Hogarth, et al. 2001] reported that acute myocardial infarction (AMI) in 
hypertensive patients resulted in greater sympathetic nervous activity, persisting for at least 
6 months longer than in normotensive subjects, indicating that AMI further augmented the 
sympathetic nerve hyperactivity of hypertension. Sympathetic nerve hyperactivity could be 
one mechanism involved in the reported worse prognosis in AMI in hypertensive patients 
[Hogarth, et al. 2001]. The sympathetic activation that follows AMI has been associated with 
increased morbidity and mortality in both anterior-AMI and inferior-AMI, with a similar 
magnitude of sympathetic nerve hyperactivity [Graham, et al. 2004]. Patients with 
congenital long-QT syndrome are susceptible to life-threatening arrhythmias, and the 
sympathetic nervous system may have an important triggering role for cardiovascular 
events this condition [Shamsuzzaman, et al. 2001]. 
Changes in heart rates during exercise and recovery from exercise are mediated by the 
balance between sympathetic and vagal activity, and changes in heart rates were evaluated 
in a total of 5,713 asymptomatic working men cohort (between the ages of 42 and 53 years) 
in whom there was no evidence of the presence or history of cardiac disease over the 
preceding 23 years. Baseline heart rates, changes in heart rates during exercise and recovery 
were strongly related to an increased risk of sudden death from myocardial infarction 
[Jeuven, et al. 2005].   
Zoccali et al. [Zoccali, et al. 2002 & 2004] examined the relationships between sympathetic 
nerve activity (plasma norepinephrine levels) and mortality and cardiovascular events in 
228 patients undergoing chronic hemodialysis originally without heart failure. They 
found 45% of dialysis subjects had significantly high plasma norepinephrine levels 
located in the upper limit of the normal range. One-hundred and twenty four (124) fatal 
and nonfatal cardiovascular events occurred in 85 patients during the follow-up period 
(34±15 months). Plasma norepinephrine levels proved to be an independent predictor of 
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fatal and nonfatal cardiovascular events in a multivariate Cox regression model.  
Recently, Joles et al. reported that sympathetic nerve stimulation contributes to the 
progression of renal disease [Joles, et al. 2004]. Masuo et al. reported that plasma 
norepinephrine levels predicted future renal injury in normotensive healthy subjects over 
a 5-year follow up study in a Japanese cohort [Masuo, et al. 2007]. They also found that 
plasma norepinephrine levels were associated with concentric left ventricular 
hypertrophy in these patients [Zoccali, et al. 2002 a & 2002b]. 
Petersson et al. [Petersson, et al. 2002] showed that increased cardiac sympathetic nervous 
activity in renovascular hypertension might lead to high cardiovascular mortality and 
morbidity. Prolonged sympathetic nerve stimulation and elevated circulating 
norepinephrine levels can induce changes in intra-renal blood vessels. Catecholamines 
can induce proliferation of smooth muscle cells and adventitial fibroblasts in vascular 
wall. 
The association between hypertension, obesity and chronic kidney disease (CKD) is well 
recognized [White, et al. 2005; Hall, et al. 2001; Zoccali, et al. 2002].  Obesity and hypertension 
also leads to an increase in the incidence of metabolic diseases such a type 2 diabetes 
mellitus, which is frequently associated with renal injury (proteinuria/microalbuminuria). In 
the majority of cases, ESRD occurs as a result of complication of diabetes or hypertension 
[WHO. 1995]. Obesity, hypertension and type 2 diabetes are characterized as stimulated 
sympathetic nervous activity and insulin resistance states, indicating renal injury and ESRD 
are strongly related to sympathetic nervous activity and insulin resistance. Masuo et al. 
reported that significant weight loss resulted in significant amelioration on renal function 
following suppression on sympathetic activation and hyperinsulinemia (insulin resistance) 
[Masuo, et al. 2012].  The findings suggest that strong linkage between sympathetic nervous 
activity, insulin resistance and renal function.  
Joles et al. reported that sympathetic nerve stimulation contributes to the progression of 
renal disease [Joles, et al. 2004]. The 40-minute infusion of NE into the renal artery of dogs 
produced a reversible ischemic model of acute renal failure [Bulger, et al. 1982]. Another 
study demonstrated renal protection by β-adrenergic receptor blockade in a 
nephrectomized rat experiment without any BP changes [Amam, et al. 2001]. There is 
consistent evidence that high plasma norepinephrine levels, as an index of heightened 
sympathetic nervous activity, predicts mortality in cardiovascular disease, such as chronic 
congestive heart failure [Cohn, et al. 1984; Brum, et al. 2006], left ventricular dysfunction 
[Benedict, et al. 1996] and end-stage renal disease (ESRD) [Masuo, et al. 2007; Ksiazek, et al. 
2008]. Renal injury also predicts the development of cardiovascular disease [Joles, et al. 
2004; Masuo, et al. 2007].  
These investigations have shown strong associations between sympathetic nervous 
activation, cardiovascular complications and renal complications. Given these observations 
it may be of importance to aim antihypertensive treatments or anti-diabetic treatment not 
only at the reduction of raised blood pressure or blood glucose but also at the excessive 
sympathetic activation and insulin resistance that may underpin these effects. 
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fatal and nonfatal cardiovascular events in a multivariate Cox regression model.  
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the majority of cases, ESRD occurs as a result of complication of diabetes or hypertension 
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sympathetic nervous activity and insulin resistance states, indicating renal injury and ESRD 
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reported that significant weight loss resulted in significant amelioration on renal function 
following suppression on sympathetic activation and hyperinsulinemia (insulin resistance) 
[Masuo, et al. 2012].  The findings suggest that strong linkage between sympathetic nervous 
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study demonstrated renal protection by β-adrenergic receptor blockade in a 
nephrectomized rat experiment without any BP changes [Amam, et al. 2001]. There is 
consistent evidence that high plasma norepinephrine levels, as an index of heightened 
sympathetic nervous activity, predicts mortality in cardiovascular disease, such as chronic 
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2008]. Renal injury also predicts the development of cardiovascular disease [Joles, et al. 
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These investigations have shown strong associations between sympathetic nervous 
activation, cardiovascular complications and renal complications. Given these observations 
it may be of importance to aim antihypertensive treatments or anti-diabetic treatment not 
only at the reduction of raised blood pressure or blood glucose but also at the excessive 
sympathetic activation and insulin resistance that may underpin these effects. 
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5.3. Sympathetic nerve hyperactivity in patients with ESRD 
Evidence now strongly indicates a role for the sympathetic nervous system in the 
pathogenesis of hypertension in renal failure (ESRD) [Hausberg, et al. 2002; Schlaich, et al. 
2009; Masuo, et al. 2010a].  Hypertension occurs commonly and early in renal disease and is 
paralleled by increases in sympathetic nerve activity, as indicated by increased muscle 
sympathetic nerve activity and circulating norepinephrine. This appears to be driven by the 
diseased kidneys, because nephrectomy or denervation has been shown to correct blood 
pressure and sympathetic nerve activity both in human and animal studies [Jacob, et al. 
2003].  
Masuo et al. [Masuo, et al. 1995 & 2010] showed that plasma norepinephrine levels  were 
significantly higher in patients with ESRD regardless of hemodialysis compared with those 
in blood pressure- and body mass index-matched hypertensive patients or healthy 
normotensive subjects (Figure 3). Further, this was recognized significantly in subjects with 
a shorter duration of ESRD with hemodialysis compared with those with longer duration, 
suggesting that sympathetic nerve hyperactivity may be of particular importance in the 
onset or the early development of ESRD or, alternatively, be influenced by long-term renal 
replacement therapy (hemodialysis). In the normal state, interactions between the kidney 
and sympathetic nervous system serve to maintain blood pressure and glomerular filtration 
rate within tightly controlled levels, but in renal failure, a defect in renal sodium excretory 
function leads to an abnormal pressure natriuresis relationship and activation of the renin-
angiotensin system (RAS), contributing to the development of hypertension and progression 
of kidney disease [Hall, et al. 1997; Lohmeier, et al. 2001]. Another mechanism could involve 
the sympathetic nervous modulation of baroreflex regulation and vasculature tone through 
the central nervous system and angiotensin II [Burke, et al. 2008]. Afferent signals from the 
kidney, detected by chemoreceptors and mechanoreceptors, feed directly into central nuclei 
regulating sympathetic nerve activity by circulating and brain-derived angiotensin II 
[Philips, et al. 2005]. Therefore, the pathogenesis of hypertension in renal failure (ESRD) is 
complex and arises most likely from the interaction of hemodynamic and neuroendocrine 
factors. Sympathetic nerve activity has strong relationships with regards to increased risk of 
cardiovascular disease including hypertension [Zoccali, et al. 2002a & 2002b] in patients with 
ESRD and the mortality and morbidity of cardiovascular disease, suggesting that we have to 
pay much attention to sympathetic nerve activation in our attempts to adequately treat 
patients with ESRD. 
Sympathetic nerve activity is consistently elevated in patients with ESRD, and in obese 
subjects and hypertensive patients in cross-sectional studies [Masuo, et al. 1995, 2011a & 
2011b).  The sympathetic nerve hyperactivity is at least in part independent of increased 
blood pressure levels or obesity. Further, patients with early-ESRD without hemodialysis 
had already significantly higher plasma norepinephrine levels compared with hypertensive 
subjects as well as normotensive subjects. Therefore, sympathetic nervous activation in 
ESRD patients may be independent from obesity or hypertension.  
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ESRD, end-stage renal disease; *P<0.05 versus healthy controls; **P<0.01 versus healthy controls;  
#P<0.05 versus hypertensive patients with normal renal function; ##P<0.01 versus hypertensive patients with normal 
renal function. [Masuo, et al. 2010a] 
Figure 3. Figure 3. Comparisons of plasma norepinephrine levels between patients with patients with 
ESRD, hypertensive patients with normal renal function and normal healthy controls.  
The amount of norepinephrine in plasma is only a fraction of the amount released into the 
synaptic cleft, and plasma norepinephrine levels are affected by dialysis therapy, so it is 
difficult to discount that the elevated plasma norepinephrine levels did not derive in part 
from reduced plasma norepinephrine clearance rather than solely from elevated 
sympathetic nerve activity. Grassi et al. [Grassi, et al. 2009] however, reported similar results 
using microneurography. In addition, plasma norepinephrine levels did not change between 
before- and after-hemodialysis therapy (data was not shown), and between after-
hemodialysis therapy and before-next hemodialysis therapy. Thus, one could speculate that 
plasma norepinephrine levels in ESRD patients are reflective of the degree of sympathetic 
nerve activity.   
5.4. β2-adrenoceptor polymorphisms accompanying sympathetic nervous 
activation may relate to renal injury  
Rao et al. [Rao, et al. 2007] and Masuo et al. [Masuo, et al. 2007] have shown strong 
associations between β2-adrenoceptor polymorphisms, elevated plasma norepinephrine 
levels and elevated HOMA-IR (insulin resistance) or future renal injury, suggesting that 
stimulated sympathetic nerve activity associated with insulin resistance, may independently 
play a major role in the onset and development of ESRD without obesity or hypertension. 
However, the precise mechanisms underlying sympathetic activation in CKD and ESRD 
have not been clarified. 
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Furthermore, Masuo et al. [Masuo, et al. 2011b] measured renal function (creatinine, BUN 
and creatinine clearance), plasma norepinephrine levels and HOMA-IR (insulin 
sensitivity) annually over a 5-year period in nonobese, normotensive men with normal 
renal function. Subjects who had a significant deterioration of renal function (more than 
10% increases from baseline of creatinine and BUN or decrease in creatinine clearance) 
over a 5-year period had higher plasma norepinephrine at the entry period, and greater 
increases in plasma norepinephrine over 5 years [Masuo, et al. 2011b]. In this study, 
subjects who had significant changes in body weight or blood pressure were excluded, 
indicating the contributions of obesity or hypertension might be excluded. Further, 
subjects who had significantly higher levels of plasma norepinephrine had a higher 
frequency of the Gly16 allele of the β2-adrenoceptor polymorphism [Masuo, et al. 2007] 
(Figure 4). The Gly16 allele of the β2-adrenoceptor polymorphism has been shown to be 
related to obesity [Masuo, et al. 2005, 2005a, 2005b], hypertension [Masuo, et al. 2005a, 
2005b, 2010b, 2011c] and metabolic syndrome development [Masuo, et al. 2005b]. Thus, 
high plasma norepinephrine levels appear to be a predictor that is determined genetically 
by the β2-adrenoceptor polymorphism (Arg16Gly) for renal injury, obesity, hypertension 
and metabolic syndrome. 
 
In 154 nonobese, normotensive subjects, renal function (creatinine clearance) was measured over a 5-year period.  
The deterioration of renal function was defined as >10% decreases in creatinine clearance over a 5-year period.  
Subjects with deterioration of renal function had higher frequency of Gly allele or Gly homozygous compared to those 
without changes in renal function. [Masuo, et al. 2011b] 
Figure 4. Subjects with deteriorations of renal function (creatinine clearance) carried higher frequency 
of the Gly16 allele of Arg16Gly, the β2-adrenoceptor polymorphisms  
These observations show that plasma norepinephrine levels associated with insulin 
resistance are strongly linked with the onset and development of renal injury. 
 
Sympathetic Nervous Activation and Insulin Resistance as Renal and Cardiac Risk 177 
6. Other medical conditions in obesity  
6.1. Obstructive sleep apnea in obesity is a risk factor for cardiovascular diseases 
Vozoris [Vozoris. 2012] investigated the relationships between prevalence of obstructive 
sleep apnea (OSA), obesity, and hypertension, diabetes, congestive heart failure, myocardial 
infarction, and stroke using a population-based multi-year cross-sectional study design 
including 12,593 individuals with data from the 2005-2008 United States National Health 
and Nutrition Examination Surveys (NHANES). They found individuals with OSA had 
elevated rates of cardiovascular diseases compared to the general population [Vozoris. 
2012]. OSA is a common disorder that has been associated with many cardiovascular disease 
processes, including hypertension and arrhythmias. OSA has also been identified as an 
independent risk factor for stroke and all-cause mortality. OSA is highly prevalent in 
patients with transient ischemic attacks and stroke [Das, et al. 2012]. Indeed, the majority of 
patients with OSA suffer from hypertension [Ziegler, et al. 2011].  The mechanisms 
underlying the link between OSA and cardiovascular disease are not completely 
established. However, there is increasing evidence that autonomic mechanisms are 
implicated. A number of studies have consistently shown that patients with OSA have high 
levels of sympathetic nerve traffic [Narkiewicz, et al. 2003]. In animal studies, intermittent 
hypoxia that simulates changes seen in OSA leads to chemoreceptor and chromaffin cell 
stimulation of sympathetic nerve activity, endothelial damage and impaired blood pressure 
modulation. Human studies reveal activation of sympathetic nerves, endothelial damage 
and exaggerated pressor responses to sympathetic neurotransmitters and endothelin 
[Ziegler, et al. 2011]. OSA is also frequently observed in obese individuals [Dos, et al. 201].2  
6.2. Gout and hyperuricacidemia in obesity 
Gout is a growing worldwide health problem, and is associated with increased prevalence 
of obesity. Gout and hyperuricacidemia are associated with the metabolic syndrome, 
diabetes mellitus, obesity and hypertension. Masuo et al. observed the importance of serum 
uric acid levels as a predictor for future obesity and hypertension [Masuo, et al. 2003]. 
Several epidemiological studies have shown the close linkage between hyperuricemia, 
obesity and hypertension [Robinson, et al. 2012]. Recently Robinson, et al. [Robinson, et al. 
2012] reviewed prevalence of hyperuricemia in Australia in 25 articles and 5 reports using a 
systematic journal search method. From 1968 to 1995/6, the prevalence of gout increased 
from 0.5% to 1.7% of the population. Especially in the Australian indigenous population a 
significant rise in the prevalence of gout from 0% in 1965 to 9.7% in 2002 in males, and 0% to 
2.9% in females were observed. Those elevations were strongly synchronized with the 
prevalence of obesity [Chang, et al. 2001]. Similar result has been reported in Taiwanese 
populations that, using a multivariate analysis, showed that BMI (obesity) was an important 
factor associated with hyperuricemia in both males and females, whereas age was associated 
with hyperuricemia only in males. In addition, the associations of basic and repeated 
measures of uric acid level with treatments for uric acid over a 11-year period, and risk of 
coronary heart disease (CHD) and stroke events were assessed  in Taiwanese populations 
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[Ziegler, et al. 2011]. OSA is also frequently observed in obese individuals [Dos, et al. 201].2  
6.2. Gout and hyperuricacidemia in obesity 
Gout is a growing worldwide health problem, and is associated with increased prevalence 
of obesity. Gout and hyperuricacidemia are associated with the metabolic syndrome, 
diabetes mellitus, obesity and hypertension. Masuo et al. observed the importance of serum 
uric acid levels as a predictor for future obesity and hypertension [Masuo, et al. 2003]. 
Several epidemiological studies have shown the close linkage between hyperuricemia, 
obesity and hypertension [Robinson, et al. 2012]. Recently Robinson, et al. [Robinson, et al. 
2012] reviewed prevalence of hyperuricemia in Australia in 25 articles and 5 reports using a 
systematic journal search method. From 1968 to 1995/6, the prevalence of gout increased 
from 0.5% to 1.7% of the population. Especially in the Australian indigenous population a 
significant rise in the prevalence of gout from 0% in 1965 to 9.7% in 2002 in males, and 0% to 
2.9% in females were observed. Those elevations were strongly synchronized with the 
prevalence of obesity [Chang, et al. 2001]. Similar result has been reported in Taiwanese 
populations that, using a multivariate analysis, showed that BMI (obesity) was an important 
factor associated with hyperuricemia in both males and females, whereas age was associated 
with hyperuricemia only in males. In addition, the associations of basic and repeated 
measures of uric acid level with treatments for uric acid over a 11-year period, and risk of 
coronary heart disease (CHD) and stroke events were assessed  in Taiwanese populations 
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[Chien, et al. 2005]. The study showed that uric acid had significant risk only in hypertension 
and metabolic syndrome subgroups, but not in their counterparts. They also observed that 
uric acid, in the baseline and time-dependent variables, could predict cardiovascular events 
in the community of relatively low CHD but high stroke risk.  
Straznicky et al. examined the effects of weight loss on serum uric acid levels, and showed 
that it had ameliorative effects on uric acid levels in the obese subjects with the metabolic 
syndrome [Straznicky, et al. 2011]. Furthermore, they compared these effects between a mild 
calorie restricted diet alone, combination with a low calorie diet and exercise and control 
groups.  Interestingly, moderate weight loss in obese patients with metabolic syndrome is 
associated with a reduction in serum uric acid levels, albuminuria and an improvement in 
eGFR which is augmented by exercise co-intervention [Straznicky, et al. 2011]. Improvement 
of insulin resistance and sympathetic activation were synchronized with a reduction in 
serum uric acid levels.   
7. Conclusion 
The role of the sympathetic nervous activity and insulin resistance plays important roles in 
the etiology of obesity, hypertension, and type 2 diabetes. Several investigations have 
demonstrated that the sympathetic nervous activation and insulin resistance are strongly 
related to cardiovascular complication (i.e. LVH, congestive heart failure) and the onset and 
development of ESRD (renal injury).  Interestingly, relevant investigations of sympathetic 
nervous activity and β2-adrenoceptor polymorphisms indicate their contribution to the 
onset and maintenance of renal injury and LVH in healthy subjects and in patients with 
chronic renal failure and cardiovascular events in ESRD patients. Interestingly, the 
prevalence of OSA and hyperuricemia (gout) are significantly linked with increases in 
obesity, and both states are connected with the cardiovascular risks associated with 
sympathetic nervous activation. Serum uric acid, which may be affected strongly by 
sympathetic nervous activity, may be a predictor for future hypertension and renal injury 
(ESRD) development.   
Recently, it has been demonstrated that renal sympathetic nerve denervation provides 
promising results in patients with refractory hypertension [Krum, et al. 2009; Symplicity 
HTN-1 Investigators. 2011]. Besides the demonstrable effect on reducing blood pressure, 
renal denervation significantly and favourably influences LV mass and improves diastolic 
function, which might have important prognostic implications in patients with resistant 
hypertension at high cardiovascular risk [Brandt, et al. 2012]. Further, renal denervations 
showed an accompanying improvements in insulin resistance [Mahfoud, et al. 2011,:  
Witkowski, et al. 2012] and OSA [Brandt, et al. 2011]. Renal sympathetic denervation may 
conceivably be a potentially useful option for patients with co-morbid refractory 
hypertension, glucose intolerance, and obstructive sleep apnea. 
A better understanding of the relationships between sympathetic nervous activity, insulin 
resistance, cardiovascular complications, and renal complications, will help to develop 
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appropriate treatment strategies targeting renal injury or cardiac risk in hypertensive and 
diabetes patients with and without ESRD or LVH.  
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groups.  Interestingly, moderate weight loss in obese patients with metabolic syndrome is 
associated with a reduction in serum uric acid levels, albuminuria and an improvement in 
eGFR which is augmented by exercise co-intervention [Straznicky, et al. 2011]. Improvement 
of insulin resistance and sympathetic activation were synchronized with a reduction in 
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function, which might have important prognostic implications in patients with resistant 
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1. Introduction 
Normal insulin sensitivity is essential for the maintenance of normal circulating 
carbohydrate and lipid levels and their metabolism. In healthy individuals elevated blood 
glucose levels stimulate the pancreas to release insulin which lowers blood glucose levels by 
stimulating glucose uptake and metabolism in muscle, adipose tissue and several other 
insulin sensitive organs. Blood glucose increases are not only countered by increased tissue 
glucose uptake but also by insulin induced suppression of hepatic glycogenolysis and 
gluconeogenesis. Besides its effects on blood glucose, insulin also affects circulating lipid 
levels by reducing hepatic very low density lipoprotein cholesterol (VLDL-cholesterol) 
formation from free fatty acids (FFAs). This is primarily due to the reduced free fatty acid 
supply to the liver caused by insulin induced suppression of lipogenesis in adipose tissue 
[1]. In addition to its effects on lipogenesis, insulin also reduces lipolysis in adipose tissue by 
inhibiting hormone sensitive lipase. The latter hydrolyses adipocyte triglycerides to release 
free fatty acids and glycerol into the circulation. When delivered acutely, insulin inhibits 
fatty acid synthase while chronic hyperinsulinaemia (as occurs in insulin resistance) may 
induce fatty acid synthase activity and increase fatty acid synthesis [2]. The net effect of 
elevated insulin in normal healthy individuals is to reduce circulating glucose and free fatty 
acid levels.  
When an individual becomes insulin resistant, control of circulating lipid and blood glucose 
levels is compromised. Insulin resistance ensues when normal physiological concentrations 
of insulin are unable to induce effective uptake of glucose by insulin sensitive tissue. As a 
compensatory mechanism aimed at maintaining euglycaemia, pancreatic insulin secretion 
increases leading to a state of hyperinsulinaemia. If the elevated insulin levels are 
inadequate to fully compensate for the insulin insensitivity glucose intolerance ensues. The 
degree of glucose intolerance in insulin resistant individuals is thus dependent on the extent 
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of the loss of the in vivo function of insulin, and the ability of the pancreas to adjust for this 
by secreting more insulin [3, 4]. Once elevated circulating levels of insulin are no longer able 
to maintain euglycaemia, and glucose levels deviate beyond normal physiological ranges an 
individual is considered to be frankly diabetic.  
Myocardial insulin resistance translates to compromised intracellular insulin signalling and 
reduced glucose oxidation rates in animal models of obesity [5] and adversely affects 
myocardial mechanical function and tolerance to ischaemia and reperfusion. In this chapter 
we will review the mechanisms implicated in the aetiology of insulin resistance (skeletal and 
heart muscle) and discuss the effects of insulin resistance on cardiac metabolism, mechanical 
function and tolerance to ischaemia and reperfusion. We will also briefly review therapies 
used to prevent or counter insulin resistance and its associated adverse effects on the 
cardiovascular system. 
2. Myocardial insulin signalling 
Insulin induced activation of the insulin receptor (IR) invokes a cascade of events which 
ultimately enhances myocardial glucose uptake and metabolism. Insulin binding to its 
receptor results in autophosphorylation and activation of the insulin receptors (IRs) intrinsic 
tyrosine kinases. Following phosphorylation the insulin receptor phosphorylates insulin 
receptor substrate (IRS) [6] which subsequently associates with phosphoinositide 3-kinase 
(PI3K) via its p85 subunit [7, 8]. These events are vital for initiating insulin’s effects on glucose 
metabolism [6, 9, 10].  Activated PI3K will induce (via various signalling mechanisms) protein 
kinase B (PKB/Akt)[11] which plays a pivotal role in glucose metabolism by regulating the 
translocation of the cytosolic glucose transporter type 4 (GLUT4), to the sarcolemma [12, 13]. 
Inhibition of PI3K and/or PKB/Akt attenuates sarcolemmal GLUT4 translocation, effectively 
reducing insulin stimulated signalling and glucose uptake [14, 15].  Besides facilitating glucose 
uptake via GLUT4, insulin stimulation also increases glycolytic flux rates through activation of 
phosphofructosekinase 2 (PFK-2) which promotes the production of fructose-2,6-bisphosphate 
from fructose-6-phosphate [16-18]. Fructose-2,6-bisphosphate stimulates PFK-1 activity, which 
will also enhance glycolysis (see review by Hue et al. [18]). 
Although insulin increases long chain fatty acid (LCFA) uptake into the cardiomyocyte by 
increasing sarcolemmal fatty acid translocase/cluster of differentiation 36 (FAT/CD36) [19], 
elevated insulin levels also suppress tissue fatty acid β-oxidation rates. This suppression is 
most likely due to the effects of by-products of elevated glucose oxidation on malonyl-CoA 
levels [20]. As acetyl-CoA levels increase, acetyl-CoA carboxylase (ACC) is activated which 
increases malonyl-CoA induced inhibition of fatty acid oxidation. 
3. The role of obesity or a high fructose diet in the aetiology of insulin 
resistance 
Insulin resistance is strongly associated with both obesity and the consumption of high 
fructose containing diets [21-25]. Although not all obese individual are insulin resistant, 
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there is a strong association between obesity and insulin resistance [21, 25]. Adipose tissue is 
not only a storage organ but also a metabolically active organ synthesising and secreting a 
large range of substances that include fatty acids, pro-inflammatory cytokines, angiotensin 
II, leptin, resistin, visfatin and other adipocytokines [26] that can all influence tissue 
metabolism. Obesity and high fructose diets both induce increases in: 1) circulating FFAs 
[27, 28], 2) renin-angiotensin system (RAS) activity [29, 30], and 3) inflammation (caused by 
tissue and macrophage derived pro-inflammatory cytokines) [31] that are all associated 
with, and implicated in insulin resistance.  
Besides the negative impact of obesity on circulating lipids, recent studies provide 
convincing evidence for a role for high fructose diets in dyslipidaemia and insulin resistance 
[24, 27, 32]. These lipid profile altering effects of high fructose diets are primarily caused by 
fructose induced alterations in hepatic lipid metabolism [22-24]. Hepatic fructose 
metabolism differs significantly from glucose metabolism with fructose being a lipogenic 
sugar that promotes the deposition of triglycerides in adipose tissue and ectopic organs such 
as the liver and muscle. This tissue triglyceride accumulation eventually contributes to 
dyslipidaemia and insulin resistance [22, 27, 33]. 
Increasing dietary fructose consumption increases plasma triglyceride levels through 
stimulation of hepatic lipogenesis [34] and decreased VLDL-triglyceride removal from the 
plasma by adipose tissue [35]. Fructose evidently also activates genes involved in hepatic de 
novo lipogenesis [36, 37] which causes increased hepatic fatty acid generation. These fatty 
acids are incorporated into hepatic triglycerides which promotes VLDL-triglyceride 
synthesis and release from the liver (Figure 1)[38].  
A recent review highlights the possible effects of high fructose diets on hepatic insulin 
resistance [22]. These authors propose that high fructose diets promote hepatic 
inflammation by increasing fatty acid -oxidation (secondary to hepatic lipid accumulation) 
which generates peroxidation products that stimulate inhibitor of nuclear factor kappa-B 
kinase subunit beta (IKK) and activate nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFB). The NFB then enters the nucleus and induces the transcription of 
genes that encode for pro-inflammatory cytokines that include tumour necrosis factor alpha 
(TNF) and interleukin-6 (IL-6). These cytokines potentially activate c-Jun N-terminal 
kinase-1 (JNK-1) which will increase inhibitory serine307 phosphorylation of IRS-1 and 
contribute to hepatic insulin resistance [22] (Figure 2).  
Because of its lipogenic effects, fructose causes more marked changes in 24 hour lipid 
profiles than does the consumption of glucose while also favouring visceral rather than 
subcutaneous fat deposition [33]. This fat deposition pattern differs from that of glucose which 
promotes subcutaneous adipose tissue deposition rather that visceral fat deposition in men 
[39].  In rodents, a high fructose diet increases intrahepatic fat content and serum VLDL-
triglyceride concentrations within 6 weeks of feeding. In the same study intramuscular fat 
content was increased within 3 months of initiating the high fructose feeding with these 
changes being closely followed by hepatic and muscle insulin resistance [32]. Another animal 
based study supports a role for high fructose diets in increased hepatic VLDL-triglyceride 
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secretion [40]. In humans increasing fructose content in the diet increases plasma triglycerides 
[34, 41], decreases VLDL-triglyceride clearance [35] and increases triglyceride deposition in 
hepatocytes and skeletal muscle within a week of increasing dietary fructose content [41]. 
 
Figure 1. Mechanism for high fructose diet induced dyslipidaemia and ectopic lipid accumulation. 
High fructose diets promote hepatic de novo lipogenesis and lipid accumulation and reduce extra-
hepatic VLDL-triglyceride clearance.  The associated hypertriglyceridaemia promotes adipose tissue 
expansion (obesity) and muscle lipid accumulation which induces insulin resistance.  
Since high fructose diets are often also associated with obesity, it is difficult to differentiate 
between the effects of the changes in dietary fructose content and the effects of obesity on 
tissue insulin sensitivity. Data from studies demonstrating that some individuals are obese 
but metabolically healthy [42] and metabolic syndrome appears to be more closely linked to 
intrahepatic fat content than obesity per se [1, 41, 43], suggests that hepatic lipid metabolism 
and circulating lipid levels play a critical role in the induction of insulin resistance in 
response to obesity and high fructose diets. Tappy and co-workers [23, 24] recently 
proposed that fructose increases hepatic de novo lipogenesis which leads to intrahepatic lipid 
deposition, hepatic insulin resistance and increased VLDL-triglyceride secretion. This 
 
Myocardial Insulin Resistance: An Overview of Its Causes, Effects, and Potential Therapy 193 
potentially leads to increased visceral fat deposition while the elevated VLDL-triglyceride 
and inhibition of lipid oxidation (induced by fructose) may promote ectopic fat deposition 
in muscle with lipotoxicity leading to systemic insulin resistance (Figure 1) [22-24] 
 
Figure 2. The proposed mechanism for intrahepatic lipid accumulation induced stimulation of -
oxidation and ROS generation. ROS induced increases in cytokine (TNF and possibly other cytokines) 
expression and synthesis activates JNK which phosphorylates IRS-1 (insulin receptor substrate) at the 
serine307 residue. This inhibitory phosphorylation of IRS-1 prevents its tyrosine phosphorylation by the 
insulin receptor and interferes with the normal insulin signalling cascade (Illustration modified from 
review by Rutledge and Adeli [22]. 
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secretion [40]. In humans increasing fructose content in the diet increases plasma triglycerides 
[34, 41], decreases VLDL-triglyceride clearance [35] and increases triglyceride deposition in 
hepatocytes and skeletal muscle within a week of increasing dietary fructose content [41]. 
 
Figure 1. Mechanism for high fructose diet induced dyslipidaemia and ectopic lipid accumulation. 
High fructose diets promote hepatic de novo lipogenesis and lipid accumulation and reduce extra-
hepatic VLDL-triglyceride clearance.  The associated hypertriglyceridaemia promotes adipose tissue 
expansion (obesity) and muscle lipid accumulation which induces insulin resistance.  
Since high fructose diets are often also associated with obesity, it is difficult to differentiate 
between the effects of the changes in dietary fructose content and the effects of obesity on 
tissue insulin sensitivity. Data from studies demonstrating that some individuals are obese 
but metabolically healthy [42] and metabolic syndrome appears to be more closely linked to 
intrahepatic fat content than obesity per se [1, 41, 43], suggests that hepatic lipid metabolism 
and circulating lipid levels play a critical role in the induction of insulin resistance in 
response to obesity and high fructose diets. Tappy and co-workers [23, 24] recently 
proposed that fructose increases hepatic de novo lipogenesis which leads to intrahepatic lipid 
deposition, hepatic insulin resistance and increased VLDL-triglyceride secretion. This 
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The experimental evidence implicating inflammation/pro-inflammatory cytokines and 
overactive renin-angiotensin systems (organ and systemic) in the aetiology of insulin 
resistance will be discussed later. We will first review the evidence for a role for elevated 
circulating free fatty acids, and tissue triglycerides and lipid intermediates accumulation in 
the aetiology of insulin resistance in skeletal and heart muscle. 
4. The role of free fatty acids and intracellular lipid accumulation in 
insulin resistance 
A prevalent metabolic change associated with obesity [44-49] and high fructose feeding [22-
24] is the increase in the circulating free fatty acids and triglycerides. Under conditions of 
over-nutrition and dyslipidaemia, not all fatty acids entering the cell are utilized for 
oxidative purposes. Long chain fatty acyl-CoA accumulation provides substrates for non-
oxidative processes such as triglyceride, diacylglycerol (DAG) and ceramide synthesis [50, 
51]. In the myocardium lipid accumulation is a direct result of a mismatch between fatty 
acid uptake and oxidation by the cell [47, 52]. What is not clear is whether this accumulation 
is due to: 1) increased FFA uptake by the heart 2) compromised FFA oxidation, or, 3) a 
combination of the two.  
There is a strong link between increased circulating free fatty acids, myocardial triglyceride 
accumulation and insulin resistance. Increased circulating free fatty acids increase the 
expression of sarcolemmal fatty acid transporters and increases fatty acid uptake into the 
myocyte. Obese Zucker rats [46, 48] and db/db mice [53] with insulin resistance have 
increased FAT/CD36 localised to the sarcolemma. The exact mechanism for the increased 
localisation of FAT/CD36 in the sarcolemma is not clear but may relate to the chronic 
hyperinsulinaemia associated with insulin resistance. It is well established that insulin 
stimulates FAT/CD36 translocation to the sarcolemma [54, 55]. This increased sarcolemmal 
FAT/CD36 content increases fatty acid uptake in cardiac myocytes and possibly leads to 
tissue fatty acyl-CoA accumulation if not metabolised through concomitant increased -
oxidation [56].  Besides its adverse effects on insulin signalling and glucose metabolism, 
excessive intramyocellular lipid accumulation may also have direct lipotoxic effects [50, 57]. 
Both altered substrate utilization and excess intramyocardial lipid accumulation which is 
characteristic of obesity, dyslipidaemia and insulin resistance may have serious cardiac 
consequences that ultimately lead to compromised cardiac metabolism, morphology and 
mechanical function.  
Lipid intermediates may adversely influence insulin signalling and contribute to insulin 
resistance [5, 58, 59]. The accumulation of triglycerides, diacylglycerol (DAG) and ceramide 
is known to activate kinases that down-regulate insulin signalling [60-62]. These kinases 
include JNK, IKK and protein kinase C (PKC) that is known to inhibit insulin signalling via 
serine phosphorylation of IRS-1 [5, 63]. 
Ceramide accumulation occurs through de novo synthesis from saturated fatty acids [64] or 
hydrolysis of sphingomyelin [65]. It has been shown to cause insulin resistance by inhibiting 
Akt phosphorylation in skeletal muscle [66-68] and adipocytes [69] with the 
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pharmacological inhibition of ceramide synthesis being effective in preventing lipid induced 
insulin resistance in rats [67, 70]. 
Models of lipotoxicity have also demonstrated that elevated myocardial ceramide levels are 
associated with increases in indices of apoptosis [52, 71]. Rat neonatal cardiomyocytes 
incubated with physiological concentrations of palmitate have increased intracellular 
triglycerides, increased ceramide levels and increased indices of apoptosis [72]. The 
mechanism implicated in ceramide induced apoptosis may involve activation of NFκB 
which in turn up regulates inducible nitric oxide synthase (iNOS) expression [73]. The 
resulting increase in nitric oxide production [74] may cause a subsequent rise in the 
formation of peroxynitrite, which induces mitochondrial cytochrome C release [75] and 
subsequent apoptosis. In addition, ceramide has been shown to directly induce the 
generation of damaging reactive oxygen species in the mitochondria [76]. Obese insulin 
resistant (prediabetic) Zucker rats also have elevated intramyocardial triglycerides which 
are accompanied by increased myocardial ceramide levels and cardiomyocyte apoptosis. 
These cellular alterations are present before the onset of diabetes and cardiac dysfunction 
[71]. Reducing myocardial lipid levels by treating the rats with peroxisome proliferator-
activated receptor gamma (PPAR) agonists lead to reduced cardiac ceramide levels and 
apoptosis and prevented cardiac dysfunction [71]. In a similar study, mice over-expressing 
cardiac specific long chain acyl-CoA synthase display high intramyocardial triglycerides 
and ceramide levels. These changes were accompanied by increased DNA fragmentation 
and cytochrome C release with the mice developing cardiac hypertrophy and left-
ventricular dysfunction [52]. 
Lipid infusion increases intracellular DAG and causes skeletal muscle insulin resistance in 
rodents [60]. This association between intracellular DAG levels and skeletal muscle insulin 
resistance has been confirmed in several rodent and human studies [77-79]. Increased 
muscle DAG is associated with increased activation of protein kinase C theta (PKC-) in 
obese and diabetic patients [80, 81]. Increased PKC- activation interferes with insulin 
signalling by increasing IRS-1 serine307 phosphorylation (Figure 3)[60, 81]. Accelerating fatty 
acid oxidation rates potentially prevents fatty acid, acetyl-CoA and subsequent DAG 
accumulation and may improve insulin sensitivity. This proposal was recently supported by 
a study showing that carnitine palmitoyltransferase I (CPT-1) over-expression in L6E9 
myotubes increases mitochondrial fatty acid uptake, decreased intracellular DAG 
concentrations and protects against elevated fatty acid induced insulin resistance [82]. 
4.1. Evidence for lipid accumulation in skeletal muscle insulin resistance  
An inverse correlation exists between intramuscular lipid content and insulin sensitivity. 
Measurements of insulin sensitivity (120 min euglycaemic hyperinsulinaemic clamp) in 
skeletal muscle from healthy subjects demonstrated that high intramuscular lipid content 
was associated with lower whole body insulin stimulated glucose uptake. These subjects 
also exhibited elevated circulating free fatty acids, reduced tyrosine phosphorylation of the 
insulin receptor (IR) and lower (insulin receptor substrate) IRS-1 mediated PI3K activation 
during hyperinsulinaemia than subjects with low intramuscular lipids [83]. Studies 
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The experimental evidence implicating inflammation/pro-inflammatory cytokines and 
overactive renin-angiotensin systems (organ and systemic) in the aetiology of insulin 
resistance will be discussed later. We will first review the evidence for a role for elevated 
circulating free fatty acids, and tissue triglycerides and lipid intermediates accumulation in 
the aetiology of insulin resistance in skeletal and heart muscle. 
4. The role of free fatty acids and intracellular lipid accumulation in 
insulin resistance 
A prevalent metabolic change associated with obesity [44-49] and high fructose feeding [22-
24] is the increase in the circulating free fatty acids and triglycerides. Under conditions of 
over-nutrition and dyslipidaemia, not all fatty acids entering the cell are utilized for 
oxidative purposes. Long chain fatty acyl-CoA accumulation provides substrates for non-
oxidative processes such as triglyceride, diacylglycerol (DAG) and ceramide synthesis [50, 
51]. In the myocardium lipid accumulation is a direct result of a mismatch between fatty 
acid uptake and oxidation by the cell [47, 52]. What is not clear is whether this accumulation 
is due to: 1) increased FFA uptake by the heart 2) compromised FFA oxidation, or, 3) a 
combination of the two.  
There is a strong link between increased circulating free fatty acids, myocardial triglyceride 
accumulation and insulin resistance. Increased circulating free fatty acids increase the 
expression of sarcolemmal fatty acid transporters and increases fatty acid uptake into the 
myocyte. Obese Zucker rats [46, 48] and db/db mice [53] with insulin resistance have 
increased FAT/CD36 localised to the sarcolemma. The exact mechanism for the increased 
localisation of FAT/CD36 in the sarcolemma is not clear but may relate to the chronic 
hyperinsulinaemia associated with insulin resistance. It is well established that insulin 
stimulates FAT/CD36 translocation to the sarcolemma [54, 55]. This increased sarcolemmal 
FAT/CD36 content increases fatty acid uptake in cardiac myocytes and possibly leads to 
tissue fatty acyl-CoA accumulation if not metabolised through concomitant increased -
oxidation [56].  Besides its adverse effects on insulin signalling and glucose metabolism, 
excessive intramyocellular lipid accumulation may also have direct lipotoxic effects [50, 57]. 
Both altered substrate utilization and excess intramyocardial lipid accumulation which is 
characteristic of obesity, dyslipidaemia and insulin resistance may have serious cardiac 
consequences that ultimately lead to compromised cardiac metabolism, morphology and 
mechanical function.  
Lipid intermediates may adversely influence insulin signalling and contribute to insulin 
resistance [5, 58, 59]. The accumulation of triglycerides, diacylglycerol (DAG) and ceramide 
is known to activate kinases that down-regulate insulin signalling [60-62]. These kinases 
include JNK, IKK and protein kinase C (PKC) that is known to inhibit insulin signalling via 
serine phosphorylation of IRS-1 [5, 63]. 
Ceramide accumulation occurs through de novo synthesis from saturated fatty acids [64] or 
hydrolysis of sphingomyelin [65]. It has been shown to cause insulin resistance by inhibiting 
Akt phosphorylation in skeletal muscle [66-68] and adipocytes [69] with the 
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pharmacological inhibition of ceramide synthesis being effective in preventing lipid induced 
insulin resistance in rats [67, 70]. 
Models of lipotoxicity have also demonstrated that elevated myocardial ceramide levels are 
associated with increases in indices of apoptosis [52, 71]. Rat neonatal cardiomyocytes 
incubated with physiological concentrations of palmitate have increased intracellular 
triglycerides, increased ceramide levels and increased indices of apoptosis [72]. The 
mechanism implicated in ceramide induced apoptosis may involve activation of NFκB 
which in turn up regulates inducible nitric oxide synthase (iNOS) expression [73]. The 
resulting increase in nitric oxide production [74] may cause a subsequent rise in the 
formation of peroxynitrite, which induces mitochondrial cytochrome C release [75] and 
subsequent apoptosis. In addition, ceramide has been shown to directly induce the 
generation of damaging reactive oxygen species in the mitochondria [76]. Obese insulin 
resistant (prediabetic) Zucker rats also have elevated intramyocardial triglycerides which 
are accompanied by increased myocardial ceramide levels and cardiomyocyte apoptosis. 
These cellular alterations are present before the onset of diabetes and cardiac dysfunction 
[71]. Reducing myocardial lipid levels by treating the rats with peroxisome proliferator-
activated receptor gamma (PPAR) agonists lead to reduced cardiac ceramide levels and 
apoptosis and prevented cardiac dysfunction [71]. In a similar study, mice over-expressing 
cardiac specific long chain acyl-CoA synthase display high intramyocardial triglycerides 
and ceramide levels. These changes were accompanied by increased DNA fragmentation 
and cytochrome C release with the mice developing cardiac hypertrophy and left-
ventricular dysfunction [52]. 
Lipid infusion increases intracellular DAG and causes skeletal muscle insulin resistance in 
rodents [60]. This association between intracellular DAG levels and skeletal muscle insulin 
resistance has been confirmed in several rodent and human studies [77-79]. Increased 
muscle DAG is associated with increased activation of protein kinase C theta (PKC-) in 
obese and diabetic patients [80, 81]. Increased PKC- activation interferes with insulin 
signalling by increasing IRS-1 serine307 phosphorylation (Figure 3)[60, 81]. Accelerating fatty 
acid oxidation rates potentially prevents fatty acid, acetyl-CoA and subsequent DAG 
accumulation and may improve insulin sensitivity. This proposal was recently supported by 
a study showing that carnitine palmitoyltransferase I (CPT-1) over-expression in L6E9 
myotubes increases mitochondrial fatty acid uptake, decreased intracellular DAG 
concentrations and protects against elevated fatty acid induced insulin resistance [82]. 
4.1. Evidence for lipid accumulation in skeletal muscle insulin resistance  
An inverse correlation exists between intramuscular lipid content and insulin sensitivity. 
Measurements of insulin sensitivity (120 min euglycaemic hyperinsulinaemic clamp) in 
skeletal muscle from healthy subjects demonstrated that high intramuscular lipid content 
was associated with lower whole body insulin stimulated glucose uptake. These subjects 
also exhibited elevated circulating free fatty acids, reduced tyrosine phosphorylation of the 
insulin receptor (IR) and lower (insulin receptor substrate) IRS-1 mediated PI3K activation 
during hyperinsulinaemia than subjects with low intramuscular lipids [83]. Studies 
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comparing lean and obese individuals have made similar observations linking intracellular 
lipid accumulation to skeletal muscle insulin resistance [84, 85]. Boden and colleagues [86] 
reported a strong association between serum free fatty acid levels, intramuscular lipid 
content and insulin resistance after lipid injection in healthy subjects. Elevated circulating 
free fatty acid levels, induced by lipid injection, was associated with a gradual increase in 
intramuscular lipid content and a 40% increase in insulin resistance. These observations also 
corroborated earlier studies demonstrating that elevated fatty acids reduced skeletal muscle 
glucose uptake in humans [87]. 
 
Figure 3. The proposed mechanism for dyslipidaemia induced insulin resistance. Increased circulating 
free fatty acids as occurs during overfeeding/obesity and/or high fructose diet feeding will increase fatty 
acid uptake. Long chain acetyl CoA not oxidised can be used in non-oxidative pathways with the 
generation of triglycerides, diacylglycerol (DAG) and ceramide. Both the latter lipid metabolites have 
been implicated in aetiology of insulin resistance through the activation of PKC, IKK and JNK.  
In rodent skeletal muscle, experimentally elevated circulating free fatty acids increased 
intracellular acetyl-CoA and DAG levels which was coupled to increased active protein 
kinase C (PKC) theta. These changes were accompanied by increased IRS-1 serine 
phosphorylation, reduced IRS-1 tyrosine phosphorylation and reduced IRS-1 associated 
PI3K activity [60, 88]. Phosphorylation of IRS-1 at serine307 evidently hinders IRS-1’s 
interaction with PI3K and therefore interferes with normal insulin signalling. 
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4.2. Evidence for lipid accumulation in cardiac muscle insulin resistance  
Similar associations between increased intracellular lipid accumulation and reduced insulin 
sensitivity have been observed in cardiac muscle from obese insulin resistant animals [47, 
71, 89, 90]. In obese insulin resistant JCR:LA-cp rats, the increased supply of circulating free 
fatty acids was associated with a 50% increase in myocardial triglyceride content and a  50% 
reduction in myocardial glycolytic flux rates [89].  
In humans, plasma free fatty acid levels correlate with intramyocardial triglyceride levels 
[91]. This association is also evident in obese [91, 92], obese glucose intolerant [93] and 
diabetic [93, 94] individuals. Excessive intramyocardial triglyceride accumulation precedes 
the development of type-2 diabetes and tends to increase linearly with the degree of 
systemic insulin resistance [93]. Obese insulin resistant humans do not always have elevated 
serum free fatty acid levels but do appear to maintain higher rates of free fatty acid uptake, 
utilization and subsequent oxidation than lean controls [95]. 
5. The role of cytokines and chronic inflammation in insulin resistance 
Obesity and insulin resistance is associated with chronic systemic inflammation caused by 
activation of the intrinsic immune systems in organs and the macrophages that infiltrate 
them [96]. The most prominent pro-inflammatory mediators involved in this inflammation 
are TNF and IL-6 that originate from: 1) macrophages in adipose tissue and the liver [97], 
2) the adipocytes themselves [97], and, 3) several other cytokine synthesising tissues in the 
body [97-99].  
Elevated free fatty acids may increase pro-inflammatory cytokine expression and synthesis 
since studies inducing acute increases in plasma free fatty acids have observed activation of 
NFB in skeletal muscle in humans [79] and increases hepatic TNF, IL-1 and IL-6 and 
circulating monocyte chemotactic protein-1 (MCP-1) in rats [100, 101]. How elevated fatty 
acid cause NFB activation is unknown but may involve DAG and PKC [102] or the Toll-like 
receptor 4 (TLR-4) [103]. MCP-1 is also known to regulate recruitment of macrophages to 
sites of inflammation and may be involved in the recruitment and differentiation of 
monocytes to macrophages that produce pro-inflammatory cytokines in conditions such as 
obesity and dyslipidaemia [97, 104].  
TNF causes insulin resistance by suppressing IRS-1 associated insulin signalling and 
glucose transport in skeletal muscle while IL-6 activates the phosphatase SHP-2 and Signal 
transducer and activator of transcription 3 (STAT3) causing increased expression of 
suppressor of cytokine signalling 3 (SOCS3) [105, 106]. IL-6 also activates several 
serine/threonine kinases such as JNK, p38 mitogen activated protein kinases and PKC- that 
contribute to reduced insulin sensitivity and glucose metabolism (Figure 4) [107, 108].  
Information relating to the possible role of inflammation in the aetiology of myocardial 
insulin resistance is limited. A recent study however reported that high fat feeding caused 
increased myocardial macrophage infiltration and increased cytokine and SOCS levels in 
cardiomyocytes from these animals [109]. These changes were associated with reduced 
myocardial insulin sensitivity and glucose metabolism.  
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Figure 4. Proposed mechanism for inflammation induced insulin resistance in muscle. Cytokines from 
macrophages and myocytes activate their receptors and associated signalling pathways to increase 
serine (inhibitory) phosphorylation of IRS-1. IL-6 is known to activate the STAT3-SOCS3 pathways 
while TNF activates JNK to phosphorylate IRS-1. 
6. The role of the Renin-Angiotensin System (RAS) in insulin resistance 
The authors [110] and others [111-115] have shown that the systemic and tissue renin-
angiotensin systems (RAS) activity is increased in obesity. The role of increased RAS activity 
in metabolic and cardiovascular disease has been reviewed in detail [29, 116-118].  A key 
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observation linking the RAS system to insulin resistance was made when it became 
apparent that hypertensive patients treated with angiotensin converting enzyme (ACE) 
inhibitors or angiotensin (AT) receptor blockers have a reduced risk of developing insulin 
resistance and type-2 diabetes when compared to patients on other conventional anti-
hypertensive therapy [119, 120]. Subsequent studies have corroborated these observations 
with RAS inhibition improving blood glucose management [121] and lowering risk of type-2 
diabetes [122]. These data provided indirect evidence to suggest that the RAS (and 
particularly over-activation) contributes to insulin resistance and type-2 diabetes. 
Several human and animal studies support a role for RAS over-activity in insulin resistance. 
Genetic abnormalities leading to over-activation of the RAS provides strong evidence for the 
involvement of the RAS in insulin resistance. In infants [123] and adults [124, 125] the DD 
genotype of the ACE I/D polymorphism is associated with glucose intolerance and insulin 
insensitivity. Similarly, AGTT174M polymorphisms are associated with metabolic syndrome 
in aboriginal Canadians [126].  
As mentioned previously, pharmacological blockade of the RAS in clinical trials has 
provided the most compelling evidence for a role for RAS over-activity in metabolic 
abnormalities such as insulin resistance. The use of ACE inhibitors for antihypertensive 
therapy reduces the risk of developing type-2 diabetes by 14% [119]. Studies on animals 
support these observations with RAS inhibition improving insulin sensitivity in rat [127] 
and mice [128]. Genetic deletion of renin [129] or ACE [130] or one of the two AT receptors  
also appears to be effective in preventing or reducing insulin resistance in mice [131, 132]. 
Besides the evidence showing that inhibition of RAS activity may improve insulin 
sensitivity, several studies also provide direct evidence implicating over-activation of the 
RAS in the aetiology of insulin resistance. Chronic angiotensin II infusion causes insulin 
resistance in rats [133, 134] while the TG(mREN2)27 rat which suffers from chronic systemic 
RAS over-activation develops muscle and systemic insulin resistance [135]. The RAS 
induced insulin resistance in these animals is improved by renin inhibition or angiotensin 
receptor blockade [135, 136]. 
The mechanism for angiotensin II (Ang II) induced insulin resistance has received 
significant attention. Ang II adversely affects glucose metabolism and decreases its uptake 
and utilisation by interfering with insulin signalling [137]. In L6 myocytes Ang II suppresses 
insulin induced phosphorylation of the tyrosine residue on IRS-1. This was associated with 
decreased activation of PKB/Akt and GLUT4 translocation to the sarcolemma. These 
changes were all AT1 receptor, NADPH oxidase and NFB dependent [138, 139]. Based on 
these observations it seems likely that Ang II activates NADPH oxidase and increases 
reactive oxygen species (ROS) generation through the angiotensin type 1 (AT1) receptor. 
ROS activate the NFB to increase transcription of cytokines that include TNF and IL-6. 
These cytokines increase SOCS3 expression which inhibits insulin signalling (Figure 5) [140]. 
In rats Ang II also reduces skeletal muscle mitochondrial content (possibly through 
increased ROS generation) which would be expected to reduce muscle glucose utilisation 
[141].  
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macrophages and myocytes activate their receptors and associated signalling pathways to increase 
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in metabolic and cardiovascular disease has been reviewed in detail [29, 116-118].  A key 
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observation linking the RAS system to insulin resistance was made when it became 
apparent that hypertensive patients treated with angiotensin converting enzyme (ACE) 
inhibitors or angiotensin (AT) receptor blockers have a reduced risk of developing insulin 
resistance and type-2 diabetes when compared to patients on other conventional anti-
hypertensive therapy [119, 120]. Subsequent studies have corroborated these observations 
with RAS inhibition improving blood glucose management [121] and lowering risk of type-2 
diabetes [122]. These data provided indirect evidence to suggest that the RAS (and 
particularly over-activation) contributes to insulin resistance and type-2 diabetes. 
Several human and animal studies support a role for RAS over-activity in insulin resistance. 
Genetic abnormalities leading to over-activation of the RAS provides strong evidence for the 
involvement of the RAS in insulin resistance. In infants [123] and adults [124, 125] the DD 
genotype of the ACE I/D polymorphism is associated with glucose intolerance and insulin 
insensitivity. Similarly, AGTT174M polymorphisms are associated with metabolic syndrome 
in aboriginal Canadians [126].  
As mentioned previously, pharmacological blockade of the RAS in clinical trials has 
provided the most compelling evidence for a role for RAS over-activity in metabolic 
abnormalities such as insulin resistance. The use of ACE inhibitors for antihypertensive 
therapy reduces the risk of developing type-2 diabetes by 14% [119]. Studies on animals 
support these observations with RAS inhibition improving insulin sensitivity in rat [127] 
and mice [128]. Genetic deletion of renin [129] or ACE [130] or one of the two AT receptors  
also appears to be effective in preventing or reducing insulin resistance in mice [131, 132]. 
Besides the evidence showing that inhibition of RAS activity may improve insulin 
sensitivity, several studies also provide direct evidence implicating over-activation of the 
RAS in the aetiology of insulin resistance. Chronic angiotensin II infusion causes insulin 
resistance in rats [133, 134] while the TG(mREN2)27 rat which suffers from chronic systemic 
RAS over-activation develops muscle and systemic insulin resistance [135]. The RAS 
induced insulin resistance in these animals is improved by renin inhibition or angiotensin 
receptor blockade [135, 136]. 
The mechanism for angiotensin II (Ang II) induced insulin resistance has received 
significant attention. Ang II adversely affects glucose metabolism and decreases its uptake 
and utilisation by interfering with insulin signalling [137]. In L6 myocytes Ang II suppresses 
insulin induced phosphorylation of the tyrosine residue on IRS-1. This was associated with 
decreased activation of PKB/Akt and GLUT4 translocation to the sarcolemma. These 
changes were all AT1 receptor, NADPH oxidase and NFB dependent [138, 139]. Based on 
these observations it seems likely that Ang II activates NADPH oxidase and increases 
reactive oxygen species (ROS) generation through the angiotensin type 1 (AT1) receptor. 
ROS activate the NFB to increase transcription of cytokines that include TNF and IL-6. 
These cytokines increase SOCS3 expression which inhibits insulin signalling (Figure 5) [140]. 
In rats Ang II also reduces skeletal muscle mitochondrial content (possibly through 
increased ROS generation) which would be expected to reduce muscle glucose utilisation 
[141].  
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Figure 5. Proposed mechanism for renin-angiotensin system over-activation induced insulin resistance. 
Angiotensin II activates NADPH oxidase to generate reactive oxygen species (ROS) which activate the 
translocation of NFB to the nucleus. Here it causes the transcription, synthesis and release  of cytokines 
(TNF and IL-6). The binding of these cytokines to their sarcolemmal receptors induce serine kinases 
and SOC3 which inhibits IRS-1 tyrosine phosphorylation, insulin signalling and GLUT4 translocation.  
Adipose tissue RAS over-activity may also contribute to systemic insulin resistance since 
Ang II from adipose tissue contributes to circulating Ang II levels. This was well 
demonstrated by a study investigating the effect of adipose tissue angiotensinogen (Agt) 
over-expression on systemic glucose tolerance and insulin resistance [142]. The over-
expression of Agt in adipose tissue caused cardiac and skeletal insulin resistance and 
reduced muscle glucose uptake. 
7. The role of adipocytokines in the aetiology of insulin resistance 
Adipocytokines released from adipose tissue perform regulatory functions in energy and 
fluid balance and satiety and have been implicated in conditions such as obesity, 
dyslipidaemia, insulin resistance/diabetes and cardiovascular disease. Besides the two pro-
inflammatory cytokines discussed previously (TNF and IL-6) adipocytes secrete several 
well characterised adipocytokines that include: leptin, adiponectin, and resistin. 
Dysregulation of the synthesis and secretion of these peptides has been associated with, and 
implicated in, the aetiology of metabolic diseases such as insulin resistance and type-2 
diabetes. A possible role for adipokines in the regulation of myocardial metabolism only 
emerged recently [143-145].  
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Leptin is synthesised by white adipose tissue and is involved in appetite control and energy 
expenditure. Although the absence of leptin leads to obesity and insulin resistance, most 
obese patients have elevated leptin levels but do not respond to the appetite suppressing 
and other effects of the peptide [146, 147]. Mutations of the leptin receptor (Ob-R) are 
associated with obesity in the db/db mouse [148] and the Zucker (fa/fa) rat [149] and leptin 
deficiency occurs in obese (ob/ob) mice [150] while the treatment of patients [151, 152] and 
animals [150] with recombinant leptin reduces body weight and improves serum lipid 
levels.  
Serum triglyceride levels and blood glucose handling also improved in women with 
lipodystrophy and leptin deficiency indicating that leptin may alter lipid metabolism and 
prevent lipotoxicity [153]. Animal studies demonstrate that leptin promotes lipid oxidation. 
In rat adipocytes leptin reduces insulin’s’ lipogenic effect by: 1) inhibiting insulin binding to 
its receptor [154], 2)  increasing adipose and non-adipose tissue -oxidation, and, 3) 
decreasing adipose tissue triglyceride content without elevating circulating free fatty acids 
(Figure 6) [74].  This reduction in serum fatty acid levels will also counter the effect of 
insulin on lipogenesis [74, 154].  
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sensitivity and inflammation.  
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There is a strong association between leptin deficiency/resistance and lipotoxicity [155]. 
The lipid lowering effects of leptin in heart muscle was demonstrated in a study where 24 
hour high fat feeding of mice was associated with cardiac lipid accumulation in animals 
with low leptin levels but not those with high plasma leptin levels [156]. Leptin 
administration decreases cardiac muscle lipotoxicity in a subsequent study by this group 
[157]. 
Leptin administration to the perfusate of isolated rat hearts perfused with palmitate and 
glucose significantly increased fatty acid oxidation and reduced intramyocardial triglyceride 
content without increasing cardiac work. This was accompanied by increased myocardial 
oxygen consumption and reduced cardiac efficiency [143].  The significance of leptin in 
metabolism is further highlighted in genetic models such as the leptin deficient ob/ob mouse 
and the leptin resistant db/db mouse that has a loss-of-function mutation on the leptin 
receptor. These animals are obese, insulin resistant and display excess intramyocardial lipid 
accumulation. They are also more prone to increased cardiomyocyte apoptosis and cardiac 
dysfunction than their control littermates [158-162]. 
Circulating adiponectin levels are reduced in obesity, insulin resistance and diabetes and 
correlate with the extent of insulin resistance and hyperinsulinaemia [163-165]. It is 
synthesised by adipocytes, skeletal muscle, heart muscle and endothelial cells [166] and is a 
key adipocytokine in the regulation of metabolism. It is considered to be an anti-diabetic, 
anti-inflammatory and anti-atherogenic agent with adiponectin deficient animals becoming 
glucose intolerant, insulin resistance and hyperleptinaemic [167, 168]. Studies utilising 
adiponectin replacement therapy have demonstrated its ability to decrease dyslipidaemia 
[169] and improve insulin sensitivity (Figure 6) [170-172]. 
Adiponectin acts via phosphorylation of 5'adenosine monophosphate-activated protein 
kinase (AMPK) to influence insulin sensitivity and fatty acid and glucose utilisation [172, 
173]. Its action is mediated through the AdipoR1 and AdipoR2 receptors [170] that are both 
expressed in cardiac tissue [174]. Receptor activation is associated with modulation of 
AMPK, PI3K, p38 MAP kinase and extracellular signal-regulated kinase (Erk) 1/2 MAP 
kinase [175-177].  
Resistin is secreted from white adipose tissue but is also expressed in other tissues [178]. It 
was given its name because it was originally shown to counter the effects of insulin by 
suppressing insulin signalling [179]. Over-expression of resistin is associated with 
dyslipidaemia and insulin resistance [180, 181] and inhibition of glucose uptake in 
cardiomyocytes [182]. In humans plasma resistin levels are closely correlated to insulin 
resistance irrespective of body weight [183]. However, these observations are not supported 
by two animal studies that found that resistin levels were not a good predictor of insulin 
resistance when corrected for body mass index (BMI) [184, 185]. In both high fat diet and 
genetic mutation induced obesity, resistin levels were closely associated with body weight 
with obese animals having significantly elevated resistin levels [179]. The exact role of 
resistin in insulin resistance is however poorly understood and unresolved. 
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8. Effects of myocardial insulin resistance on myocardial metabolism, 
mechanical function and tolerance to ischaemia and reperfusion 
The heart utilises glucose, fatty acids and lactate as fuels for the production of ATP. Cardiac 
metabolism is under the control of several hormones with insulin being a key regulator of 
glucose, fatty acid and lactate metabolism. Changes in myocardial insulin sensitivity disrupt 
the hearts’ normal substrate metabolism and potentially decrease mechanical function and 
myocardial tolerance to ischaemia/reperfusion.   
8.1. Myocardial metabolism 
The heart is a dynamic organ, constantly requiring energy in the form of ATP in order to 
meet its homeostatic and contractile demands. This is achieved through a constant supply of 
oxidizable substrates from the circulation. The most important substrates utilized by the 
heart are: fatty acids, glucose and lactate. Although the adult heart is capable of oxidizing a 
variety of substrates, the majority of ATP (60-70%) generated by the heart originates from 
the oxidation of fatty acids [186, 187]. However, in the presence of elevated glucose and 
insulin levels as occurs immediately following a meal, 60-70% of ATP may be derived from 
glucose metabolism [188]. 
Circulating fatty acids are taken up by the heart either in their free form (as free fatty acids 
(FFAs)) bound to albumin, or they can be released from the triglyceride component of 
chylomicrons or very-low-density-lipoproteins (VLDL) [189]. The concentration of fatty 
acids present in blood greatly dictates their uptake and metabolism by the heart [190]. 
Under normal physiological conditions, long chain fatty acids (LCFAs) are the principal 
fatty acids oxidized by the heart [191]. The entry of LCFAs across the sarcolemma into the 
cytoplasm of the cardiomyocyte occurs though passive diffusion or membrane protein 
mediated transport, the latter accounting for the majority of fatty acid translocation to the 
cytosol [192]. This membrane protein mediated transport is facilitated by fatty acid 
translocase (FAT)/CD36, plasma membrane fatty acid binding protein (FABPpm) and fatty 
acid transport protein (FATP) [192]. Once inside the cell, non-esterified LCFAs are 
transported via cytoplasmic heart-type FABPs through the cytoplasm to the location where 
they will be utilized [193-195]. LCFAs are then esterified by acyl-CoA synthetase to form 
long chain fatty acyl-CoA’s (LCFA-CoA) [55]. LCFA-CoAs can be stored in intracellular 
lipid pools where they can be converted to additional lipid intermediates (triglycerides, 
diacylglycerol (DAG) or ceramide), or are transported to the mitochondria where they 
undergo β-oxidation.  
Glucose enters the cardiomyocyte through either the basal uptake glucose transporter, 
GLUT1, or via the insulin dependent glucose transporter, GLUT4 [196]. GLUT4 is stored in 
cytoplasmic vesicles which are recruited to the sarcolemma in response to insulin 
stimulation or cardiac contraction. Glucose itself can also induce GLUT4 translocation with 
this and insulin stimulated translocation determining the glucose flux rate into the 
cardiomyocyte [197]. Inside the cell hexokinase converts glucose to glucose-6-phosphate 
which can be stored as glycogen (after conversion by glycogen synthase) or it can undergo 
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mechanical function and tolerance to ischaemia and reperfusion 
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metabolism is under the control of several hormones with insulin being a key regulator of 
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the hearts’ normal substrate metabolism and potentially decrease mechanical function and 
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undergo β-oxidation.  
Glucose enters the cardiomyocyte through either the basal uptake glucose transporter, 
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this and insulin stimulated translocation determining the glucose flux rate into the 
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which can be stored as glycogen (after conversion by glycogen synthase) or it can undergo 
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glycolysis to yield pyruvate and ATP.  During adequate myocardial oxygen availability 
pyruvate is transported into the mitochondria via a mitochondrial monocarboxylate 
transporter [198] and subsequently oxidized by pyruvate dehydrogenase (PDH) to produce 
acetyl-CoA (reviewed by Stanley et al. [199]). During anaerobic conditions as occurs during 
myocardial ischaemia, pyruvate may be converted to lactate. 
The rate of glucose oxidation is also influenced by fatty acid β-oxidation rates since 
hexokinase, PFK and PDH activity are all inhibited by various  products of fatty acid 
metabolism (for a review see Hue and Taegtmeyer [200]). There is a delicate interplay in the 
utilisation of these two myocardial substrates which is intricately related to their circulating 
levels. The common endpoint where glucose and fatty acid metabolism converge is the 
production of acetyl-CoA which enters the tricarboxylic acid/Krebs cycle where it is used to 
generate ATP during oxidative phosphorylation [187, 201]. Alternatively the acetyl-CoA can 
be utilised in non-oxidative pathways for the production of triglycerides, DAG and 
ceramide. 
8.2. Impact of myocardial insulin resistance on myocardial metabolism 
The early onset of insulin resistance in obesity may be a physiological response to increased 
lipid availability leading to increased lipid utilisation and a reciprocal reduction in glucose 
metabolism. Chronic dysregulation of glucose uptake and metabolism by dyslipidaemia and 
inflammation may however induce pathological changes in cardiac metabolism that 
compromise cardiac morphology and mechanical function.  
High fat feeding of C57BL/6 mice induces myocardial insulin resistance within 10 days. This 
insulin resistance was associated with reduced myocardial glucose uptake, PKB/Akt activity 
and GLUT4 protein levels and preceded and occurred independently of systemic insulin 
resistance [202]. With myocardial insulin resistance, fatty acid oxidation rates are normal or 
elevated, while glucose oxidation rates are normally reduced both in the presence or 
absence of insulin stimulation [5, 44, 45, 203-205]. Although a limited number of studies 
have reported similar myocardial fatty acid and glucose oxidation rates in obese, insulin 
resistant animals when compared to lean controls, they have all found that insulin stimulated 
myocardial glycolytic flux rates remain suppressed with insulin resistance [89, 206]. In humans 
similar increases in myocardial fatty acid metabolism were reported in obese men and women. 
Gender however also played and important role in determining the impact of obesity of 
glucose and fatty acid uptake and utilization [207]. Women were less prone to obesity induced 
dysregulation of myocardial metabolism than their obese male counterparts. These gender 
based differences in myocardial metabolism in response to obesity may translate to differences 
in the development of obesity-related cardiovascular diseases. 
8.3. Effect of insulin resistance on cardiac mechanical function 
Increased lipid uptake and oxidation as seen with insulin resistance potentially leads to 
cellular lipid intermediate accumulation, excessive mitochondrial or peroxisomal ROS 
generation and functional derangement in the heart [71]. This is well demonstrated by a 
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study showing that cardiac specific PPAR over-expression which increases cardiac lipid 
oxidation causes metabolic derangements and leads to adverse structural and function 
changes in the heart [208]   
Pre-diabetic (insulin resistant) obese Zucker rats display cardiac dysfunction [47]. These 
observations were corroborated in obese insulin resistant mice (ob/ob and db/db) that had 
increased myocardial lipid oxidation rates, decreased glucose oxidation rates and decreased 
cardiac efficiency. These changes were also associated with systolic dysfunction when 
compared to lean insulin sensitive littermates [45].  
Although genetic models of obesity do not accurately resemble the phenotype of human 
obesity, the recent development of a number of models of diet-induced  obesity have 
contributed to a better understanding of the impact of obesity and insulin resistance on 
myocardial function. High fat feeding induced insulin resistance in C57BL/6 mice also 
causes cardiac remodelling and systolic dysfunction [202]. The authors and other research 
groups have however also shown that rodent models of diet-induced obesity with insulin 
resistance have either normal [90, 203, 205, 209, 210] or compromised [110, 203, 204, 211, 212] 
cardiac mechanical function. It is currently not possible to conclusively attribute the cardiac 
dysfunction reported in these studies to myocardial insulin resistance since there are several 
studies that have reported normal cardiac function in animal models with insulin resistance 
[90, 203, 205, 209, 210].  
Reduced cardiac efficiency possibly contributes to cardiac dysfunction in obesity, insulin 
resistance and diabetes [44, 45, 213]. Animals [44, 45, 162, 213] and humans [95] that are 
obese and insulin resistant or diabetic have increased myocardial oxygen consumption 
which reflects a decreased cardiac efficiency as determined by the myocardial work to 
myocardial oxygen consumption ratio [214]. Mitochondria isolated from obese insulin 
resistant mice have reduced oxidative capacity, and display fatty acid induced uncoupling 
of mitochondrial oxygen consumption and ATP production which is evident from the 
reduced ATP-to-O ratios [162, 213]. This data from human and rodent studies also implicate 
impaired mitochondrial energetics in the cardiac dysfunction associated with obesity and 
insulin resistance. Recent epidemiological evidence points to an important mediatory role 
for insulin resistance in the development of obesity related congestive heart failure [215]. 
8.4. Effect of dyslipidaemia and insulin resistance on myocardial tolerance to 
ischaemia/reperfusion 
A key feature of myocardial ischaemia is the reduced oxygen and substrate availability that 
results in lower mitochondrial oxidative phosphorylation rates. Ischaemia essentially 
disrupts the tightly coupled ATP breakdown and re-synthesis equilibrium that exists during 
normoxia and leads to an ATP deficit. Cellular ATP becomes depleted with the extent of this 
depletion being dependent on the duration and severity of ischaemia [216].  
Although oxidative metabolism is reduced during ischaemia, reperfusion after ischaemia is 
associated with an initial increase in glycolytic flux rate which quickly declines to normal 
levels [217]. Despite glycolysis only accountings for a small amount of the total ATP 
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study showing that cardiac specific PPAR over-expression which increases cardiac lipid 
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normoxia and leads to an ATP deficit. Cellular ATP becomes depleted with the extent of this 
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associated with an initial increase in glycolytic flux rate which quickly declines to normal 
levels [217]. Despite glycolysis only accountings for a small amount of the total ATP 
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production under aerobic conditions, glycolytically generated ATP becomes invaluable in 
the maintenance of cellular ion pump function and ion homeostasis and the reduction of 
myocardial damage during mild ischaemia [218]. While glycolytically produced ATP may 
aid in maintaining ion homeostasis during ischaemia, it is insufficient for the maintenance of 
myocardial contractile function [218]. Under conditions of severe ischaemia in the absence of a 
glucose and oxygen, myocardial glycogen stores undergoing glycolysis do not only contribute 
to the ATP synthesised, but greatly increase cytosolic proton accumulation and a decline in 
intracellular pH [219]. Despite its potential adverse effect on pH, elevated glycogen levels at 
the onset of myocardial ischaemia may be important in maintaining tissue ATP levels since it 
has been associated with improved functional recovery after ischaemia [220].  
Despite myocardial ischaemia decreasing mitochondrial substrate oxidation, fatty acid 
oxidation predominates during ischaemia and subsequent early reperfusion [221].  During 
early ischaemia there is a transient increase in anaerobic glycolysis while glucose oxidation 
decreases [199, 221-224]. Under these conditions normal or increased glucose uptake (under 
the influence of insulin) may be important for the delivery of glycolytic ATP to maintain ion 
homeostasis. Hearts from animal models of obesity and insulin resistance [211], isolated 
insulin resistance [225] and diabetes [226] have a reduced tolerance to ischaemia and 
reperfusion and suffer more severe ischaemia/reperfusion injury. Myocardial insulin 
resistance potentially decreases myocardial tolerance to ischaemia by decreasing glucose 
uptake, glycogen synthesis and glycolysis which all play a critical role in the delivery of 
ATP for cellular homeostasis in the ischaemic/reperfused heart.  
Although fatty acids are predominantly oxidized by the ischaemic heart, the preference for 
fatty acid oxidation as occurs under dyslipidaemic conditions also has adverse effects on the 
ischaemic and reperfused heart. The mitochondrion generates 12% less ATP per oxygen 
molecule through the oxidation of fatty acids compared to glucose oxidation during 
normoxia [187]. Increased fatty acid oxidation consequently reduces cardiac efficiency 
during ischaemia and subsequent reperfusion. During reperfusion the glycolytic flux rate 
exceeds glucose oxidation rates which remains suppressed due to increased fatty acid 
oxidation during reperfusion [224, 227]. This fatty acid induced uncoupling of glucose 
oxidation from glycolysis results in an accumulation of hydrogen ions which can damage 
the heart and affect post ischaemic function [199, 228-230]. These detrimental effects of 
increased fatty acid -oxidation during both ischaemia and reperfusion would be expected 
to be pronounced in dyslipidaemia (as occurs in obesity and high fructose feeding) and 
insulin resistance and exacerbate ischaemic injury.  
Pharmacological inhibition of myocardial fatty acid oxidation prior to the onset of, or during 
reperfusion results in increased glucose oxidation and improved cardiac functional recovery 
following the ischaemic episode [224, 227]. Hearts from prediabetic obese Zucker rats have 
reduced GLUT4 expression, reduced glucose uptake and larger reductions in tissue ATP 
levels during low-flow ischaemia. These changes are associated with poorer post-ischaemic 
functional recoveries when compared to their lean control littermates [231]. Treating these 
rats with rosiglitazone (the insulin sensitizer) normalized myocardial total GLUT4 protein 
expression, myocardial ischaemic substrate metabolism and improved reperfusion 
functional recovery. 
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8.5. The effect of insulin resistance on myocardial pro-survival signalling and 
ischaemic tolerance 
The ability of the heart to withstand injury during ischaemia and reperfusion is not only 
dependent on myocardial metabolism but also upon the expression and functionality of its 
intrinsic pro-survival signalling pathways. Investigations into cardioprotection with 
preconditioning and postconditioning has revealed common signalling elements that 
transduce protective stimuli and converge on mitochondrial targets [232-234]. These stimuli 
recruit paths comprising cell surface G-protein coupled receptors (GPCRs), signalling kinase 
networks (e.g. PI3K-Akt-eNOS, Erk1/2, PKC, p38-MAPK, Glycogen synthase kinase 3 beta 
(GSK3)) that have been dubbed the Reperfusion Injury Salvage Kinases (RISKs), and 
mitochondrial components that may represent end-effectors. These end-effectors include KATP 
channels and the mitochondrial permeability transition pore - mPTP (Figure. 7). Central to the 
RISK pathways is protein kinase B (PKB)/Akt which is not only key to myocardial insulin 
signalling  [188] and physiological hypertrophy/remodelling [235] but is also considered a pro-
survival/anti-apoptotic kinase in the context of myocardial ischaemia/reperfusion. 
 
Figure 7. An illustration demonstrating the pivotal role of PKB/Akt in the RISK and insulin signalling 
pathways and the possible impact of dyslipidaemia and insulin resistance on these signalling pathways. 
Broken line represents the proposed mechanism linking insulin resistance with PKB/Akt 
inhibition/inactivation and Reperfusion Injury Salvage Kinase (RISK) pathway dysfunction. 
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Insulin regulates cardiac metabolism, growth and mitogen-activated protein kinase (MAPK) 
pathways through pivotal PKB/Akt. Dyslipidaemia induced insulin resistance which is 
characterized by PI3K/Akt dysregulation possibly also negatively influences the 
functionality of the RISK pathway in the heart during ischaemia/reperfusion.  
Early experimental evidence has emerged to support a role for obesity with insulin 
resistance in RISK pathway dysfunction. Wagner and co-workers [236] have shown loss of 
preconditioning in a rat model of established metabolic syndrome. In the leptin-deficient 
(ob/ob) mouse cardiac benefit from postconditioning is impaired [237], while there is also 
evidence of failed preconditioning in obese insulin-resistant rats [238]. Failure of a variety of 
cardioprotective interventions involving multiple and varied triggers, implicates dysfunction 
of the signalling paths of the RISK pathway that are common to these interventions. This is 
also supported by the recent findings of Bouhidel and co-workers [237] who reported 
impaired phosphorylation of Akt, Erk1/2 and p70S6K1 in ob/ob mice while others [236] 
presented evidence of impaired Erk1/2 activation and failure to phosphorylate and inactivate 
GSK3β. Ineffective protection in obese insulin resistance rats is also associated with impaired 
activation of the mitochondrial KATP channel [238]. All early indications suggest that distinct 
changes in intrinsic cardioprotective signalling occur in myocardial insulin resistance.  
9. Interventions and therapy for the treatment of insulin resistance 
Compelling scientific evidence indicates that obesity and/or lipogenic diets that lead to 
dyslipidaemia promote insulin resistance. Besides the dyslipidaemia, abnormal RAS activity 
and perturbations in adipocytokine levels also contribute to tissue insulin insensitivity. The 
primary goal of therapy for the treatment of insulin resistance should therefore be to 
prevent or reduce obesity (adipose tissue expansion) and dyslipidaemia. In addition to 
normalising circulating lipid levels, weight loss would normalise adipose tissue content and 
its associated pro-inflammatory cytokine and adipocytokine levels and ultimately improve 
insulin resistance.  Since there is a direct correlation between obesity and RAS over-
activation, weight loss and/or RAS inhibition has the potential to attenuate the adverse 
effects of abnormal RAS activity on tissue insulin signalling.   
9.1. Lifestyle changes:  Physical activity and diet 
Maintaining normal body weight or reducing body weight in overweight patients is the 
preferred approach for the prevention or treatment of the underlying causes of insulin 
resistance. Regular physical activity aimed at balancing caloric intake with caloric 
expenditure is recommended to maintain body weight. To reduce body weight caloric intake 
should be reduced and caloric expenditure increased until the desired body weight has been 
achieved. Current recommendations are to do 30 minutes moderate intensity exercise daily in 
order to maintain normal body weight and reduce the risk of developing medical conditions 
such as cancer, insulin resistance, diabetes and cardiovascular disease [239].  
In addition to regular exercise to maintain normal body weight or promote weight loss, 
individuals with a genetic predisposition to obesity, insulin resistance and diabetes should 
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carefully manage their diet and reduce their intake of refined sugars, trans- and saturated 
fats and cholesterol and increase their consumption of grains, and fruit and vegetables [240]. 
Based on recent evidence provided by studies investigating the potential role of fructose in 
dyslipidaemia and metabolic diseases [24, 27, 41], it would also be prudent to avoid the 
overconsumption of fructose rich foods and beverages.  
The larger the BMI loss achieved through exercise and/or dietary restriction, the larger the 
metabolic improvements that are achieved. Weight loss improves lipid profiles and blood 
glucose levels in metabolic syndrome patients [241] with a weight loss of more than 10% 
reversing metabolic disorders in two-thirds of metabolic syndrome patients studied [242]. 
These patients no longer met the criteria for metabolic syndrome. Lifestyle interventions 
also decreases the progression from insulin resistance to type-2 diabetes. In the US Diabetes 
Prevention Program, interventions aimed at reducing body weight by 7% succeeded in 
preventing progression from insulin resistance to type- 2 diabetes by 58% [243]. In this study 
38% of the patients with metabolic syndrome at entry into the study had a reversal of 
metabolic syndrome with body weight loss.  
9.2. Drug therapy that improves insulin sensitivity 
Although lifestyle changes should remain the therapy of choice for the reduction of body 
weight and normalisation of metabolic disorders, not all patients respond to lifestyle 
changes to the same extent. In many cases lifestyle changes fail to achieve the intended 
objective of adequate weight loss. Under these circumstances pharmacological interventions 
have to be considered. Several drugs have been developed to improve lipid profiles and 
insulin sensitivity/action but have been disappointing and have in some cases had adverse 
side effects.  
9.2.1. Lipid lowering drugs  
Dyslipidaemia which presents as elevated circulating triglycerides and LDL-cholesterol and 
low HDL-cholesterol can be treated with statins (3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase inhibitors) that reduce levels of all forms of Apo B containing 
lipoproteins [244-247]. These drugs reduce the conversion of acetyl-CoA to mevalonate and 
the eventual synthesis of cholesterol in the liver by blocking HMG-CoA reductase. There are 
several studies that have demonstrated that statins (simvastatin and atorvastatin) improve 
plasma triglyceride and glycosylated haemoglobin in non insulin dependent diabetics [246]. 
Fluvastatin also improved lipid profiles and insulin resistance in nondiabetic dyslipidaemic 
patients. These researchers however concluded that the insulin sensitising effects of 
fluvastatin were not related to its triglyceride lowering effects [247].   
Another class of lipid lowering drug that has achieved satisfactory results is the fibrates that 
activate peroxisome proliferator-activated receptor (PPARs) and facilitate lipid metabolism. In 
humans, fibrates lower circulating triglyceride and LDL-C levels [248, 249] and elevate HDL-C 
levels [249]. PPARα agonists possibly improve lipid profiles by increasing the synthesis of 
both apolipoprotein A-I [248] and A-II [250] which would assist in increasing HDL-cholesterol 
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while reducing apolipoprotein B which is a major lipoprotein constituent of LDL-cholesterol. 
PPARα agonists also increase hepatic mitochondrial β-oxidation which reduces hepatic free 
fatty acids that are an essential component of VLDL and LDL-cholesterol.  
Since PPARα agonists have repeatedly been demonstrated to have both systemic and tissue 
specific insulin sensitizing effects [251-254] their potential for the treatment of insulin 
resistance and diabetes is encouraging. The insulin sensitising effects of the fibrates 
probably relate to their lipid lowering effects since a PPARα agonist significantly increases 
hepatic and skeletal muscle insulin receptor and IRS-1 tyrosine phosphorylation, while 
increasing IRS-associated PI3K activity in obese (ob/ob) mice [252]. These insulin sensitising 
effects were accompanied by reduced hepatic, skeletal muscle [252] and heart muscle [255] 
lipid accumulation.   
Combination therapy using statins and fibrates has been an attractive possibility but the 
results have been disappointing. The fibrate gemfibrozil in combination with statins has 
been associated with increased risk of myopathy [256]. It has however been proposed that 
the adverse effects of gemfibrozil and statin combination therapy may be due to a 
pharmacological interaction between  these two drugs and that other fenofibrates may be 
more suitable for combination therapy with statins [257]. 
9.2.2. Insulin sensitizers 
The two most promising insulin sensitizers are metformin and the glitazones. Metformin 
decreases hepatic gluconeogenesis and triglyceride production which in turn enhances 
insulin sensitivity [258]. Metformin reduced the progression of insulin resistance (pre-
diabetic) to type-2 diabetes in the Diabetes Prevention Program [243].  
Thiazolidinediones (TZDs) are PPAR agonists that regulate insulin sensitivity in the liver, 
muscle and adipose tissue by increasing fatty acid oxidation and decreasing fatty acid 
synthesis [258]. TZDs are also believed to have anti-inflammatory effects. Pioglitazone was 
used in the ACT-NOW study in which it improved HDL-cholesterol and triglyceride levels 
and reduced the incidence of type-2 diabetes by 78% in prediabetic patients followed up over 2 
years [259]. The Pioglitazone In Prevention Of Diabetes (PIPOD) study demonstrated that 
pioglitazone reduced the incidence of diabetes in premenopausal women [260]. It similarly 
improves insulin sensitivity and reduces both blood FFA and triglycerides levels in obese non-
diabetic patients [261]. The usefulness of pioglitazone for the management of insulin 
sensitivity is however limited since it promotes fluid retention which increases risk of heart 
failure in certain patient populations with cardiovascular disease. In the diabetes reduction 
assessment with ramipril and rosiglitazone medication (DREAM) trial, rosiglitazone showed 
potential in preventing diabetes but appeared to increase the risk of heart failure [262]. 
9.2.3. RAS inhibitors or AT receptor blockers 
Obesity and high fat feeding increases both systemic and adipose tissue RAS activity [110, 
112-115]. As discussed previously in this chapter, the most compelling evidence for a role 
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for the RAS in the aetiology of insulin resistance comes from studies using ACE inhibitors 
and AT receptor antagonists to control blood pressure. Both these therapies are associated 
with reduced risk of developing insulin resistance and type-2 diabetes in patients [119, 122, 
263-266] and in rodent models of obesity and insulin resistance [127, 128]. Although these 
antihypertensives are not prescribed for the treatment of abnormal RAS activity, they 
potentially improve insulin sensitivity in a patient population that is at high risk of 
cardiovascular disease due to their hypertension.     
9.2.4. Anti-inflammatory therapy  
Several lines of evidence implicate chronic inflammation in the aetiology of insulin 
resistance. Obesity is associated with elevated circulating cytokines and C-reactive protein 
which can be normalised by weight loss [267]. Although no drugs are currently available to 
treat chronic systemic inflammation, the use of lipid lowering drugs have been associated 
with reduced C-reactive protein levels in patients [267-269]. These drugs are not prescribed 
to specifically reduce inflammation but may contribute to improved insulin sensitivity by 
improving dyslipidaemia and decreasing its stimulation of -oxidation and ROS generation. 
Increase ROS generation potentially increase cytokine synthesis and release in certain 
organs (Figure 2).  
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1. Introduction 
Metabolic syndrome (MS), that has received increased attention in the past few years, 
consists of multiple, interrelated risk factors of metabolic origin that appear to directly 
promote the development of atherosclerotic cardiovascular disease (ASCVD). Most 
important of these underlying risk factors are abdominal obesity and insulin resistance. 
Other associated conditions include physical inactivity, aging, hormonal imbalance, and 
genetic or ethnic predisposition 1. 
The measurement of abdominal obesity through waist circumference (WC) has been 
established as a simple, inexpensive and useful method for the diagnosis of abdominal 
obesity. Thus, WC has been proposed as a key element for the diagnosis of MS and its use 
suggested as a part of the routine general physical examination in clinical practice2. 
Moreover, WC correlates with visceral obesity, and in clinical studies, it has been associated 
with increased cardiovascular risk3. It has been proposed as a part of the routine general 
physical examination in clinical practice.  
It is shown that mesenteric fat thickness is an independent determinant of metabolic 
syndrome, with an odds ratio of 1.35 for every 1 mm increase, at least within the observed 
range of mesenteric fat thickness. The discriminating cut-off point of 10 mm indicates the 
presence of metabolic syndrome and identifies subjects with increased intima-media 
thickness4.  
Hypotheses relating central adiposity to the metabolic syndrome focus on the newly 
emerging understanding that adipose tissue (particularly visceral adipose tissue) is a source 
of factors [including free fatty acids, tumour necrosis factor-alpha (TNF-α)] that impair 
insulin action in skeletal muscle. In addition, the adipose specific collagen-like molecule, 
adiponectin, has been found to have antidiabetic, anti-atherosclerotic and anti-inflammatory 
 The Author(s). Licensee InTech. T is chapter is distribut d under the te ms of the Creative Commons 
Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
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functions. Excessive adipose tissue is associated with a decreased production of adiponectin 
which may impair insulin sensitivity.  
Measurement of mesenteric fat thickness may potentially be developed into an alternative 
tool to identify subjects at risk for cardiovascular diseases5. 
Newer clinical studies showed that WC not always correlates with visceral obesity and 
associated risk for cardiovascular diseases in clinical studies6. Therefor, several imaging 
methods have been proposed for estimation of visceral adipose tissue. Recent advances in 
imaging techniques and an understanding of differences in the molecular biology of the 
different adipose tissue depots have been reported. Computed tomography (CT) and 
especially Magnetic Resonance Imaging (MRI), the gold standard technique, provide non 
invasive estimation of VAT (visceral adipose tissue) amount safely and accurately. 
Unfortunately, both MRI and CT are high-cost technologies, and CT requires radiation 
exposure. In addition, a great variability in the precise definition of adipose tissue 
compartments by CT and MRI measurements is found in clinical studies. The measurement 
of visceral fat volume using ultrasonography (US) could calculate as effective as using CT. 
This method should be practiced in clinics due to its low cost, no side effects and technical 
suitability7,8. 
2. Computed tomography 
In 1999, Yoshizumi et al. presented the standard technique for fat visceral fat measurement 
at CT which is used in all further published studies9. CT (TCT-900S Helix; Toshiba, Tokyo, 
Japan) was performed with all subjects supine (120 kV, 200 mA, section thickness of 5 mm, 
scanning time of 2 seconds, field of view of 400 mm). In subjects, subcutaneous and visceral 
fat areas were measured on one cross-sectional scan obtained at the umbilicus. A region of 
interest of the subcutaneous fat layer was defined by tracing its contour on each scan, and 
the attenuation range of CT numbers (in Hounsfield units) for fat tissue was calculated. A 
histogram for fat tissue was computed on the basis of mean attenuation plus or minus 2 SD. 
Intraperitoneal tissue was defined by tracing its contour on the scan; within that region of 
interest, tissue with attenuation within the mean plus or minus 2 SD was considered to be 
the visceral fat area. The pixels with attenuation values in the selected attenuation range 
were depicted as white. From those white regions, the total fat area was calculated by 
counting the number of pixels in each; the visceral fat area was subtracted, and the 
remainder was defined as the subcutaneous fat area. Results with this method were 
compared to those with a computerized planimetric method (KL 4300 Digitizer; Graphtec, 
Tokyo) and with a fixed attenuation range from 2190 to 230 HU as the standard of reference. 
3. Magnetic Resonance Imaging 
The basic method of visceral fat measurement by MR is as described by Demerath et al10. 
Images were obtained with a Magnetom Vision 1.5 Tesla whole-body scanner (Siemens, 
Mississauga, Canada) using a T1-weighted fast-spin echo pulse sequence (TR 322 ms, TE 
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12 ms). The subjects were instructed to lie in the magnet in a supine position with arms 
extended above the head. A breath-hold sequence (≈22 s per acquisition) was used to 
minimize the effects of respiratory motion on the images. All images were acquired on a 256 
× 256 mm matrix and a 480-mm field of view. Slice thickness was 10 mm, and images were 
obtained every 10 mm from the 9th thoracic vertebra (T9) to the first sacral vertebra (S1). 
Depending on the height of the person, this resulted in a total of 21–40 axial images per 
person. The images were retrieved from the scanner according to a DICOM (Digital Imaging 
and Communications in Medicine) protocol (National Electrical Manufacturer’s Association, 
Rosslyn, VA). Segmentation of the axial images into VAT and subcutaneous adipose tissue 
(SAT) areas was performed by 2 trained observers using image analysis software (Slice-O-
Matic, version 4.2; Tomovision Inc, Montreal, Canada). Tagging of adipose tissue began at 
the first image, containing the upper margin of the liver and continued down to the L5-S1 
image, which increased the likelihood that all intraabdominal adipose tissue was included 
in the estimate. To calculate VAT and SAT volumes, the VAT and SAT areas for each image 
were summed across all images. A significant advantage of the contiguous image approach 
is that no geometrical assumptions have to be made regarding how to interpolate between 
consecutive slices for the calculation of total volumes. 
4. Ultrasonography 
Ultrasonography (US) is a simple and reliable method for measuring both subcutaneous and 
visceral fat showing a strong correlation with both adiposities measured with computed 
tomography scan11.  
Different techniques are presented by different authors, and no standard method of 
measurement is still proposed.  
In 1990. Armellini et al.12 proposed the use of ultrasonography for the first time for the 
quantification of visceral adiposity as an alternative technique to CT.  
There are several proposed techniques, but the most reliable technique of ultrasonographic 
measurement of fat tissue thickness was presented by Meriño-Ibarra et al.13. Sonography 
measurements were performed using a linear-array probe (Aloka SSD-900, Tokyo, Japan) 
(7.5 MHz and 42 mm) in supine position. It was kept perpendicular to the skin on the upper 
median abdomen, and longitudinal scan was done in the midpoint between the xiphoid 
appendix and the navel along the alba line with regard to the surface of the liver, to be 
almost parallel to the skin. Subcutaneous fat thickness (STh) and area (SA) were measured 
on the xiphoumbilical line in both longitudinal and transverse views. Measurements were 
taken 3 times directly from the screen using the electronic calipers at the inner edge of the 
skin and at the outer edge of the alba line and the fat-muscle interfaces for area. 
Preperitoneal fat thickness or visceral-fat thickness (VTh) and area (VA) were measured in 
the same sites and views (Fig. 1). In this case, measurements were taken at the inner edge of 
the alba line and at the peritoneal line for thickness and area. Then mean values were 
calculated. Preperitoneal circumference (PC) was calculated as: 
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Depending on the height of the person, this resulted in a total of 21–40 axial images per 
person. The images were retrieved from the scanner according to a DICOM (Digital Imaging 
and Communications in Medicine) protocol (National Electrical Manufacturer’s Association, 
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(SAT) areas was performed by 2 trained observers using image analysis software (Slice-O-
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the first image, containing the upper margin of the liver and continued down to the L5-S1 
image, which increased the likelihood that all intraabdominal adipose tissue was included 
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measurement is still proposed.  
In 1990. Armellini et al.12 proposed the use of ultrasonography for the first time for the 
quantification of visceral adiposity as an alternative technique to CT.  
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2( )PC WC STh    
This measurement assumes that WC is a circumference, hence after measuring WC and STh, 
the intra-abdominal radius and PC can be easily calculated with the formula cited 
previously. All the subjects were asked to hold their breath during the examination. Special 
care was taken to keep the probe just touching the skin to prevent compression of the fat 
layers. 
 
Figure 1. Subcutaneous and visceral fat thickness measurement 
Other authors, as well contributed to this topic, Suzuki et al.14 proposed a new index as a 
good non/invasive indicator of viscerl fat deposition. They calculated the abdominal wall fat 
index as preperitoneal fat/subcutaneous fat ratio. The thickness of subcutaneous as 
preperitoneal fat layers was measured directly on the screen using electronic callipers. The 
maximum thickness of preperitoneal fat and the minimum thickness of subcutaneous fat 
were used as representative markers.  
Hirooka et al.15 proposed an another technique. This group measured the distance between 
the internal surface of the abdominal muscle and splenic vein, the distance between the 
internal surface of the abdominal muscle and the posterior wall of the aorta of the aorta on 
the umbilicus and the thickness of the posterior right renal wall in the right posterior 
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perinephritic space. A 3.5MHz convex-array probe was used to measure each 
parameter,other than the thickness of both the subcutaneous and the preperitoneal fat layers 
at the xyphoid process by performing a longitudinal scan, which was measured using 
7.5MHz linear-array probe. The transducer was placed vertically against the skin as lightly 
as possible to prevent compression of the fat layers. The distance between the internal 
surface of the abdominal muscle and the splenic vein was scanned transversely in the 
midline. When the splenic vein could not be visualized clearly, this vein was detected by 
using color Doppler flow. The equation was calculated as follows: 
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There was a good correlation between the visceral fat volume calculated by the above 
equation and the volume by CT described. 
Visceral fat amount can be estimated by measurement of perirenal fat, as presented by 
Kawasaki et al.16. This group performed sonography using a Power Vision 8000 scanner 
(Toshiba, Tokyo, Japan) equipped with a 3.75-MHz convex probe. On sonography, the 
thickness of combined para- and perirenal fat was measured between the kidney and the 
inner aspect of the abdominal musculature. Measurements on both sides were averaged. 
The results correlated with CT measurement, as well as with laboratory values.  
5. Conclusion 
Since 1990, CT has been proposed as the gold standard method to quantify abdominal 
adiposity17. Despre´s and Lamarche18 observed that a visceral fat area of 130 cm2 was 
associated with a high risk of cardiovascular events, although prospective studies are still 
lacking to confirm such an association. In the meantime, other techniques have been used to 
predict cardiovascular risk. Undoubtedly, BMI is the most common method for estimating 
body fat, and several epidemiological studies have reinforced its role in the prediction of 
morbidity and mortality19,20. However, an increased BMI does not show which body 
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predict cardiovascular risk. Undoubtedly, BMI is the most common method for estimating 
body fat, and several epidemiological studies have reinforced its role in the prediction of 
morbidity and mortality19,20. However, an increased BMI does not show which body 
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compartment (fat or lean mass) is inadequate and cannot differentiate subcutaneous from 
visceral fat accumulation. The use of US in the assessment of intra-abdominal fat, initially 
proposed by Armellini et al.12, was further confirmed by strong correlations with the CT-
determined visceral fat area14,21. US is expected to be the most specific method because it 
allows the individual visualization of subcutaneous and intra-abdominal (visceral) fat. In 
addition, US is a noninvasive and quick method with good reproducibility rates (intra-
examination variation <1%) and lower costs than CT scans. However, specific equipment 
and a welltrained examiner are required. Despite the fact that body composition might be 
attributable to ethnic differences, changes in the US-determined visceral-to-subcutaneous fat 
ratio can potentially be monitored for the risk associated with visceral fat accumulation. 
Also, US may represent a useful method for monitoring weight loss, variations in visceral 
fat, and associated risks22.  
Whatever technique is used, ultrasonography is a reliable method for measurement visceral 
fat amount and assessment of metabolic syndrome presence and risk for cardiovascular 
diseases development. 
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1. Introduction 
Vascular dysfunction is a highly complex biological process, and cardiovascular diseases are 
a leading cause of morbidity and mortality in the United States [1]. It is estimated that 
approximately 80 million US adults (>1 in 3) have one or more types of cardiovascular (CV) 
disease, including hypertension, atherosclerosis, and congestive heart failure. CV disease 
has been estimated to account for 34.3% of all deaths in the United States in 2006 [1]. 
Vascular or endothelial dysfunction is caused by many interrelated factors including 
oxidative stress, hypertension, diabetes mellitus, renal disease, smoking, inflammation and 
atherosclerosis.  
In this chapter we will review results from large-scale clinical trials to determine if inhibitors 
of the renin–angiotensin system (RAS), including angiotensin-converting enzyme inhibitors 
(ACEIs) and angiotensin type II receptor blockers (ARBs) and calcium channel blockers 
(CCBs), may have beneficial effects on central aortic pressure (CAP) and the biomarkers 
high-sensitivity C-reactive protein (hsCRP), adiponectin, cystatin C, homeostasis model 
assessment of insulin resistance (HOMA-IR), procollagen, tumor necrosis factor- (TNF-), 
and interleukin-6 (IL-6).  
Biomarkers are playing an increasing role in the study of CV disease and we attempt to 
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Some of the benefits of inhibiting RAS with ARBs and ACEIs have been shown to be 
independent of blood pressure (BP) reduction [5] [6]. Surrogate biomarkers are diverse, and 
they may provide a viable means of measuring the response to treatment. This chapter will 
focus on the following eight biomarkers, which have been used as predictors of vascular 
outcome in patients with hypertension and those with metabolic syndrome: CAP, hsCRP, 
adiponectin, cystatin C, HOMA-IR, procollagen, TNF-α, and IL-6. 
Anti-inflammatory, anti-atherogenic, and/or improved metabolic homeostasis, independent 
of BP lowering, which is seen with some antihypertensives, may benefit high-risk patient 
populations or those who do not achieve adequate BP control. These include ethnic groups 
such as African Americans, obese patients, and patients with renal disease, metabolic 
syndrome, diabetes mellitus, and/or existing vascular disease. Improvements in 
inflammatory and other biomarkers has been reported with ARBs and ACEIs in obese 
patients with metabolic syndrome [7, 8] and in hypertensive patients with and without type 
2 diabetes mellitus (T2DM) [9, 10]. Similarly, CCBs have been shown to improve markers of 
inflammation in patients with hypertension [11, 12], while -blockers such as nebivolol were 
shown to modify markers of inflammation and obesity in obese African Americans with 
hypertension [13]. As a class, ARBs are known to have anti-inflammatory properties, which 
may contribute to their pharmacologic effects. Biomarker studies in hypertensive patients 
have demonstrated the effects of ARBs on inflammatory and other biomarkers [7, 14], 
including CAP [15, 16], hsCRP [14, 17-19], adiponectin [20], cystatin [21, 22], HOMA-IR [23-
25], procollagen [26-28], TNF-α [29-31], and IL-6 [32-34]. 
This chapter summarizes the role of biomarkers as surrogate endpoints in the treatment of 
hypertensive patients and discusses the evidence for the effects of ARBs and other 
antihypertensive drugs on biomarkers and their correlation with clinical efficacy. The source 
material for this review was derived from a MEDLINE literature search, performed from 
1999 to 2011, to identify published studies investigating the use of selective antihypertensive 
agents using at least one of the eight previously mentioned biomarkers. The agents specified 
in the search were amlodipine, olmesartan medoxomil, combination amlodipine plus 
olmesartan medoxomil, losartan, hydrochlorothiazide (HCTZ), and combination losartan 
plus HCTZ. 
2. A review of anti-hypertensive drugs 
Hypertension is a strong contributor to cardiovascular disease in patients with the 
cardiometabolic syndrome. It has been shown to not only be an independent risk factor, but 
it also contributes to the development of other risk factors for cardiovascular disease. Over 
the last few decades, a number of classes of anti-hypertensive drugs have been used to treat 
hypertension, with the ultimate goal of reducing the incidence of endpoints such as heart 
attacks and stroke. Some of the broad categories of antihypertensives include thiazide 
diuretics, ARBs, ACEIs, CCBs and β-blockers.  
The first step in atherosclerosis is endothelial dysfunction. It has been shown that the RAS is 
involved in the development of atherosclerosis through many different mechanisms 
including increasing oxidative stress, vasoconstriction, inflammation and reduced ability of 
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the endothelium to regenerate itself (reviewed in [35]). The blockage of the RAS through 
ACEIs and ARBs, aids in slowing down the processes of endothelial dysfunction and 
subsequent atherosclerosis. ACEIs reduce angiotensin II production and suppress the 
degradation of bradykinin. This results in reduced oxidative stress, improved vasodilation 
and improved endothelial function [36, 37]. Some common ACEIs include ramipril, 
enalapril, lisinopril, perindopril and fosinopril. The Heart Outcomes Prevention Evaluation 
(HOPE) study evaluated the benefits of ramipril as compared to placebo [38]. Ramipril 
(10mg/day) resulted in a reduction of cardiovascular death (26% RR), nonfatal myocardial 
infarction (MI) (20% RR) and stroke (32% RR). Ramipril was shown to be beneficial in all 
subgroups of patients in the HOPE Study. The Efficacy of Perindopril in Reduction of 
Cardiovascular Events Among Patients with Stable Coronary Artery Disease (EUROPA) 
study, Perindopril Protection Against Recurrent Stroke (PROGRESS) study and the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study 
are some other large, outcome trials which also showed a positive effect of ACEIs on 
cardiovascular events and mortality [39-41]. 
ARBs also block the RAS. This is accomplished through blocking of the angiotensin I 
receptor which leads to an upregulation of the angiotensin II receptor and the conversion of 
of angiotensin II to angiotensin (1-7) which has vasodilatory, antioxidant and pro-apoptotic 
properties [42, 43]. Some common ARBs include losartan, telmisartan, valsartan, olmesartan, 
candesartan and irbesartan. Large outcome trials such as the Renal Outcomes with 
Telmisartan, Ramipril, or Both, in People at High Vascular Risk (ONTARGET) study, and 
the Valsartan in Acute Myocardial Infarction (VALIANT) study have shown that ARBs are 
comparable to ACEIs in reducing cardiovascular risk, without the side effect of excess 
coughing that is frequently experienced by patients who are taking ACEIs [44] [45]. 
Combination of ARBs with β-blockers or statins have also shown positive results [46, 47]. 
CCBs are another class of antihypertensives which provide similar blood pressure lowering 
effects of ACEIs and ARBs, but they provide better protection against stroke and heart 
failure [48]. CCBs inhibit the flow of extracellular calcium through ion-specific channels that 
span the cell wall. This causes vascular smooth muscle cells to relax and thereby results in 
vasodilation, blood pressure lowering and reduced peripheral arterial resistance. 
Commonly prescribed CCBs include amlodipine, benidipine, azelnidipine and manidipine.  
β-blockers are another group of antihypertensives which are divided into two main 
categories. Traditional (non-vasodilatory) β-blockers such as atenolol, metropolol and 
propanolol reduce blood pressure by reducing cardiac output [49]. These β-blockers are 
effective at lowering brachial blood pressure, however data from studies including the 
Conduit Artery Function Evaluation (CAFÉ) study suggests that these compounds do not 
adequately control central aortic pressure [50]. This can then lead to an increase in vascular 
events including stroke [51]. Additionally, these agents have been shown to increase plasma 
triglyceride levels [52] and the risk of new-onset diabetes by about 20-30% [53, 54]. The other 
group of β-blockers are the vasodilatory β-blockers which includes labetalol, carvediol and 
nebivolol. These drugs reduce systemic vascular resistance while maintaining cardiac 
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subgroups of patients in the HOPE Study. The Efficacy of Perindopril in Reduction of 
Cardiovascular Events Among Patients with Stable Coronary Artery Disease (EUROPA) 
study, Perindopril Protection Against Recurrent Stroke (PROGRESS) study and the Anglo-
Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study 
are some other large, outcome trials which also showed a positive effect of ACEIs on 
cardiovascular events and mortality [39-41]. 
ARBs also block the RAS. This is accomplished through blocking of the angiotensin I 
receptor which leads to an upregulation of the angiotensin II receptor and the conversion of 
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CCBs are another class of antihypertensives which provide similar blood pressure lowering 
effects of ACEIs and ARBs, but they provide better protection against stroke and heart 
failure [48]. CCBs inhibit the flow of extracellular calcium through ion-specific channels that 
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output. Additionally, these agents do not negatively affect glycemic control and may even 
provide beneficial metabolic effects [55-57]. 
Diuretics include HCTZ , chlorthalidone and the loop diuretics such as furosemide. 
According to the Joint National Committee on Prevention, Detection, Evaluation , and 
Treatment of High Blood Pressure (JNC 7) guidelines, diuretics are recommended as the 
first line of therapy for hypertension [58]. Chlorothalidone is more potent at 25mg dosing 
than 50mg of HCTZ. Also, chlorothalidone has been shown to improve cardiovascular 
outcomes [59]. Certain subpopulations, including diabetics, the elderly and blacks have 
lower renin levels and they respond favorably to diuretic therapy [60]. Diuretics, 
particularly HCTZ, are often combined with antihypertensives from another class, such as 
ARBs and ACEIs, to provide enhanced therapeutic benefits [61]. 
The newest category of anytihypertensives include direct renin inhibitors (DRIs). Aliskiren 
is the most common DRI. This class of drugs works by inhibiting the first rate-limiting step 
in the RAS, resulting in a more complete inhibition of the RAS cascade as compared to 
ACEIs and ARBs [62]. Additionally, DRIs reduce the production of aldosterone, which in 
addition to its sodium retension effects, also is a mediator in oxidative stress and 
inflammation [63] [64]. The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) 
study and the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial show that 
aliskiren has renal and cardio protective effects in addition to blood pressure regulation [65, 
66]. 
3. Role of biomarkers and mechanisms in specific patient groups 
3.1. CAP 
While brachial BP is easily measured and has been shown to be predictive of CV morbidity 
and mortality, it is an imperfect surrogate measure of CAP. Peripheral systolic BP (SBP) 
measured at the brachial artery does not accurately reflect CAP, particularly in youths, as a 
result of peripheral amplification of the pulse pressure wave [67-69]. This amplification 
difference decreases with age and arterial stiffness. Central aortic systolic pressure or pulse 
pressure has been shown to be a powerful and more robust predictor of end organ damage 
and CV mortality than brachial BP, irrespective of whether the central pressures were 
derived from noninvasive pulse wave analysis or measured directly during routine 
catheterization [68]. Although techniques have been developed to a stage where direct 
noninvasive measurement of CAP could be readily applied to routine clinical practice, the 
studies conducted to-date, assessing the predictive value of CAP, have been relatively small. 
Thus, additional data from large interventional studies of clinical outcomes and larger-scale 
longitudinal epidemiological studies of clinical outcomes are required to confirm the utility 
of CAP as a predictor of vascular risk before it becomes part of routine clinical practice [67-
69]. 
Noninvasive assessment of the central pulse pressure waveform is performed by 
applanation tonometry, which involves applying a pressure sensor (tonometer) with mild 
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pressure over the radial or carotid artery. The recorded waveform is then used to 
algorithmically derive central pressure indices from a peripheral brachial BP measurement 
[69]. In addition, aortic pulse wave velocity (PWV), which is usually recorded between the 
carotid and femoral arteries, is used to determine vessel distensibility; the velocity of the 
pulse wave increases with decreasing vessel distensibility (increased arterial stiffness) [67]. 
Increased PWV, an indication of arterial stiffness, appears to be associated with endothelial 
dysfunction, inflammation, and atherosclerosis, and has been shown to be an independent 
predictor of coronary events and CV mortality [67]. Hence, arterial stiffness is an emerging 
biomarker for therapeutic interventions. 
3.2. hsCRP 
C-reactive protein (CRP), an acute phase reactant predominantly produced in the liver in 
response to IL-6, interleukin-1β, and TNF-α, is a marker of the general inflammatory 
response. Current technology permits the quantification of CRP through a high-sensitivity  
assay, therefore this marker is referred to as hsCRP. Epidemiological studies have 
established that individuals with higher levels of hsCRP have increased CV risk [70]. The 
nature of the relationship between hsCRP and CV disease is unclear, but hsCRP provides a 
useful measure of risk and the effects of interventions [70, 71].  
Studies have shown a continuous independent association between serum CRP levels and 
elevated BP [72]. In elderly, normotensive individuals, higher baseline CRP levels were 
associated with a higher incidence of new-onset hypertension after 2 years [73]. Moreover, 
in apparently healthy adults representative of the US population, a 10-mmHg increase in 
pulse pressure was associated with significant increases of 12%–15% in the odds of having 
an elevated CRP level, independent of SBP or diastolic BP (DBP), or demographic factors 
[74]. There are even suggestions that hsCRP may be a better marker of coronary artery 
disease (CAD) than low-density lipoprotein cholesterol (LDL-C) [2, 75]. Evidence suggests 
that inhibition of the RAS with certain agents, particularly ARBs and ACEIs, may improve 
CV outcomes by reducing vascular inflammation and remodeling independently of BP 
reductions [76]. 
3.3. Adiponectin 
Adiponectin is one of the adipocyte-derived hormones that has profound anti-inflammatory 
and anti-atherogenic properties. It is also thought to play an important role in the 
modulation of glucose and lipid metabolism [2, 77]. Reduced adiponectin levels have been 
noted in males, obese subjects, and patients with hypertension, CAD, or T2DM [78]. 
Reduced adiponectin levels are predictive of CAD and MI [79]. Animal studies have shown 
that increased adiponectin levels are protective against atherosclerosis, while clinical studies 
with antihypertensive drugs, including ARBs, ACEIs, and CCBs, have associated 
improvements in BP and insulin resistance with increased adiponectin levels [78, 80]. In 
obese subjects, serum adiponectin levels were inversely associated with intima-media 
thickness, a surrogate measure of subclinical atherosclerosis, and positively associated with 
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arterial compliance [79]. The mechanism behind the beneficial effects of adiponectin is 
uncertain; one hypothesis suggests that adiponectin increases nitric oxide activity, thereby 
inhibiting platelet activation, while another hypothesis suggests it suppresses monocyte 
activation [78].  
3.4. Cystatin C 
The serum cystatin C level directly correlates with the glomerular filtration rate (GFR) and is 
produced constantly, independent of muscle mass, age, or sex. It is therefore an easily 
obtained biomarker for renal dysfunction that may be more reliable than measurement of 
creatinine levels in certain patient populations, particularly in children  [81-83]. However, 
there are concerns over the cost of the immunoassay, intraindividual variability, and its 
sensitivity in transplant patients or its suitability in patients with cancer, where cystatin C 
production may vary [82]. Notably, a study in patients after heart transplantation found that 
cystatin C was superior to creatinine as a prognostic indicator of early renal dysfunction 
during 4 years of follow-up [84]. 
Cystatin C is a predictor of CV morbidity and mortality, and it has been suggested that this 
association may be independent of renal function [85, 86]. In one study, cystatin C, but not 
creatinine or GFR, was closely associated with left ventricular (LV) mass in patients with 
hypertension, suggesting utility as a marker for cardiac hypertrophy [86]. 
3.5. HOMA-IR 
HOMA-IR is a mathematical model prediction that provides an accurate quantitative 
assessment of insulin resistance [87], which is associated with hypertension, obesity, and 
diabetes, and an increased risk of CAD [88]. 
Many CV drugs adversely affect glucose and lipid homeostasis, and insulin resistance is an 
important mediator of these adverse effects on glucose metabolism [88]. Direct RAS 
inhibitors (ARBs and ACEIs) and some other antihypertensives provide beneficial effects in 
terms of glucose homeostasis [88]. 
3.6. Procollagen 
Collagen fractions in the extracellular matrix are intimately involved in the atherosclerotic 
process and the vascular remodeling that occurs in CV disease [89]. There is evidence that 
altered collagen metabolism (eg, elevated serum levels of tissue inhibitor of 
metalloproteinase-1) is associated with hypertension [89], and that plasma markers of 
collagen metabolism are positively correlated with arterial stiffness measured by PWV in 
hypertensive patients with LV hypertrophy [90]. 
Therefore, measurement of serum procollagen fractions as indicators of myocardial fibrosis 
may be useful in the clinical assessment of CV risk [91]. 
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3.7. TNF- 
TNF-α is a marker of inflammation and is believed to promote the development of insulin 
resistance and hyperinsulinemia, and thereby affect BP [29]. TNF-α is released from mast 
cells and macrophages in the myocardial endothelium during acute MI, and from 
cardiomyocytes during persistent ischemia. The released TNF-α contributes to ischemic 
and/or reperfusion injury and is believed to contribute to cardiac contractile dysfunction 
after MI via a local inflammatory reaction [31]. Surprisingly, low levels of TNF-α may be 
beneficial and display a cardioprotective effect, reducing infarct size [31]. TNF-α is also 
believed to play a role in the development of atherosclerosis by up-regulating cell surface 
receptors for advanced glycation end products that promote the release of inflammatory 
mediators in the endothelium [30]. The differential effects are possibly related to which of 
the two tumor necrosis receptor types (TNF-R1 or TNF-R2) the TNF-α molecule interacts. 
3.8. IL-6 
IL-6 is an inflammatory cytokine that, along with TNF-α, is one of the main inducers of 
acute phase reactants, such as CRP. It has been positively correlated with CV risk. For 
instance, in elderly subjects without known CV disease, serum levels of IL-6 were 
significantly associated with CAD, stroke, and congestive heart failure events, and to a 
greater extent than CRP or TNF-α levels [92]. Similarly, in older men without CAD, IL-6 was 
found to be more discriminating than CRP and fibrinogen in predicting a first coronary 
artery ischemic event, being associated with MI/coronary death but not CAD endpoints 
(angina) [33]. However, not all studies have found strong correlations between IL-6 and 
CAD [34]. 
4. Antihypertensive drugs: benefits beyond just blood pressure lowering 
Clinical evidence that many current antihypertensive agents have a beneficial effect on 
putative biomarkers of CV pathology or risk continues to accumulate and indicates that not 
all drugs or patient subpopulations are equal.  
4.1. CAP 
Of the various antihypertensive drug classes, RAS inhibitors (ARBs and ACEIs) and CCBs 
generally appear to have greater effects on CAP than -blockers and thiazide diuretics. 
Despite similar brachial BP reductions, the combination of amlodipine plus perindopril was 
associated with greater reductions in CAP than atenolol plus a thiazide diuretic [93]. 
Lisinopril also significantly reduced central SBP, central pulse pressure, and the 
augmentation index, while bisoprolol only significantly lowered central DBP and actually 
increased the augmentation index [94]. The combination of olmesartan and azelnidipine was 
compared to olmesartan and amlodipine [95]. While both combinations had similar brachial 
BP lowering effects, there was a greater reduction in CAP with the olmesartan/azelnidipine 
combination. Another study showed significant reductions in both brachial and central BP 
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arterial compliance [79]. The mechanism behind the beneficial effects of adiponectin is 
uncertain; one hypothesis suggests that adiponectin increases nitric oxide activity, thereby 
inhibiting platelet activation, while another hypothesis suggests it suppresses monocyte 
activation [78].  
3.4. Cystatin C 
The serum cystatin C level directly correlates with the glomerular filtration rate (GFR) and is 
produced constantly, independent of muscle mass, age, or sex. It is therefore an easily 
obtained biomarker for renal dysfunction that may be more reliable than measurement of 
creatinine levels in certain patient populations, particularly in children  [81-83]. However, 
there are concerns over the cost of the immunoassay, intraindividual variability, and its 
sensitivity in transplant patients or its suitability in patients with cancer, where cystatin C 
production may vary [82]. Notably, a study in patients after heart transplantation found that 
cystatin C was superior to creatinine as a prognostic indicator of early renal dysfunction 
during 4 years of follow-up [84]. 
Cystatin C is a predictor of CV morbidity and mortality, and it has been suggested that this 
association may be independent of renal function [85, 86]. In one study, cystatin C, but not 
creatinine or GFR, was closely associated with left ventricular (LV) mass in patients with 
hypertension, suggesting utility as a marker for cardiac hypertrophy [86]. 
3.5. HOMA-IR 
HOMA-IR is a mathematical model prediction that provides an accurate quantitative 
assessment of insulin resistance [87], which is associated with hypertension, obesity, and 
diabetes, and an increased risk of CAD [88]. 
Many CV drugs adversely affect glucose and lipid homeostasis, and insulin resistance is an 
important mediator of these adverse effects on glucose metabolism [88]. Direct RAS 
inhibitors (ARBs and ACEIs) and some other antihypertensives provide beneficial effects in 
terms of glucose homeostasis [88]. 
3.6. Procollagen 
Collagen fractions in the extracellular matrix are intimately involved in the atherosclerotic 
process and the vascular remodeling that occurs in CV disease [89]. There is evidence that 
altered collagen metabolism (eg, elevated serum levels of tissue inhibitor of 
metalloproteinase-1) is associated with hypertension [89], and that plasma markers of 
collagen metabolism are positively correlated with arterial stiffness measured by PWV in 
hypertensive patients with LV hypertrophy [90]. 
Therefore, measurement of serum procollagen fractions as indicators of myocardial fibrosis 
may be useful in the clinical assessment of CV risk [91]. 
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3.7. TNF- 
TNF-α is a marker of inflammation and is believed to promote the development of insulin 
resistance and hyperinsulinemia, and thereby affect BP [29]. TNF-α is released from mast 
cells and macrophages in the myocardial endothelium during acute MI, and from 
cardiomyocytes during persistent ischemia. The released TNF-α contributes to ischemic 
and/or reperfusion injury and is believed to contribute to cardiac contractile dysfunction 
after MI via a local inflammatory reaction [31]. Surprisingly, low levels of TNF-α may be 
beneficial and display a cardioprotective effect, reducing infarct size [31]. TNF-α is also 
believed to play a role in the development of atherosclerosis by up-regulating cell surface 
receptors for advanced glycation end products that promote the release of inflammatory 
mediators in the endothelium [30]. The differential effects are possibly related to which of 
the two tumor necrosis receptor types (TNF-R1 or TNF-R2) the TNF-α molecule interacts. 
3.8. IL-6 
IL-6 is an inflammatory cytokine that, along with TNF-α, is one of the main inducers of 
acute phase reactants, such as CRP. It has been positively correlated with CV risk. For 
instance, in elderly subjects without known CV disease, serum levels of IL-6 were 
significantly associated with CAD, stroke, and congestive heart failure events, and to a 
greater extent than CRP or TNF-α levels [92]. Similarly, in older men without CAD, IL-6 was 
found to be more discriminating than CRP and fibrinogen in predicting a first coronary 
artery ischemic event, being associated with MI/coronary death but not CAD endpoints 
(angina) [33]. However, not all studies have found strong correlations between IL-6 and 
CAD [34]. 
4. Antihypertensive drugs: benefits beyond just blood pressure lowering 
Clinical evidence that many current antihypertensive agents have a beneficial effect on 
putative biomarkers of CV pathology or risk continues to accumulate and indicates that not 
all drugs or patient subpopulations are equal.  
4.1. CAP 
Of the various antihypertensive drug classes, RAS inhibitors (ARBs and ACEIs) and CCBs 
generally appear to have greater effects on CAP than -blockers and thiazide diuretics. 
Despite similar brachial BP reductions, the combination of amlodipine plus perindopril was 
associated with greater reductions in CAP than atenolol plus a thiazide diuretic [93]. 
Lisinopril also significantly reduced central SBP, central pulse pressure, and the 
augmentation index, while bisoprolol only significantly lowered central DBP and actually 
increased the augmentation index [94]. The combination of olmesartan and azelnidipine was 
compared to olmesartan and amlodipine [95]. While both combinations had similar brachial 
BP lowering effects, there was a greater reduction in CAP with the olmesartan/azelnidipine 
combination. Another study showed significant reductions in both brachial and central BP 
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reductions with different drug classes in the following order: CCBs > diuretics (HCTZ) > 
ACEIs [96]. -blockers did not significantly lower peripheral or central BP.  
Similar brachial BP and CAP reductions were achieved with valsartan plus HCTZ versus 
amlodipine; however, valsartan plus HCTZ provided a greater reduction in arterial stiffness 
(estimated by aortic PWV) [97]. Reductions in central SBP were greater with fosinopril plus 
HCTZ than with indapamide or amlodipine; this correlated with 24-hour and nighttime SBP 
reductions, but not with seated cuff SBP [98].  
Recent studies have shown that PWV is significantly reduced with candesartan or 
benidipine treatment, as compared to amlodipine [99, 100]. Arterial stiffness, measured 
through cardioankle vascular index was significantly decreased with combination of 
olmesartan and azelnidipine, but not with olmesartan monotheraphy [101]. However, 
arterial index decreased significantly with monotheraphy and combination therapy in this 
study. On the other hand, another recent study showed that monotheraphy with olmesartan 
does significantly decrease arterial stiffness [102]. 
The effects of antihypertensives on flow mediated dilation (FMD) has also been measured. 
Olmesartan has been shown to positively impact FMD and while amlodipine treatment has 
no effect on FMD [103], the combination of amlodipine and atorvastatin has significant 
improvements on this marker, even more than atorvastatin alone [104]. Another study 
found the same effects of amlodipine and atorvastatin combination on patients with 
hypertension and hyperglycemia [105]. The combination of amlodipine and valsartan was 
also found to improve FMD in diabetics with early hypertension, even more than the effects 
of the individual drugs [106]. 
4.2. hsCRP 
Several antihypertensive drug classes, such as ARBs, ACEIs, and CCBs, lower serum 
hsCRP in addition to BP, indicating a reduction in the inflammatory processes involved in 
the progression of atherosclerosis. ARBs, in particular, seem to have a strong depressor 
effect on this marker of inflammation. Patients with chronic kidney disease (CKD), who 
have higher baseline levels of inflammation than control subjects with normal renal 
function, displayed significant reductions in hsCRP and brachial BP with olmesartan 
medoxomil treatment [107]. In a small study of 10 patients with mild-to-moderate 
hypertension, olmesartan medoxomil did not reduce BP significantly, but did produce 
significant reductions in hsCRP and appeared to improve myocardial function 
independent of BP lowering [19]. In another study, hsCRP levels significantly dropped in 
hypertensive patients who were treated with olmesartan for 6 month [102]. In non-
diabetic patients with hypertension and the metabolic syndrome, both olmesartan 
medoxomil plus amlodipine and olmesartan medoxomil plus HCTZ effectively reduced 
BP and CRP with no differences between groups. However, olmesartan plus amlodipine 
produced greater reductions in all other inflammatory markers [108]. Olmesartan 
treatment was compared to candesartan treatment in hypertensive patients with T2DM 
[109]. BP and hsCRP reductions were similar in both treatment groups. In a separate 
 
The Effects of Antihypertensive Agents in Metabolic Syndrome – Benefits Beyond Blood Pressure Control 245 
study, these researchers also found that monotherapy with either losartan or ramapril is 
equally beneficial in lowering hsCRP [109]. 
In a study comparing the CCB azelnidipine or the thiazide diuretic trichlormethiazide 
added to an ARB, the ARB plus azelnidipine combination produced significantly greater 
reductions in hsCRP than the ARB plus thiazide combination; this reduction mirrored the 
BP-lowering effects [110]. Similar data were shown in a 4-month crossover study comparing 
olmesartan medoxomil plus azelnidipine or trichlormethiazide [111]. Azelnidipine was 
shown to be superior to amlodipine with regards to hsCRP lowering in nondiabetic 
hypertensive patients and the beneficial effects of azelnidipine also included improved 
glucose tolerance and insulin sensitivity [112]. When combined with atorvastatin, 
amlodipine therapy reduces plasma hsCRP significantly [104]. In the recent Effects of 
Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and 
Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with 
Metabolic Syndrome: the MARCADO Study, a number of monotherapies (manidipine, 
amlodipine, teimisartan) and combination therapy (manidipine/lisionpril) were compared 
for treatment of non-diabetic, hypertensive patients with the metabolic syndrome. Levels of 
hsCRP reduced with all of these treatments, but the most significant reduction was with the 
manidipine/lisinopril combination therapy [113]. Comparison of 12 weeks of combination 
therapy with enalapril plus add-on losartan with higher dose enalapril monotherapy 
showed a significant reduction in hsCRP with combination therapy, but not with high-dose 
enalapril alone; BP reductions were significant and similar in both groups [114]. In another 
study, patients who were on olmesartan therapy received additional HCTZ or azelnidipine 
therapy for 24 weeks. HsCRP levels dropped significantly with the azelnidipine add-on 
therapy but there was no change with HCTZ therapy [115].  
Evidence suggests that ARBs may differ in their anti-inflammatory effects. For instance, in 
patients with CAD, olmesartan medoxomil and valsartan both produced significant 
reductions in BP, but only olmesartan medoxomil induced a significant reduction in hsCRP 
[116]. Losartan has also been shown to reduce hsCRP in newly diagnosed hypertensive 
patients who are at CV disease risk [117]. Studies comparing the hsCRP-lowering effects of 
ARBs and CCBs have shown variable results. One study found no difference in hsCRP 
reductions after 8 weeks of therapy with losartan or amlodipine regimens [118]. The effects 
on hsCRP and other inflammatory markers did not explain the greater improvements in 
insulin sensitivity seen with ARBs over CCBs. However, in patients with hypertension and 
other CV risk factors, therapy with valsartan plus HCTZ was significantly more effective 
than amlodipine in reducing hsCRP. These biomarker results correlated with BP reductions 
[119]. HsCRP improvement did not correlate with endothelial function in a study comparing 
candesartan with amlodipine; both treatments significantly improved endothelial function 
(assessed by changes in forearm blood flow in reactive hyperemia), whereas significant 
reductions in hsCRP levels were seen only with candesartan and not amlodipine therapy 
[120]. The study investigators concluded that the anti-inflammatory effects observed with 
candesartan may be related to observed improvement in insulin sensitivity. In a study of 
patients with CAD, treatment with irbesartan did not lower hsCRP levels. [121] The lack of 
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reductions with different drug classes in the following order: CCBs > diuretics (HCTZ) > 
ACEIs [96]. -blockers did not significantly lower peripheral or central BP.  
Similar brachial BP and CAP reductions were achieved with valsartan plus HCTZ versus 
amlodipine; however, valsartan plus HCTZ provided a greater reduction in arterial stiffness 
(estimated by aortic PWV) [97]. Reductions in central SBP were greater with fosinopril plus 
HCTZ than with indapamide or amlodipine; this correlated with 24-hour and nighttime SBP 
reductions, but not with seated cuff SBP [98].  
Recent studies have shown that PWV is significantly reduced with candesartan or 
benidipine treatment, as compared to amlodipine [99, 100]. Arterial stiffness, measured 
through cardioankle vascular index was significantly decreased with combination of 
olmesartan and azelnidipine, but not with olmesartan monotheraphy [101]. However, 
arterial index decreased significantly with monotheraphy and combination therapy in this 
study. On the other hand, another recent study showed that monotheraphy with olmesartan 
does significantly decrease arterial stiffness [102]. 
The effects of antihypertensives on flow mediated dilation (FMD) has also been measured. 
Olmesartan has been shown to positively impact FMD and while amlodipine treatment has 
no effect on FMD [103], the combination of amlodipine and atorvastatin has significant 
improvements on this marker, even more than atorvastatin alone [104]. Another study 
found the same effects of amlodipine and atorvastatin combination on patients with 
hypertension and hyperglycemia [105]. The combination of amlodipine and valsartan was 
also found to improve FMD in diabetics with early hypertension, even more than the effects 
of the individual drugs [106]. 
4.2. hsCRP 
Several antihypertensive drug classes, such as ARBs, ACEIs, and CCBs, lower serum 
hsCRP in addition to BP, indicating a reduction in the inflammatory processes involved in 
the progression of atherosclerosis. ARBs, in particular, seem to have a strong depressor 
effect on this marker of inflammation. Patients with chronic kidney disease (CKD), who 
have higher baseline levels of inflammation than control subjects with normal renal 
function, displayed significant reductions in hsCRP and brachial BP with olmesartan 
medoxomil treatment [107]. In a small study of 10 patients with mild-to-moderate 
hypertension, olmesartan medoxomil did not reduce BP significantly, but did produce 
significant reductions in hsCRP and appeared to improve myocardial function 
independent of BP lowering [19]. In another study, hsCRP levels significantly dropped in 
hypertensive patients who were treated with olmesartan for 6 month [102]. In non-
diabetic patients with hypertension and the metabolic syndrome, both olmesartan 
medoxomil plus amlodipine and olmesartan medoxomil plus HCTZ effectively reduced 
BP and CRP with no differences between groups. However, olmesartan plus amlodipine 
produced greater reductions in all other inflammatory markers [108]. Olmesartan 
treatment was compared to candesartan treatment in hypertensive patients with T2DM 
[109]. BP and hsCRP reductions were similar in both treatment groups. In a separate 
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study, these researchers also found that monotherapy with either losartan or ramapril is 
equally beneficial in lowering hsCRP [109]. 
In a study comparing the CCB azelnidipine or the thiazide diuretic trichlormethiazide 
added to an ARB, the ARB plus azelnidipine combination produced significantly greater 
reductions in hsCRP than the ARB plus thiazide combination; this reduction mirrored the 
BP-lowering effects [110]. Similar data were shown in a 4-month crossover study comparing 
olmesartan medoxomil plus azelnidipine or trichlormethiazide [111]. Azelnidipine was 
shown to be superior to amlodipine with regards to hsCRP lowering in nondiabetic 
hypertensive patients and the beneficial effects of azelnidipine also included improved 
glucose tolerance and insulin sensitivity [112]. When combined with atorvastatin, 
amlodipine therapy reduces plasma hsCRP significantly [104]. In the recent Effects of 
Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and 
Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with 
Metabolic Syndrome: the MARCADO Study, a number of monotherapies (manidipine, 
amlodipine, teimisartan) and combination therapy (manidipine/lisionpril) were compared 
for treatment of non-diabetic, hypertensive patients with the metabolic syndrome. Levels of 
hsCRP reduced with all of these treatments, but the most significant reduction was with the 
manidipine/lisinopril combination therapy [113]. Comparison of 12 weeks of combination 
therapy with enalapril plus add-on losartan with higher dose enalapril monotherapy 
showed a significant reduction in hsCRP with combination therapy, but not with high-dose 
enalapril alone; BP reductions were significant and similar in both groups [114]. In another 
study, patients who were on olmesartan therapy received additional HCTZ or azelnidipine 
therapy for 24 weeks. HsCRP levels dropped significantly with the azelnidipine add-on 
therapy but there was no change with HCTZ therapy [115].  
Evidence suggests that ARBs may differ in their anti-inflammatory effects. For instance, in 
patients with CAD, olmesartan medoxomil and valsartan both produced significant 
reductions in BP, but only olmesartan medoxomil induced a significant reduction in hsCRP 
[116]. Losartan has also been shown to reduce hsCRP in newly diagnosed hypertensive 
patients who are at CV disease risk [117]. Studies comparing the hsCRP-lowering effects of 
ARBs and CCBs have shown variable results. One study found no difference in hsCRP 
reductions after 8 weeks of therapy with losartan or amlodipine regimens [118]. The effects 
on hsCRP and other inflammatory markers did not explain the greater improvements in 
insulin sensitivity seen with ARBs over CCBs. However, in patients with hypertension and 
other CV risk factors, therapy with valsartan plus HCTZ was significantly more effective 
than amlodipine in reducing hsCRP. These biomarker results correlated with BP reductions 
[119]. HsCRP improvement did not correlate with endothelial function in a study comparing 
candesartan with amlodipine; both treatments significantly improved endothelial function 
(assessed by changes in forearm blood flow in reactive hyperemia), whereas significant 
reductions in hsCRP levels were seen only with candesartan and not amlodipine therapy 
[120]. The study investigators concluded that the anti-inflammatory effects observed with 
candesartan may be related to observed improvement in insulin sensitivity. In a study of 
patients with CAD, treatment with irbesartan did not lower hsCRP levels. [121] The lack of 
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effect of irbesartan may have been due to low levels of hsCRP at study baseline. Patients 
were also receiving statin and aspirin therapy, which also lower levels of this marker. In a 
recent study, olmesartan reduced hsCRP levels in patients with essential hypertension while 
amlodipine had no effects on hsCRP [103]. 
As with ARBs, CCBs seem to differ in their ability to reduce inflammatory markers. In 
hypertensive patients with the metabolic syndrome, similar significant reductions in hsCRP 
and BP were seen with manidipine and amlodipine, but these data did not correlate with 
changes in other biomarkers, such as adiponectin, HOMA-IR, and TNF-α, which showed 
greater improvements with manidipine than with amlodipine [122]. In a different study in 
patients with arterial hypertension and insulin resistance who were already receiving at 
least two antihypertensive agents, neither moxonidine nor amlodipine showed significant 
changes in hsCRP, whereas both treatments resulted in significant BP lowering [123]. 
Adding a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor 
(atorvastatin) to amlodipine therapy produced significantly greater reductions in BP and 
hsCRP than was seen with amlodipine alone [124], but losartan plus simvastatin achieved 
similar reductions in hsCRP compared with losartan or simvastatin alone [47]. BP 
reductions were significantly greater with losartan or losartan plus simvastatin than with 
simvastatin alone. The combination of rosuvastatin and a number of ARBs was studied as 
treatment in adults with the metabolic syndrome [125]. While rosuvastatin and telmisartan 
reduced hsCRP by 44% after 24 weeks of therapy, there was less reduction in hsCRP with 
the combination of rosuvastatin  and irbesartan or rosuvastatin and olmesartan. 
These observations suggest that RAS antagonists such as ARBs and ACEIs have a significant 
anti-inflammatory effect, and there may be variations within these classes. As diseases such 
as diabetes mellitus and atherosclerosis are inflammatory processes, the clinical benefits 
seen with these classes of antihypertensives may be a combination of the suppression of 
inflammation and the reduction of BP. 
4.3. Adiponectin 
Studies assessing the effect of the selected antihypertensive drugs on the serum levels of 
adiponectin are discussed here. Antihypertensive agents do not uniformly influence 
metabolic parameters in patients with hypertension. In a comparison of telmisartan and 
irbesartan in obese, insulin-resistant, hypertensive patients, increases were significantly 
greater with telmisartan, although both treatments resulted in significant increases in 
adiponectin levels [126]. Adiponectin changes correlated inversely with changes in BP for 
telmisartan, but not for irbesartan. The investigators speculate that the differences between 
the two agents may be partly due to partial peroxisome proliferator-activated receptor- 
(PPAR-γ) agonist activity exhibited by telmisartan, although a study by Kintscher et al in 
14,200 patients confirmed that irbesartan also activates PPAR-γ [127]. Despite similar 
reductions in BP, olmesartan medoxomil plus amlodipine produced significant increases in 
adiponectin levels in patients with hypertension and the metabolic syndrome, whereas 
olmesartan medoxomil plus HCTZ did not [108]. The increase in adiponectin correlated 
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with a lower risk for developing T2DM and paralleled reductions (improvements) in 
HOMA-IR index and fasting plasma insulin levels. 
In nondiabetic, proteinuric patients, treatment with losartan plus HCTZ reduced BP, 
proteinuria, and LDL-C, and increased adiponectin, but the change in adiponectin 
correlated with adverse reductions in high-density lipoprotein cholesterol (HDL-C) levels 
[128]. In a crossover study that investigated possible factors to explain improvements in 
insulin sensitivity with ARB therapy compared with CCB therapy in patients with 
hypertension, between group differences were not noted for increases in adiponectin levels 
or reductions in BP after 8 weeks of therapy with losartan or amlodipine [118]. In contrast, 
although both telmisartan and amlodipine increased adiponectin levels in patients with 
hypertension and T2DM, the increases were higher with telmisartan than with amlodipine 
[129]. Both groups showed a similar significant decrease in BP. Similarly, in patients with 
prediabetes, losartan produced greater increases in adiponectin than a CCB, whereas BP 
reduction was similar and significant in both groups [130]. Within CCBs, candesartan, but 
not olmesartan therapy, over the period of a year resulted in increased adiponectin and 
insulin sensitivity in T2DM hypertensive patients, even though BP lowering was similar in 
both treatment groups [109]. When compared to the ACEI ramipril, losartan treatment 
significantly improved adiponectin levels and overall metabolic parameters while ramipril 
had no effect on adiponectin or any other metabolic markers [131]. In obese hypertensive 
patients, telmisartan, but not losartan raised serum adiponectin levels [132].  
ARBs and statins have additive effects on adiponectin. Losartan plus simvastatin or losartan 
alone resulted in significantly greater increases in adiponectin levels from baseline than with 
simvastatin alone [47]. This correlated with BP reductions, which were greater with losartan 
or losartan plus simvastatin than with simvastatin alone. A correlation was also observed 
with LDL reductions, which were greater with simvastatin or simvastatin with losartan 
relative to losartan alone. 
There were no changes in adiponectin levels with the aldosterone blocker spironolactone or 
the CCB amlodipine in patients with diabetic nephropathy or in controls. However, 
spironolactone, but not amlodipine, increased adiponectin in a subgroup of patients with 
poor baseline glycemic control, i.e. glycosylated hemoglobin (HbA1c) ≥8%. A significant 
decrease in SBP, but not DBP, was observed in both treatment groups [133]. This link 
between the renin-angiotensin cascade and aldosterone suggests a possible mechanism by 
which spironolactone provides an increased level of adiponectin in hyperglycemia.  
In a comparison of enalapril, metoprolol, amlodipine, and indapamide, no changes in 
adiponectin level were seen with enalapril, amlodipine, or metoprolol, whereas a reduction 
in adiponectin was seen with indapamide. This reduction in adiponectin with the thiazide-
like diuretic correlated with increased insulin resistance [134]. In a comparison of 
metoprolol, amlodipine, ramipril, doxazosin, and valsartan in hypertensive patients with 
the metabolic syndrome, both ramipril and valsartan resulted in significantly higher 
increases in adiponectin than the other regimens; adiponectin levels inversely correlated 
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effect of irbesartan may have been due to low levels of hsCRP at study baseline. Patients 
were also receiving statin and aspirin therapy, which also lower levels of this marker. In a 
recent study, olmesartan reduced hsCRP levels in patients with essential hypertension while 
amlodipine had no effects on hsCRP [103]. 
As with ARBs, CCBs seem to differ in their ability to reduce inflammatory markers. In 
hypertensive patients with the metabolic syndrome, similar significant reductions in hsCRP 
and BP were seen with manidipine and amlodipine, but these data did not correlate with 
changes in other biomarkers, such as adiponectin, HOMA-IR, and TNF-α, which showed 
greater improvements with manidipine than with amlodipine [122]. In a different study in 
patients with arterial hypertension and insulin resistance who were already receiving at 
least two antihypertensive agents, neither moxonidine nor amlodipine showed significant 
changes in hsCRP, whereas both treatments resulted in significant BP lowering [123]. 
Adding a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor 
(atorvastatin) to amlodipine therapy produced significantly greater reductions in BP and 
hsCRP than was seen with amlodipine alone [124], but losartan plus simvastatin achieved 
similar reductions in hsCRP compared with losartan or simvastatin alone [47]. BP 
reductions were significantly greater with losartan or losartan plus simvastatin than with 
simvastatin alone. The combination of rosuvastatin and a number of ARBs was studied as 
treatment in adults with the metabolic syndrome [125]. While rosuvastatin and telmisartan 
reduced hsCRP by 44% after 24 weeks of therapy, there was less reduction in hsCRP with 
the combination of rosuvastatin  and irbesartan or rosuvastatin and olmesartan. 
These observations suggest that RAS antagonists such as ARBs and ACEIs have a significant 
anti-inflammatory effect, and there may be variations within these classes. As diseases such 
as diabetes mellitus and atherosclerosis are inflammatory processes, the clinical benefits 
seen with these classes of antihypertensives may be a combination of the suppression of 
inflammation and the reduction of BP. 
4.3. Adiponectin 
Studies assessing the effect of the selected antihypertensive drugs on the serum levels of 
adiponectin are discussed here. Antihypertensive agents do not uniformly influence 
metabolic parameters in patients with hypertension. In a comparison of telmisartan and 
irbesartan in obese, insulin-resistant, hypertensive patients, increases were significantly 
greater with telmisartan, although both treatments resulted in significant increases in 
adiponectin levels [126]. Adiponectin changes correlated inversely with changes in BP for 
telmisartan, but not for irbesartan. The investigators speculate that the differences between 
the two agents may be partly due to partial peroxisome proliferator-activated receptor- 
(PPAR-γ) agonist activity exhibited by telmisartan, although a study by Kintscher et al in 
14,200 patients confirmed that irbesartan also activates PPAR-γ [127]. Despite similar 
reductions in BP, olmesartan medoxomil plus amlodipine produced significant increases in 
adiponectin levels in patients with hypertension and the metabolic syndrome, whereas 
olmesartan medoxomil plus HCTZ did not [108]. The increase in adiponectin correlated 
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with a lower risk for developing T2DM and paralleled reductions (improvements) in 
HOMA-IR index and fasting plasma insulin levels. 
In nondiabetic, proteinuric patients, treatment with losartan plus HCTZ reduced BP, 
proteinuria, and LDL-C, and increased adiponectin, but the change in adiponectin 
correlated with adverse reductions in high-density lipoprotein cholesterol (HDL-C) levels 
[128]. In a crossover study that investigated possible factors to explain improvements in 
insulin sensitivity with ARB therapy compared with CCB therapy in patients with 
hypertension, between group differences were not noted for increases in adiponectin levels 
or reductions in BP after 8 weeks of therapy with losartan or amlodipine [118]. In contrast, 
although both telmisartan and amlodipine increased adiponectin levels in patients with 
hypertension and T2DM, the increases were higher with telmisartan than with amlodipine 
[129]. Both groups showed a similar significant decrease in BP. Similarly, in patients with 
prediabetes, losartan produced greater increases in adiponectin than a CCB, whereas BP 
reduction was similar and significant in both groups [130]. Within CCBs, candesartan, but 
not olmesartan therapy, over the period of a year resulted in increased adiponectin and 
insulin sensitivity in T2DM hypertensive patients, even though BP lowering was similar in 
both treatment groups [109]. When compared to the ACEI ramipril, losartan treatment 
significantly improved adiponectin levels and overall metabolic parameters while ramipril 
had no effect on adiponectin or any other metabolic markers [131]. In obese hypertensive 
patients, telmisartan, but not losartan raised serum adiponectin levels [132].  
ARBs and statins have additive effects on adiponectin. Losartan plus simvastatin or losartan 
alone resulted in significantly greater increases in adiponectin levels from baseline than with 
simvastatin alone [47]. This correlated with BP reductions, which were greater with losartan 
or losartan plus simvastatin than with simvastatin alone. A correlation was also observed 
with LDL reductions, which were greater with simvastatin or simvastatin with losartan 
relative to losartan alone. 
There were no changes in adiponectin levels with the aldosterone blocker spironolactone or 
the CCB amlodipine in patients with diabetic nephropathy or in controls. However, 
spironolactone, but not amlodipine, increased adiponectin in a subgroup of patients with 
poor baseline glycemic control, i.e. glycosylated hemoglobin (HbA1c) ≥8%. A significant 
decrease in SBP, but not DBP, was observed in both treatment groups [133]. This link 
between the renin-angiotensin cascade and aldosterone suggests a possible mechanism by 
which spironolactone provides an increased level of adiponectin in hyperglycemia.  
In a comparison of enalapril, metoprolol, amlodipine, and indapamide, no changes in 
adiponectin level were seen with enalapril, amlodipine, or metoprolol, whereas a reduction 
in adiponectin was seen with indapamide. This reduction in adiponectin with the thiazide-
like diuretic correlated with increased insulin resistance [134]. In a comparison of 
metoprolol, amlodipine, ramipril, doxazosin, and valsartan in hypertensive patients with 
the metabolic syndrome, both ramipril and valsartan resulted in significantly higher 
increases in adiponectin than the other regimens; adiponectin levels inversely correlated 
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with SBP [135]. In a study comparing manidipine, amlodipine, telmisartan, and the 
combination therapy of manidipine and lisinopril, adiponectin levels increased with all of 
the treatments except amlodipine. The greatest increase in adiponectin was seen with 
manidipine [113]. The combination of amlodipine and atorvastatin resulted in a greater 
increase in adiponectin than treatment with amlodipine alone [104]. Similar results were 
seen in patients with hypertension and hyperglycemia that were treated with amlodipine 
and atorvastatin [105].  
In a small study in patients with hypertension, ramipril, candesartan, and amlodipine were 
associated with greater increases in adiponectin levels while thiazide and atenolol were 
associated with a decrease in adiponectin. There were no correlations with BP lowering, 
which was greatest with atenolol, amlodipine, and candesartan therapies than with ramipril 
[136].  
Unlike the situation with hypertensive, obese, or diabetic patients, where adiponectin levels 
are reportedly reduced, the levels of adiponectin are raised in patients with renal disease 
when compared with healthy controls. Thus, in patients with renal disease, a positive 
correlation between adiponectin and insulin resistance is seen, and increased adiponectin 
levels are associated with increased all-cause and CV mortality (the opposite of that seen in 
obese patients or those with T2DM without renal disease). Paradoxically, short-term 
losartan therapy in patients with T2DM nephropathy was associated with a significant 
decrease in adiponectin levels compared with amlodipine therapy [137]. 
Adiponectin, secreted by fat cells, regulates the insulin response and has a favorable effect 
on glucose and lipid metabolism. Insulin resistance is a hallmark for the progression of 
vascular disease. The quantitative changes in adiponectin provide insight into how 
antihypertensive agents such as ARBs may be effective in attenuating or reversing the 
pathogenesis of atherosclerosis and diabetes mellitus. 
4.4. Cystatin C 
Only three studies have assessed the effect of the selected antihypertensive drugs on serum 
cystatin C levels. In one study, a significant decrease in cystatin C with olmesartan 
medoxomil therapy correlated with improvements in BP, LV mass index, and LV 
hypertrophy at 6 months [138]. Another study found that cystatin C levels decreased in 
patients who were on olmesartan or olmesartan with HCTZ, but in this study, there was no 
correlation between cyctatin C and BP levels [139]. However, the third study found no 
significant decrease in cystatin C with enalapril/losartan combination therapy or with high-
dose enalapril, despite significant reductions in BP [114].  
The use of cystatin C as an early marker for CKD may be helpful in longitudinal follow-up 
analyses. The findings in the above studies are preliminary but suggest that BP reduction 
may be associated with lower cystatin C levels. It is too early to determine whether 
inhibition of the RAS (in the form of ACEIs or ARBs) may have an effect on cystatin C that is 
superior to other antihypertensive drugs. 
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4.5. HOMA-IR 
HOMA-IR is a model and calculation to determine quantification of insulin resistance. 
Antihypertensive drugs appear to have differing effects on insulin resistance, with ARBs 
foremost among those improving insulin sensitivity, although considerable variability has 
been observed and not all ARBs may be equal in this regard. RAS inhibitors generally have 
greater effects on glucose homeostasis than CCBs, which are usually considered to have 
neutral effects. 
In hypertensive patients, a significantly greater reduction in HOMA-IR was seen with 
losartan/amlodipine therapy than with high-dose amlodipine [118]. The addition of losartan 
therapy to chronic heart failure patients who were on ACEIs resulted in a reduction of 
HOMA-IR as well as inflammatory cytokines after 24 weeks of therapy [140]. The 
MARCADOR Study compared the effects of manidipine, amlodipine, telmisartan, and 
manidipine combined with lisinopril. While BP lowering was similar with all of these 
treatments, HOMA-IR levels improved in all of the treatments except for amlodipine, and 
the greatest change in HOMA-IR was seen with manidipine treatment [113]. In contrast to 
previous results, both losartan and telmisartan had neutral effects on insulin resistance in 42 
hypertensive patients with the metabolic syndrome, with no significant reductions in 
HOMA-IR in either group; BP reductions were similar for both ARBs [141]. In a more recent 
study, obese hypertensive patients were treated with telmisartan or olmesartan. While 
olmesartan improved BP levels, only telmisartan improved insulin glucose and HOMA-IR 
levels in addition to improving BP levels [25]. Others have also shown that telmisartan 
therapy helps to reduce HOMA-IR levels as compared to other ARBs and CCBs [132, 142]. 
Researchers studied the effects of irbesartan as compared to olmesartan in obese 
hypertensive females and found that while both treatments improved BP and lipid levels, 
only olmesartan resulted in HOMA-IR changes [143]. Olmesartan was also found to reduce 
HOMA-IR in hypertensive patients with sleep disordered breathing. Positive changes in BP 
level and left ventricular ejection fraction were also seen in these patients with olmesartan 
treatment [144].  
Non-diabetic CKD patients have a high prevalence of insulin resistance, metabolic 
syndrome, and chronic inflammation. Treatment with olmesartan medoxomil for 16 weeks 
was associated with a significant reduction in HOMA-IR, along with reductions in markers 
of inflammation [107]. Losartan therapy was associated with improvements in fasting 
plasma insulin and HOMA-IR in patients with T2DM nephropathy, in parallel with 
reductions in adiponectin levels [137]. Both olmesartan medoxomil and telmisartan were 
shown to improve HOMA-IR in patients with nonalcoholic fatty liver disease and chronic 
hepatitis C, conditions with a greater incidence of insulin resistance than other liver diseases 
[145]. 
In a study investigating the effect of combination therapy with amlodipine plus olmesartan 
medoxomil on HOMA-IR in hypertensive patients with the metabolic syndrome, HOMA-IR 
was significantly reduced with olmesartan medoxomil/amlodipine, whereas no significant 
changes were seen with olmesartan medoxomil/HCTZ. The reductions in the HOMA-IR 
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with SBP [135]. In a study comparing manidipine, amlodipine, telmisartan, and the 
combination therapy of manidipine and lisinopril, adiponectin levels increased with all of 
the treatments except amlodipine. The greatest increase in adiponectin was seen with 
manidipine [113]. The combination of amlodipine and atorvastatin resulted in a greater 
increase in adiponectin than treatment with amlodipine alone [104]. Similar results were 
seen in patients with hypertension and hyperglycemia that were treated with amlodipine 
and atorvastatin [105].  
In a small study in patients with hypertension, ramipril, candesartan, and amlodipine were 
associated with greater increases in adiponectin levels while thiazide and atenolol were 
associated with a decrease in adiponectin. There were no correlations with BP lowering, 
which was greatest with atenolol, amlodipine, and candesartan therapies than with ramipril 
[136].  
Unlike the situation with hypertensive, obese, or diabetic patients, where adiponectin levels 
are reportedly reduced, the levels of adiponectin are raised in patients with renal disease 
when compared with healthy controls. Thus, in patients with renal disease, a positive 
correlation between adiponectin and insulin resistance is seen, and increased adiponectin 
levels are associated with increased all-cause and CV mortality (the opposite of that seen in 
obese patients or those with T2DM without renal disease). Paradoxically, short-term 
losartan therapy in patients with T2DM nephropathy was associated with a significant 
decrease in adiponectin levels compared with amlodipine therapy [137]. 
Adiponectin, secreted by fat cells, regulates the insulin response and has a favorable effect 
on glucose and lipid metabolism. Insulin resistance is a hallmark for the progression of 
vascular disease. The quantitative changes in adiponectin provide insight into how 
antihypertensive agents such as ARBs may be effective in attenuating or reversing the 
pathogenesis of atherosclerosis and diabetes mellitus. 
4.4. Cystatin C 
Only three studies have assessed the effect of the selected antihypertensive drugs on serum 
cystatin C levels. In one study, a significant decrease in cystatin C with olmesartan 
medoxomil therapy correlated with improvements in BP, LV mass index, and LV 
hypertrophy at 6 months [138]. Another study found that cystatin C levels decreased in 
patients who were on olmesartan or olmesartan with HCTZ, but in this study, there was no 
correlation between cyctatin C and BP levels [139]. However, the third study found no 
significant decrease in cystatin C with enalapril/losartan combination therapy or with high-
dose enalapril, despite significant reductions in BP [114].  
The use of cystatin C as an early marker for CKD may be helpful in longitudinal follow-up 
analyses. The findings in the above studies are preliminary but suggest that BP reduction 
may be associated with lower cystatin C levels. It is too early to determine whether 
inhibition of the RAS (in the form of ACEIs or ARBs) may have an effect on cystatin C that is 
superior to other antihypertensive drugs. 
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4.5. HOMA-IR 
HOMA-IR is a model and calculation to determine quantification of insulin resistance. 
Antihypertensive drugs appear to have differing effects on insulin resistance, with ARBs 
foremost among those improving insulin sensitivity, although considerable variability has 
been observed and not all ARBs may be equal in this regard. RAS inhibitors generally have 
greater effects on glucose homeostasis than CCBs, which are usually considered to have 
neutral effects. 
In hypertensive patients, a significantly greater reduction in HOMA-IR was seen with 
losartan/amlodipine therapy than with high-dose amlodipine [118]. The addition of losartan 
therapy to chronic heart failure patients who were on ACEIs resulted in a reduction of 
HOMA-IR as well as inflammatory cytokines after 24 weeks of therapy [140]. The 
MARCADOR Study compared the effects of manidipine, amlodipine, telmisartan, and 
manidipine combined with lisinopril. While BP lowering was similar with all of these 
treatments, HOMA-IR levels improved in all of the treatments except for amlodipine, and 
the greatest change in HOMA-IR was seen with manidipine treatment [113]. In contrast to 
previous results, both losartan and telmisartan had neutral effects on insulin resistance in 42 
hypertensive patients with the metabolic syndrome, with no significant reductions in 
HOMA-IR in either group; BP reductions were similar for both ARBs [141]. In a more recent 
study, obese hypertensive patients were treated with telmisartan or olmesartan. While 
olmesartan improved BP levels, only telmisartan improved insulin glucose and HOMA-IR 
levels in addition to improving BP levels [25]. Others have also shown that telmisartan 
therapy helps to reduce HOMA-IR levels as compared to other ARBs and CCBs [132, 142]. 
Researchers studied the effects of irbesartan as compared to olmesartan in obese 
hypertensive females and found that while both treatments improved BP and lipid levels, 
only olmesartan resulted in HOMA-IR changes [143]. Olmesartan was also found to reduce 
HOMA-IR in hypertensive patients with sleep disordered breathing. Positive changes in BP 
level and left ventricular ejection fraction were also seen in these patients with olmesartan 
treatment [144].  
Non-diabetic CKD patients have a high prevalence of insulin resistance, metabolic 
syndrome, and chronic inflammation. Treatment with olmesartan medoxomil for 16 weeks 
was associated with a significant reduction in HOMA-IR, along with reductions in markers 
of inflammation [107]. Losartan therapy was associated with improvements in fasting 
plasma insulin and HOMA-IR in patients with T2DM nephropathy, in parallel with 
reductions in adiponectin levels [137]. Both olmesartan medoxomil and telmisartan were 
shown to improve HOMA-IR in patients with nonalcoholic fatty liver disease and chronic 
hepatitis C, conditions with a greater incidence of insulin resistance than other liver diseases 
[145]. 
In a study investigating the effect of combination therapy with amlodipine plus olmesartan 
medoxomil on HOMA-IR in hypertensive patients with the metabolic syndrome, HOMA-IR 
was significantly reduced with olmesartan medoxomil/amlodipine, whereas no significant 
changes were seen with olmesartan medoxomil/HCTZ. The reductions in the HOMA-IR 
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index strongly correlated with the increases in adiponectin level in the group treated with 
olmesartan medoxomil/amlodipine [108]. 
In a crossover study of amlodipine with or without atorvastatin therapy in obese patients 
with hypertension and normal lipid profiles, combination amlodipine/atorvastatin therapy 
produced a significantly greater reduction in HOMA-IR than amlodipine monotherapy; 
there was no correlation with BP reduction with either treatment [29]. The combination of 
rosuvastatin with telmisartan significantly lowered HOMA-IR and fasting serum insulin 
levels in metabolic syndrome patients, but when irbesartan or olmesartan was combined 
with rosuvastatin, HOMA-IR and fasting insulin levels increased [125]. In non-diabetic 
patients with the metabolic syndrome, manidipine, but not amlodipine, significantly 
reduced HOMA-IR [122]. 
In patients with hypertension and insulin resistance, neither moxonidine nor amlodipine 
produced changes in HOMA-IR. Both treatments significantly lowered BP and increased 
HDL-C, but only moxonidine reduced serum triglycerides. Neither drug affected serum 
CRP levels [123].  
In patients with T2DM nephropathy, losartan, but not amlodipine, reduced HOMA-IR from 
baseline, but the between-group difference was not significant. However, other parameters 
of glucose metabolism (eg, fasting blood glucose, HbA1c, and insulin sensitivity) were 
improved to a greater extent with losartan than with amlodipine [146]. In patients with 
hypertension and T2DM, telmisartan resulted in greater improvements in HOMA-IR than 
amlodipine [129]. 
Similar results with losartan and amlodipine were seen in patients with prediabetes, with 
greater improvements in HOMA-IR with losartan than with amlodipine; the two agents 
resulted in similar BP reductions [130]. 
In a study in hypertensive patients, both candesartan and amlodipine significantly 
improved endothelial function, but significant decreases in HOMA-IR and CRP were only 
observed with candesartan [120]. 
In a comparison of losartan and amlodipine in Japanese patients with hypertension, with or 
without diabetes, losartan provided greater increases in adiponectin than amlodipine. These 
increases correlated with HOMA-IR changes [147]. 
In agreement with the adiponectin results discussed earlier, indapamide treatment 
increased HOMA-IR in patients with hypertension, whereas no changes in HOMA-IR were 
seen with enalapril, metoprolol, or amlodipine [134]. In patients with hypertension and the 
metabolic syndrome, doxazosin, amlodipine, ramipril, and valsartan produced significant 
reductions in HOMA-IR, whereas no changes were seen with metoprolol [135]. 
Insulin resistance is a central force in the pathogenesis of vascular diseases, and HOMA-IR 
provides a reasonable assessment of the quantification of insulin resistance. Several long-
term clinical studies have demonstrated the clinical benefit of ARBs in diabetic kidney 
disease, both in late stage [the Reduction of Endpoints in NIDDM with Angiotensin II 
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Antagonist Losartan (RENAAL) study and the Irbesartan Diabetic Nephropathy Trial 
(IDNT) study] and early stage [The Effect  of Irbesartan on the Development of Diabetic 
Nephropathy in Patients with Type 2 Diabetes (IRMA-2) study]. The role of HOMA-IR may 
be beneficial in clinical practice, and quantitative and longitudinal analysis could provide 
long-term follow-up of disease management. 
4.6. Procollagen 
Several studies have assessed the effect of antihypertensive agents on procollagen fractions 
as a marker of atherogenesis and vascular remodeling. Valsartan and ramipril, but not 
amlodipine, were associated with reductions in procollagen. Despite similar BP lowering, 
valsartan and ramipril were more effective than amlodipine in preventing new episodes of 
atrial fibrillation [148]. 
Another study showed a significant difference in procollagen type I carboxy-terminal 
peptide (PICP) lowering between candesartan and amlodipine. Although BP control was 
similar, 24-hour SBP was significantly lower and LV mass index significantly decreased 
with amlodipine, while the effect of ARBs on procollagen indicate that they protect against 
CV fibrosis and renal injury [149]. 
There were no differences in procollagen markers with losartan- or atenolol-based regimens 
after the first year of treatment; changes in PICP during the first year of treatment were 
related to subsequent changes in LV mass index after 2 and 3 years of treatment in patients 
randomized to losartan, but not atenolol [26]. Losartan-related reduction in procollagen was 
shown to be greater in patients with higher baseline levels (those with hypertension and 
severe myocardial fibrosis) [150] and was significantly associated with symptom 
improvement [151]. 
4.7. TNF-α and IL-6 
The effects of antihypertensive drugs on the inflammatory biomarker TNF-α have been 
somewhat variable. In patients with hypertension, olmesartan medoxomil reduced TNF-α 
levels in one study [152], but in another study in Japanese patients, neither losartan nor the 
CCB amlodipine significantly affected TNF-α levels [147]. In obese hypertensive patients, 
telmisartan, but not losartan treatment, was shown to reduce serum TNF-α levels [132]. 
Conversely, another study showed that in newly diagnosed hypertension patients, losartan 
lowers TNF-α levels [117]. In chronic heart failure patients, the addition of losartan to ACEI 
therapy resulted in a significant reduction of TNF-α levels [140]. Amlodipine was effective 
in reducing TNF-α, but was significantly more effective when combined with atorvastatin 
[153]. Another study found no difference between losartan and amlodipine in TNF-α levels 
after treatment, but the investigators did not appear to perform baseline assessments in 
order to determine if either drug reduced TNF-α from baseline levels [118]. Manidipine and 
lisinopril combination therapy was shown to have a highly significant effect on TNF-α 
levels in non-diabetic, hypertensive patients with the metabolic syndrome [113]. 
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index strongly correlated with the increases in adiponectin level in the group treated with 
olmesartan medoxomil/amlodipine [108]. 
In a crossover study of amlodipine with or without atorvastatin therapy in obese patients 
with hypertension and normal lipid profiles, combination amlodipine/atorvastatin therapy 
produced a significantly greater reduction in HOMA-IR than amlodipine monotherapy; 
there was no correlation with BP reduction with either treatment [29]. The combination of 
rosuvastatin with telmisartan significantly lowered HOMA-IR and fasting serum insulin 
levels in metabolic syndrome patients, but when irbesartan or olmesartan was combined 
with rosuvastatin, HOMA-IR and fasting insulin levels increased [125]. In non-diabetic 
patients with the metabolic syndrome, manidipine, but not amlodipine, significantly 
reduced HOMA-IR [122]. 
In patients with hypertension and insulin resistance, neither moxonidine nor amlodipine 
produced changes in HOMA-IR. Both treatments significantly lowered BP and increased 
HDL-C, but only moxonidine reduced serum triglycerides. Neither drug affected serum 
CRP levels [123].  
In patients with T2DM nephropathy, losartan, but not amlodipine, reduced HOMA-IR from 
baseline, but the between-group difference was not significant. However, other parameters 
of glucose metabolism (eg, fasting blood glucose, HbA1c, and insulin sensitivity) were 
improved to a greater extent with losartan than with amlodipine [146]. In patients with 
hypertension and T2DM, telmisartan resulted in greater improvements in HOMA-IR than 
amlodipine [129]. 
Similar results with losartan and amlodipine were seen in patients with prediabetes, with 
greater improvements in HOMA-IR with losartan than with amlodipine; the two agents 
resulted in similar BP reductions [130]. 
In a study in hypertensive patients, both candesartan and amlodipine significantly 
improved endothelial function, but significant decreases in HOMA-IR and CRP were only 
observed with candesartan [120]. 
In a comparison of losartan and amlodipine in Japanese patients with hypertension, with or 
without diabetes, losartan provided greater increases in adiponectin than amlodipine. These 
increases correlated with HOMA-IR changes [147]. 
In agreement with the adiponectin results discussed earlier, indapamide treatment 
increased HOMA-IR in patients with hypertension, whereas no changes in HOMA-IR were 
seen with enalapril, metoprolol, or amlodipine [134]. In patients with hypertension and the 
metabolic syndrome, doxazosin, amlodipine, ramipril, and valsartan produced significant 
reductions in HOMA-IR, whereas no changes were seen with metoprolol [135]. 
Insulin resistance is a central force in the pathogenesis of vascular diseases, and HOMA-IR 
provides a reasonable assessment of the quantification of insulin resistance. Several long-
term clinical studies have demonstrated the clinical benefit of ARBs in diabetic kidney 
disease, both in late stage [the Reduction of Endpoints in NIDDM with Angiotensin II 
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Antagonist Losartan (RENAAL) study and the Irbesartan Diabetic Nephropathy Trial 
(IDNT) study] and early stage [The Effect  of Irbesartan on the Development of Diabetic 
Nephropathy in Patients with Type 2 Diabetes (IRMA-2) study]. The role of HOMA-IR may 
be beneficial in clinical practice, and quantitative and longitudinal analysis could provide 
long-term follow-up of disease management. 
4.6. Procollagen 
Several studies have assessed the effect of antihypertensive agents on procollagen fractions 
as a marker of atherogenesis and vascular remodeling. Valsartan and ramipril, but not 
amlodipine, were associated with reductions in procollagen. Despite similar BP lowering, 
valsartan and ramipril were more effective than amlodipine in preventing new episodes of 
atrial fibrillation [148]. 
Another study showed a significant difference in procollagen type I carboxy-terminal 
peptide (PICP) lowering between candesartan and amlodipine. Although BP control was 
similar, 24-hour SBP was significantly lower and LV mass index significantly decreased 
with amlodipine, while the effect of ARBs on procollagen indicate that they protect against 
CV fibrosis and renal injury [149]. 
There were no differences in procollagen markers with losartan- or atenolol-based regimens 
after the first year of treatment; changes in PICP during the first year of treatment were 
related to subsequent changes in LV mass index after 2 and 3 years of treatment in patients 
randomized to losartan, but not atenolol [26]. Losartan-related reduction in procollagen was 
shown to be greater in patients with higher baseline levels (those with hypertension and 
severe myocardial fibrosis) [150] and was significantly associated with symptom 
improvement [151]. 
4.7. TNF-α and IL-6 
The effects of antihypertensive drugs on the inflammatory biomarker TNF-α have been 
somewhat variable. In patients with hypertension, olmesartan medoxomil reduced TNF-α 
levels in one study [152], but in another study in Japanese patients, neither losartan nor the 
CCB amlodipine significantly affected TNF-α levels [147]. In obese hypertensive patients, 
telmisartan, but not losartan treatment, was shown to reduce serum TNF-α levels [132]. 
Conversely, another study showed that in newly diagnosed hypertension patients, losartan 
lowers TNF-α levels [117]. In chronic heart failure patients, the addition of losartan to ACEI 
therapy resulted in a significant reduction of TNF-α levels [140]. Amlodipine was effective 
in reducing TNF-α, but was significantly more effective when combined with atorvastatin 
[153]. Another study found no difference between losartan and amlodipine in TNF-α levels 
after treatment, but the investigators did not appear to perform baseline assessments in 
order to determine if either drug reduced TNF-α from baseline levels [118]. Manidipine and 
lisinopril combination therapy was shown to have a highly significant effect on TNF-α 
levels in non-diabetic, hypertensive patients with the metabolic syndrome [113]. 
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Losartan therapy significantly reduced TNF-α in patients with hypertension and T2DM 
[154]. However, olmesartan medoxomil combined with HCTZ had no effect on TNF-α in 
patients with hypertension and the metabolic syndrome (without diabetes), but when 
olmesartan medoxomil was combined with amlodipine, the combination did significantly 
reduce TNF-α levels [108]. Amlodipine was shown to reduce serum TNF-α levels, as well as 
mRNA expression of TNF-α in hypertensives with and without diabetes [155]. Interestingly, 
amlodipine alone was shown in another study to have no effect on TNF-α levels in patients 
with hypertension and the metabolic syndrome, whereas manidipine monotherapy was 
effective in lowering TNF-α [122]. Olmesartan medoxomil had no effect on TNF-α levels in 
patients with stage 3 or 4 CKD [107], and TNF-α was unaffected by amlodipine or 
spironolactone in patients with diabetic nephropathy [133]. 
Studies investigating the effect of antihypertensive drugs on IL-6 levels are summarized 
here. In an open-labeled study, losartan therapy reduced IL-6 levels in recently diagnosed 
hypertension without other CV disease risk factors [117]. Olmesartan medoxomil reduced 
IL-6 levels in one study in patients with hypertension [152], but had no effect in patients 
with stage 3 or 4 CKD [107]. Olmesartan medoxomil was ineffective when combined with 
HCTZ in patients with hypertension and the metabolic syndrome, but was effective in these 
patients when combined with amlodipine [108]. Valsartan combined with HCTZ was more 
effective than amlodipine alone in reducing IL-6 [156]. Another study showed that diabetics 
with hypertension have higher IL-6 levels than non-diabetics with hypertension, and 
amlodipine reduced serum IL-6 as well as mRNA expression of IL-6 in diabetics and non-
diabtetics [155]. In a crossover study with non-diabetic hypertensive patients, IL-6 levels 
were reduced with azelnidipine therapy, but not with amlodipine [112]. In the MARCADOR 
study, the greatest reduction in IL-6 was achieved with a combination of manidipine and 
lisinopril, while there was no change in IL-6 with amlodipine [113]. Another study found a 
greater reduction in IL-6 with benidipine treatment as compared to amlodipine treatment 
[100]. Losartan, as add-on therapy has also been shown to reduce IL-6 levels [140]. 
These cytokines are rather non-specific for quantification of inflammation; however, these 
studies do reflect the general state of inflammation in the vasculature. Clinical studies that 
measure the level of the cytokines demonstrate variable results. Multiple studies with 
antihypertensives indicate a general reduction in the levels of cytokines, suggesting a 
decrease in vascular inflammation. In context with the clinical situation and other risk 
factors, the measurement of these biomarkers may be useful. 
5. Conclusions 
It can be expected that biomarkers will continue to play an increasing role in the 
management of CV disease. Their importance or significance is likely to increase in direct 
proportion to the growth in our knowledge of disease pathophysiology and the mechanisms 
of drug action. The use of biomarkers does, however, depend upon the markers being 
accurate, relevant to the purpose, easy to measure, and consistently reproducible. 
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There is a wealth of evidence for improvement of validated biomarkers of vascular disease 
with most classes of antihypertensive treatment in a range of high-risk patient populations. 
These include obese patients, patients with diabetes, patients with renal disease and/or 
metabolic syndrome, existing vascular disease, and African American patients. Benefits 
have also been observed in those with normal BP, but with other CV risk factors. There is 
some evidence to suggest that at least part of the effect seen with some antihypertensives on 
these biomarkers may be independent of BP reduction. Different drugs may have quite 
different effects on biomarkers, despite very similar or equivalent effects on BP. However, 
with other drugs, the changes in certain biomarkers appear to parallel changes in BP. In 
addition, there appear to be clear associations between certain biomarkers, such as HOMA-
IR and adiponectin, and the manner in which they are affected by certain antihypertensive 
drugs.  
There is particularly compelling evidence that RAS inhibitors (ACEIs and ARBs) and CCBs 
may have beneficial effects beyond BP control, making them particularly attractive for either 
monotherapy or combination therapy. In contrast, other drugs, such as the thiazide diuretic 
HCTZ, appear to counter the beneficial effects on biomarkers normally observed with ARBs 
when they are used in combination.  
Of the biomarkers selected for review in this chapter, the benefits of antihypertensive 
therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term 
vascular benefits. However, more evidence is required to elucidate the mechanisms 
involved and understand the variability and apparent anomalies observed. In addition, 
more information about any differences between specific antihypertensive agents within the 
same class is needed. Additional evidence is required to determine the relevance of 
improvements observed with antihypertensive therapy on CAP, cystatin C, procollagen, 
TNF-α, and IL-6 to a reduction in the risk of subsequent vascular events. 
Further research is required to determine the extent to which these antihypertensive-related 
improvements in biomarkers contribute to the overall clinical outcome achieved in tandem 
with other CV risk reduction strategies and interventions. In addition, long-term studies 
with biomarkers are also required to show whether biomarkers correlate with long-term 
clinical outcomes. 
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Losartan therapy significantly reduced TNF-α in patients with hypertension and T2DM 
[154]. However, olmesartan medoxomil combined with HCTZ had no effect on TNF-α in 
patients with hypertension and the metabolic syndrome (without diabetes), but when 
olmesartan medoxomil was combined with amlodipine, the combination did significantly 
reduce TNF-α levels [108]. Amlodipine was shown to reduce serum TNF-α levels, as well as 
mRNA expression of TNF-α in hypertensives with and without diabetes [155]. Interestingly, 
amlodipine alone was shown in another study to have no effect on TNF-α levels in patients 
with hypertension and the metabolic syndrome, whereas manidipine monotherapy was 
effective in lowering TNF-α [122]. Olmesartan medoxomil had no effect on TNF-α levels in 
patients with stage 3 or 4 CKD [107], and TNF-α was unaffected by amlodipine or 
spironolactone in patients with diabetic nephropathy [133]. 
Studies investigating the effect of antihypertensive drugs on IL-6 levels are summarized 
here. In an open-labeled study, losartan therapy reduced IL-6 levels in recently diagnosed 
hypertension without other CV disease risk factors [117]. Olmesartan medoxomil reduced 
IL-6 levels in one study in patients with hypertension [152], but had no effect in patients 
with stage 3 or 4 CKD [107]. Olmesartan medoxomil was ineffective when combined with 
HCTZ in patients with hypertension and the metabolic syndrome, but was effective in these 
patients when combined with amlodipine [108]. Valsartan combined with HCTZ was more 
effective than amlodipine alone in reducing IL-6 [156]. Another study showed that diabetics 
with hypertension have higher IL-6 levels than non-diabetics with hypertension, and 
amlodipine reduced serum IL-6 as well as mRNA expression of IL-6 in diabetics and non-
diabtetics [155]. In a crossover study with non-diabetic hypertensive patients, IL-6 levels 
were reduced with azelnidipine therapy, but not with amlodipine [112]. In the MARCADOR 
study, the greatest reduction in IL-6 was achieved with a combination of manidipine and 
lisinopril, while there was no change in IL-6 with amlodipine [113]. Another study found a 
greater reduction in IL-6 with benidipine treatment as compared to amlodipine treatment 
[100]. Losartan, as add-on therapy has also been shown to reduce IL-6 levels [140]. 
These cytokines are rather non-specific for quantification of inflammation; however, these 
studies do reflect the general state of inflammation in the vasculature. Clinical studies that 
measure the level of the cytokines demonstrate variable results. Multiple studies with 
antihypertensives indicate a general reduction in the levels of cytokines, suggesting a 
decrease in vascular inflammation. In context with the clinical situation and other risk 
factors, the measurement of these biomarkers may be useful. 
5. Conclusions 
It can be expected that biomarkers will continue to play an increasing role in the 
management of CV disease. Their importance or significance is likely to increase in direct 
proportion to the growth in our knowledge of disease pathophysiology and the mechanisms 
of drug action. The use of biomarkers does, however, depend upon the markers being 
accurate, relevant to the purpose, easy to measure, and consistently reproducible. 
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There is a wealth of evidence for improvement of validated biomarkers of vascular disease 
with most classes of antihypertensive treatment in a range of high-risk patient populations. 
These include obese patients, patients with diabetes, patients with renal disease and/or 
metabolic syndrome, existing vascular disease, and African American patients. Benefits 
have also been observed in those with normal BP, but with other CV risk factors. There is 
some evidence to suggest that at least part of the effect seen with some antihypertensives on 
these biomarkers may be independent of BP reduction. Different drugs may have quite 
different effects on biomarkers, despite very similar or equivalent effects on BP. However, 
with other drugs, the changes in certain biomarkers appear to parallel changes in BP. In 
addition, there appear to be clear associations between certain biomarkers, such as HOMA-
IR and adiponectin, and the manner in which they are affected by certain antihypertensive 
drugs.  
There is particularly compelling evidence that RAS inhibitors (ACEIs and ARBs) and CCBs 
may have beneficial effects beyond BP control, making them particularly attractive for either 
monotherapy or combination therapy. In contrast, other drugs, such as the thiazide diuretic 
HCTZ, appear to counter the beneficial effects on biomarkers normally observed with ARBs 
when they are used in combination.  
Of the biomarkers selected for review in this chapter, the benefits of antihypertensive 
therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term 
vascular benefits. However, more evidence is required to elucidate the mechanisms 
involved and understand the variability and apparent anomalies observed. In addition, 
more information about any differences between specific antihypertensive agents within the 
same class is needed. Additional evidence is required to determine the relevance of 
improvements observed with antihypertensive therapy on CAP, cystatin C, procollagen, 
TNF-α, and IL-6 to a reduction in the risk of subsequent vascular events. 
Further research is required to determine the extent to which these antihypertensive-related 
improvements in biomarkers contribute to the overall clinical outcome achieved in tandem 
with other CV risk reduction strategies and interventions. In addition, long-term studies 
with biomarkers are also required to show whether biomarkers correlate with long-term 
clinical outcomes. 
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